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Proteus mirabilis e Klebsiella pneumoniae uropatogénicos em animais de companhia: 
epidemiologia molecular, resistência aos antimicrobianos e potencial zoonótico 
 
As infeções bacterianas do trato urinário (ITU) são frequentemente diagnosticadas em animais 
de companhia e no homem. O aumento da resistência e multirresistência aos antimicrobianos 
é um reconhecido problema na sociedade moderna que resulta na diminuição de opções 
terapêuticas. Com o crescente contacto entre os animais de companhia e o homem, a 
disseminação de bactérias resistentes a antimicrobianos criticamente importantes levanta 
também grandes preocupações de saúde pública. 
Seguindo o modelo utilizado pelo European Centre for Disease Prevention and Control 
(ECDC) nos relatórios de resistência aos antimicrobianos de bactérias invasivas de origem 
humana, o primeiro estudo apresentado nesta tese pretendeu avaliar a etiologia e a 
distribuição geográfica da resistência aos antimicrobianos em bactérias (n= 22 256) isoladas 
de animais de companhia com ITU em 14 países Europeus. Este estudo mostrou que, em 
2012-2013, a frequência de resistência aos antimicrobianos em Escherichia coli e  
Proteus mirabilis era significativamente superior nos países estudados do Sul da Europa 
(Portugal, Espanha, Itália e Grécia) quando comparada com os países estudados do Norte da 
Europa (Dinamarca e Suécia). O mesmo aconteceu quanto a E. coli e P. mirabilis 
multirresistente (MDR). 
A elevada resistência aos antimicrobianos detetada em cães e gatos com ITU em Portugal 
(Lisboa) motivou a realização de um segundo estudo, retrospetivo, com o objetivo de avaliar 
a evolução temporal da resistência aos antimicrobianos, nesta região, ao longo de um período 
de 16 anos (1999-2014). Este estudo confirmou a ocorrência de um aumento significativo de 
resistência ao longo do tempo quanto à amoxicilina/clavulanato, cefalosporinas de terceira 
geração (C3G), trimetoprim/sulfametoxazol, fluoroquinolonas, gentamicina e tetraciclina  
(P < 0,001) em Enterobacteriaceae de animais de companhia com ITU. Adicionalmente, foi 
detetado um aumento significativo no isolamento de Enterobacteriaceae MDR (P < 0,0001). 
A resistência a C3G esteve associada a fenótipos de MDR e à presença de blaCTX-M-15 e  
blaCMY-2 em E. coli e de blaCMY-2 em P. mirabilis. No que respeita a bactérias Gram-positivo, foi 
observado um aumento significativo na resistência à meticilina em Staphylococcus 
pseudintermedius (P = 0,0069). A caracterização por MLST de E. coli, Staphylococcus spp. e 
Enterococcus spp. positivos a mecanismos de resistência clinicamente relevantes revelou que 
os animais de companhia podem desenvolver ITUs causadas por bactérias pertencentes a 
linhagens clonais de elevado risco para o homem, nomeadamente, E. coli O25b:H4-B2-
ST131, CC23 e ST648 resistente a C3G, Staphylococcus aureus meticilina-resistente do CC5, 
Staphylococcus epidermidis meticilina-resistente do CC5, Enterococcus faecalis do CC6 com 
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resistência à gentamicina em alto nível pela presença da enzima bifuncional e Enterococcus 
faecium do CC17 com resistência à ampicilina. 
Ambos os estudos confirmaram a predominância de ITUs causadas por E. coli em cães e 
gatos. No entanto, algumas diferenças na etiologia da ITU foram detetadas, sendo as mais 
relevantes a frequência superior de P. mirabilis em cães e de Enterococcus spp. em gatos  
(P < 0,0001). 
Klebsiella pneumoniae e P. mirabilis são importantes bactérias associadas a ITUs 
nosocomiais no homem. Embora K. pneumoniae seja menos frequente em animais de 
companhia, é a segunda bactéria mais frequente na ITU da mulher e está intimamente 
associada à disseminação de b-lactamases de espectro alargado (ESBL – Extended-
Spectrum Beta-Lactamases) e carbapenemases. Os estudos epidemiológicos sobre  
K. pneumoniae e P. mirabilis em animais de companhia com ITU são escassos. No entanto, 
é essencial entender o papel dos cães e gatos com ITU na disseminação de K. pneumoniae 
e P. mirabilis, bem como a sua relevância numa perspetiva One Health. 
Na segunda parte desta tese, constam dois estudos em que foi caracterizada a estrutura da 
população, a resistência aos antimicrobianos e a presença de genes de virulência em  
K. pneumoniae e P. mirabilis isolados de animais de companhia (K. pneumoniae n= 25;  
P. mirabilis n= 107) e humanos (K. pneumoniae n= 77; P. mirabilis n= 76) com ITU. 
Os animais de companhia com ITU apresentaram um elevado número de K. pneumoniae 
MDR (80%, n= 20/25) e resistente a C3G (60%, n= 15/25). Em concordância com estudos 
Europeus anteriores, o gene blaCTX-M-15 mostrou-se disseminado em K. pneumoniae resistente 
a 3GC tanto de origem em animais de companhia como de origem humana. Sessenta por 
cento (n=15/25) de K. pneumoniae isolada de animais de companhia com ITU em Portugal 
(Lisboa) pertenceu à linhagem clonal de elevado risco ST15. Outras linhagens clonais de 
elevado risco de K. pneumoniae isoladas de animais de companhia incluíram o ST11 (n= 1), 
ST37 (n= 1) e ST147 (n= 1), todos eles MDR e resistentes a C3G. K. pneumoniae resistente 
a C3G de origem humana mostrou ser mais diversificada, pertencendo a um maior número 
de linhagens clonais. Na análise de electroforese em gel de campo pulsado (PFGE – Pulsed-
Field Gel Electrophoresis), a maioria das estirpes de K. pneumoniae ST15 de animais de 
companhia agrupou em dois clusters (C4 e C5; >80% de índice Dice/UPGMA, XbaI, 1,5% de 
tolerância), os quais incluíram algumas estirpes de origem humana. A linhagem clonal ST11 
foi detetada num gato (n= 1) e num humano (n= 1); ambos MDR e com 81,1% de índice 
Dice/UPGMA. De notar que, duas estirpes pertencentes ao ST348, resistentes a 3GC e com 
86,7% de índice Dice/UPGMA foram também isoladas de um gato e um humano.  
K. pneumoniae de ambas as origens apresentaram dois genótipos de virulência principais, 
nomeadamente fimH-1/mrkD/entB/ycfM/kfu e fimH-1/mrkD/entB/ycfM/kpn. A ilha de elevada 
patogenicidade yersiniabactina foi também comum em K. pneumoniae de animais de 
companhia (16%) e humanos (42,8%). 
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Como acima mencionado, a resistência às C3G em P. mirabilis de animais de companhia com 
ITU aumentou ao longo do tempo e esteve associada à presença de blaCMY-2. Na análise de 
PFGE, um elevado número de clusters (43,6%, n= 17/39; >80% de índice Dice/UPGMA, NotI, 
1,5% de tolerância) incluiu estirpes de P. mirabilis isoladas de animais de companhia e de 
humanos. É de notar que uma estirpe de P. mirabilis isolada de um cão foi 100% semelhante 
por PFGE (Dice/UPGMA), a uma estirpe isolada de um humano. Os genes de virulência 
testados (fimbria: mrpA, pmfA, ucaA; hemolisina: HmpA/HmpB) foram detetados na maioria 
das estirpes de ambas as origens (85% - 100%). 
Ambos os estudos apresentados na segunda parte desta tese mostraram que K. pneumoniae 
e P. mirabilis de animais de companhia com ITU podem conter genes de resistência 
clinicamente importantes e que a maioria das estirpes de K. pneumoniae era MDR e pertencia 
a linhagens clonais de elevado risco para o Homem. 
Durante a ITU, os animais de companhia apresentam uma elevada carga de bactérias 
uropatogénicas na urina pelo que poderão contribuir para a sua disseminação. O papel dos 
animais de companhia saudáveis como reservatórios de bactérias patogénicas é também uma 
preocupação de saúde pública. Estudos anteriores mostraram que estirpes de E. coli são 
partilhadas entre animais de companhia e humanos a viver juntos. Contudo, tanto quanto nos 
foi possível averiguar, tais estudos não foram realizados relativamente a K. pneumoniae e  
P. mirabilis. Para tal, na terceira parte desta tese, animais de companhia (n= 18 cães e n= 8 
gatos) e humanos (n= 24) saudáveis de 18 agregados familiares foram rastreados para a 
presença de K. pneumoniae e P. mirabilis em amostras fecais. 
A colonização intestinal por K. pneumoniae e P. mirabilis foi detetada em cães e humanos, 
contudo, nenhuma das estirpes isoladas era MDR. 
As estirpes fecais de K. pneumoniae isoladas de cães pertenceram às linhagens clonais ST17, 
ST188, ST252, ST281, ST423, ST1093, ST1241, ST3398 e ST3399. Notavelmente, um dos 
agregados familiares (H15) incluiu dois cães que partilhavam uma estirpe cada com um dos 
humanos a viver no mesmo agregado familiar. As estirpes de K. pneumoniae partilhadas entre 
os pares cão/humano pertenciam ao mesmo ST (ST252 e ST1241) e apresentavam o mesmo 
padrão de restrição de PFGE (Dice/UPGMA, XbaI, 1,5% de tolerância), perfil de resistência 
aos antimicrobianos e genótipo de virulência. Foram detetados também dois humanos e um 
cão, de agregados familiares distintos, colonizados por uma estirpe de K. pneumoniae ST17 
com perfil de restrição de PFGE idêntico e fenótipo de resistência aos antimicrobianos 
diferenciado. 
No caso de P. mirabilis, os cães apresentaram uma frequência de colonização intestinal 
significativamente superior aos humanos (44,4% e 12,5%, respetivamente; P = 0,0329). Neste 
caso, um par cão/humano e um par cão/cão partilhavam estirpes de P. mirabilis com padrão 
de restrição de PFGE similar (Dice/UPGMA, NotI, 1,5% de tolerância). 
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Os resultados apresentados nesta tese, quanto à distribuição de resistência aos 
antimicrobianos em bactérias isoladas de animais de companhia com ITU na Europa e 
Portugal (Lisboa) , suportam a necessidade de implementação de programas de antimicrobial 
stewardship, sobretudo nos países do sul da Europa (Portugal, Espanha, Itália e Grécia).  
A deteção de bactérias MDR pertencentes a linhagens clonais de elevado risco nos animais 
de companhia com ITU e as semelhanças detetadas entre K. pneumoniae e P. mirabilis de 
origem animal e humana levantam preocupações de saúde pública e corroboram a 
necessidade de uma abordagem One Health. 
 





Uropathogenic Proteus mirabilis and Klebsiella pneumoniae in companion animals: 
molecular epidemiology, antimicrobial resistance and zoonotic potential 
 
Urinary tract infections (UTI) are frequently diagnosed in companion animals and the increase 
in antimicrobial resistance leads to therapeutic limitations and public health concerns. 
The study of the geographic distribution of antimicrobial resistance in bacteria (n= 22 256) 
causing UTI in companion animals from 14 European countries showed that, in 2012-2013, 
the frequency of Escherichia coli and Proteus mirabilis antimicrobial resistance in Southern 
countries (Portugal, Spain, Italy, Greece) was significantly higher than in Northern countries 
(Denmark, Sweden). In a retrospective study conducted in Portugal (Lisbon), the antimicrobial 
resistance of clinical Enterobacteriaceae from companion animals with UTI increased 
significantly over 16 years (1999-2014; P <  0.001). Bacteria from companion animals with UTI 
harboured important antimicrobial resistance mechanisms and belonged to high-risk clonal 
lineages, namely third-generation cephalosporin (3GC)-resistant E. coli O25b:H4-B2-ST131, 
CC23 and ST648, methicilin-resistant Staphylococcus aureus CC5, methicilin-resistant 
Staphylococcus epidermidis CC5, high-level gentamicin-resistant Enterococcus faecalis CC6 
and ampicillin-resistant Enterococcus faecium CC17. 
The blaCTX-M-15 gene was disseminated among 3GC-resistant K. pneumoniae from companion 
animals and humans with UTI. Most K. pneumoniae from companion animals where 3GC, 
multidrug-resistant (MDR) and belonged to the high-risk clonal lineage ST15. K. pneumoniae 
high-risk clonal lineages ST11, ST37 and ST147 were also detected in companion animals. 
3GC-resistance in P. mirabilis from companion animals with UTI was associated with the 
presence of blaCMY-2, which increased significantly over time. A high number of PFGE clusters 
(43.6%, n =  17/39) included P. mirabilis strains from companion animals and humans. 
Gut colonisation by K. pneumoniae and P. mirabilis was detected in healthy dogs and humans; 
however, none of the strains was MDR. K. pneumoniae faecal strains from dogs belonged to 
ST17, ST188, ST252, ST281, ST423, ST1093, ST1241, ST3398 and ST3399. Remarkably, 
two colonised dogs were found to shared PFGE undistinguishable K. pneumoniae strains with 
one co-living human. P. mirabilis gut colonisation was significantly higher in dogs (P = 0.0329). 
One human/dog and one dog/dog pair shared PFGE undistinguishable P. mirabilis strains. 
The antimicrobial resistance frequencies reported in these studies support the need to 
implement antimicrobial stewardship programmes in veterinary medicine. The detection of 
MDR high-risk clonal lineages causing UTI in companion animals and the similarities detected 
in K. pneumoniae and P. mirabilis from companion animals and humans raises public health 
concerns and highlights the need for a One Health approach. 
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Chapter 1 Introduction 
1.1 Urinary tract infections 
Urinary tract infections (UTI) are frequently diagnosed in humans and companion animals 
(Harding & Ronald, 1994; Weese et al., 2011). In Humans from the United States, UTIs 
account for 0.7% of primary diagnosis at ambulatory care visits (Schappert & Rechtsteiner, 
2011). When considering human healthcare-associated infections in the United States and 
Europe, the prevalence of UTIs is much higher (European Centre for Disease Prevention and 
Control [ECDC], 2013; Magill et al., 2014). Ling1 (Ling 1984 cited by Thompson, Litster, Platell 
& Trott, 2011) has estimated that around 14% of dogs visiting a veterinarian will develop a UTI 
during their life time. The frequency of urinary tract infections among cats with lower urinary 
tract disease has been considered to be low (<2%) (Kruger et al., 1991; Buffington et al., 1997; 
Gunn-Moore, 2003); however, some studies found higher frequencies, varying between 8% 
and 25% (Lekcharoensuk, Osborne & Lulich, 2001; Gerber et al., 2005; Eggertsdóttir, Lund, 
Krontveit & Sørum, 2007; Sævik, Trangerud, Ottesen, Sørum & Eggertsdóttir, 2011). 
 
1.1.1 Pathogenesis of bacterial urinary tract infections 
UTI is a consequence of the host defence mechanisms failure allowing the adherence, 
multiplication and persistence of virulent bacteria in the urinary tract (Bartges, 2004). 
UTI usually initiates with the adherence and colonisation of bacteria into the urethra followed 
by migration to the bladder. Complex host-pathogen interactions will determine the outcome 
of the bacteria migration. When successful, the bacteria will multiply and colonise the bladder 
and may ascend to the kidney. Ultimately, bacteria will cross the tubular epithelial barrier into 
the blood stream, resulting in bacteraemia (Flores-Mireles, Walker, Caparon & Hultgren, 
2015). 
Ascending bacteria from the lower urinary tract is the main route of upper urinary tract infection 
as opposed to haematogenous/lymphatic route or infection from surrounding tissues 
(Thompson, 2011; Smee, Loyd & Grauer, 2013). Most of the bacteria causing UTI originate 
from the gastrointestinal tract or skin surrounding the vulva and prepuce (Bartges, 2004). 
                                               
1 Ling, G.V. (1984). Therapeutic strategies involving antimicrobial therapy of the canine urinary tract. Journal of the American 
Veterinary Medical Association, 185, 1162–1164. 
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The adherence, migration and persistence of bacteria in the urinary tract relies on several 
virulence factors such as: fimbriae (pili) and adhesins that recognise receptors on the urinary 
tract epithelium and mediate colonisation/migration; toxins and proteases that release nutrient 
from host cells; and siderophores that mediate iron acquisition (Flores-Mireles et al., 2015). 
Host predisposing diseases associated with higher UTI frequencies include diabetes mellitus 
in dogs, cats and humans; chronic kidney disease in cats and humans; hyperthyroidism in cats 
and hyperadrenocorticism and bladder transitional cell carcinoma in dogs (Saitoh, Nakamura, 
Hida & Satoh, 1985; Forrester, Troy, Dalton, Huffman & Holtzman, 1999; Hess, Saunders, Van 
Winkle & Ward, 2000; Mayer-Roenne, Goldstein & Erb, 2007; Bailiff et al., 2006; Hirji, Guo, 
Andersson, Hammar & Gomez-Caminero, 2012; Budreckis et al., 2015). Seguin et al. (2003) 
found that dogs with urine specific gravity higher than 1.025 are less likely to develop UTI by 
E. coli. Martinez-Ruzafa et al. (2012) detected a significant association between low urine 
specific gravity and UTI in cats. Contrary, several studies found that dogs and cats with low 
urine specific gravity do not seem to be predisposed to UTI (McGuire, Schulman, Ridgway & 
Bollero, 2002; Seguin, Vaden, Altier, Stone & Levine, 2003; Bailiff et al., 2008). The existence 
of anatomical abnormalities or diseases promoting urine retention and abnormal micturition 
(e.g. urinary obstruction or neurologic diseases) also promote UTI (Seguin et al., 2003; 
Bubenik & Hosgoof, 2008; Stiffler et al., 2006; Graves et al., 2007; Eriksson, Gustafson, 
Fagerström & Olofsson, 2010; Martinez-Ruzafa et al., 2012). Furthermore, corticoid treatment 
also seems to predispose to UTI (Freshman, Reif, Allen & Jones, 1989; Torres et al., 2005). 
UTI is more frequent in female dogs, cats and humans (Lekcharoensuk et al., 2001; Ling et 
al., 2001; Cohn, Gary, Fales & Madsen, 2003; Bailiff et al., 2006; Graves et al., 2007; Mayer-
Roenne et al., 2007; Bailiff et al., 2008; Flores-Mireles et al., 2015). The mean age of UTI 
diagnosis is similar between female and male dogs ranging between 7 and 8 years-old (Ling 
et al., 2001; Seguin et al., 2003; Cohn et al., 2003); nevertheless, age may vary widely (Norris 
et al., 2000). Spayed female dogs have higher risk for developing UTI (Cohn et al., 2003; 
Seguin et al., 2003). Persian and Abyssinian breeds, increasing age and low body weight are 
associated with increased risk of UTI in cats (Lekcharoensuk et al., 2001; Bailiff et al., 2008). 
In men, the risk of UTI increases with age (Griebling, 2005). Other, human related predisposing 
factors for UTI include intercourse frequency/partner, use of certain contraceptives, hygiene 
patterns, indwelling urinary catheters, prior UTI, among others (Foxman et al., 2000; Scholes 
et al., 2000; Graves et al., 2007; Badran et al., 2015). 
 
1.1.2 Classification of urinary tract infections 
In veterinary medicine, there is a dedicated guideline for the antimicrobial treatment of UTI in 
companion animals that was developed by a Working Group of the International Society for 
Companion Animal Infectious Diseases (Weese et al., 2011). One focal point of the ITU 
treatment decision making in this guideline relies on the classification of the type of UTI. 
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In human medicine, there are several UTI guidelines using different classification systems 
(European Association of Urology [EAU], 2017). Johasen et al. (2011) revised the main human 
guidelines used at the time and proposed a new classification system accounting for the clinical 
presentation of the UTI, categorisation of UTI risk factors and availability of appropriate 
antimicrobial therapy. Recently, this guideline was further improved (Smelov, Naber & 
Johansen, 2016; EAU, 2017). 
The human UTI classification system (Smelov et al., 2016) is more complex and the main 
classification groups vary from the ones proposed by Weese et al. (2011) for companion 
animals (Figure 1 and Figure 2). 
 




Bacteriuria can be detected in patients with or without clinical signs (symptomatic versus 
asymptomatic) (Weese et al., 2011; Smelov et al., 2016). Clinical signs are not pathognomonic 
and may include dysuria, pollakiuria, stranguria, haematuria, urgency to urinate, fever, 
abdominal/flank pain, vocalisation (in companion animals), among others (Bartges et al., 2004; 
Gerber et al., 2005; Weese et al., 2011; Johasen et al., 2011; Passmore, Sherington & 
Stegemann, 2008). 
According to the clinical presentation of symptomatic bacteriuria, UTIs are considered upper 
UTIs or pyelonephritis (kidney) or lower UTIs or cystitis (bladder) (Weese et al., 2011; Smelov 
et al., 2016). Human UTI guidelines also consider urosepsis as an additional clinical 
presentation and grade clinical signs in 6 levels of severity: cystitis, mild and moderate 
pyelonephritis, severe pyelonephritis, urosepsis, severe urosepsis and urosepsic shock 





Figure 2 - Classification of UTIs in humans according to Smelov et al. (2016) 
 
Legend: *please refer to Table 2 to obtain information about the ORENUC classification system. 
 
Based on the frequency of UTI episodes within the last 12 months, UTIs can be classified as 
simple (<3 episodes) or recurrent (≥3 episodes) (Weese et al., 2011; Smelov et al., 2016). 
Repeated UTIs may be considered as reinfection, relapse or refractory UTIs (Table 1). 
 
Table 1 – Repeated UTIs 
 Description 
Reinfection* 
- within 6 months of cessation of previous UTI, 
- after apparent successful treatment, 
- isolation of a different microorganism. 
Relapse* 
- within 6 months of cessation of previous UTI (usually weeks), 
- after apparent successful treatment, 
- isolation of an indistinguishable organism from the previous UTI. 
Refractory 
- persistently positive culture during treatment, 
- no period of negative bacteriuria during or after treatment, 
- isolation of an indistinguishable organism from the previous UTI. 
Legend: *subtype of recurrent UTI 
 
Uncomplicated UTIs in companion animals, include cystitis diagnosed in patients that are 
otherwise healthy (i.e. without comorbidities) and with normal genitourinary tract anatomy and 
function (Weese et al., 2011). Uncomplicated UTIs in companion animals are always simple 
UTIs, since recurrent UTIs are considered by Weese et al. (2001) as a sign of presence of 
undiagnosed comorbidities. The uncomplicated UTI definition for humans differs significantly, 
since besides simple acute cystitis it also includes recurrent acute cystitis and simple and 
recurrent acute pyelonephritis (Smelov et al., 2016). Furthermore, in human guidelines, risk 
factors for UTI are graded according to the ORENUC classification, and patients with low 
severity risk factors are included in the uncomplicated UTI group (Table 2) (Smelov et al., 
2016). 
Complicated UTI in companion animals are those occurring in patients with comorbidities (e.g. 
urinary obstruction, renal failure, diabetes mellitus) or predisposing factors for UTI such as 
anatomic or functional abnormalities of the genitourinary tract (Weese et al., 2011). As 
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mentioned above, all recurrent UTIs are considered as complicated UTIs in companion 
animals (Weese et al., 2011). In humans, a complicated UTI is a simple/recurrent 
cystitis/pyelonephritis associated with a structural or functional abnormality of the genitourinary 
tract or an underlying disease with high risk for severe outcome (Figure 2 and Table 2) (Smelov 
et al., 2016). Finally, in companion animals, pyelonephritis is considered a UTI group by itself 
(Weese et al., 2011). 
 
Table 2 – Host risk factors in UTI categorised according to the ORENUC system from 
the human UTI guidelines (adapted from Smelov et al., 2016) 
Phenotype Category of risk factor 
O No known risk factor. 
R 
Risk factors for recurrent urinary tract infection but no risk of more severe 
outcome. 
E Extraurogenital risk factors with risk of more severe outcome. 
N Nephropathic diseases with risk of more severe outcome. 
U 
Urologic risk factors with risk of more severe outcome, which can be resolved 
during therapy. 
C 
Permanent urinary catheter and unresolvable urologic risk factors with risk of more severe 
outcome. 
 
Since, clinical signs of UTI are non-specific, UTI diagnosis and classification should include 
the clinical evaluation of the patient, complete urinalysis including urine specific gravity and 
sediment analysis, the necessary diagnostic workout to detect suspected comorbidities, and 
quantitative urine culture (Wilson & Gaido, 2004; Weese et al., 2011). The presence of 
bacteriuria and pyuria (more than three to five white blood cells per high-power field) in urine 
sediment strongly correlates with the presence of UTI, however it is not diagnostic (Kahlmeter 
& ECO.SENS, 2003; Bartges et al., 2004; Mayer-Roenne, 2007). Quantitative urine culture is 
the gold standard for diagnosis of significant bacteriuria2 (Bartges et al., 2004; Weese et al., 
2011; Smelov et al., 2016) and ideally should always be performed together with antimicrobial 
susceptibility testing to confirm empiric diagnosis, to adjust initial empiric therapeutics, to guide 
in recurrent UTI diagnosis and to gather epidemiological data on local aetiology and 
susceptibility patterns (Weese et al., 2011). 
In companion animals, urine should be preferably collected by cystocentesis, followed by 
catheterisation or free-catch (midstream voiding or manual expression) to avoid sample 
contamination. The use of free-catch urine in companion animals is controversial among 
authors (Bartges et al., 2004; Weese et al., 2011; Soerensen et al., 2016). In humans, 
midstream voiding is frequently used because it is less invasive and less time consuming than 
                                               
2 Significant bacteriuria – this term is used to describe bacteriuria associated with UTI, and when in the absence of clinical signs, 
asymptomatic bacteriuria (Bartges et al., 2004). 
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cystocentesis and catheterisation (Wilson & Gaido, 2004). Urine culture should always be 
quantitative so that significant bacteriuria can be diagnosed accounting for the number of 
colony forming units per urine volume and the urine collection method (Bartges et al., 2004; 
Wilson & Gaido, 2004; Smelov et al., 2016). 
 
1.1.3 Aetiology 
Until recently, the bladder was believed to be a sterile environment, however due to the arising 
of high-throughput DNA-sequencing techniques, the urine microbiota started to be unravelled 
in healthy humans and dogs (Wolfe et al., 2012; Burton et al., 2017). Results from several 
studies show that part of the urine “healthy microbiota” is composed of slow-growing bacteria, 
therefore not detectable using classic aerobic urine culture procedures (Brubaker & Wolfe, 
2017; Hilt et al., 2014). These findings lead Hilt et al. (2014) to propose an enhanced 
quantitative urine culture (EQUC) procedure that succeeded in demonstrating the existence of 
live microbiota in urine. Nevertheless, the role of the “healthy microbiota” and slow growing or 
anaerobic micro-organisms in urine from healthy individuals still needs to be explored 
(Brubaker & Wolfe, 2017). Interestingly, early studies on asymptomatic bacteriuria in women 
have suggested that it might have a protective effect against UTI (Cai et al., 2012). 
Despite the new developments on the urine microbiota, current knowledge of UTI aetiology is 
still mainly based on quantitative urine culture conducted by classic microbiology. 
Studies on UTI from companion animals report different proportions of aetiological agents 
maybe reflecting different geographical/temporal trends as well as different inclusion criteria. 
Geographical differences in the aetiology of UTIs has been previously pointed out in humans 
(Kahlmeter & ECO.SENS, 2003). The different inclusion criteria among studies and the 
different UTI classification in human and veterinary medicine limits straightforward 
comparisons among and between companion animals and humans. 
Usually UTIs are caused by a single bacterium, but polimicrobial infections may also occur 
(Hess et al., 2000; Ling et al., 2001; Litster, Moss, Honnery, Rees & Trott, 2007b; Forrester et 
al., 1999). In humans, dogs and cats, E. coli (uropathogenic E. coli - UPEC) is by far the most 
common isolated bacteria in all types of UTIs. Nonetheless, UTIs can be caused by other 
Gram-negative and Gram-positive bacteria, and more rarely by fungi and viruses (Bush, 1976; 
Wooley & Blue, 1976; Forrester et al., 1999; Gupta, Hooton, Wobbe & Stamm, 1999; Hess et 
al., 2000; Ling et al., 2001; Cohn et al., 2003; Kahlmeter & ECO.SENS, 2003; Pressler, Vaden, 
Lane, Cowgill & Dye, 2003; Torres et al., 2005; Bailiff et al., 2006; Litster et al., 2007b; Mayer-
Roenne et al., 2007; Passmore et al., 2008; Martinez-Ruzafa et al., 2012; Dorsch, von 
Vopelius-Feldt, Wolf, Straubinger & Hartmann, 2015; Flores-Mireles et al., 2015; Moyaert et 
al., 2017). 
Cats are usually reported as having a high frequency of UTIs caused by Enterococcus spp. 
and Staphylococcus spp. (Wooley & Blue, 1976; Bailiff et al., 2006; Litster et al., 2007b; Mayer-
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Roenne et al., 2007; Bailiff et al., 2008; Passmore et al., 2008; Martinez-Ruzafa et al., 2012; 
Dorsch et al., 2015; Moyaert et al., 2017; Teichmann-Knorrn, Reese, Wolf, Hartmann & 
Dorsch, 2018). Enterococcus faecalis is the most prevalent Enterococcus species isolated in 
cats with UTI, followed by Enterococcus faecium that is rarely isolated (Litster et al., 2007b; 
Mayer-Roenne et al., 2007). Several Staphylococcus species may cause UTI in cats including 
Staphylococcus aureus and Staphylococcus pseudintermedius (Litster et al., 2007b; Couto et 
al., 2016). Recently, Litster et al. (2007b) highlighted the high frequency of UTIs caused by 
Staphylococcus felis in cats from Australia. Other less frequent bacteria causing UTIs in cats 
include Proteus mirabilis, Pseudomonas aeruginosa, Streptococcus spp., Pasteurela spp., 
Klebsiella pneumoniae, among others. Frequencies of UTI aetiological agents vary according 
to the study design (Wooley & Blue, 1976; Lekcharoensuk et al., 2001; Bailiff et al., 2006; Bailiff 
et al., 2008; Litster et al., 2007b). 
In dogs, P. mirabilis usually is the second most common Enterobacteriaceae causing UTI 
(Wooley & Blue, 1976; Ling et al., 2001; Cohn et al., 2003; Moyaert et al., 2017). Other 
common causes of UTI in dogs include Staphylococcus spp., Enterococcus spp. and more 
rarely Pseudomonas spp., Klebsiella spp., Streptococcus spp., among others (Forrester et al., 
1999; Norris et al., 2000; Ling et al., 2001; Prescott, Hanna, Reid-Smith & Drost, 2002; Cohn 
et al., 2003). Staphylococcus pseudintermedius is the most common Staphylococcus species 
isolated from dogs with UTI, although several other species have been identified (Prescott et 
al., 2002; Cohn et al., 2003; Penna, Varges, Martins, Martins & Lilenbaum, 2010). Studies in 
dogs with complicated/recurrent UTI show higher frequencies of less common bacteria such 
as K. pneumoniae, Enterococcus spp. and Pseudomonas spp. (Forrester et al., 1999; Norris 
et al., 2000; Torres et al., 2005). Additionally, some studies have identified different bacteria 
frequencies according to the dog gender (Norris et al., 2000; Ling et al., 2001; Cohn et al., 
2003). 
K. pneumoniae and P. mirabilis are the most common Gram-negative bacteria in women with 
uncomplicated UTI after E. coli (Gupta et al., 1999). Gram-positive bacteria are frequently 
isolated, namely Staphylococcus saprophyticus and less frequently Enterococcus spp. (Gupta 
et al., 1999; Kahlmeter & ECO.SENS, 2003). S. saprophyticus has also been found to cause 
UTIs in dogs (Penna et al., 2002). When considering complicated and health-care associated 
UTIs, Klebsiella spp., Enterococcus spp., and other less common bacteria occur more 
frequently (Ronald, 2003; Wagenlehner, Niemetz, Weidner & Naber, 2007; Magill et al., 2014; 
Flores-Mireles et al., 2015). 
 
1.2 Antimicrobial treatment for UTI and antimicrobial resistance genes 
The increasing antimicrobial resistance trends in humans and companion animals are a 
worldwide concern (World Health Organization [WHO], 2017a). The selective pressure 
employed due to antimicrobial use is believed to be a key factor contributing to the rising 
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antimicrobial resistance trends (Guardabassi, Schwarz & Lloyd, 2004; Paterson & Bonomo, 
2005; Pomba et al., 2017; WHO, 2017a). Since antimicrobials are the cornerstone of UTI 
treatment and are frequently required, correct UTI diagnosis and proper antimicrobial selection 
is crucial to avoid antimicrobial misuse (Weese et al., 2011). Human and companion animal 
guidelines for UTI treatment propose a rational list of antimicrobials to be used according to 
the type of UTI (Weese et al., 2011; EAU, 2017) (Table 3). These guidelines should be adjusted 
considering the geographic particularities such as antimicrobial resistance rates, antimicrobial 
availability and prescribing regulations (Weese et al., 2011; EAU, 2017). 
Generally, antimicrobial treatment in asymptomatic bacteriuria it is not required (Weese et al., 
2011; EAU, 2017); however, treatment may be considered in companion animals with high risk 
of ascending/systemic infection (Weese et al., 2011). 
Antimicrobials for UTI treatment ideally should achieve high concentrations in the active form 
in urine. The main antimicrobials used for UTI treatment in veterinary medicine are also used 
in human medicine, namely b-lactams, fluoroquinolones and trimethoprim/sulfamethoxazole 
(Table 3). The WHO (2017a) has grouped antimicrobials according to their importance to 
human medicine into 3 categories (important, highly important and critically important 
antimicrobials [CIA]) using two criteria (Annex 1). CIA were recently further divided into high 
or highest priority antimicrobials based on 3 additional prioritisation criteria (Annex 1) (WHO, 
2017a). It is important to stand out that most antimicrobials approved for UTI treatment in 
veterinary medicine are considered CIAs of highest priority (third-generation cephalosporins 
and fluoroquinolones) and CIAs of high priority (aminoglycosides, aminopenicillins) (Table 3). 
Therefore, careful choice of the antimicrobial therapy in veterinary medicine is of the upmost 
importance. The choice of the appropriate antimicrobial should always be supported on culture 
and antimicrobial susceptibility data (Weese et al., 2011). However, empirical antimicrobial 
treatment is sometimes necessary to relieve patient discomfort and prevent systemic infection 
(Weese et al., 2011). Sørensen et al. (2018) showed that a high percentage of dogs with 
suspected UTI are unnecessarily treated empirically regardless of the diagnostic work up 
followed. Interistingly, the EAU (2017) accepts that human UTI diagnosis of uncomplicated 
cystitis may be reasonably based on urine dipstick testing alone together with a complete 
clinical evaluation. When needed, the empirical antimicrobial choice should rely on first-line 
antimicrobials and then adjusted based on antimicrobial susceptibility data if necessary 
(Weese et al., 2011). Updated epidemiological data (aetiology and resistance trends) is crucial 
in guiding empirical treatment since bacteria may have specific intrinsic3 (Table 4) and acquired 
resistance mechanisms. According to the Infectious Diseases Society of America guidelines 
for treatment of acute uncomplicated cystitis and pyelonephritis in women, an antimicrobial 
 
                                               
3 “Intrinsic (inherent) resistance, as opposed to acquired and/or mutational resistance, is a characteristic of all or almost all isolates 
of the bacterial species. The antimicrobial activity of the drug is clinically insufficient or antimicrobial resistance is innate, rendering 
it clinically useless.” (Leclercq et al., 2013). 
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Companion animals2 Humans3 
b-Lactams    
      Amoxicillin CIA - HP First-line option for UTI treatment. First-line 
option for empirical treatment of 
uncomplicated and complicated UTI. 
 
Not recommended for empiric treatment of uncomplicated 
cystitis or complicated UTI due to high resistance rates. May 
be used in selected cases. 
Recommended for complicated UTI treatment in combination 
with aminoglycosides. 
 
      Amoxicillin/clavulanate CIA - HP Unknown advantage over amoxicillin alone. If 
amoxicillin-resistance rates are high, it may 
be a good first-line option for the treatment 
and empirical treatment of uncomplicated 
and complicated UTI. 
 
Not recommended for empiric treatment of uncomplicated 
cystitis or complicated UTI due to high resistance rates. May 
be used in selected cases. 
 
      Second and third-generation 
cefalosporins 




Second-line option for UTI treatment. Oral cephalosporins are not recommended for empiric 
treatment of uncomplicated cystitis due to high resistance 
rates. May be used in selected cases. 
Third-generation cephalosporins are recommended for 
uncomplicated pyelonephritis treatment. Recommended for 
complicated UTI treatment in combination with 
aminoglycosides. 
      Carbapenems CIA - HP Last-resort antimicrobial. Off-lable use.4 
 
Last-resort antimicrobial. Suitable for uncomplicated 
pyelonephritis treatment. 
 
      Other b-lactams HP (pivmecillinam, 
cefadroxil) 
CIA - HP 
(piperacillin/tazobactam) 
CIA - HestP (cefepime) 
- Pivmecillinam: First-line option for uncomplicated cystitis. Not 
recommended for pyelonephritis treatment. 
Cefadroxil: Second-line option for uncomplicated cystitis. 









Companion animals2 Humans3 
Aminoglycosides CIA - HP Not recommended for routine use due to side 
effects. Although not included in Weese et al. 
(2011) guidelines, gentamicin is suitable for 
UTI treatment (Ling & Ruby, 1979). 
Suitable for uncomplicated pyelonephritis treatment. 
Recommended for complicated UTI in combination with 
amoxicillin or third-generation cephalosporins. 




Doxycycline HIA Not recommended for routine use. 
 
May be used for treatment of uncomplicated cystitis in patient 
with renal insufficiency. 
Fluoroquinolones CIA - HestP Second-line option for UTI treatment. 
Considered a good first-line option for empiric 
antimicrobial treatment of pyelonephritis. 
 
Not considered first-line option for the treatment of 
uncomplicated cystitis due to ecological effects and selection 
for resistance. 
Recommended for uncomplicated pyelonephritis treatment. 
May not be suitable for empiric treatment of complicated UTIs. 
 
Fosfomycin CIA - HP Not included Weese et al. (2011) guidelines. First-line option for empirical treatment of uncomplicated 
cystitis. Not recommended for pyelonephritis treatment. 
Nitrofurantoin IA Second-line antimicrobial. Off-lable use.4 
Reserved for uncomplicated UTIs caused by 
multidrug-resistant bacteria. 
 
First-line option for empirical treatment of uncomplicated 
cystitis. Not recommended for pyelonephritis treatment. 
Trimethoprim/sulfamethoxazole HIA First-line option for UTI treatment. First-line 
option for empirical treatment of 
uncomplicated and complicated UTI. 
 
Trimethoprim or trimethoprim/sulfamethoxazole is a second-
line option for uncomplicated cystitis. Can be considered a 
first-line option if local E. coli resistance rates are lower than 
20%. May be suitable for uncomplicated pyelonephritis 
treatment. Not recommended for empiric treatment of 
complicated UTI due to high resistance rates. 
Legend:1CIA, critically important antimicrobial; HIA, highly important antimicrobial; IA, important antimicrobial; HP, high priority; HestP, highest priority; 2Major data 
according to Weese et al. (2011); 3Data according to EAU (2017); 4Off-label use is defined in Directive 2001/82/EC as ‘the use of a veterinary medicinal product that 




Table 4 – Intrinsic resistances of common bacteria causing UTI (European Committee 
on Antimicrobial Susceptibility Testing, 2016) 
Bacteria Intrinsic resistance 
Enterobacteriaceae 
Benzylpenicillin, glycopeptides, fusidic acid, macrolides (with some 
exceptions), lincosamides, streptogramins, rifampicin, daptomycin 
and linezolid. 
Escherichia coli - 
Klebsiella pneumoniae Ampicillin and ticarcillin. 
Proteus mirabilis Nitrofurantoin, tetracycline, tigecycline, polymixin B and colistin. 
Non-fermentative Gram-negative 
Benzylpenicillin, first- and second-generation cephalosporins, 
glycopeptides, fusidic acid, macrolides, lincosamides, 
streptogramins, rifampicin, daptomycin and linezolid. 
Pseudomonas aeruginosa 
Ampicillin, amoxicillin/clavulanate, ampicillin/sulbactam, cefazolin, 
cefalothin, cefalexin, cefadroxil, cefotaxime, ceftriaxone, 
ertapenem, chloramphenicol, kanamycin, neomycin, trimethoprim, 
tetracycline and tygecicline. 
Gram-positive Aztreonam, temocillin, polymyxin B/colistin and nalidixic acid. 
Staphylococcus spp. 
Ceftazidime, fusidic acid (S. saprophyticus), fosfomycin  
(S. saprophyticus and S. capitis) and novobiocin (S. saprophyticus,  
S. cohnii and S. xylosus). 
Streptococcus spp. Ceftazidime, fusidic acid and low-level amynoglicosides. 
Enterococcus faecalis 
Cephalosporins, fusidic acid, low-level amynoglicosides, 
erythromycin, clindamycin, quinupristindalfopristin and 
sulfonamides. 
Enterococcus faecium Cephalosporins, fusidic acid, low-level amynoglicosides
1, 
erythromycin and sulfonamides. 
Legend: 1produces a chromosomal AAC(6’)-I enzyme leading to the loss of synergism between 
aminoglycosides (except gentamicin, amikacin and streptomycin) and penicillins or glycopeptides. 
 
should only be considered suitable for empirical treatment of uncomplicated UTIs or upper 
UTIs if antimicrobial resistance frequencies are lower than 20% or 10%, respectively (Gupta 
et al., 2011). 
It is interesting to notice that the recommended UTI treatment duration in companion animals 
is significantly longer than in humans (uncomplicated UTI: 3-5 days in humans, 7-14 days in 
companion animals; complicated UTI: 7-14 days in humans, 4 weeks in companion animals, 
4-6 weeks in companion animals with pyelonephritis) (Weese et al., 2011; Smelov et al., 2016). 
In fact, treatment duration recommendations in companion animals are supported by little 
scientific evidence (Weese et al., 2011). 
Few studies have reported short-duration antimicrobial treatment protocols for UTI in 
companion animals (Westropp et al., 2012; Clare et al., 2014). However, studies comparing 
the same antimicrobial regime with differing durations are lacking (Jessen, Sørensen, 





b-Lactams are among the most used antimicrobials in human and veterinary medicine 
(European Centre for Disease Prevention and Control [ECDC], 2016a; European Medicines 
Agency [EMA], 2017b), and are characterised by the presence of a b-lactam ring (Smet et al., 
2010). b-lactams are bactericidal agents that prevent bacterial cell-wall synthesis by binding 
to an active serine site from penicillin-binding proteins (PBPs) in Gram-negative and Gram-
positive bacteria (Smet et al., 2010; Bush & Bradford, 2016). 
The first b-lactam (penicillin) was discovered by Alexander Fleming in 1929 (Fleming, 1929). 
Since then, several other b-lactams were discovered that may be grouped into penicillins, 
cephalosporins, carbapenems and monobactams (Bush & Bradford, 2016). 
Penicillins include penicillin G and penicillin V, two natural occurring penicillins, initially and still 
used to treat streptococcal infections (Smet et al., 2010). The arising of resistant bacteria due 
to the production of b-lactamases prompted the discovery of new penicillins such as methicillin, 
oxacillin, cloxacillin, and nafcillin (used for staphylococcal infections) (Bush & Bradford, 2016). 
In the 1970s, ampicillin and amoxicillin with improved activity against Enterobacteriaceae were 
introduced (Bush & Bradford, 2016). This group also includes anti-pseudomonal penicilins (e.g. 
carbenicillin, piperacillin, ticarcillin), mecillinam and temocillin (Bush & Bradford, 2016). 
Amoxicillin is excreted in urine predominantly in the active form (Weese et al., 2011) and 
therefore is the recommended aminopenicillin for companion animal UTI treatment (Table 3). 
The first cephalosporins were discovered in the 1950s (Asbel & Levison, 2000; Fernandes, 
Amador & Prudêncio, 2013). The high number of cephalosporins discovered to date, are 
grouped into 5 generations according to their spectrum of activity (Fernandes et al., 2013). 
Cephalosporin activity varies from Gram-positive to Gram-negative or both (Asbel & Levison, 
2000; Fernandes et al., 2013). In veterinary medicine, the approved cephalosporins belong to 
the first to forth-generations (Smet et al., 2010). It is noteworthy that the third-generation 
cephalosporin available for UTI treatment in companion animal use (cefovecin) (Passmore et 
al., 2008) is a long action antimicrobial leading to higher impact on the selection of resistant 
bacteria. 
Carbapenems, such as imipenem and meropenem, are last resort antimicrobials (critically 
important antimicrobial of highest priority) with resistance to most b-lactamases and activity 
against Gram-positive and Gram-negative bacteria (Papp-Wallace, Endimiani, Taracila & 
Bonomo, 2011; Fernandes et al., 2013; Bush & Bradford, 2016). These are not approved for 
veterinary use. 
Finally, monobactams (aztreonam) have antimicrobial activity especially directed towards 
Gram-negative bacteria (Asbel & Levison, 2000), and are also not approved for veterinary use. 




b-Lactam-resistance can be caused by several mechanisms such as porin deficiency, 
overexpression of efflux pumps, modification of the PBPs and production of b-lactamases 
(Bush & Jacoby, 2010; Fernandes et al., 2013). 
PBP mutations are responsible for an important resistance mechanism in Staphylococcus 
species, namely methicillin-resistance (Fernandes et al., 2013). The methicillin-resistant 
staphylococcus aureus (MRSA) is a major pathogen to humans (Hiramatsu, Cui, Kuroda & Ito, 
2001). Methicillin-resistance is conferred by a mobile genetic element (staphylococcal 
chromosome cassette mec [SCCmec]) which contains the mecA gene that encodes a 
modified, but active, PBP (PBP2a) with lower affinity to penicillins, cephalosporins and 
carbapenems (Hiramatsu et al., 2001; Weese & van Duijkeren, 2010; Fernandes et al., 2013). 
More recently a mecC gene has been identified (García-Álvarez et al., 2011). Methicillin-
resistant Staphylococcus, including MRSA, have been reported in companion animals 
(Weese, 2010; Weese & van Duijkeren, 2010; Couto et al., 2016). 
The production of b-lactamases is the most common b-lactam-resistance mechanism in 
clinically relevant Gram-negative bacteria (Bush & Jacoby, 2010). Several b-lactamases are 
plasmid-mediated which leads to rapid worldwide resistance dissemination (Cantón & Coque, 
2006; Fernandes et al., 2013). 
b-Lactamase inhibitors were discovered in the attempt to overcome the b-lactamase activity of 
b-lactam-resistant bacteria (Bush & Bradford, 2016). Clavulanic acid acts synergistically with 
penicillins and cephalosporins allowing the b-lactam to kill bacteria producing clavulanic acid 
sensitive b-lactamases (Fernandes et al., 2013; Bush & Bradford, 2016). Other b-lactamase 
inhibitors include sulbactam and tazobactam (Bush & Bradford, 2016). In veterinary medicine 
the most used combination is amoxicillin/clavulanate. 
The first evidence of b-lactamase activity was described in a E. coli by Abraham and Chain 
(1940) in 1940. The first Gram-negative plasmid-mediated b-lactamase, TEM-1, was detected 
in a E. coli in the 1960s (Fernandes et al., 2013). Since then, more than 1300 distinct  
b-lactamases have been characterised (Bush, 2013). 
Through the years, several classification systems have been proposed aiming to systematise 
the big diversity of b-lactamase enzymes (Bush, 2013). Currently, the main classification 
system results from the fusion of the molecular classification initiated by Ambler (1980) and 
the Bush (1989) functional classification. This fusion was proposed by Bush, Jacoby and 
Medeiros (1995) and later updated by Bush and Jacoby (2010) (Table 5). Based on the 
molecular characterisation, b-lactamases may be divided in four main classes according to 
their amino acid sequence (A, B, C e D) (Bush, 2013). The functional classification is based 
on key b-lactam substrates and inhibitors which define 3 main b-lactamase groups and 
respective subgroups according to their hydrolytic and inhibitor profile (Bush, 2013) (Table 5). 
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Molecular class B (functional group 3a and 3b) b-lactamases are metallo-b-lactamases4 while 
the remaining enzymes are serino-b-lactamases5 (Bush, 2013; Bush & Jacoby, 2010). 
Third-generation cephalosporins and carbapenems are CIAs of highest priority to humans 
(WHO, 2017a). Therefore, b-lactamase production has an important clinical impact, especially 
in healthcare settings (Bush, 2013; Fernandes et al., 2013). In fact, the World Health 
Organization has recognised third-generation cephalosporin and carbapenem-resistant 
Enterobacteriaceae as a highest priority pathogen for research (World Health Organization 
[WHO], 2017b). Third-generation cephalosporin and carbapenem hydrolysing b-lactamases 
are frequently plasmid-mediated leading, as mentioned above, to their easy dissemination 
(Cantón & Coque, 2006; Bush & Jacoby, 2010). Furthermore, b-lactamase plasmid-mediated 
resistance is associated with multidrug resistance due to co-transfer of several resistance 
mechanisms in the same plasmid which creates big therapeutic challenges (Cantón & Coque, 
2006). 
The commonly named extended-spectrum beta-lactamases (ESBL) are enzymes belonging to 
the 2be group (Bush & Jacoby, 2010), that hydrolyse penicillins, first, second and third-
generation cefalosporins and aztreonam, and that are inhibited by clavulanic acid (Paterson & 
Bonomo, 2005). Although ESBLs are inhibited by clavulanic acid, due to limited reseach data, 
b-lactam/ b-lactam inhibitor combinations are not considered as suitable first line options for 
the treatment of serious infections caused by ESBL-producing bacteria (Paterson & Bonomo, 
2005). Nevertheless, successful treatment using amoxicillin/clavulanate in humans with UTI 
caused by fully amoxicillin/clavulanate-susceptible ESBL-producing E. coli has been reported 
(Lagacé-Wiens et al., 2006; Beytur, Yakupogullari, Oguz, Otlu & Kaysadu, 2015). 
ESBLs include clinically important b-lactamases from several enzyme families such as TEM, 
SHV and CTX-M (Bush & Jacoby, 2010). The first ESBLs were described in Europe in the 
1980s, and since then ESBLs have been reported worldwide (Paterson & Bonomo, 2005; 
Fernandes et al., 2013). The CTX-M family has become the most frequent ESBL in bacteria 
causing health-care and community associated infections and is now endemic worldwide 
(Cantón & Coque, 2006; Doi, Iovleva & Bonomo, 2017), which reveals their public health 
relevance (Fernandes et al., 2013). There is host and geographic variation of the CTX-M 
enzymes distribution; nevertheless, some enzymes, such as CTX-M-15, are worldwide 
disseminated (Cantón & Coque, 2006; Nicolas-Chanoine et al., 2008; Smet et al., 2010; Ewers, 
Bethe, Semmler, Guenther & Wieler, 2012; Bevan, Jones & Hawkey, 2017). CTX-M-15 seems 
to be more common in humans, but it is also frequently found in companion animals (Coque, 
Baquero & Canton, 2008; Ewers et al., 2012). CTX-M-1 is the most frequent CTX-M enzyme 
detected in bacteria from companion animals from Europe (Coque, Baquero & Canton, 2008; 
 
                                               
4 Metallo-b-lactamases are those containing a zinc active site(s) (Bush, 2013). 
5 Serine-b-lactamases are those containing a serine active site(s) (Bush, 2013). 
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enzymes CA/TZB EDTA 
1 C Cephalosporins No No Greater hydrolysis of cephalosporins than 
benzylpenicillin; hydrolyzes cephamycins. 
E. coli AmpC, P99, ACT-1, 
CMY-2, FOX-1, MIR-1  
1e C Cephalosporins No No Increased hydrolysis of ceftazidime and often other 
oxyimino-b-lactams. 
GC1, CMY-37 
2a A Penicillins Yes No Greater hydrolysis of benzylpenicillin than 
cephalosporins. 
PC1  
2b A Penicillins, early 
cephalosporins 
Yes No Similar hydrolysis of benzylpenicillin and 
cephalosporins. 
TEM-1, TEM-2, SHV-1  
2be A Extended-spectrum 
cephalosporins, monobactams 
Yes No Increased hydrolysis of oxyimino-b-lactams 
(cefotaxime, ceftazidime, ceftriaxone, cefepime and 
aztreonam). 
TEM-3, SHV-2, CTX-M-15, 
PER-1, VEB-1 
2br A Penicillins No No Resistance to clavulanic acid, sulbactam and 
tazobactam. 
TEM-30, SHV-10 
2ber A Extended-spectrum 
cephalosporins, monobactams 
No No Increased hydrolysis of oxyimino-b-lactams 
combined with resistance to clavulanic acid, 
sulbactam and tazobactam. 
TEM-50 
2c A Carbenicillin Yes No Increased hydrolysis of carbenicillin PSE-1, CARB-3 
2ce A Carbenicillin, cefepime Yes No Increased hydrolysis of carbenicillin, cefepime and 
cefpirome. 
RTG-4 
2d D Cloxacillin Variable No Increased hydrolysis of cloxacillin or oxacillin. OXA-1, OXA-10 
2de D Extended-spectrum 
cephalosporins 
Variable No Hydrolyzes cloxacillin or oxacillin and oxyimino-b-
lactams. 
OXA-11, OXA-15 
2df D Carbapenems Variable No Hydrolyzes cloxacillin or oxacillin and carbapenems. OXA-23, OXA-48 
2e A Extended-spectrum 
cephalosporins 
Yes No Hydrolyzes cephalosporins. Inhibited by clavulanic 
acid but not aztreonam. 
CepA 
2f A Carbapenems 
 
Variable No Increased hydrolysis of carbapenems, oxyimino-b-
lactams and cephamycins. 
KPC-2, IMI-1, SME-1 
3a B (B1) Carbapenems 
 
No Yes Broad-spectrum hydrolysis including carbapenems 
but not monobactams. 
IMP-1, VIM-1, CcrA, IND-1 
 B (B3)     L1, CAU-1, GOB-1, FEZ-1 
3b B (B2) Carbapenems No Yes Preferential hydrolysis of carbapenems. CphA, Sfh-1 
Legend: CA, clavulanic acid; TZB, tazobactam.
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Ewers et al., 2012). CTX-M enzymes can be found in Enterobacteriaceae, especially E. coli 
and Klebsiella spp. (Doi et al., 2017). It is noteworthy that there is a strong association between 
E. coli sequence type (ST) 1316 clonal lineage, especially the O25b:H4-B2-ST131 (Nicolas-
Chanoine et al., 2008), and the dissemination of CTX-M-15 (Coque et al., 2008; Doi et al., 
2017). This clone is also relevant because it exhibits a wide virulence gene profile (Nicolas-
Chanoine et al., 2008) and it is an important uropathogen (Vimont et al., 2012). Furthermore, 
O25b:H4-B2-ST131 CTX-M-15-producing E. coli has been reported in humans and more 
rarely in companion animals (Nicolas-Chanoine et al., 2008; Pomba, da Fonseca, Baptista & 
Correia, 2009; Ewers et al., 2010). 
Although still less common than ESBLs (Jacoby, 2012; Smet et al., 2010; Ewers et al., 2012), 
AmpC cephalosporinases (class C, groups 1 and 1e), are also clinically relevant and may be 
chromosomal or plasmid encoded (Bush et al., 1995; Jacoby, 2012). These also include 
several enzymes families (e.g. MOX, FOC, DHA, ACC, MIR, CMY) that are more hydrolytic 
than ESBL, are usually resistant to clavulanic acid and active on cephamicyns (Jacoby, 2012; 
Bush & Jacoby, 2010). The most common AmpC cephalosporinases in humans and 
companion animals is CMY-2 (Smet et al., 2010; Ewers et al., 2012). 
ESBL and AmpC b-lactamases may also confer resistance to carbapenem when associated 
with other resistance mechanisms such porin deficiency or overexpression of efflux pumps 
(Bradford et al., 1997; Quale, Bratu, Gupta & Landman, 2006; Wozniak et al., 2012). 
Carbapenemases belong to b-lactamase class B (group 3a and 3b), class A and class D (group 
2f and 2df, respectively), are able to hydrolyse almost all b-lactams including carbapenems 
and may not be inhibited by b-lactamase inhibitors (Queenan & Bush, 2007). These  
b-lactamases can be chromosomal or plasmid-mediated and belong to several clinically 
relevant enzyme families (Bush & Jacoby, 2010). Among carbapenemases, KPC, IMP, VIM, 
NDM and OXA are enzyme families of particular interest because of their dissemination 
potential since they are plasmid-mediated and can be found in several Gram-negative bacteria 
(Queenan & Bush, 2007). The detection of carbapenemases in companion animals is still rare, 
however, the number of reports of companion animals infection (including UTI) and 
colonisation by carbapenemase-producing Gram-negative bacteria is increasing (Shaheen, 
Nayak & Bootheb, 2013; Stolle et al., 2013; Pomba et al., 2014a; Schmiedel et al., 2014; 
Abraham et al., 2016; Ewers et al., 2016; González-Torralba et al., 2016; Hérivaux et al., 2016; 
Liu et al., 2016; Yousfi et al., 2016; Ewers et al., 2017; Melo et al., 2017; Yousfi et al., 2017; 
Chanchaithong et al., 2018; Cui et al., 2018; Daniels et al., 2018; Fernandes et al., 2018a; 
Grönthal et al., 2018; Hong et al., 2018; Köck et al., 2018; Pulss et al., 2018). 
 
                                               




Trimethoprim and sulfonamides are synthetic antimicrobials that when in combination have a 
synergistic effect with broader spectrum of activity and bactericidal action (Bushby & Hitchings, 
1968). These antimicrobials act at different steps of the bacteria tetrahydrofolic acid 
biosynthesis, which is essential for bacteria amino acid and nucleotide synthesis (Eliopoulos 
& Huovinen, 2001). 
Discovered in the 1930s, sulfonamides competitively inhibit the enzyme dihydropteroate 
synthase (DHPS) at an early step of the folate synthesis pathway (Figure 3) (Sköld, 2000). 
Trimethoprim competitively inhibits the enzyme dihydrofolate reductase (DHFR) at the final 
step of tetrahydrofolic acid synthesis and was first used in the 1960s (Huovinen, 1987). 
Although trimethoprim/sulfamethoxazole is considered useful for UTI treatment in humans 
since 1968 (Eliopoulos & Huovinen, 2001), its use has become limited in some countries due 
to current high trimethoprim/sulfamethoxazole-resistance rates (EAU, 2017). The 
trimethoprim/sulfamethoxazole combination is considered a good first choice for UTI treatment 
in companion animals (Table 3) (Weese et al., 2011). 
 




Acquired trimethoprim-resistance may be related to chromosomal mutations (e.g. promoter 
mutations or mutations in the DHFR gene) or by the acquisition of exogenous genes encoding 
a DHFR with an altered active site (Eliopoulos & Huovinen, 2001). A high number of 
transferable trimethoprim-resistant DHFRs genes located in gene cassettes have been 
described and are grouped in two families (dfrA and dfrB) (White & Rawlinson, 2001). 
Resistance to sulfonamides may also be caused by chromosomal mutations or plasmid borne 
mechanisms (Sköld, 2000). The main clinical acquired sulfonamide-resistance mechanism in 
Enterobacteriaceae, is the presence of DHPS with low sulfonamide affinity encoded in mobile 
elements (Wise & Abou-Donia, 1975; Sköld, 1976; Sköld, 2000). The first transferable 
sulfonamide-resistance genes, sul1 and sul2, were described in the 1980s while only in 2003 
sul3 was dicovered (Rådström & Swedberg, 1988; Sundström, Rådström, Swedberg & Sköld, 
1988; Perreten & Boerlin, 2003). More recently, sul4 was noticed by next generation 
sequencing (Razavi et al., 2017). The sul1 and sul2 genes are very common among 
Enterobacteriaceae resistant clinical isolates (Rådström, Swedberg & Sköld, 1991; Grape, 

















higher frequency of sul2 and dfrA1 (Kerrn, Klemmensen, Frimodt-Møller & Espersen, 2002; 
Grape et al., 2003; Blahna et al., 2006). The sul3 is less common (Grape et al., 2003; Blahna 
et al., 2006) and, due to its novelty, little is known about sul4. 
 
1.2.3 Fluoroquinolones 
Quinolone are synthetic antimicrobials with good oral bioavailability, a good safety profile and 
achieve good urinary concentrations (Andriole, 2005; Weese et al., 2011; Hooper & Jacoby, 
2015). Quinolones act by interacting with DNA gyrase and topoisomerase IV bacterial 
enzymes that are essential to regulate the topology of the bacterial chromosome and adequate 
DNA replication (Andriole, 2005; Hooper & Jacoby, 2015). Both enzymes are heterotetrameric 
proteins composed of two subunits, gyrA and gyrB in DNA gyrase and parC and parE in 
topoisomerase IV (Andriole, 2005; Hooper & Jacoby, 2015). By interacting with DNA gyrase 
and topoisomerase IV, quinolones inhibit DNA synthesis leading to bacterial death (Andriole, 
2005; Hooper & Jacoby, 2015). Quinolone affinity to both enzymes may vary depending on 
the quinolone and bacterial species (Hoshino et al., 1994; Blanche et al., 1996). In Gram-
negative bacteria, DNA gyrase is usually the main target (Hoshino et al., 1994). 
After b-lactams, quinolones are among the most sold antimicrobial in humans and companion 
animals (ECDC, 2016a; EMA, 2017b). Nalidixic acid was the first quinolone described in the 
1960s for UTI treatment (Lesher et al., 1962). Since then, several other quinolones were 
discovered including for veterinary use. Quinolones can be classified into first to forth-
generation based on their spectrum of activity. Nevertheless, there are slight variations in its 
classification system according to the author (King, Malone & Lilley, 2000; Andriole, 2005). In 
veterinary medicine, there are quinolones available from the first, second (e.g. marbofloxacin, 
enrofloxacin) and third-generation (e.g. pradofloxacin), some of which are recommended for 
UTI treatment (Cotard et al., 1995; Weese et al., 2011). Although not referred in Weese et al. 
(2011) UTI guidelines, pradofloxacin has been shown to be useful for the treatment of UTIs in 
cats (Litster et., 2007a). Fluoroquinolones are CIAs of highest importance for humans (WHO, 
2017a) and have been shown to increase the risk for selection of resistant bacteria such as 
MRSA (Venezia, Domaracki, Evans, Preston & Graffunder, 2001; Weber, Gold, Hooper, 
Karchmer & Carmeli, 2003). Although fluoroquinolones should be regarded as second line 
treatment option in companion animals with UTI (Weese et al., 2011), a short duration protocol 
(3 days) using high dose of enrofloxacin in dogs with uncomplicated UTI has been shown to 
be successful (Westropp et al., 2012). Ciprofloxacin concentrations atchieved in urine with 
such high dose enrofloxacin protocol were considered protective against E. coli mutant 
selection in urine (Daniels, Tracy, Irom & Lakritz, 2014). Nevertheless, the impact on the 
commensal bacteria resistome in comparison with current first line treatment options still needs 
to be studied (Daniels et al., 2014). 
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In Gram-negative bacteria, resistance to quinolones may result from different resistance 
mechanisms such as topoisomerase target mutations, cell wall permeability changes, 
topoisomerase target protection by specific proteins and drug inactivation (Hooper & Jacoby, 
2015). 
Low quinolone affinity due to topoisomerase target mutations in the quinolone resistance-
determining regions (QRDRs) is the main quinolone acquired resistance mechanism (Willmott 
& Maxwell, 1993; Barnard & Maxwell, 2001; Rodríguez-Martínez, Cano, Velasco, Martínez-
Martínez & Pascual, 2011). Single topoisomerase mutations may not confer clinically 
significant resistance in Enterobacteriaceae. The accumulation of multiple mutations is 
involved in quinolone-resistance evolution and increases the resistance level (Deguchi et al., 
1997; Komp Lindgren, Karlsson & Hughes, 2003). In fact, DNA gyrase and topoisomerase IV 
are prone to acquire an increasing number of mutations when exposed to quinolones (Jacoby, 
2005). In Gram-negative bacteria, the first step mutation usually occurs in the gyrA and less 
frequently in gyrB gene (Nakamura, Nakamura, Kojima & Yoshida, 1989; Khodursky, 
Zechiedrich & Cozzarelli, 1995; Deguchi et al., 1997; Hooper & Jacoby, 2015). In these 
bacteria, ParC and ParE are usually the target of second-step mutations (Khodursky, 
Zechiedrich & Cozzarelli, 1995; Breines et al., 1997; Deguchi et al., 1997). QRDR mutations 
can lead to 10- to 100-fold increases in resistance (Yoshida, Kojima, Yamagishi & Nakamura, 
1988; Khodursky et al., 1995). 
Since the DNA gyrase and topoisomerase IV are located in the bacteria cytoplasm, changes 
in the cell permeability may lead to quinolone-resistance (Hirai, Aoyama, Irikura, Iyobe & 
Mitsuhashi, 1986; Hooper & Jacoby, 2015). Plasmid encoded active efflux pumps responsible 
for quinolone-resistance in Gram-negative bacteria have been reported, such as QepA and 
OqxAB (Hansen, Johannesen, Burmølle, Sørensen & Sørensen, 2004; Yamane et al., 2007). 
These increase the resistance to hydrophilic fluoroquinolones like norfloxacin, ciprofloxacin, 
and enrofloxacin, and to other antimicrobial classes (Hansen et al., 2004; Hansen, Jensen, 
Sørensen & Sørensen, 2007; Yamane et al., 2007). In K. pneumonia, OqxAB efflux pump may 
be plasmid or chromosome encoded (Kim et al., 2009c; Rodríguez-Martínez et al., 2013). 
Plasmid-encoded Qnr proteins (small pentapeptide-repeat proteins) bind to the topoisomerase 
targets, protecting them from quinolones, therefore leading to increased resistance (Tran & 
Jacoby, 2002). The first plasmid-mediated Qnr determinant, QnrA, was described in 1998 in a 
K. pneumoniae (Martínez-Martínez, Pascual & Jacoby, 1998). Several additional plasmid-
encoded qnr alleles (qnrB, qnrC, qnrD, qnrS and qnrVC) and multiple variants have been 
described since then in Gram-negative bacteria (Jacoby et al., 2008; Rodríguez-Martínez et 
al., 2011; Fonseca & Vicente, 2013). These proteins are disseminated worldwide in Gram-
negative bacteria, however, Qnr determinants seem to still be rare except in some groups such 
as ESBL-producers (Hooper & Jacoby, 2015). QnrB seems to the most common (Kim et al., 
2009a; Jacoby, Strahilevitz & Hooper, 2014). 
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Quinolone-resistance may also be caused by quinolone modification by a plasmid-encoded 
mutated aminoglycoside acetyltransferase (AAC(6’)-Ib-cr) that evolved to acetylate quinolones 
such as ciprofloxacin (Robicsek et al., 2006a). This enzyme is generally plasmid encoded but 
has already been found encoded in the chromosome of Enterobacteriaceae (Ruiz et al., 2012). 
This resistance mechanism is worldwide disseminated in Enterobacteriaceae such as E. coli 
and K. pneumoniae and is likely the most common plasmid-mediated quinolone resistance 
(PMQR) determinant (Park, Robicsek, Jacoby, Sahm & Hooper, 2006; Robicsek et al., 2006a; 
Pitout, Wei, Church & Gregson, 2008; Kim et al., 2009b; Musumeci et al., 2012; Ruiz et al., 
2012). 
PMQRs are responsible for low-level quinolone resistance (Robicsek et al., 2006a; Rodríguez-
Martínez et al., 2011). However, by reducing quinolone-susceptibility even at low level, PMQR 
determinants favour the selection of QRDR mutants evolving towards higher and clinically 
relevant resistance levels (Rodríguez-Martínez et al., 2011; Jacoby, 2005; Hooper & Jacoby, 
2015). These resistance determinants may be encoded in plasmids harbouring ESBL and 
other resistance genes, thus, the use of quinolones may contribute to the co-selection of 
ESBLs and other resistance determinants and vice versa (Rodríguez-Martínez et al., 2011; 
Ruiz et al., 2011; Liu et al., 2013; Jacoby, Strahilevitz & Hooper, 2014). PMQRs are detected 
worldwide and have been found in Enterobacteriaceae isolated from humans and companion 
animals (Jacoby, Strahilevitz & Hooper, 2014). 
 
1.2.4 Aminoglycosides 
Aminoglycosides are broad spectrum bactericidal antimicrobials (except spectinomycin and 
kasugamycin) that interfere with protein synthesis by binding to the bacterial ribosome (16S 
rRNA of the 30S ribosomals subunit) (Ramirez & Tolmasky, 2010). Since the first clinical use 
of aminoglycosides (streptomycin) in the 1940s, several synthetic derivates have been 
developed with different spectrums of activity (Ramirez & Tolmasky, 2010; European 
Medicines Agency [EMA], 2017a). Aminoglycosides can be divided in 4 groups based on their 
structure (EMA, 2017a). Aminoglycosides, especially gentamicin, tobramycin and amikacin, 
are clinically relevant for the treatment of multidrug-resistant (MDR) Gram-negative bacteria 
infection and in critical care of humans (EMA, 2017a). Furthermore, aminoglycosides are CIAs 
of high priority to humans (WHO, 2017a). Aminoglycosides are mainly excreted by glomerular 
filtration in the active form (Ramirez & Tolmasky, 2010) but are not usually considered as a 
first line treatment option for UTI due to its nephrotoxicity side effects (Weese et al., 2011). In 
Weese et al. (2011) companion animal antimicrobial guideline, amikacin is recommended for 
the treatment of UTI by MDR bacteria if renal insufficiency is absent. It is noteworthy that 




The most common aminoglycoside resistance mechanism is the production of 
aminoglycoside-modifying enzymes (AMEs). Nevertheless, ribosomal target modification and 
changes in cell wall aminoglycoside uptake can also be involved (Garneau-Tsodikova & Labby, 
2016; EMA, 2017a). 
AMEs can be grouped into 3 major sub-classes according to the type of chemical modification 
they produce in the target aminoglycoside, namely O-phosphotransferases (APH),  
N-acetyltransferases (AAC) and O-nucleotidyltransferases (ANT) (Ramirez & Tolmasky, 
2010). Each AME sub-class includes several enzymes with different spectrums of activity. 
Among the high number of AMEs described so far, the AAC(6’)-Ib, is the most prevalent and 
clinically relevant AME in Gram-negative bacteria (Ramirez & Tolmasky, 2010; Ramirez, 
Nikolaidis & Tolmasky, 2013; Garneau-Tsodikova & Labby, 2016). Several AAC(6’)-Ib enzyme 
variations have been described including the widely disseminated ciprofloxacin modifying 
variant AAC(6’)-Ib-cr (Ramirez et al., 2013). Some AMEs may act on aminoglycosides by two 
different reactions (Ramirez & Tolmasky, 2010). The bifunctional enzyme (AAC(6′)-Ie-
APH(2′′)-Ia), is of clinical importance in Enterococcus spp. because it confers high-level 
resistance to most aminoglycosides precluding the synergistic action with b-lactams (Chow, 
2000). AMEs are often encoded in mobile elements such as plasmids and may be associated 
with additional resistance genes towards other antimicrobials (Garneau-Tsodikova & Labby, 
2016). 
Aminoglycosides target the A-site of bacterial ribosome, so the modification of the 
aminoglycoside ribosomal binding site may lead to aminoglycoside-resistance (Garneau-
Tsodikova & Labby, 2016). Modification of the ribosomal binding site can be caused by 
ribosomal protein mutation; however, these mutations are rare (Garneau-Tsodikova & Labby, 
2016). The ribosomal binding site may also be modified enzymatically by 16S ribosomal RNA 
methyltransferases (16S rRNA methylases) (Wachino & Arakawa, 2012). The 16S rRNA 
methylases can be classified into two families according to the nucleotide position where 
methylation occur (Garneau-Tsodikova & Labby, 2016). The 16S rRNA methylases may have 
a broader substrate than AMEs. Since these enzymes can be plasmid-mediated in Gram-
negative bacteria, its dissemination is a concern (Wachino & Arakawa, 2012). These enzymes 
have been reported worldwide in Enterobacteriaceae, with RtmB and ArmA as the most 
common. Although 16S rRNA methylases frequency is still low, reports are becoming more 
common including in companion animals (Deng et al., 2011; Wachino & Arakawa, 2012; 
Hidalgo et al., 2013; Xia et al., 2017). 
To reach the cytoplasm of Gram-negative bacteria aminoglycosides first need to transverse 
the cell wall. Low aminoglycoside uptake leading to resistance may result from porin changes, 






Tetracyclines are bacteriostatic broad-spectrum antimicrobials that bind to the 30S ribosomal 
subunit (A-site) and inhibit bacterial protein synthesis (Chopra & Roberts, 2001). Among 
tetracyclines, doxycicline may be used for the treatment of UTIs in humans and companion 
animals (Weese et al., 2011; Wilso et al., 2006; EAU, 2017). However, is not considered a first 
line option (Weese et al., 2011). 
With the widespread use of tetracyclines after their discovery in the 1940s, resistance started 
to increase (Chopra & Roberts, 2001). In Gram-negative bacteria, clinical tetracycline-
resistance may result from active efflux systems or from ribosomal target protection. 
Active efflux of tetracycline from the bacterial cell is mediated by membrane-bound efflux 
proteins encoded by several tet gene groups. Efflux proteins of group 1, including tet(A) and 
tet(B), are widely distributed in Gram-negative bacteria (Chopra & Roberts, 2001; Roberts, 
2017). Most of these efflux systems are responsible for resistance to tetracycline but not to 
minocycline or tigecycline (Chopra & Roberts, 2001), except tet(B) that is also responsible for 
minocycline-resistance. These are frequently encoded in conjugative plasmids harbouring 
resistance genes to several other antimicrobials (Chopra & Roberts, 2001). 
Tetracyclines can also be inhibited by the production of cytoplasmic proteins that protect the 
ribosome. Most ribosomal protection proteins are encoded by tet genes and are responsible 
for resistance to tetracyclines, doxycicline and minocycline (Chopra & Roberts, 2001). 
 
1.2.6 Nitrofurantoin 
Nitrofurantoin is a synthetic, bactericidal, broad-spectrum activity antimicrobial that it is 
effective against most Gram-positive and Gram-negative bacteria (Huttner et al., 2015). 
Nitrofurantoin is an old antimicrobial, discovered in the 1940s, that resurged due to the 
increase in antimicrobial resistance to other antimicrobial classes and the emergence of 
important resistance mechanisms such as ESBLs (Huttner et al., 2015). Currently, 
nitrofurantoin is considered one of the first option antimicrobials for the treatment of 
uncomplicated UTIs in humans (EAU, 2017). Despite only concentrating well in the lower 
urinary tract, nitrofurantoin showed equivalent efficacy to newer antimicrobials when 
prescribed for 5-7 days (Huttner et al., 2015). Furthermore, nitrofurantoin has the advantage 
of not being prone to become resistant nor to select resistance to other antimicrobials such as, 
for example, fluoroquinolones (Gupta, Hooton & Stamm, 2005; Sandegren, Lindqvist, 
Kahlmeter & Andersson, 2008; Huttner et al., 2015). Resistance to nitrofurantoin seems to be 
associated with chromosomal mutations, nevertheless, the OqxAB plasmid-mediated efflux 
pump may contribute to nitrofurantoin-resistance in E. coli (Ho et al., 2016). 
Nitrofurantoin is not approved for veterinary use; however, its off-lable use is recommended 
by Weese et al. (2011) guidelines as a second line option for the treatment of MDR 
uncomplicated UTIs in companion animals. There is a lack of studies reporting the 
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concentration of nitrofurantoin achieved in urine in companion animals, nevertheless the 
successful use of nitrofurantoin in the treatment of a cat with UTI has been reported (Pomba, 
Couto & Moodley, 2010). 
 
1.2.7 Fosfomycin 
Fosfomycin is a bactericidal broad-spectrum antimicrobial discovered in the 1960s that inhibits 
cell wall and early murein/peptidoglycan synthesis (Kahan, Kahan, Cassidy & Kropp, 1974; 
Pérez, Tapia & Soraci, 2014). Fosfomycin may have synergistic effect with other antimicrobials 
including in infections by E. coli and K. pneumoniae (Pérez el al., 2014). In humans, fosfomycin 
is excreted mainly in urine in the active form and is considered a first line option for the 
treatment of uncomplicated cystitis (Pérez el al., 2014; EAU, 2017). This antimicrobial is not 
included in Weese et al. (2011) guidelines for companion animals with UTI. In cats, but not in 
dogs, the use of fosfomycin seems to induce renal changes leading to kidney insufficiency 
(Fukata, Imai & Shibata, 2008). So far, only few studies have been conducted regarding the 
use of fosfomycin in dogs, none of which was focussed on UTI (Gutierrez, Ocampo, Aguilera, 
Luna & Sumano, 2008; Fukata et al., 2008). 
Several fosfomycin-resistance mechanisms have been described involving decreased 
antimicrobial uptake, modification of the target site and antimicrobial inactivation 
(Karageorgopoulos, Wang, Yu & Falagas, 2012). Several of these resistance mechanisms 
result from chromosomal mutations, nonetheless some inactivation enzymes may be plasmid-
mediated, such as fosA and fosB (Karageorgopoulos et al., 2012). In vitro fosfomycin 
mutational rate is high, however the same does not seem to be true in vivo (Karageorgopoulos 
et al., 2012). In agreement, fosfomycin-resistance rates seem to be relatively stable, even in 
countries in which fosfomycin is systemically prescribed (Karageorgopoulos et al., 2012). 
Plasmid-mediated fosfomycin-resistance mechanisms have been detected in human and 
companion animal Enterobacteriaceae (Mendes et al., 2016; Yao et al., 2016). 
 
1.2.8 Choramphenicol and florfenicol 
Chloramphenicol and florfenicol are bacteriostatic, broad-spectrum antimicrobials that inhibit 
protein synthesis by binding to the 50S ribosomal subunit (Schwarz, Kehrenberg, Doublet & 
Cloeckaert, 2004). Chloramphenicol is used in human and veterinary medicine while florfenicol 
is licensed only for veterinary use in farm animals (Schwarz et al., 2004). Due to the occurrence 
of side effects such as aplastic anaemia in humans, chloramphenicol is reserved for MDR life-
threatening infections (Schwarz et al., 2004). Chloramphenicol is reserved in Weese et al. 
(2011) guidelines for the treatment of UTI caused by MDR bacteria in companion animals. 
However, care must be taken with adverse side effects (Weese et al., 2011). 
The most common resistance mechanism to chloramphenicol is caused by antimicrobial 
inactivation by chloramphenicol acetyltransferase (CAT) enzymes. Florfenicol is not 
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inactivated by CAT enzymes (Schwarz et al., 2004). Resistance may also be caused by other 
mechanisms such as efflux systems and target mutations. Combined resistance to 
chloramphenicol and florfenicol can be caused by plasmid-mediated efflux systems such as 
floR. This latter has been mostly described in Enterobacteriaceae from farm animals, but 
reports from companion animals and humans have also been done (Schwarz et al., 2004; 
Derakhshandeh et al., 2018) 
 
1.3 Antimicrobial resistance surveillance in uropathogenic bacteria from 
companion animals 
Updated antimicrobial resistance data is crucial to guide empirical antimicrobial treatment and 
to evaluate antimicrobial resistance trends. The use of antimicrobials contributes to increasing 
resistance trends, therefore data on antimicrobial usage is also of great importance 
(Guardabassi et al., 2004; Prescott, 2017). Only recently, since 2010, the European Medicine 
Agency started reporting data on antimicrobial sales for companion animals (EMA, 2017b). 
Data revealed that b-lactams, including potentiated penicillins, are the most frequently sold for 
companion animals in most European countries (EMA, 2017b). Nevertheless, there are 
profound antimicrobial sales differences between countries (Figure 4). 
 
Figure 4 – Antimicrobial sales in companion animals (adapted from EMA, 2017b) 
a)                    b)      
          
Legend: a) distribution of sales of antimicrobial tablets, in tonnes of active ingredient, by antimicrobial 
class, by country, for 2015; b) distribution of sales (by weight of active ingredient) of tablets containing 
penicillins by subclass, by country, in 2015. 
 
In human medicine, the European Antimicrobial Resistance Surveillance Network (EARS-Net) 
actively gathers and reports annual data on antimicrobial resistance of invasive bacteria from 
several countries in Europe (European Centre for Disease Prevention and Control [ECDC], 
2017). EARS-Net reports have shown striking geographical variations in antimicrobial 
resistance frequencies as well as increasing resistance temporal trends to CIAs (ECDC, 2017) 
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(Figure 5). Studies focussed on UTI in humans also show geographical differences in 
antimicrobial resistance frequencies (Kahlmeter & ECO.SENS, 2003). 
There have been some national antimicrobial resistance surveillance networks in place for 
companion animals in Germany, Sweden and France (Swedres-Svarm, 2016; Moyaert et al., 
2017). In 2008, the European Animal Health Study Centre started an initiative (Compath) 
gathering bacterial isolates from companion animals in Europe and just recently published data 
regarding UTI isolates from 2008-2010 (de Jong et al., 2013; Moyaert et al., 2017). Results 
from Moyaert et al. (2017) revealed overall high susceptibility to all tested antimicrobials (e.g. 
>90% for most antimicrobials in E. coli). Since results are presented for all countries as a group 
and no temporal trends were analysed, it is not possible to perceive any geographical or 
temporal antimicrobial resistance variations in the 10 included European countries. 
Comparison of published data is frequently difficult because studies report antimicrobial 
resistance frequencies using different inclusion criteria (e.g. diabetic animals, recurrent UTI, 
etc.) (Bailiff et al., 2006), different time periods, grouping results of different sites of infection 
(Normand, Gibson, Reid, Carmichael & Taylor, 2000a; Normand, Gibson, Taylor, Carmichael 
& Reid, 2000b; Authier, Paquette, Labrecque & Messier, 2006; Pedersen et al., 2007; Harada, 
Niina, Nakai, Kataoka & Takahashi, 2012a; Beever et al., 2015), combining different bacteria 
genera (Ball, Rubin, Chirino-Trejo & Dowling, 2008; Hall, Holmes & Baines, 2013; Dorsch et 
al., 2015; Wong, Epstein & Westropp, 2015; Rampacci et al., 2018; Teichmann-Knorrn et al., 
2018) and data from several countries (Meunier, Acar, Martel, Kroemer & Valle, 2004; Kroemer 
et al., 2014; Moyaert et al., 2017). 
 
Figure 5 – E. coli antimicrobial resistance of invasive isolates from humans, by 
country (adapted from ECDC, 2017) 
       
Legend: Left image, third-generation cephalosporins; Right image, fluoroquinolones. 
 
Therefore, the analysis of the geographical and temporal distribution of antimicrobial 
resistance in companion animals with UTI is limited. Furthermore, little is known about Portugal 
since only early studies report data from companion animals with UTI (Féria, Correia, 
Machado, Vidal & Gonçalves, 2000; Féria, Ferreira, Correia, Gonçalves & Caniça, 2002). 
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Kroemer et al. (2014) European study has found lower antimicrobial susceptibility rates among 
E. coli and P. mirabilis from companion animals with UTI isolated in 2002-2009 than Moyaert 
et al. (2017). Notably, P. mirabilis showed high trimethoprim/sulfamethoxazol-resistance 
(~53%) (Kroemer et al., 2014). Overall high antimicrobial susceptibility frequencies were also 
detected in Sweden (2009, 2014) (Swedres-Svarm, 2016; Windahl, Holst, Nyman, Grönlund 
& Bengtsson, 2014), Norway (2003-2009) (Lund, Skogtun, Sørum & Eggertsdóttir, 2014) and 
Switzerland (E. coli, 1999-2001) (Lanz, Kuhnert & Boerlin, 2003). Nevertheless, most studies 
show varying antimicrobial resistance frequencies. Higher levels of resistance to some 
antimicrobials in bacteria from companion animals with UTI have been reported in Portugal 
(e.g. E. coli 25% to cephalotin, 19% to amoxicillin/clavulanate) (Féria et al., 2002), Brazil (e.g. 
staphylococci 28-74% to all tested antimicrobials, 2006-2007; E. coli 40% to aminoglycosides, 
40% to sulfonamides, 16% to fluoroquinolones) (Penna et al., 2010; Osugui, de Castro, Iovine, 
Irino & Carvalho, 2014), Cornell USA (e.g. E. coli ~35% to ampicillin, ~70% to cephalotin, 
~20% to enrofloxacin, ~40% to gentamicin) (Cummings, Aprea & Altier, 2015); Taiwan (E. coli 
50% amoxicillin, 39% trimethoprim/sulfamethoxazole, 2010-2011) (Chang, Lo, Wei & Kuo, 
2015), Australia (e.g. E. coli 29% to amoxicillin/clavulanate, 5-9% to ceftriaxone, 2013) 
(Saputra et al., 2017), Switzerland (E. coli, 10-35% to third-generation cephalosporin [ESBL-
producers], 2012-2016) (Zogg, Zurfluh, Schmitt, Nüesch-Inderbinen & Stephan, 2018b), 
Belgium (e.g. E. coli 12% to amoxicillin/clavulanate, 17% to enrofloxacin, 2010-2012) (Criel, 
Steenbergen & Stalpaert, 2015), Virginia USA (E. coli, 18% to amoxicillin/clavulanate, 15% to 
trimethoprim/sulfamethoxazole,1986-1996) (Forrester et al., 1999) and Italy (2013-3015) 
(Rampacci et al., 2018). Furthermore, changing antimicrobial resistance trends in bacteria 
isolated from companion animals have been reported (Normand et al., 2000a; Authier et al., 
2006; Thompson et al., 2011; Beever et al., 2015; Couto et al., 2016), including in 
uropathogenic bacteria from California (fluoroquinolones, 1992-2001) (Cohn et al., 2003; 
Cooke, Singer, Jang & Hirsh, 2002), Canada (fluoroquinolones, 1984-1998; several 
antimicrobials, 2002-2007) (Prescott et al., 2002; Ball et al., 2008), United Kingdom 
(enrofloxacin, cephalexin and oxytetracicline, 1999-2009) (Hall et al., 2013) and New Zealand 
(amoxicillin/clavulanate, cephalotin, enrofloxacin, 2005-2012) (McMeekin, Hill, Gibson, 
Bridges & Benschop, 2016). 
Care must be taken when comparing different studies since differences in the inclusion criteria 
may affect antimicrobial resistance frequencies. For instance, studies from referral hospitals 
or recurrent UTIs (patients that have likely undergone prior antimicrobial treatments) may have 
a bias towards resistance when compared to studies focussed on first opinion patients (Wong 
et al., 2015). Another important limiting factor in comparing studies is the use of different 
susceptibility testing interpretation criteria over time, since clinical breakpoints are regularly 
updated (Hombach, Bloemberg & Böttger, 2012). Currently, the most frequently used clinical 
breakpoints are the ones proposed by the Clinical and Laboratory Standards Institute (CLSI) 
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and by the European Committee on Antimicrobial Susceptibility Testing (EUCAST). Only CLSI 
has published a limited number of specific breakpoints for animals (Toutain et al., 2017). 
Nevertheless, since 2015 the EUCAST created a subcommittee, VetCAST, that will also 
propose specific clinical breakpoints for animals in the future (Toutain et al., 2017). 
The detection of MDR bacteria in companion animals creates important therapeutic limitations 
and raises public health concerns. MDR bacteria have been widely detected in companion 
animals with UTI and may be associated with clinically relevant and mobile resistance 
mechanisms such as ESBLs and carbapenemases in Enterobacteriaceae and the mecA gene 
in staphylococci (Prescott et al., 2002; Harada et al., 2012a; Pomba et al., 2014a; Osugui et 
al., 2014; Wagner, Gally & Argyle, 2014; Windahl et al., 2014; Chang et al., 2015; Thungrat, 
Price, Carpenter & Boothe, 2015; Wong et al., 2015; Couto et al., 2016; Zogg et al., 2018b). 
The definition of MDR bacteria varies significantly among studies, which impares 
straightforward comparisons. This issue also occurs in studies of bacteria from humans and 
prompted Magiorakos et al. (2012) through a joint initiative by the European Centre for Disease 
Prevention and Control and the Centres for Disease Control and Prevention to propose a 
standartised definition of MDR, extensively drug-resistant (XDR) and pandrug-resistant (PDR) 
bacteria. These concepts were recently adapted for companion animal isolates aiming to also 
harmonise future antimicrobial resistance surveillance reports in veterinary medicine 
(Sweeney, Lubbers, Schwarz & Watts, 2018). 
 
1.4 Klebsiella pneumoniae 
Klebsiella species are ubiquitous, non-motile, encapsulated Gram-negative 
Enterobacteriaceae that can be found in nature (e.g. plants and soil) and colonising healthy 
animals and humans (Podschun & Ullmann, 1998; Brisse et al., 2006). Klebsiella species can 
cause several types of infections in humans and companion animals and K. pneumoniae is 
the most frequently identified species (Podschun & Ullmann, 1998; Brisse et al., 2006; Ewers 
et al., 2014b, Paczosa & Mecsas, 2016). 
K. pneumoniae was first described in 1882 by Carl Friedlander from a patient with pneumonia 
(Friedlaender, 1882). K. pneumoniae is an important worldwide ESKAPE7 nosocomial 
pathogen, which is responsible for ~8-9% of nosocomial infections in the United States of 
America and Europe (Rice, 2008; ECDC, 2013; Magill et al., 2014). The frequent  
K. pneumoniae MDR profile and association with ESBLs and carbapenemase b-lactamases 
(Brisse et al., 2006; ECDC, 2017; Navon-Venezia, Kondratyeva & Carattoli, 2017), leads to 
big therapeutic limitations. The urinary tract is among the most common sites of nosocomial 
infection by K. pneumoniae in humans (Podschun & Ullmann, 1998). Also,  
K. pneumoniae is the second most common pathogen in women with uncomplicated UTI 
                                               
7 ESKAPE is an acronym encompassing the names of six bacterial pathogens: Enterococcus faecium, Staphylococcus aureus, 
Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter spp.. 
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(Gupta et al., 1999). Importatly, K. pneumoniae are prone to nosocomial dissemination which 
increases their public health relevance (Brisse et al., 2006). 
K. pneumoniae is frequently referred to as an opportunistic agent since usually affects 
hospitalised or immunocompromised patients (Podschun & Ullmann, 1998). More recently, 
new hypervirulent K. pneumoniae strains able to cause severe infections in otherwise healthy 
patients are being increasingly reported (Shon, Bajwa & Russo, 2013; Paczosa & Mecsas, 
2016). 
 
1.4.1 Population structure 
Since its discovery, several Klebsiella species have been described and its taxonomy has been 
continuously revised due to novel scientific findings (Podschun & Ullmann, 1998; Brisse, 
Grimont & Grimont, 2006; Brisse, Passet & Grimont, 2014). According to the Ørskov 
classification, adopted in America and most European countries, K. pneumoniae includes 
three subspecies, namely Klebsiella pneumoniae subspecies pneumoniae, Klebsiella 
pneumoniae subspecies ozaenae and Klebsiella pneumoniae subspecies rhinoscleromatis 
(Ørskov 19848 cited by Podschun & Ullmann, 1998). 
Based on several phylogenetic molecular markers, K. pneumoniae subspecies were shown to 
be closely related in agreement with Ørskov classification (Brisse & Verhoef, 2001; Drancourt, 
Bollet, Carta & Rousselier, 2001; Brisse et al., 2014). Although it is still unknown, sequencing 
data suggests that Klebsiella granulomatis is also a K. pneumoniae subspecies (Drancourt et 
al., 2001; Brisse et al., 2006). 
In Brisse and Verhoef (2001) study, strains classically identified as K. pneumoniae appeared 
to be composed of three major clusters (KpI, KpII and KpIII). These clusters did not correspond 
to the known taxonomic K. pneumoniae subspecies since these latter all belonged to KpI 
(Brisse & Verhoef, 2001). Latter studies have clarified that KpI indeed includes the three  
K. pneumoniae subspecies while KpII and KpIII are distinct Klebsiella species (Brisse et al., 
2014). Cluster KpII was shown to contain a novel Klebsiella species, Klebsiella 
quasipneumoniae, that includes clusters KpII-A and KpII-B, corresponding to two subspecies 
(K. quasipneumoniae subspecies quasipneumoniae and K. quasipneumoniae subspecies 
similipneumoniae, respectively) (Brisse et al., 2014). KpIII corresponded to Klebsiella variicola 
(syn. Klebsiella singaporensis) first described in 2004 (Rosenblueth, Martínez, Silva & 
Martínez-Romero, 2004; Brisse et al., 2014). Due to its recent discovery, not much is yet known 
about KpII or KpIII epidemiology and previous studies may have misidentified them with  
K. pneumoniae (KpI). Using strains from several European hospitals, Brisse, van Himbergen, 
Kusters and Verhoef (2004b) showed that cluster KpI (corresponding to K. pneumoniae) is 
responsible for 80% of hospital infections, followed by cluster KpIII and KpII. Nevertheless, 
                                               
8 Ørskov, I. (1984). Genus Klebsiella. In: Krieg N.R. & Holt J.G. (ed.) Bergey’s manual of systematic bacteriology. Baltimore: The 
Williams & Wilkins Co.. 
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KpI, KpII and KpIII may all be associated with UTIs in humans (Long et al., 2017). In animal 
infections, KpI is also the most common cluster, followed by KpIII and KpII (Brisse & Duijkeren, 
2005). KpI, KpII and KpIII have been detected in infected dogs and only KpI has been reported 
in infected cats (Brisse & Duijkeren, 2005; Brisse et al., 2014; Harada et al., 2016). 
Furthermore, KpI strains have been isolated from companion animals with UTI (Brisse & 
Duijkeren, 2005; Harada et al., 2016). 
The analysis of the K. pneumoniae population structure is essential to assist in epidemiological 
investigations and to recognise clonal groups and their links to pathophysiological specificities 
(Brisse et al., 2013). Early K. pneumoniae typing was conducted using phenotypic features 
such as biotyping, serotyping, phage typing and bacteriocin typing (Podschun & Ullmann, 
1998). However, most of these techniques did not allow true evaluation of epidemiological 
relatedness among K. pneumoniae isolates (Podschun & Ullmann, 1998; Brisse et al., 2006). 
With the arising and evolution of molecular typing methods, higher discriminatory power was 
achieved (Brisse et al., 2006). Several molecular techniques are currently used, and the most 
relevant will be given in more detail. 
 
1.4.1.1 K-typing 
Typing of Klebsiella spp. can be based on O and K-antigen characterisation, that was originally 
conducted by serotyping (Podschun & Ullmann, 1998; Brisse et al., 2006). Due to the low 
number of Klebsiella spp. O-types described, K-typing (syn. capsular typing) is considered 
more useful for epidemiology studies (Brisse et al., 2006). Typically, Klebsiella spp. have well 
developed polysaccharide capsules that are responsible for their mucoid appearance 
(Podschun & Ullmann, 1998). To date, a total of 78 K-antigens are recognised internationally 
(Ørskov & Fife-Asbury, 1977; Pan et al., 2008). K-typing is highly discriminatory (Hansen, 
Skov, Benedí, Sperling & Kolmos, 2002), however, since for a long period it required the use 
of non-commercially available specific anti-sera, the technique was only available in reference 
centres (Podschun & Ullmann, 1998; Brisse et al., 2006). To overcome this limitation, Brisse, 
Issenhuth-Jeanjean & Grimont (2004a) devised a K-typing method using restriction fragment 
length polymorphism (RFLP) after amplification of the cps gene locus which is responsible for 
the synthesis of the K-antigens. Furthermore, allelic-specific PCRs (polymerase chain 
reaction) were also developed to detect clinically relevant K-antigens (Brisse et al., 2013; Pan 
et al., 2013). Although more practical than classical serotyping, Brisse et al. (2004a) method 
is still complex and the allelic-specific PCRs only cover a limited number of K-antigens (Brisse 
et al., 2013). More recently, Brisse et al. (2013) developed a sequenced-based K-typing 
method supported by the analysis of polymorphisms of one cps locus conserved gene, wzi. 
This new method allowed good predictability of K-antigens and higher discriminatory power 
(Brisse et al., 2013). The wzi alleles are available and curated as part of a free on-line database 
allowing international comparability of results (Institut Pasteur Bigsdb, 2018). Similarly, Pan et 
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al. (2013) developed a K. pneumoniae capsular genotyping method based on sequencing of 
the wzc gene of the cps locus. In 2016, a new molecular typing method relying on whole-
genome sequencing was proposed in which the entire cps locus (K-locus) is included (Wyres 
et al., 2016). In this study, the K-locus typing nomenclature was defined and an on-line 
database (Kaptive) was launched, assuring that the new K-locus typing system is comparable 
worldwide (Wyres et al., 2016). 
 
1.4.1.2 Pulse field gel electrophoresis 
Pulse field gel electrophoreses (PFGE) relies on the cleavage of highly purified genomic 
bacterial DNA with a restriction endonuclease, followed by separation of the resulting large 
DNA fragments in an agarose gel electrophoresis in which the electric field changes 
periodically (Sabat et al., 2013). Comparison of the resulting restriction pattern is used to infer 
the relatedness between isolates (Tenover et al., 1995). For many years, PFGE has been one 
of the most used DNA fingerprint methods for bacterial typing, including for Klebsiella spp. 
(Sabat et al., 2013; Brisse et al., 2006). 
Among the advantages of this technique is that it uses a large portion of the genome (>90%), 
it has high concordance with epidemiological relatedness, it has excellent discriminatory 
power, good typeability and intra-laboratory reproducibility (Sabat et al., 2013; Centres for 
Disease Control and Prevention [CDC], 2016). However, this technique suffers from some 
pitfalls, such as being technically demanding, labour-intensive and time-consuming (Sabat et 
al., 2013). Also, it is important to notice that PFGE may not distinguish bands of nearly identical 
size and that similar sized bands between strains are not necessarily equal in genomic content. 
Moreover, PFGE restriction patterns may slightly vary between laboratories and the analysis 
of PFGE patterns is somewhat subjective (Tenover et al., 1995; Sabat et al., 2013; CDC, 
2016). 
To improve inter-laboratory comparisons, PFGE protocols for several bacteria were 
standardised through initiatives, such as PulseNet (CDC, 2016). However, there is no 
standardised PFGE protocol for K. pneumoniae (CDC, 2016) leading to difficult inter-
laboratory/study comparability. 
In Klebsiella species, the restriction enzymes include HaeIII, XbaI or SpeI, which have been 
mainly used to characterise K. pneumoniae outbreaks (Brisse et al., 2006). When compared 
with K-typing, ribotyping or multilocus sequence typing (MLST), PFGE has higher 
discriminatory power (Hansen et al., 2002; Vimont, Mnif, Fevre & Brisse, 2008). However, 
PFGE has lower standardisation and inter-laboratory reproducibility then K-typing and MLST 
(Hansen et al., 2002; Vilmont et al., 2008). 
In companion animals, PFGE has been used in studies with selected K. pneumoniae samples 
such as ESBL-, carbapenemase- and 16S rRNA methylase-producers (Haenni, Ponsin, 
Métayer, Médaille & Madec, 2012; Hidalgo et al., 2013; Stolle et al., 2013; Donati et al., 2014; 
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Ewers et al., 2014b; Wohlwend, Endimiani, Francey & Perreten, 2015; Harada et al., 2016; Xia 
et al., 2017). Like in human hospitals, some studies in companion animals highlighted the  
K. pneumoniae predisposition for nosocomial dissemination (Haenni et al., 2012; Ewers et al., 
2014b; Wohlwend et al., 2015; Harada et al., 2016; Xia et al., 2017). Only few of these studies, 
using a limited number of isolates, have also included strains from human infection (Stolle et 
al., 2013; Ewers et al., 2014b; Wohlwend et al., 2015). Ewers et al. (2014b) detected high 
similarity between some human and animal strains. However, the same was not true in 
Wohlwend et al. (2015) study. Most studies included at least one K. pneumoniae from UTI 
(Haenni et al., 2012; Hidalgo et al., 2013; Stolle et al., 2013; Donati et al., 2014; Ewers et al., 
2014b; Wohlwend et al., 2015; Xia et al., 2017), however none of them was focussed on UTI 
epidemiology in companion animals. 
 
1.4.1.3 Multilocus sequence typing 
MLST is based on the sequencing and comparison of several housekeeping genes (Maiden 
et al., 2013; Sabat et al., 2013). All unique allele sequences of each locus are assigned 
arbitrary numbers and the combination of alleles in an isolate determines its sequence type 
(ST) (Maiden et al., 2013; Sabat et al., 2013). The housekeeping genes considered vary 
according to the bacteria species (Sabat et al., 2013). Diancourt, Passet, Verhoef, Grimont 
and Brisse (2005) developed a K. pneumoniae MLST scheme based on rpoB, gapA, mdh, pgi, 
phoE, infB and tonB housekeeping genes. All allele and ST numbering is standardised and 
available in an international database (Institut Pasteur Bigsdb, 2018). Therefore, MLST has 
the advantage of being comparable worldwide, unambiguous and highly reproducible (Sabat 
et al., 2013). Although the number of allelic sequence differences is not considered, the 
comparison of the allelic profiles among known STs allows to determine their genetic 
relatedness (Sabat et al., 2013). Of note, MLST is less discriminatory than PFGE (Vilmont et 
al., 2008). In 2005, Diancourt et al. (2005) described 40 different STs, hence, pointing to a high 
diversity within K. pneumoniae. Currently, more than 3000 STs have been designated (Institut 
Pasteur Bigsdb, 2018). 
In companion animals several studies have determined the K. pneumoniae clonal lineages 
through MLST (Table 6). Although most studies include a varying number of K. pneumoniae 
isolated from companion animal’s urine, MLST typing is mostly conducted in selected bacteria 
such as ESBL-producers. Poirel et al. (2013) found that urine and faecal K. pneumoniae from 
animals in France belonged mainly to ST274, while in human faecal and urine samples a 
higher number of STs could be found. Higher clonal diversity among human K. pneumoniae 
was also noticed by Wohlwend et al. (2015) in Switzerland, although nosocomial spread of  
K. pneumoniae strains among the included companion animals was suspected. Overall, the  
K. pneumoniae ST15 seems to be the most frequent ST in companion animals and has been 
detected worldwide (Table 6). 
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Country Source (number) Species Choice reasoning 
Haenni et al., 2012 2008-2010 n= 24 ST15 (24) Paris Urine (24) Cat and dog ESBL-producers 
Poirel et al., 2013 2011-2012 n= 11 ST 15 (1) Paris Urine (1) Dog ESBL/carbapenemase-producers  
   ST274 (10) Paris Urine (5) and faeces Cat and dog ESBL/carbapenemase-producers 
Stolle et al., 2013 2012 n= 5 ST15 (5) Germany Varied (urine, 1) Dog Carbapenemase-producers 
Hidalgo et al., 2013 2008-2010 n= 7 ST11 (7) Spain Abcess and urine (6) Cat and dog Aminoglycoside-resistant 
Ewers et al., 2014b 2008-2010 n= 65 ST70 (2) Germany Swab trachea Cat and dog ESBL-producers  




Swab wound, swab 
trachea, faeces and 
Uncertain 
Cat and dog ESBL-producers  
   ST188 (1) Luxemburg Swab trachea Dog ESBL-producers  
   ST989 (1) Italy Urine (1) Cat ESBL-producers  
   ST991 (1) Germany Faeces Dog ESBL-producers  
Donati et al., 2014 2006-2012 n= 15 ST11 (1) Italy Dermatitis Dog ESBL-producers 
   ST15 (4) Italy Pneumonia, otitis and 
septicemia 
Cat and dog ESBL-producers 
   ST101 (8) Italy Varied (urine, 2) Cat and dog ESBL-producers 
   ST340 (2) Italy Intracardiac clot Cat and dog ESBL-producers 















Country Source (number) Species Choice reasoning 
Harada et al., 2016 2003-2015 n= 34 ST15 (16) Japan Varied (urine, 11) Cat and dog ESBL-producers 
   ST34 (1) Japan Urine (1) Dog ESBL-producers 
   ST37 (1) Japan Oral cavity Dog ESBL-producers 
   ST147 (1) Japan Urine Dog ESBL-producers 
   ST301 (3) Japan Pus and urine (2) Cat and dog ESBL-producers 
   ST337 (1) Japan Skin Cat ESBL-producers 
   ST655 (5) Japan Varied (urine, 1) Cat and dog ESBL-producers 
   ST709 (1) Japan Urine (1) Dog ESBL-producers 
   ST753 (1) Japan Ascites fluid Dog ESBL-producers 
   ST881 (1) Japan Urine (1) Dog ESBL-producers 
   ST1844 (2) Japan Urine (2) Dog ESBL-producers 
   ST2173 (1) Japan Urine (1) Dog ESBL-producers 
González-Torralba et al., 2016 2014-2015 n= 1 ST2090 (1) Spain Rectal swab Dog Carbapenemase-producers 
Kuan et al., 2016 2011-2013 n= 5 ST138 (1) Taiwan Urine (1) Dog ESBL-producers 
   ST750 (1) Taiwan Urine (1) Cat ESBL-producers 
   ST709 (1) Taiwan Urine (1) Cat ESBL-producers 
   ST15 (1) Taiwan Urine (1) Dog ESBL-producers 
   ST11 (1) Taiwan Urine (1) Dog ESBL-producers 
Overejo et al., 2017 2010 n= 2 ST11 (1) Spain Uncertain Dog Tigecycline-resistant 












Country Source (number) Species Choice reasoning 
Xia et al., 2017 2010-2012 n= 12 ST37 (9) China Uncertain Cat and dog 16S rRNA methylase 
   ST147 (1) China Uncertain Cat 16S rRNA methylase 
   ST395 (1) China Uncertain Cat 16S rRNA methylase 
   ST2018 (1) China Uncertain Dog 16S rRNA methylase 
Taniguchi et al., 2017 2016 n= 1 ST37 (1) Japan Urine (1) Dog Colistin/tigecycline-resistant 
Sato et al., 2018 2003-2016 n= 7b ST11 (1) Japan Urine (1) Dog Tigecycline-non-susceptible 
   ST32 (1) Japan Ear discharge Dog Tigecycline-non-susceptible 
   ST15 (1) Japan Urine Dog Tigecycline-non-susceptible 
   ST314 (1) Japan Utereus Dog Tigecycline-non-susceptible 
   ST655 (1) Japan Nasal cavity Dog Tigecycline-non-susceptible 
   ST1043 (2) Japan Urine (2) Dog Tigecycline-non-susceptible 
Maeyama et al., 2018 2016 n= 21 ST15 (7) Japan Uncertain Uncertain ESBL/AmpC-producers 
   ST655 (3) Japan Uncertain Uncertain ESBL/AmpC-producers 
   ST11 (2) Japan Uncertain Uncertain ESBL/AmpC-producers 
   ST147 (2) Japan Uncertain Uncertain ESBL/AmpC-producers 
   ST307 (2) Japan Uncertain Uncertain ESBL/AmpC-producers 
   ST709 (2) Japan Uncertain Uncertain ESBL/AmpC-producers 
   ST4 (1) Japan Uncertain Uncertain ESBL/AmpC-producers 
   ST37 (1) Japan Uncertain Uncertain ESBL/AmpC-producers 
   ST45 (1) Japan Uncertain Uncertain ESBL/AmpC-producers 











Country Source (number) Species Choice reasoning 
Zogg et al., 2018a 2012-2016 n= 11 ST11(1) Switzerland Abscess Dog ESBL-producers 
   ST15 (3) Switzerland Urine (1) and wound Cat and dog ESBL-producers 
   ST147 (6) Switzerland Urine (5) and other Cat and dog ESBL-producers 
   ST778 (1) Switzerland Urine (1) Dog ESBL-producers 
Pulss et al., 2018 2012-2016 n= 82c ST11 (17) Mainly Germany Uncertain Dog Carbapenemase-producers 
   ST15 (61) Mainly Germany Uncertain Cat and dog Carbapenemase-producers 
   ST307 (2) Mainly Germany Uncertain Dog Carbapenemase-producers 
   ST661 (1) Mainly Germany Uncertain Cat Carbapenemase-producers 
   ST895 (1) Mainly Germany Uncertain Dog Carbapenemase-producers 
Chatzopoulou et al., 2018  n= 1 ST194 (1) Greece Urine (1) Dog ESBL-producers 
Silva et al., 2018  n= 1 ST231 (1) Brasil Nasal discharge Dog ESBL-producers 




The Institut Pasteur Bigsdb (2018) database includes additional STs isolated from animals, of 
which ST74, ST30, ST989 and ST1463 were obtained from companion animals with 
cystitis/UTI in Europe. 
In a recent review, nine worldwide disseminated XDR K. pneumoniae high-risk clonal lineages9 
causing nosocomial outbreaks in humans were identified (Navon-Venezia et al., 2017). These 
XDR high-risk clonal lineages included ST11, ST14, ST15, ST17, ST37, ST101, ST147, ST258 
and ST512 (Navon-Venezia et al., 2017). Other STs were acknowledged as important 
epidemic international outbreak clones (ST16, ST20, ST48, ST307, ST340, ST336 and ST395) 
even though, currently, they did not meet the criteria to be classified as high-risk clonal lineages 
(Navon-Venezia et al., 2017). Clonal group (CG) 258, which includes ST258, ST11 and ST512, 
were responsible for 68% of published nosocomial outbreaks followed by CG15 (~20%, 
includes ST15 and ST14) (Navon-Venezia et al., 2017). K. pneumoniae CG258, ST14, ST37 
and ST147 are frequently carbapenemases-producers, while ST15 and ST17 are mostly 
ESBL-producers (Navon-Venezia et al., 2017). In parallel, important clonal lineages of 
hypervirulent K. pneumoniae such as ST23 have also been identified (Bialek-Davenet et al., 
2014). 
As in companion animals, studies determining the clonal lineages of K. pneumoniae isolated 
from humans usually focus on specific populations (e.g. carbapenemase-producers) or 
nosocomial outbreaks, thus, not aiming at characterising the specific epidemiology in UTI. 
Studies on K. pneumoniae clonal lineages in Portugal are lacking in companion animals and 
were mostly centred on ESBL/carbapenemase-producers from hospitals in humans (Table 7). 
The most frequent K. pneumoniae clonal lineages detected in urine samples from Portugal 
were the ST11, ST14, ST15, ST147, ST348 and ST336 (Table 7). 
 
1.4.1.4 Ribosomal multilocus sequence typing 
The comparison of the ribosomal RNA gene restriction patterns is the bases for the rybotyping 
method, extensively used in K. pneumoniae (Brisse et al., 2006). The 16S ribosomal RNA (16S 
rRNA) genes are present in all bacteria, thus providing a general framework for analysis of 
bacterial diversity and classification (Jolley et al., 2012). With the expansion of whole genome 
sequence methodologies, the 16S rRNA genes became more easily accessible. Jolley et al. 
(2012) proposed a new MLST scheme, the ribosomal MLST (rMLST), that compares the 53 
loci of 16S rRNA and can be used regardless of the bacterial species being studied. Since 
rMLST includes a larger number of loci that are shared by all bacteria, it is more discriminatory 
than MLST and can be used as a universal typing tool (Jolley et al., 2012). Nevertheless, 
rMLST does not preclude the usefulness of MLST for epidemiological purposes (Jolley et al.,  
 
                                               
9 High-risk clonal lineages were defined as clones that caused at least four recognised outbreaks and that were reported from ≥10 
countries (Navon-Venezia et al., 2017). 
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Source (number) Origin Choice reasoning 
Diancourt et al., 2005 Unknown n= 2 ST12 (1) Blood Hospital - 
   ST15 (1) Urine (1) Hospital - 
Machado et al., 2010 2010 n= 2 ST11 (2) Blood Hospital Carbapenemase-producers 
Calisto et al., 2012 2009-2011 n= 4 ST14 (4) Uncertain Hospital Carbapenem-resistant 
Novais et al., 2012 2010 n= 10 ST14 (1) Urine (1) Hospital Ertapenem-resistant 
   ST15 (8) Urine (5) and blood Hospital Ertapenem-resistant 
   ST45 (1) Exudate Hospital Ertapenem-resistant 
Rodrigues et al., 2014ab 2006-7/2010 n= 57 ST14 (1) Exudate Hospital ESBL-producers 
   ST15 (16) Urine (12), spuctum and other Hospital ESBL-producers 
   ST147 (9) Urine (5), blood and other Hospital ESBL-producers 
   ST336 (31) Urine (27), blood and exudate Hospital ESBL-producers 
Rodrigues et al., 2014b 2011-2012 n= 2 ST15 (2) Urine (2) Hospital Carbapenemase-producers 
Manageiro et al., 2015 2006-2013 n= 26 ST11 (2) Uncertain Hospital Carbapenemase-producers 
   ST14 (3) Uncertain Hospital Carbapenemase-producers 
   ST15 (4) Uncertain Hospital Carbapenemase-producers 
   ST34 (1) Uncertain Hospital Carbapenemase-producers 
   ST59 (1) Uncertain Hospital Carbapenemase-producers 
   ST147 (4) Uncertain Hospital Carbapenemase-producers 
   ST231 (4) Uncertain Hospital Carbapenemase-producers 
   ST416 (1) Uncertain Hospital Carbapenemase-producers 
   ST698 (1) Uncertain Hospital Carbapenemase-producers 










Source (number) Origin Choice reasoning 
Manageiro et al., 2015   ST1138 (4) Uncertain Hospital Carbapenemase-producers 
Papagiannitis et al., 2015 2009 n= 1 ST252 (1) Faecal carriage Hospital ESBL/carbapen.-producers 
Rodrigues et al., 2016 2014-2015 n= 20 ST15 (5) Urine (4) and spuctum Communityc Carbapenemase-producers 
   ST109 (1) Urine (1) Communityc Carbapenemase-producers 
   ST147 (10) Urine (10) Communityc Carbapenemase-producers 
   ST231 (3) Urine (3) Communityc Carbapenemase-producers 
   ST348 (1) Urine (1) Communityc Carbapenemase-producers 
Vubil et al., 2017 2013 n= 6 ST15 (3) Urine (2) and sputum Hospital Ertapenem-resistant 
   ST348 (2) Urine (1) and sputum Hospital Ertapenem-resistant 
   ST11 (1) Urine (1) Hospital Ertapenem-resistant 
Rodrigues et al., 2017 2015-2016 n= 16 ST15 (11) Faecal carriage Long-term care facility ESBL/carbapen.-producers 
   ST11 (1) Faecal carriage Long-term care facility ESBL/carbapen.-producers 
   ST348 (1) Faecal carriage Long-term care facility ESBL/carbapen.-producers 
   ST262 (1) Faecal carriage Long-term care facility ESBL/carbapen.-producers 
   ST252 (1) Faecal carriage Long-term care facility ESBL/carbapen.-producers 
   ST661 (1) Faecal carriage Long-term care facility ESBL/carbapen.-producers 
Bandeira et al., 2017 1980/2010 n= 3 ST14 (2) Skin and surgical wound Health-care-associated - 
   ST15 (1) Urine (1) Health-care-associated - 
Pereira et al., 2017 - n= 1 ST23 (1) Hepatic abscess Community - 
Mendes et al., 2018 2015-2017 n= 24 ST45 (23) Urine (3), faecal carriage, blood 
and peritoneal fluid 
Hospital Carbapenemase and mcr-1 










Source (number) Origin Choice reasoning 
Manageiro et al., 2018 2013-2014 n= 13 ST11 (1) Uncertain Hospital ESBL/carbapen.-producers 
   ST14 (1) Uncertain Hospital ESBL/carbapen.-producers 
   ST15 (1) Uncertain Hospital ESBL/carbapen.-producers 
   ST17 (1) Uncertain Hospital ESBL/carbapen.-producers 
   ST34 (1) Uncertain Hospital ESBL/carbapen.-producers 
   ST45 (2) Uncertain Hospital ESBL/carbapen.-producers 
   ST231 (2) Uncertain Hospital ESBL/carbapen.-producers 
   ST348 (1) Uncertain Hospital ESBL/carbapen.-producers 
   ST395 (1) Uncertain Hospital ESBL/carbapen.-producers 
   ST1513 (2) Uncertain Hospital ESBL/carbapen.-producers 
Caneiras et al., 2018 1990-2011 n= 25 ST11 (2) Uncertain Hospital ESBL/carbapen.-producers 
   ST14 (15) Uncertain Hospital ESBL/carbapen.-producers 
   ST15 (5) Uncertain Hospital ESBL/carbapen.-producers 
   ST133 (1) Uncertain Hospital ESBL/carbapen.-producers 
   ST 147 (1) Uncertain Hospital ESBL/carbapen.-producers 
   ST276 (1) Uncertain Hospital ESBL/carbapen.-producers 
Legend: aTotal number of K. pneumoniae typed; bIncludes reference to unpublished data stating that the K. pneumoniae ST15 is common in community settings in 
Portugal; cLong-term care facilities, nursing homes and ambulatory.
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2012). As with the MLST scheme, the rMLST alleles are freely available on the BigsDB 
database (Institut Pasteur Bigsdb, 2018). 
 
1.4.1.5 Core multilocus sequence typing 
The core multilocus sequence typing (cgMLST) comes as a natural evolution of the use of next 
generation sequence technologies aiming at higher discriminatory power and a more precise 
definition of relevant resistant and/or virulent clonal groups (Bialek-Davenet et al., 2014). In 
Bialek-Davenet et al. (2014) cgMLST scheme, a set of 634 core loci, defined as strict cgMLST, 
are combined with the 7 MLST genes and 53 rMLST genes. The cgMLST was shown to be 
more discriminatory, reproducible and to overcome spurious ST associations obtained by 
MLST analysis (Bialek-Davenet et al., 2014). So far, cgMLST showed that, overall, MDR CGs 
do not seem to overlap the hypervirulent K. pneumoniae CGs (Bialek-Davenet et al., 2014).  
Although cgMLST is more discriminatory, studies on recent outbreaks may require more 
resolution by using additional loci (Bialek-Davenet et al., 2014). 
 
1.4.1.6 Whole genome sequencing 
Whole genome sequencing (WGS) is a powerful tool that provides access to most of the 
bacterial genome sequence (Maiden et al., 2013; Quainno et al., 2017). Therefore, WGS 
provides maximal strains discrimination for epidemiological typing (Struelens & Brisse, 2013; 
Quainno et al., 2017). On-line databases are available, including for K. pneumoniae, that allow 
easy retrieval of typing information such as MLST, rMLST or cgMLST as well as data on 
resistance and virulence determinants (Maiden et al., 2013; Struelens & Brisse, 2013; Quainno 
et al., 2017; Institut Pasteur Bigsdb, 2018). Methods to compare WGS data include single 
nucleotide polymorphisms (SNP) and whole-genome MLST (wgMLST) analysis (Maiden et al., 
2013; Quainno et al., 2017). The comparison of a larger amount of the bacterial genome allows 
for higher resolution between isolates and is useful for epidemiological purposes such as the 
characterisation of nosocomial outbreaks (Figure 6) (Quainno et al., 2017). Currently, WGS is 
considered the ultimate tool since it is portable, reproducible and allows maximum resolution 
(Struelens & Brisse, 2013; Quainno et al., 2017). 
 
1.4.2 Antimicrobial resistance genes 
Besides being an important pathogen, K. pneumoniae is also a major source of antimicrobial 
resistance, which has increased in the past decades (Navon-Venezia et al., 2017; Martin & 
Bachman, 2018). K. pneumoniae shows higher resistance rates than E. coli when considering 
invasive isolates from Europe, highlighting their role in the worldwide antimicrobial resistance 





Figure 6 – Molecular typing methods and discriminatory power (adapted from Maiden 





K. pneumoniae are intrinsically resistant to ampicillin, amoxicillin, carbenicillin and ticarcillin 
due to constitutive expression of chromosomal encoded b-lactamases, namely from SHV 
family (Babini & Livermore, 2000; Hæggman, Löfdahl, Paauw, Verhoef & Brisse, 2004). 
Nevertheless, ampicillin-susceptible K. pneumoniae have been reported (Kahlmeter & 
ECO.SENS., 2003; Mendonça, Ferreira, Louro, ARSIP Participants & Caniça, 2009), which 
may be related to changes in SHV expression (Fu et al., 2007). 
The first ESBL-producing K. pneumoniae were described in the 1980s and since then  
K. pneumoniae became a major ESBL-carrying pathogen, especially in hospital settings 
(Paterson & Bonomo, 2005; Reinert et al., 2007; Calbo & Garau, 2015). Although SHV and 
TEM ESBLs predominated initially, since the 2000s, CTX-M b-lactamases, particularly  
CTX-M-15, became dominant (Coque et al., 2008; Rossolini, D'Andrea & Mugnaioli, 2008; 
Calbo & Garau, 2015; Navon-Venezia et al., 2017). The worldwide dissemination of  
CTX-M-15 among K. pneumoniae seems to be a joint result of the dissemination of epidemic 
clonal lineages and the dissemination of different multidrug-resistant plasmids (Calbo & Garau, 
2015). For instance, the high-risk clonal lineage ST15 seems to be mainly a  
CTX-M-15-producer (Navon-Venezia et al., 2017). Notably, the expansion of CTX-M-15-
producing epidemic K. pneumoniae clones showing co-resistance to ciprofloxacin has been 
reported in Hungary (Damjanova et al., 2008). Nevertheless, K. pneumoniae has been found 
to harbour several ESBL enzymes, sometimes simultaneously (Machado et al., 2007; Navon-
Venezia et al., 2017). 
In companion animals, CTX-M-15 is among the most common ESBLs (frequencies as high as 
85% of third-generation cephalosporin resistant K. pneumoniae in some studies), although 
other ESBLs have been also detected including SHV-2, -12, -27, TEM-52 and CTX-M-1, -2,  
-3, -9, -11, -14, -27, -55 (Haenni et al., 2012; Poirel et al., 2013; Stolle et al., 2013; Donati et 
al., 2014; Ewers et al., 2014b; Schmiedel et al., 2014; Wohlwend et al., 2015; González-
Torralba et al., 2016; Harada et al., 2016; Kuan, Chang, Lee & Yeh, 2016; Ovejero et al., 2017; 
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Xia et al., 2017; Chatzopoulou et al., 2018; Maeyama et al., 2018; Pulss et al., 2018; Silva et 
al., 2018; Zhang et al., 2018). The high-risk clonal lineage ST15 harbouring CTX-M-15 seems 
to be disseminated in companion animals from several countries (Haenni et al., 2012; Stolle 
et al., 2013; Ewers et al., 2014b; Harada et al., 2016; Pulss et al., 2018). The co-production of 
CTX-M-15 with OXA-1 and/or TEM-1 has been repeatedly reported (Machado et al., 2006; 
Haenni et al., 2012; Poirel et al., 2013; Stolle et al., 2013; Donati et al., 2014; Kuan et al., 2016; 
Pulss et al., 2018). 
Portugal has a high incidence of ESBL according to EARS-Net report and K. pneumoniae is 
among the most frequent ESBL-producer detected in humans (Machado et al., 2007; 
Mendonça et al., 2009; Manageiro et al., 2010). Furthermore, ESBL-producing K. pneumoniae 
frequently show co-resistance to other antimicrobial classes (Espinar, Rocha, Ribeiro, 
Gonçalves Rodrigues & Pina-Vaz, 2011). Studies of K. pneumoniae from Portuguese patients 
revealed the detection of TEM-3, -4, -10, -12, -24, -52; SHV-2, -5, -12, -55, -90, -106; GES-1, 
-7 and CTX-M-1, -3, -9, -15, -32, -61 ESBLs (Barroso et al., 2000; Duarte et al., 2003; 
Conceição, Brízio & Duarte, 2005; Machado et al., 2006; Mendonça, Ferreira & Caniça, 2006; 
Machado et al., 2007; Fernandes, Vieira, Ferraz & Prudêncio, 2008; Mendonça et al., 2009; 
Fernandes & Prudêncio, 2010; Ferreita et al., 2010; Novais et al., 2010; Calisto et al., 2012; 
Manageiro et al., 2012a; Manageiro et al., 2012b; Novais et al., 2012; Calhau, Boaventura, 
Ribeiro, Mendonça & da Silva, 2014; Fernandes, Amador, Oliveira & Prudêncio, 2014; Freitas, 
Machado, Ribeiro, Novais & Peixe, 2014; Rodrigues, Machado, Ramos, Peixe & Novais, 
2014a; Rodrigues et al., 2016; Rodrigues et al., 2017; Caneiras et al., 2018; Manageiro et al., 
2018). Additionally, several other non-ESBL SHV and TEM b-lactamases have also been 
described in Portugal (Mendonça et al., 2009; Calisto et al., 2012; Caneiras et al., 2018; 
Manageiro et al., 2018). The presence of ESBL in human patients from Portugal has been 
found mostly in ST15 but also in other epidemic clonal lineages such as ST11, ST147 and 
ST336 (Novais et al., 2012; Rodrigues et al., 2014a; Managueiro et al., 2015; Rodrigues et al., 
2016; Rodrigues et al., 2017). 
Although less frequently than ESBLs, K. pneumoniae may also harbour several plasmid-
mediated AmpC b-lactamases (Jacoby, 2009). DHA-1 followed by CMY-2 are the most 
common AmpC b-lactamases detected in K. pneumoniae from companion animals (Ma et al., 
2009; Hidalgo et al., 2013; Stolle et al., 2013; Poirel et al., 2013; Bogaerts et al., 2014; Donati 
et al., 2014; Wohlwend et al., 2015; González-Torralba et al., 2016; Harada et al., 2016; Liu, 
Yang, Chen & Xia, 2017; Ovejero et al., 2017; Taniguchi et al., 2017; Maeyama et al., 2018; 
Pulss et al., 2018). CMY-2 and DHA-1 are also the most common AmpC b-lactamases in  
K. pneumoniae from humans (Freitas et al., 2014; Navon-Venezia et al., 2017), and the latter 
has been detected in several studies in Portugal (Manageiro et al., 2012b; Ferreira et al., 2010; 
Freitas et al., 2014; Rodrigues et al., 2017; Vubil et al., 2017; Manageiro et al., 2018). Third-
generation cephalosporin-resistance in K. pneumoniae may also be related with the 
 
 43 
combination of SHV-1 hyperproduction and outer membrane modifications (Rice et al., 2000). 
Furthermore, the combination of ESBL/AmpC b-lactamases with porin loss (e.g. OmpK36 and 
OmpK35) or increased efflux in K. pneumoniae may lead to carbapenem-resistance (Bradford 
et al., 1997; Calisto et al., 2012; Navon-Venezia et al., 2017; Hamzaoui et al., 2018). 
K. pneumoniae is a major carbapenemase-producing pathogen that may harbour a wide range 
of carbapenemases (Queenan & Bush, 2007; Albiger et al., 2015; Grundmann et al., 2017; 
Navon-Venezia et al., 2017). CG258, ST14, ST37, ST147 and ST101 are the clonal lineages 
more frequently found associated with carbapenemases worldwide (Navon-Venezia et al., 
2017). In Europe, KPC followed by OXA-48-like are the most disseminated carbapenemases 
in K. pneumoniae overall (Grundmann et al., 2017). In Portugal, KPC-3 was found to be the 
most common KPC among K. pneumoniae and was frequently associated with high-risk clonal 
lineages such as ST11, ST14, ST15 and ST147 (Manageiro et al., 2015; Rodrigues et al., 
2016; Vubil et al., 2017; Caneiras et al., 2018; Manageiro et al., 2018). In companion animals, 
there are only sporadic reports of the detection of carbapenemase-producing K. pneumoniae 
harbouring OXA-48 in Spain and Germany (Stolle et al., 2013; Schmiedel et al., 2014; 
González-Torralba et al., 2016; Pulss et al., 2018). 
 
1.4.2.2 Fluoroquinolones 
K. pneumoniae may harbour all the known quinolone-resistance mechanisms described in 
Gram-negative bacteria (Navon-Venezia et al., 2017). 
K. pneumoniae from companion animals have been found to frequently have gyrA and parC 
mutations (Guillard et al., 2016; de Jong et al., 2018). Although, less frequently, aac(6')-Ib-cr, 
qnrB, qnrS and qnrA have also been detected (Hidalgo et al., 2013; Stolle te al., 2013; Ewers 
et al., 2014b; Donati et al., 2014; Schlüter et al., 2014; Schmiedel et al., 2014; Wohlwend et 
al., 2015; Harada et al., 2016; Guillard et al., 2016; Ovejero et al., 2017; Chatzopoulou et al., 
2018; de Jong et al., 2018; Silva et al., 2018; Zhang et al., 2018). In K. pneumoniae from 
companion animals, aac(6')-Ib-cr followed by qnrB seems to be the more common PMQR, in 
particular among ESBL-producers (Ma et al., 2009; Stolle te al., 2013; Donati et al., 2014; 
Wohlwend et al., 2015; Harada et al., 2016; de Jong et al., 2018). Furthermore, chromosome 
encoded OqxAB is highly frequent in K. pneumoniae from companion animals while QepA is 
rare (Ma et al., 2009; Harada et al., 2016; Guillard et al., 2016; de Jong et al., 2018). 
K. pneumoniae isolated from humans, including in Portugal, show similar resistant 
determinants to quinolones as those described in companion animals (Deguchi et al., 1997; 
Machado et al., 2006; Ferreira et al., 2010; Rodríguez-Martínez et al., 2011; Ruiz et al., 2012; 
Rodríguez-Martínez et al., 2013; Jacoby et al., 2014; Schmiedel et al., 2014; Holt et al., 2015; 
Wohlwend et al., 2015; Navon-Venezia et al., 2017; Mendes et al., 2018). Adicionally, qnrD 
has been seldomly detected in human K. pneumoniae (Zhang et al., 2013). 
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1.4.2.3 Other antimicrobials 
Most studies on resistance determinants of K. pneumoniae epidemiology are focussed on  
b-lactamases (ESBLs, AmpCs and carbapenemases-producers) and on fluoroquinolones to a 
lesser extent. Also, there is only a limited number of studies including K. pneumoniae from 
companion animals. Nevertheless, K. pneumoniae may acquire resistance determinants to 
several other antimicrobial classes (Wyres & Holt, 2016; Holt et al., 2015). 
Notably, Holt et al. (2015) detected more than 100 resistance determinants in a large collection 
of K. pneumoniae from humans and bovines by WGS. In addition to oqxAB and blaSHV, fosA, 
which confers low resistance to fosfomycin, was found as part of K. pneumoniae core 
resistome (Holt et al., 2015). 
In Holt et al. (2015) study, sul1 and sul2 frequency in K. pneumoniae was high while sul3 was 
rarely found. In K. pneumoniae from companion animals, the same seems to be true (Donati 
et al., 2014; Ewers et al., 2014b; Schlüter et al., 2014; Wohlwend et al., 2015; González-
Torralba et al., 2016; Zhang et al., 2018). Nevertheless, sul1 and sul2 frequencies vary 
between studies (Donati et al., 2014; Ewers et al., 2014b; Zhang et al., 2018). Several dfrA 
genes have been reported in K. pneumoniae from humans and companion animals, with 
dfrA14 and dfrA12 being the most common in most studies (Donati et al., 2014; Schlüter et al., 
2014; Holt et al., 2015; Wohlwend et al., 2015; González-Torralba et al., 2016; Taitt et al., 
2017; Silva et al., 2018; Zhang et al., 2018). 
Regarding aminoglycosides, Holt et al. (2015) also detected several AMEs genes, including 
aac(3)-II and aac(6')-Ib-cr, that showed the higher frequencies. The acc(3)-II and acc(6')-Ib 
were also the main detected genes by Haldorsen, Simonsen, Sundsfjord and Samuelsen 
(2014) in K. pneumoniae from Norway. Interestingly, Taitt et al. (2017) found lower aac(6’)-Ib 
frequencies in faecal K. pneumoniae from humans from Kenya. As mentioned above,  
aac(6')-Ib-cr is common among K. pneumoniae from companion animals while little in known 
about other AMEs (Ma et al., 2009; Stolle te al., 2013; Donati et al., 2014; Wohlwend et al., 
2015; Harada et al., 2016; de Jong et al., 2018). Plasmid-mediated 16S rRNA methylases have 
been detected in K. pneumoniae from animals and humans, although reports from companion 
animals are scarse (Deng et al., 2011; Wachino & Arakawa, 2012; Hidalgo et al., 2013; Xia et 
al., 2017). 
K. pneumoniae may harbour a wide number of different tetracycline-resistance tet genes 
(Roberts, 2017). According to Holt et al. (2015) findings, tet(A) was the most disseminated 
followed by tet(D). Taitt et al. (2017) also frequently found tet(B) in K. pneumoniae from Kenya. 
In companion animals, Ewers et al. (2014b) detected tet(A) in most K. pneumoniae (~50%) 
while tet(B) and tet(C) were less common. Furthermore, Donati et al. (2014) and Chatzopoulou 
et al. (2018) also found tet(D) in K. pneumoniae from companion animal. 
Finally, Holt et al., 2015 study showed the presence of catA, catB, cmlA and floR 
chloramphenicol-resistance genes in K. pneumoniae from humans and bovine. The catA, catB 
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and floR have also been reported among K. pneumoniae from companion animals (Wohlwend 
et al., 2015; González-Torralba et al., 2016; Chatzopoulou et al., 2018; Silva et al., 2018; 
Zhang et al., 2018). 
 
1.4.3 Virulence 
K. pneumoniae virulence factors are encoded in its core genome but also in accessory 
genomes such as plasmids (Martin & Bachman, 2018). K. pneumoniae is highly resilient due 
to its defensive rather than offensive mechanisms (Paczosa & Mecsas, 2016). Nevertheless, 
the emergence of hypervirulent K. pneumoniae (capable of causing disease in otherwise 
healthy patients), as opposed to classic K. pneumoniae, is worrisome (Shon, Bajwa & Russo, 
2013; Paczosa & Mecsas, 2016). Currently, MDR K. pneumoniae seems to be associated with 
less virulent strains and vice versa (Bialek-Davenet et al., 2014; Paczosa & Mecsas, 2016). 
However, there are already some reports of resistant and hypervirulent K. pneumoniae strains 
(Bialek-Davenet et al., 2014; Holt et al., 2015; Paczosa & Mecsas, 2016; Harada & Doi, 2018). 
Studies reporting the virulence of K. pneumoniae from companion animals are rare (Sato et 
al., 2018). 
K. pneumoniae has four main virulence factor groups that have been extensively studied, 
namely the capsule, the lipopolysaccharide (LPS) and several siderophores and fimbriae 
(Paczosa & Mecsas, 2016) (Figure 7). 
 





The capsule is a complex acid polysaccharide matrix that is attached to the outside of the  
K. pneumoniae outer membrane (Podschun & Ullmann, 1998). The capsule is a major 
virulence factor used by K. pneumoniae to evade the immune system during infection through 
multiple mechanisms (Paczosa & Mecsas, 2016). Notably, acapsular K. pneumoniae have 
been shown to be less virulent including in in vivo UTI models (Camprubí, Merino, Benedí & 
Tomás, 1993; Struve & Krogfelt, 2003; Paczosa & Mecsas, 2016). As mentioned before, the 
capsule may be used for K. pneumoniae typing by serological or molecular methods. Capsule 
types K1 and K2 seems to be more virulent and also highly associated with hypervirulent  
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K. pneumoniae (Paczosa & Mecsas, 2016; Martin & Bachman, 2018). Furthermore, some 
serotypes, seem to be more frequent in clinical isolates, with K2 being common among classic 
K. pneumoniae strains causing UTI (Riser & Noone, 1981; Podschun, Sievers, Fischer & 
Ullmann, 1993; Lin et al., 2014; Paczosa & Mecsas, 2016). 
K. pneumoniae may have a hypermucoviscous phenotype, associated with the capsule hyper-
production, that is characterised by a positive “string” test10, which may contribute to a higher 
K. pneumoniae virulence (Shon et al., 2013; Paczosa & Mecsas, 2016; Martin & Bachman, 
2018). This hypermucoviscous phenotype is frequently associated with hypervirulent  
K. pneumoniae strains, although it is important to notice that it has also been detected in classic 
K. pneumoniae (Catalán-Nájera, Garza-Ramos & Barrios-Camacho, 2017). The 
hypermucoviscous phenotype may result from the expression of the regulator of mucoid 
phenotype genes rmpA and rpmA2; or with the regulation of the capsule synthesis A and B 
genes (rcsA and rcsB) (Shon et al., 2013; Paczosa & Mecsas, 2016). Moreover, the 
hypermucoviscous phenotype may be associated with the chromosomal-associated gene A 
(magA), which was found to be specific of K1 capsule type and thus later renamed wzy_K1 
(Paczosa & Mecsas, 2016). External cues such as increased glucose or iron concentrations 
may also increase or decrease capsule production, respectively (Paczosa & Mecsas, 2016). 
Notably, the detection of conflicting phenotypes/genotype associations, such as rpmA/A2-
positive strains without hypermucoviscous phenotype highlights the need for further studies to 
uncover the complexity of this K. pneumoniae phenotype (Catalán-Nájera et al., 2017).  
A human infection caused by a hypervirulent and hypermucoviscous K. pneumoniae has been 
recently reported in Portugal, although its corresponding genotype was not determined 
(Pereira et al., 2017). 
 
1.4.3.2 Lipopolysaccharide 
The LPS is a component of the Gram-negative cell membrane and is typically composed of an 
O-antigen, a core oligosaccharide, and lipid A (Paczosa & Mecsas, 2016). K. pneumoniae 
lacking or producing incomplete LPS seem to be less virulent (Paczosa & Mecsas, 2016). LPS 
protects the bacteria against humoral immune response but may also act as an immune 
activator (Paczosa & Mecsas, 2016). For instance, LPS protects bacteria against the 
complement by means of the O-antigen (Li, Zhao, Liu, Chen & Zhou, 2014). Furthermore,  
O-antigens have been implicated in increased serum-resistance together with the capsule and 
other membrane lipoproteins, such as the TraT lipoprotein (Podschun & Ullmann, 1998). It 
shoud be noted that some studies point out that LPS and serum-resistance may be important 
virulent factors for UTI (Camprubí et al., 1993; Podschun et al., 1993). 
 
                                               




1.4.3.3 Siderophores and iron transport systems 
Iron, which is essential for bacterial survival, is not readily available in most infection sites such 
the urinary tract (Podschun & Ullmann, 1998; Paczosa & Mecsas, 2016). Siderophores are 
low-molecular weight molecules with high affinity to iron that are secreated by bacteria to 
increase iron acquisition and are, therefore, important virulence factors (Holden & Bachman, 
2015; Paczosa & Mecsas, 2016). K. pneumoniae have been shown to secrete several types 
of siderophores with different virulence capabilities and iron affinities (Holden & Bachman, 
2015; Paczosa & Mecsas, 2016). Siderophore systems may be dependent on TonB which is 
encoded in K. pneumoniae core genome, regulates iron transport and acts as a virulence factor 
(Martin & Bachman, 2018). 
Enterobactin is a catecholate siderophore that is part of the core genome of K. pneumoniae 
and thus is ubiquitous and a primary iron uptake sytem (Podschun & Ullmann, 1998; Paczosa 
& Mecsas, 2016; Martin & Bachman, 2018). However, the hosts innate immune system has 
developed conterating ways, namely through the action of lipocain-2 (Holden & Bachman, 
2015; Paczosa & Mecsas, 2016; Martin & Bachman, 2018). Enterobactin biosynthesis and 
transport mediating proteins are chromosome encoded in the entABCDEF and fepABCDG 
gene clusters, respectively (Paczosa & Mecsas, 2016). Salmochelin is a c-glucosylated 
enterobactin-derivative catecholate siderophore which is able to evade the action of  
lipocain-2, consequently leading to higher virulence (Holden & Bachman, 2015; Paczosa & 
Mecsas, 2016). Salmochelin codifying genes (iroABCDE gene cluster) may be chromosomal 
or plasmid encoded (Paczosa & Mecsas, 2016). The membrane receptor of salmochelin (IroN) 
also has specificity for other siderophores and has been shown to contribute to the ivasion of 
urothelial cells by E. coli in vitro (Feldmann, Sorsa, Hildinger & Schubert, 2007; Müller, 
Valdebenito & Hantke, 2009). Interestingly, salmochelin and IroN prevalence has been shown 
to be higher in hypervirulent K. pneumoniae strains (Hsieh, Lin, Lee, Tsai & Wang, 2008; Holt 
et al., 2015). 
Yersiniabactin is a mixed-type siderophore that was originally identified in Yersinia species and 
is encoded in a chromosomal “high pathogenicity island” containing genes for its biosynthesis, 
transport, and regulation (Paczosa & Mecsas, 2016; Martin & Bachman, 2018). It may have 
additional functions such as copper-resistance (Holden & Bachman, 2015; El Fertas-Aissani, 
Messai, Alouache & Bakour, 2013). Yersiniabactin can evade lipocain-2 (Bachman et al., 
2011) and has been linked to invasive K. pneumoniae infections (Holt et al., 2015). In fact, 
yersiniabactin is particularly frequent among hypervirulent K. pneumoniae in contrast to classic 
K. pneumoniae (~17% overall and 9% in urine samples) (Hsieh et al., 2008; Bachman et al., 
2011; Compain et al., 2014). Nevertheless, El Fertas-Aissani et al. (2013) detected higuer 
frequencies also in isolates from UTI (~30%). 
Aerobactin, is also a mixed-type siderophore that is usually plasmid-encoded (Martin & 
Bachman, 2018). Aerobactin is a major virulence factor in K. pneumoniae since it is linked to 
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higher invasiveness and is extremely common among hypervitulent K. pneumoniae (Hsieh et 
al., 2008; Compain et al., 2014; Holt et al., 2015; Paczosa & Mecsas, 2016). On the other 
hand, it is less frequent (7-18%) among classic K. pneumoniae (Russo et al., 2014). 
Aerobaction is usually associated with rpmA since aerobactin codifing gene cluster (iucABCD) 
and transporter (iutA) are frequently encoded in the same plasmid (Russo et al., 2014; Holt et 
al., 2015; Paczosa & Mecsas, 2016). 
Finally, Kfu is an ABC iron transport system that seem to be associated to hipervirulent  
K. pneumoniae strains (Hsieh et al., 2008; Compain et al., 2014; Paczosa & Mecsas, 2016). 
Nonetheless, it is also present in classic K. pneumoniae (Holt et al., 2015; Sato et al., 2018). 
The secretion of several sidephores may lead to better bacterial evation to the hosts immune 
system and may lead to increased collonization success (Koczura & Kaznowski, 2003; Russo 
et al., 2014; Holden & Bachman, 2015; Holt et al., 2015; Paczosa & Mecsas, 2016). 
Furthermore, siderophore specificities may impact the bacterial virulence (Holden & Bachman, 
2015). In fact, studies in E. coli have shown that siderophores, particularly yersiniabactin and 
aerobactin, are important virulent factors for UTI (Garcia, Brumbaugh & Mobley, 2011). 
Hypervirulent K. pneumoniae usually harbour a higer number of siderophores that are also 
more active (Russo et al., 2011; Russo et al., 2014). Aerobactin seems to have a pivotal role 
in successful infection by hypervirulent K. pneumoniae over enterobactin, yersiniabactin or 
salmochelin (Russo et al., 2014; Russo, Olson, MacDonald, Beanan & Davidson, 2015). 
In K. pneumoniae isolated from UTI, enterobactin is ubiquitous and followed in frequency by 
Kfu and yersiniabactin, while aerobactin and IroN are seldom detected (Tarkkanen et al., 1992; 
Podschun et al., 1993; Koczura & Kaznowski, 2003; El Fertas-Aissani et al., 2013; Calhau et 
al., 2014; Ranjbar, Memariani, Sorouri & Memariani, 2016; Sato et al., 2018). Interistingly, 
aerobactin was apparently more frequent among strains causing pyelonephritis when 
compared to cystitis or asymptomatic UTI in humans (Podschun et al., 1993). 
 
1.4.3.4 Pilli (Fimbriae) 
Pilli (fimbriae) are filamentous structures extending from the surface of bacteria that play an 
important role in bacterial adhesion to the host cells (Paczosa & Mecsas, 2016; Martin & 
Bachman, 2018). Two main types of pilli have been described in K. pneumoniae, namely type-
1 and type-3 pilli (Martin & Bachman, 2018). These seem to be encoded in the K. pneumoniae 
core genome and are therefore highly frequent, including in strains causing UTI (Podschun & 
Sahly, 1991; Tarkkanen et al., 1992; Podschun et al., 1993; El Fertas-Aissani et al., 2013; 
Paczosa & Mecsas, 2016; Ranjbar et al., 2016; Sato et al., 2018; Martin & Bachman, 2018). 
Although, other adhesive structers have been identified in K. pneumoniae, these have been 




Type-1 pili are “mannose-sensitive”, thin and thread-like cell protrusions frequently expressed 
by K. pneumoniae that seem to be involved in adherence to human mucosal or epithelial 
surfaces (Paczosa & Mecsas, 2016). The K. pneumoniae and E. coli type-1 pilli gene cluster 
is homologous but different (Struve, Bojer & Krogfelt, 2008; Struve, Bojer & Krogfelt, 2009). 
The FimH minor subunit is located on the tip of type-1 pilli and is responsible for its adhesive 
properties (Paczosa & Mecsas, 2016). Type-1 pilli contributes to UTI development although it 
seems not to be involved in early collonization (Podschun et al., 1993; Rosen et al., 2008; 
Struve et al., 2008; Struve et al., 2009; Murphy, Mortensen, Krogfelt & Clegg, 2013). 
Interestingly, Stahlhut et al. (2009) found that FimH is targeted by adaptive point mutations, 
suggesting a pathoadaptive nature of this adhesin (Stahlhut et al., 2009). 
Type-3 pili are “mannose-insensitive”, helix-like filaments which adhere to cell surfaces and 
are strong biofilm promoters (Struve et al., 2009; Schroll, Barken, Krogfelt & Struve, 2010; 
Paczosa & Mecsas, 2016). The mrkD gene included in the type-3 pilli gene cluster, encodes 
for the MrkD adhesin located in the pilli tip (Paczosa & Mecsas, 2016). Nevertheless, it is MrkA 
that seems to be the key for biofilm formation (Langstraat, Bohse & Clegg, 2001). Type-3 pilli 
have been shown to bing type IV and V collagen (Sebghati, Korhonen, Hornick & Clegg, 1998). 
Although type-3 pilli can bind to bladder epithelial cells in vitro, it does not seem to contribute 
to UTI (Struve et al., 2009; Paczosa & Mecsas, 2016). However, type-3 pilli may be a significant 
virulence factor in catheter associated UTIs (CAUTI) due to their ability to promote biofilm 
formation (Schroll et al., 2010). 
 
1.4.3.5 Other virulence factors 
Additional less characterised virulence factors have been identified in K. pneumoniae, such as 
the outer membrane protein porins, efflux pumps and genes involved in allantoin metabolism 
(Brisse et al., 2006; Li et al., 2014; Paczosa & Mecsas, 2016). The peptidoglycan-associated 
lipoprotein (Pal) and murein lipoprotein (LppA) are among the outer membrane proteins (OMP) 
that have been considered as important for K. pneumoniae virulence (Hsieh et al., 2013). 
Although the lack of OmpK36 porin has been associated with changes in antimicrobial 
resistance, its presence has been shown to contribute to K. pneumoniae virulence (Li et al., 
2014; Paczosa & Mecsas, 2016). 
Efflux pumps are also frequently associated with antibiotic resistance in K. pneumoniae due to 
their ability to export antibiotics from bacterial cells (Martin & Bachman, 2018). Some efflux 
pumps, such as AcrAB, also play a role in virulence in the lung (Padilla et al., 2010; Paczosa 
& Mecsas, 2016). 
The allantoin utilisation system allows K. pneumoniae to obtain nitrogen and carbon from the 
environment and may be encoded in the core or accessory genome (Martin & Bachman, 2018). 
The presence of an allantoin utilisation operon has been associated with hypervirulent  
K. pneumoniae strains that cause pyogenic liver abscesses (Chou et al., 2004; Hsieh et al., 
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2008; Compain et al., 2014). Furthermore, the deletion of a regulator gene (allS) in the allantoin 
utilisation system operon reduced K. pneumoniae virulence (Chou et al., 2004). 
 
1.5 Proteus mirabilis 
Proteus species are motile, Gram-negative bacteria that are well known for their swarming 
ability across agar surfaces (O’hara, Brenner & Miller, 2000; Szabo & Paterson, 2002; 
Drzewiecka, 2016). Proteus species can be found in the environment, food and colonising 
several animals including humans and companion animals (O’hara et al., 2000; Manos & 
Belas, 2006; Drzewiecka, 2016). 
P. mirabilis is the most frequent Proteus species associated with human and companion animal 
infections (Szabo & Paterson, 2002; Manos & Belas, 2006; Drzewiecka, 2016). P. mirabilis is 
considered an opportunistic bacterium that is commonly isolated from uncomplicated, 
complicated and catheter associated UTIs (Szabo & Paterson, 2002; Manos & Belas, 2006; 
Drzewiecka, 2016). UTIs by Proteus species are linked with urinary stone formation, due to 
urine alkalinisation, and are prone to persistence and to secondary complications such as 
obstruction and pyelonephritis (Szabo & Paterson, 2002; Manos & Belas, 2006; Armbruster, 
Mobley & Pearson, 2018). In addition, P. mirabilis may be implicated in respiratory tract, eye, 
ear, nose, skin, throat, burns, wounds, among other infections (O’hara et al., 2000; Szabo & 
Paterson, 2002; Wang et al., 2014; Drzewiecka, 2016). Likewise, in companion animals,  
P. mirabilis is also a frequent cause of UTIs among other infections (Wooley & Blue, 1976; 
Normand et al., 2000a; Ling et al., 2001; Cohn et al., 2003; Harada et al., 2014; Schultz et al., 
2015). 
Although P. mirabilis is not included among ESKAPE nosocomial pathogens, it is frequently 
found as a nosocomial pathogen in humans especially when associated with CAUTI 
(Armbruster & Mobley, 2012; Armbruster et al., 2018). Furthermore, P. mirabilis may acquire 
several antimicrobial resistant mechanisms, such as ESBL, AmpC and Carbapenemase  
b-lactamases, and therefore also play an important role in antimicrobial resistance (Szabo & 
Paterson, 2002). 
 
1.5.1 Population structure 
Proteus species taxonomy has evolved over time (O’hara et al., 2000; Manos & Belas, 2006). 
Proteus species are traditionally considered as part of the Enterobacteriaceae family and the 
Proteeae tribe which also includes Morganela spp. and Providencia spp. (O’hara et al., 2000). 
More recently, Adeolu, Alnajar, Naushad and Gupta (2016) proposed the division of the 
Enterobacteriaceae family reassining the Proteus genus into a Morganellaceae fam. nov. 
based on WGS data of more than 1500 genes. First decribed in 1985, the genus Proteus 
currently includes several species with P. mirabilis being by far the most common in humans 
and companion animals (O’hara et al., 2000; Manos & Belas, 2006). 
 
 51 
There are several typing systems that have been used for Proteeae characterisation such as 
phage, bacteriocin, protein profile, serological, restriction fragment length polymorphisms, 
PCR, PFGE and more recently WGS (O’hara et al., 2000; Manos & Belas, 2006; Aogáin, 
Rogers & Crowley, 2016). However, comparable typing systems worldwide such as MLST 
have not been established yet. 
The Dienes test is a typing method based on the mutual inhibition of two non-isogenic  
Proteus spp. strains when swarming towards one another on an agar surface (Manos & Belas, 
2006; Pfaller, Mujeeb, Hollis, Jones & Doern, 2000). When genetically different, a clear line 
will form on the edge of the swarming where the stains meet (Pfaller et al., 2000). Interestingly, 
Dienes test seems to have a high discriminatory power as other, more complex, typing 
methods such as ribotyping and PFGE (Pfaller et al., 2000). This test is not frequently used 
due to difficulties in result interpretation (Manos & Belas, 2006). Another important limitation is 
that it does not allow the determination of more complex phylogenetic relationships (Sabbuba, 
Mahenthiralingam & Stickler, 2003). Nevertheless, Dienes test has been used in 
epidemiological studies, one of which showed that there was no predominant Proteus spp. 
Dienes type among patients with bacteriuria (Clarke & McIntyre, 1996). 
Proteus species can also be typed according to the O-antigen (Drzewiecka, 2016). 
Interestingly, a high number of O-antigens have been described and some seem to be more 
associated with clinical strains (Drzewiecka, 2016). 
A comparison of several PCR-based typing methods has shown that the random amplified 
polymorphic DNA (RADP) analysis, the enterobacterial repetitive intergenic consensus 
sequence (ERIC)-PCR and the BOX-PCR allowed a good discrimination among P. mirabilis 
clinical isolates and have the advantage of being faster than PFGE or ribotyping (Michelim et 
al., 2008). However, Michelim et al. (2008) did not compare the PCR-based results with PFGE. 
PFGE is still one of the gold standard methods for typing bacteria (Sabat et al., 2013). Like  
K. pneumoniae, there is no standard PFGE protocol proposed by PulseNet for P. mirabilis 
(CDC, 2016). Two main restriction enzymes are used by most authors, namely SfiI and NotI 
(Sabbuba et al., 2003; Goering, 2010). By using PFGE, Sabbuba et al. (2003) highlighted the 
persistence of P. mirabilis causing UTI by confirming that a single genotype of P. mirabilis from 
catheterised patients can persist despite changes of catheter, periods of non-catheterisation 
and antibiotic therapy. To date, only two studies have included and compared strains from 
companion animals and humans by PFGE (Schultz et al., 2015; Schultz, Cloeckaert, Doublet, 
Madec & Haenni, 2017b). These studies included a small and selected resistant population of 
P. mirabilis from different infection sites. Notably, one of these studies found one close related 
strain infecting one unrelated companion animal and one human (Schultz et al., 2015). 
The use of next-generation sequencing techniques provides a greater phylogenetic resolution 
and overcomes some limitations of 16S rRNA based studies (Choudoir, Campbell & Buckley, 
2012). Studies using WGS of P. mirabilis are increasing, however there is still a lack of data 
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regarding companion animals. Reports on WGS of single or multiple P. mirabilis isolates are 
unravelling potential virulence genes, new resistance mechanisms and identifying potential 
multidrug-resistant clones (Pearson et al., 2008; Siebor & Neuwirth, 2014; Aogáin et al., 2016).  
A bigger number of studies using WGS (Aogáin et al., 2016) or the definition of a standardised 
MLST scheme are still needed for a better understanding of the population structure of  
P. mirabilis worldwide. 
 
1.5.2 Antimicrobial resistance genes 
P. mirabilis are naturally resistant to nitrofurantoin, tetracycline, tigecycline, polymixin B and 
colistin (Table 4) (Stock, 2003). In addition, P. mirabilis may present high minimum inhibitory 
concentrations to carbapenems, namely imipenem, through mechanism other than 
carbapenemases (Szabo & Paterson, 2002). 
Some studies have shown that P. mirabilis resistance frequencies can be low (Fluit et al., 2000; 
Mutnick, Turner & Jones, 2002; Szabo & Paterson, 2002; Kahlmeter & ECO.SENS, 2003; 
Seguin et al., 2003; Authier et al., 2006; Pedersen et al., 2007; Harada et al., 2014; Kroemer 
et al., 2014; Wang et al., 2014; Criel et al., 2015; Moyaert et al., 2016). However, there are 
geographical variations and antimicrobial resistance frequencies may be higher according to 
the P. mirabilis source (Pedersen et al., 2007; Harada et al., 2014; Wang et al., 2014). For 
instance, ear isolates tend to be more resistant than P. mirabilis from UTIs in companion 
animals (Pedersen et al., 2007). Furthermore, some studies report the detection of important 
multidrug resistance genomic islands, namely Salmonella genomic island 1 (SGI1) and 
Proteus genomic island 1 (PGI1), in P. mirabilis from humans and companion animals 
highlighting its important role in the dissemination of resistance (Szabo & Paterson, 2002; 
Siebor & Neuwirth, 2014; Schultz et al., 2015). In fact, resistant and multidrug-resistant  
P. mirabilis is becoming more common in humans and companion animals (Normand et al., 
2000a; Luzzaro et al., 2009). 
 
1.5.2.1 b-Lactams 
Proteus mirabilis is able to acquire plasmid and chromosomal b-lactamases including ESBLs, 
AmpCs and Carbapenemases (Chanal et al., 2000; Bonnet et al., 2002; Szabo & Paterson, 
2002; Song et al., 2011; Schultz et al., 2017b). TEM-1 and TEM-2 are very common  
b-lactamases among amoxicillin-resistant P. mirabilis (~40%) from humans (Chanal et al., 
2000; Harada et al., 2014; Huang et al., 2015). Several studies point to the emergence of ESBL 
and AmpC-producing P. mirabilis in humans (Luzzaro et al., 2009; Kanayama et al., 2010; 
D'Andrea et al., 2011; Song et al., 2011; Wang et al., 2014). Notably, some results also seem 
to point to the dissemination of specific ESBL or AmpC-producing P. mirabilis clones (Luzzaro 
et al., 2009; Kanayama et al., 2010; D'Andrea et al., 2011; Aogáin et al., 2016). CTX-M are 
among the most frequent ESBLs detected in P. mirabilis, but TEM followed by SHV ESBLs are 
 
 53 
also found (Bonnet et al., 1999; Szabo & Paterson, 2002; Kanayama et al., 2010; Song et al., 
2011; Huang et al., 2015). The blaCMY-2-like genes are the most common AmpCs detected in  
P. mirabilis from humans of several European countries (Aragón et al., 2008; D'Andrea et al., 
2011; Song et al., 2011; Miró et al., 2013a). Interestingly, in Luzzaro et al. (2009) study, CMY-
producers were mostly associated with UTIs. Chromosomal encoded CMY b-lactamase in  
P. mirabilis have been found as part of a SXT/R391-like integrative and conjugative element 
(ICE), which frequency seems to be increasing (Mata et al., 2011; Aogáin et al., 2016). In  
P. mirabilis, like in other Enterobacteriaceae, the ESBL/AmpC b-lactamases are frequently 
associated with resistance to other antimicrobials, such as fluoroquinolones (Kanayama et al., 
2010; Wang et al., 2014; Aogáin et al., 2016). 
Although less frequently than in other bacteria, carbapenemases are being increasingly 
reported in P. mirabilis from human patients leading to great therapeutic limitations. Several 
carbapenemases have been detected in P. mirabilis, including those belonging to OXA, NDM, 
IMP, VIM and KPC carbapenemase families (Bonnet et al., 2002; Szabo & Paterson, 2002; 
Miró et al., 2013a; Chen et al., 2015; Cabral, Maciel, Barros, Antunes & Lopes, 2015; Girlich, 
Dortet, Poirel & Nordmann, 2015; Di Pilato et al., 2016; Lange et al., 2017; Ohno et al., 2017; 
Potter et al., 2018; Valentin et al., 2018). 
Studies on antimicrobial resistance mechanisms of P. mirabilis from humans and companion 
animals from Portugal are lacking. Nevertheless, one study on the genetic background of TEM-
24 ESBL has included positive P. mirabilis strains from Portuguese patients (Novais et al., 
2010). In companion animals, third-generation cephalosporin-resistant P. mirabilis frequently 
harbours CMY-2, which is worldwide disseminated (Dierikx et al., 2012; Hordijk et al., 2013; 
Harada et al., 2014; Schultz et al., 2017b). Other b-lactamases have also been described in 
companion animal P. mirabilis, namely PSE-1, OXA-10, CTX-M-2, -15, VEB-6, CMY-4 and 
DHA-1, -16 (Harada et al., 2014; Schultz et al., 2015; Schultz et al., 2017b; Maeyama et al., 
2018; Zhang et al., 2018). Furthermore, TEM-1 is also common among P. mirabilis from 
companion animals (Harada et al., 2014). 
 
1.5.2.2 Fluoroquinolones 
P. mirabilis may acquire several fluoroquinolone-resistance mechanisms, with QRDR being 
more frequent than PMQR (Weigel et al., 2002; Jacoby et al., 2014). Interestingly, there are 
some QRDR mutations in P. mirabilis that are linked to higher resistance to enrofloxacin than 
to ciprofloxacin (Harada et al., 2014; Schultz et al., 2017a). Additionally, Weigel et al. (2002) 
found that gyrB mutations are surprisingly frequent among P. mirabilis. 
P. mirabilis may harbour most qnr genes (Martínez-Martínez, Cano, Rodríguez-Martínez, 
Calvo & Pascual, 2008; Jacoby et al., 2014). Proteeae, which includes P. mirabilis, seems to 
be an essential carrier of qnrD-harbouring plasmids (Zhang et al., 2013; Hooper & Jacoby, 
2015). QnrC is also associated with P. mirabilis (Rodríguez-Martínez et al., 2011; Hooper & 
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Jacoby, 2015). P. mirabilis may harbour aac(6')-Ib-cr, although it is less frequent than qnr 
genes (Mokracka, Gruszczyńska & Kaznowski, 2012; Ramirez et al., 2013; Zhang et al., 2013).  
Some studies in companion animals report high P. mirabilis enrofloxacin-resistance 
frequencies (Harada et al., 2014; Criel et al., 2015). Guillard et al. (2016) and de Jong et al. 
(2018) showed that quinolone-resistance in P. mirabilis from companion animals in Europe is 
mainly associated with QRDR mutations. The same studies also detected qnrD and less 
frequently qnrS PMQRs (Guillard et al., 2016; de Jong et al., 2018). The qnrD sequences from 
companion animal P. mirabilis were similar to previous published data about isolates from 
humans (Guillard et al., 2016). Similar distribution of resistance determinants was reported in 
earlier studies of companion animals (Zhang et al., 2013; Harada et al., 2014; Schultz et al., 
2017a). Additionally, qnrA was found as part of a SGI1 in P. mirabilis from dogs (Schultz et al., 
2015). Although, aac(6')-Ib-cr is rare in P. mirabilis, it has been detected in companion animals 
(Zhang et al., 2013). 
 
1.5.2.3 Other antimicrobials 
P. mirabilis is naturally susceptible to trimethoprim/sulfamethoxazole, however studies from 
human and companion animal clinical strains tend to report high frequencies of resistance 
(Szabo & Paterson, 2002; Stock, 2003; Pedersen et al., 2007; Harada et al., 2014; Kroemer 
et al., 2014; Wang et al., 2014; Criel et al., 2015; Moyaert et al., 2016). Likewise, P. mirabilis 
also usually have high frequencies of chloramphenicol-resistance (Stock, 2003; Harada et al., 
2014). There is a lack of studies focussed on determining the frequency of trimethoprim and 
sulfonamide-resistance mechanisms in P. mirabilis. Nevertheless, some mobile resistance 
determinants described in P. mirabilis have sul and dfr genes in its composition, such as the 
SXT/R391-related ICEs, SGI1, PGI1 and class 1 integrons (Grape, Farra, Kronvall & 
Sundström, 2005; Siebor & Neuwirth, 2014; Schultz et al., 2015; Aogáin et al., 2016, Li et al., 
2016). Overall, sul1, sul2 and sul3 have been detected in P. mirabilis of different sources 
(Grape, Farra, Kronvall & Sundström, 2005; Siebor & Neuwirth, 2014; Schultz et al., 2015; Li 
et al., 2016; Jiang et al., 2017; Siebor, de Curraize & Neuwirth, 2018). 
The frequency of chloramphenicol-resistance mechanism in P. mirabilis is also poorly studied. 
However, there are reports of mobile chloramphenicol-resistance mechanisms in P. mirabilis 
such as cmlA and floR (Li et al., 2016; Jiang et al., 2017; Siebor et al., 2018). 
According to Ramirez and Tolmasky (2010) review, P. mirabilis may harbour AAC(3)-Ia, 
AAC(3)-Id, AAC(3)-Ie and AAC(6′)-Ib AMEs. Posterior studies have shown that P. mirabilis 
may also carry additional AMEs (Miró et al., 2013b; Aogáin et al., 2016; Chen, Lai, Wu & Wu, 
2017; Siebor et al., 2018). 16S rRNA methylases have also been detected among P. mirabilis 
(Yu et al., 2010; Wachino et al., 2012). Interestingly, in a study regarding class 1 integrons, 
Chen et al. (2017) showed that the most frequent gene cassetes in Proteus mirabilis isolates 
from urine samples in China contained resistance mechanisms against aminoglycosides 
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(aac(6’)-Ib, aacA7, aadAl, aadA2, and aadAla), trimethoprim (dfrAl and dfrA12) and 
chloramphenicol (catB and cmlA). 
 
1.5.3 Virulence 
Despite being considered an opportunistic bacteria, P. mirabilis genome is known to encode a 
wide range of virulence factors (Pearson et al., 2008; Armbruster & Mobley, 2012) (Figure 8). 
Several of these P. mirabilis virulence factors have been shown to play an important role in 
uropathogenesis (Coker, Poore, Li & Mobley, 2000; Pearson et al., 2008; Armbruster & 
Mobley, 2012) and to be possible vaccine candidates or therapeutic targets (Schaffer & 
Pearson, 2015; Armbruster et al., 2018). Regarding companion animals, the frequency or 
characterisation of virulence factors of P. mirabilis has been seldomly addressed (Bijlsma, van 
Dijk, Kusters & Gaastra, 1995; Gaastra et al., 1996). 
 
1.5.3.1 Fimbriae (Pilli) 
Analysis of the first P. mirabilis complete genome sequence revealed a total of 17 potential 
chaperone–usher fimbrial operons (Pearson et al., 2008). Kuan, Schaffer, Zouzias and 
Pearson (2014) noted that 16 of these were encoded by most P. mirabilis, thus being likely 
highly conserved. Only five of these 17 fimbriae had been characterised at the time, of which 
three were known to contribute to uropathogenesis, namely mannose-resistant Proteus-like 
fimbriae (MR/P), urothelial cell adhesion fimbriae (UCA/NAF, also known as non-agglutinating 
fimbriae) and Proteus mirabilis fimbriae (PMF) (Rocha, Pelayo & Elias, 2007; Pearson et al., 
2008; Schaffer & Pearson, 2015). These fimbriae possibly act in concert to optimise the urinary 
tract colonisation (Massad, Bahrani & Mobley, 1994a; Zunino et al., 2007). 
The MR/P fimbriae is the best characterised P. mirabilis fimbriae (Schaffer & Pearson, 2015; 
Armbruster et al., 2018). Several studies have demonstrated that MR/P fimbriae undergoes 
phase variation and that it plays an important role in uropathogenesis (Jansen, Lockatell, 
Johnson & Mobley, 2004; Bahrani & Mobley,1994; Rocha, Pelayo & Elias, 2007; Schaffer & 
Pearson, 2015; Armbruster et al., 2018). Notably, MR/P fimbriae were found to be highly 
expressed by most P. mirabilis during an ascending UTI murine model (Jansen et al., 2004; 
Pearson, Yep, Smith & Mobley, 2011) and are also expressed during pyelonephritis (Mobley 
& Chippendale, 1990). The MR/P gene cluster is constituted by the mrp operon 
(mrpABCDEFGHJ) which has several similarities with E. coli Fim and Pap fimbriae genes (Li, 
Johnson & Mobley, 1999; Bahrani & Mobley,1994). MR/P fimbriae promotes initial biofilm 
production, bind to uroepithelial cells and are essential for colonisation of the bladder and 
kidneys (Sareneva, Holthöfer & Korhonen, 1990; Jansen et al., 2004; Schaffer & Pearson, 
2015; Armbruster et al., 2018). 
First described in 1986, the UCA/NAF fimbriae is organised as long and flexible rods and is 
encoded in an operon containing 5 genes (Wray, Hull, Cook, Barrish & Hull, 1986; Rocha et 
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al., 2007; Pearson et al., 2008). The major subunit ucaA gene was found to be more variable 
than other fimbriae (Kuan et al., 2014). These fimbriae adheres to uroepithelial cells, Madin-
Darby canine kidney cells in vitro and play an important role in the colonisation of the urinary 
tract in the mouse model, including towards the kidney (Wray et al., 1986; Cook, Mody, Valle 
& Hull, 1995; Lee, Harrison, Latta & Altman, 2000; Pellegrino, Scavone, Umpiérrez, Maskell & 
Zunino, 2013). It is interesting to notice that UCA/NAF fimbriae is able to bind to GalNAcβ1-
4Gal like other fimbriae of uropathogenic E. coli (Lee, Harrison, Latta & Altman, 2000). 
 
Figure 8 – P. mirabilis virulence factors (adapted from Norsworthy and Pearson, 2017) 
 
Legend: 1. Metal uptake: systems of iron and zinc scavenging; 2. Toxins: proteins such as HpmA/HpmB 
(haemolysin) and Pta (Proteus toxic agglutinin); 3. Autotransporter: such as Taap (trimeric 
autoagglutination autotransporter of Proteus, PMI2575), AipA (adhesion and invasion mediated by the 
Proteus autotransporter, PMI2122) and Pta; 4. Fimbriae: such as MR/P (mannose-resistant Proteus-like 
fimbriae), UCA (urothelial cell adhesion fimbriae), PMF (Proteus mirabilis fimbriae), FIM14 (Fimbriae 14) 
and PMP (P. mirabilis P-like); 5. Chemotaxis: proteins that allow the bacteria to follow chemical 
gradients; 6. Flagella: needed for swarming motility; 7. Urease: key contributor for stone formation during 
UTI; 8. Virulence regulation: essential for the coordination of all steps of infection; 9. Metabolism: likely 
needed to support nutritional niches, compete with other bacteria and interact with the host cues;  
10. Immune evasion: includes several factors, such as antibody and antimicrobial peptide degradation 
and LPS (lipopolysaccharide); 11. Biofilm formation: associated with persistence and antimicrobial 
resistance. 
 
The PMF fimbriae is encoded in an operon composed by five functional genes (pmfACDEF) 
where the pmfA encodes the major structural subunit (Massad & Mobley, 1994). The PMF 
fimbriae has a role in the bladder colonisation in vivo, however studies do not agree regarding 
to its role in kidney colonisation (Massad, Lockatell, Johnson & Mobley, 1994b; Zunino et al., 
2003). Despite MR/P and PMF fimbriae having specific and additive roles during P. mirabilis 




Kuan et al., 2014 published that most P. mirabilis fimbriae belong to 3 groups of the Greek 
classification. The MR/P fimbriae belongs to the same group as E. coli type-1 fimbriae 
(associated with UTI) while the UCA/NAF and PFM fimbriae belongs to the same group as the 
uropathogenic E. coli P fimbriae (associated with pyelonephritis). 
The two-other characterised P. mirabilis fimbriae for which no relation with uropathogenesis 
has been found include the P. mirabilis P-like (PMP) fimbriae and ambient-temperature 
fimbriae (ATF). The PMP fimbriae was first detected in P. mirabilis from dogs with UTI and was 
present in high frequency (Bijlsma et al., 1995; Rocha et al., 2007). Since then it has been 
found in the genome of strains from humans, but its role in pathogenesis is unclear (Pearson 
et al., 2008; Baldo & Rocha, 2014). The ATF fimbriae has its optimal expression at 23ºC and 
seems to have a role in P. mirabilis environmental lifestyle (Massad et al., 1994a; Rocha et al., 
2007). Zunino, Geymonat, Allen, Legnani-Fajardo and Maskell (2000) demonstrated that the  
P. mirabis ATF fimbriae does not play a crucial role in UTI. 
Early studies also describe an additional fimbria, the mannose-resistant Klebsiella-like (MR/K) 
fimbriae that was found to adherence to the Bowman’s capsules of the kidney glomeruli, to the 
tubular basement membranes and to the interstitial tissue (Sareneva et al., 1990; Rocha et al., 
2007). This fimbria is poorly studied because its encoding genes have not been identified 
(Rocha et al., 2007; Kuan et al., 2014). 
The MR/P, UCA/NAF and PMF fimbriae seem to be highly frequent among P. mirabilis from 
humans regardless of the isolation site (Old & Adegbola, 1982; Mobley & Chippendale, 1990; 
Sosa, Schlapp & Zunino, 2006; Kuan et al., 2014). Regarding companion animals, Gaastra et 
al. (1996) showed that P. mirabilis from urine and faecal samples of dogs with recurrent UTI 
were all positive for MR/P and almost all positive for UCA/NAF fimbriae. Bijlsma et al. (1995) 
also detected the UCA/NAF fimbriae among P. mirabilis from dogs. Furthermore, Garcia, 
Hamers, Bergmans, van der Zeijst and Gaastra (1988) showed that the uropathogenic  
P. mirabilis adhesion to dog kidney epithelial cells and T24 cells was not species specific when 
comparing isolates from dogs (provided that P. mirabilis was fimbriated) and humans. 
 
1.5.3.2 Urease 
One hallmark of P. mirabilis UTI pathogenesis is the formation of urinary stones (Baldo & 
Rocha, 2014). This leads to adverse consequences for the infected patient (e.g. blockage of 
urinary flow, catheter blockage, etc.) and provides a protective environment for P. mirabilis 
(Armbruster & Mobley, 2012; Baldo & Rocha, 2014; Schaffer & Pearson, 2015; Armbruster et 
al., 2018). Urinary stones may also be used by other bacteria as a starting point to develop 
UTI (Armbruster & Mobley, 2012; Schaffer & Pearson, 2015; Armbruster et al., 2018). In dogs, 
uroliths have been found to sometimes be colonised by varied bacteria genus despite negative 
urine culture (Gatoria, Saini, Rai & Dwivedi, 2006). Stone formation is driven by increased 
urine pH which leads to the precipitation of calcium and magnesium ions with the subsequent 
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formation of magnesium ammonium phosphate (struvite) and calcium phosphate (apatite) 
stones (Griffith & Musher, 1976). The increased urine pH results from the activity of P. mirabilis 
urease by hydrolysing urea into ammonia and carbon dioxide (Griffith & Musher, 1976). The 
urease is a multimeric nickel-metalloenzyme encoded by ureRDABCEFG gene cluster which 
expression is induced and upregulated during UTI (Zhao, Thompson, Lockatell, Johnson & 
Mobley, 1998; Pearson et al., 2008; Pearson et al., 2011). In fact, urease is a crucial virulence 
factor in P. mirabilis colonisation, urolithiasis and severe acute pyelonephritis (Mobley, 
Chippendale, Swihart & Welch, 1991; Johnson et al., 1993). Interestingly, the resulting 
increased ammonia content in the urine seems to enhance the colonisation by uropathogenic 
E. coli (Armbruster & Mobley, 2012). Due to the relevant role of urease and pH increase in the 
pathogenesis of UTI, these factors are actively investigated in the pursue of new therapeutic 
options (Schaffer & Pearson, 2015). 
 
1.5.3.3 Haemolysin 
P. mirabilis produces a calcium-independent haemolysin that is a two-partner secretion 
system, HpmA and HpmB, where HpmB transports and activates HpmA (Swihart & Welch, 
1990a; Uphoff & Welch, 1990; Coker et al., 2000). HpmA has cytotoxic activity onto several 
types of cells in vitro, including T24 human bladder epithelial cells and human renal proximal 
tubular epithelial cells (Peerbooms, Verweij & MacLaren, 1983; Swihart & Welch, 1990a; 
Mobley et al., 1991). HmpA did not seem to affect the P. mirablis kidney colonisation or 
histologic damage in vivo (Swihart & Welch, 1990a; Mobley et al., 1991), however, one HmpA-
mutant P. mirabilis had a six-fold lower 50% lethal dose in mice injected intravenously (Swihart 
& Welch, 1990a). Interestingly, hmpA was not found to be upregulated during UTI (Pearson et 
al., 2011). Some authors hypothesise that despite not being involved in colonisation, 
haemolysin may contribute to the spread of infection into the kidneys and lead to acute 
pyelonephritis (Coker et al., 2000). 
Most P. mirabilis are haemolytic and encode for HpmA/HpmB, including those causing human 
UTI (Mobley & Chippendale, 1990; Swihart & Welch, 1990b; Sosa et al., 2006; Cestari et al., 
2013). P. mirabilis from companion animals are also frequently haemolytic (Gaastra et al., 
1996). Although no study has tested for the presence of HpmA/HpmB genes in P. mirabilis 
strains from companion animals, based on current knowledge, one could expect it to be equally 
frequent. 
 
1.5.3.4 Other toxins 
Early studies and recent sequencing data shows that P. mirabilis genome encodes several 
known and putative toxins (Armbruster & Mobley, 2012). 
Proteus toxic agglutinin (Pta) is a bifunctional outer-membrane autotransporter that mediates 
cell–cell aggregation and acts as a cytotoxic protease capable of lysing kidney and bladder 
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cells (Alamuri & Mobley, 2008; Alamuri, Eaton, Himpsl, Smith & Mobley, 2009). Pta is further 
noteworthy in the scope of UTI because loss of this gene significantly reduces P. mirabilis 
colonisation of the bladder, kidneys and spleen (Alamuri & Mobley, 2008; Alamuri et al., 2009). 
Pta and HmpA seem to have addictive cytotoxicity (Alamuri et al., 2009) and Pta has higher 
expression in alkaline pH (Alamuri & Mobley, 2008). 
 
1.5.3.5 Swarming motility 
The swarming ability of P. mirabilis is a complex process that has been extensively studied 
and is recognised as an important virulence factor (Coker et al., 2000; Armbruster & Mobley, 
2012; Schaffer & Pearson, 2015). Swarming involves P. mirabilis differentiation into swarmer 
cells that are long, polyploid, hyperflagelated and able to move as a population on a solid 
surface (Schaffer & Pearson, 2015). The classic bull’s-eye pattern results from cyclic 
differentiation between swarm cells, which are capable of migration, and a shorter morphotype 
(swimmer cell) (Manos & Belas, 2006; Armbruster & Mobley, 2012; Schaffer & Pearson, 2015). 
There are conflicting results in the literature regarding the role of swarming in uropathogenesis 
(Schaffer & Pearson, 2015; Armbruster et al., 2018). This phenomenon is considered important 
in the uropathogenic nature of P. mirabilis since it assists in urinary catheter colonisation and 
has the potential to influence polymicrobial UTIs (Armbruster & Mobley, 2012; Schaffer & 
Pearson, 2015). Interestingly, fimbriae and flagella regulation seem to be reciprocal since  
P. mirabilis highly express either one or the other in swimmer and swarmer cells, respectively 
(Armbruster & Mobley, 2012). Non-flagelated P. mirabilis mutants were attenuated in an 
experimental model of ascending UTI (Allison, Emödy, Coleman & Hughes, 1994; Mobley et 
al., 1996). Based on expression studies, swarmer cell may be important at later stages of UTI 
infection (Armbruster & Mobley, 2012; Schaffer & Pearson, 2015). 
 
1.5.3.6 Other virulence factors 
P. mirabilis has additional virulence factors that may contribute to UTI, such as in assisting 
immune evasion (Baldo & Rocha, 2014; Armbruster et al., 2018). For instance, the ZapA 
metalloproteinase cleaves serum/secretory immuno-globulins and complement components 
and its absence reduces the recovery of P. mirabilis from urine, bladder and kidneys 
(Armbruster & Mobley, 2012; Schaffer & Pearson, 2015; Armbruster et al., 2018). Another 
example is the AipA (adhesion and invasion mediated by the Proteus autotransporter, 
PMI2122) and the TaaP (trimeric autoagglutination autotransporter of Proteus, PMI2575) 
trimeric autotransporters which absence decreases the urinary tract colonisation by P. mirabilis 
(Schaffer & Pearson, 2015; Armbruster et al., 2018). The formation of crystalline biofilms is 
also a major P. mirabilis virulence factor, especially in catheterised patients (Armbruster et al., 
2018). P. mirabilis iron acquisition systems have been less studied than in other bacteria, but 
also seem to be important during UTI (Armbruster & Mobley, 2012). Notably, P. mirabilis may 
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harbour a mobile pathogenicity island (ICEpm1), encoding several virulence genes, that was 
found to be more frequent among isolates from UTI (Flannery, Mody & Mobley, 2009; Flannery, 
Antczak & Mobley, 2011; Armbruster et al., 2018). On the contrary, other studies have found 
that several virulence factors involved in UTI (e.g. fimbriae, haemolysin, swarming) were 
equally common among P. mirabilis from different sources (Peerbooms, Verweij, Oe & 
MacLaren, 1986; Sosa et al., 2006). 
 
1.6 Animal-human transfer and colonisation by K. pneumoniae and P. mirabilis 
Over the last 50 years the number of companion animals has significantly increased 
(Guardabassi et al., 2004; Pomba et al., 2017). The closer contact between owners and 
companion animals created opportunities for pathogen interchange through direct and indirect 
contact (Guardabassi et al., 2004; Damborg et al., 2016). With the increasing resistance trends 
and detection of MDR bacteria in companion animals, a concern regarding the role of 
companion animals in the dissemination of resistant bacteria has been raised (Guardabassi et 
al., 2004; Damborg et al., 2016; Pomba et al., 2017). These concerns are reinforced by studies 
that have shown that companion animals may share bacteria with household members and 
studies reporting colonised and/or infected companion animals with bacteria belonging to 
important clonal lineages to humans (Guardabassi et al., 2004; Damborg et al., 2016; Pomba 
et al., 2017). As examples, companion animals have been found to be colonised by CC17  
E. faecium11, MRSA and ST131 E. coli (Guardabassi et al., 2004; Damborg et al., 2009; 
Weese, 2010; Johnson et al., 2016; Pomba et al., 2017). As mentioned previously, several 
studies on resistant K. pneumoniae detected high-risk clonal lineages to humans infecting 
companion animals (some with UTI) (Table 6). Furthermore, dogs may share ESBL/AmpC and 
carbapenemase-producing E. coli with their household members (Ljungquist et al., 2016; 
Grönthal et al., 2018). Just recently, Grönthal et al. (2018) demonstrated that two dogs with 
otitis shared NDM-5-producing E. coli strains with one human living in the same household. 
Since uropathogenic bacteria, including K. pneumoniae and P. mirabilis, are thought to make 
part of the normal gut flora (Podschun & Ullmann, 1998; Drzewiecka, 2016; Johnson et al., 
2016; Martin et al., 2016), colonisation of companion animals may also represent an important 
hazard for the transmission and persistence of uropathogens. Interestingly, pet ownership 
(dogs, cats and other companion animals) was suggested to be a risk factor for human gut 
colonisation by ESBL-producing E. coli (Meyer, Gastmeier, Kola & Schwab, 2012). Regarding 
UTI, companion animals from the same household may be colonised and share uropathogenic 
E. coli of the O25b:H4-B2-ST131 clonal lineage (Johnson, Miller, Johnston, Clabots & DebRoy, 
2009; Johnson et al., 2016). The transfer of bacteria from humans to companion animals is 
also a concern in an animal health perspective. In fact, humans with UTI may share the index 
uropathogenic E. coli with household members including the family dogs and cats (Murray, 
                                               
11 E. faecium CC 17 is a hospital-adapted clonal complex associated with human infection (Damborg et al., 2009). 
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Kuskowski & Johnson, 2004; Johnson & Clabots, 2006; Damborg et al., unpublished data12). 
Little is known about K. pneumoniae and P. mirabilis when compared with E. coli. However, 
understanding the colonisation of healthy and infected companion animals is crucial to clarify 
the role of dogs and cats as reservoir of K. pneumoniae and P. mirabilis. 
 
1.6.1 K. pneumoniae gut colonisation 
K. pneumoniae spreads easily through person-to-person contact (healthcare workers, 
patients) and contaminated surfaces and instrumentation (Martin & Bachman, 2018). In the 
colonised human, K. pneumoniae can be found mainly in the nasopharynx and the 
gastrointestinal tract (Podschun & Ullmann, 1998). The gastrointestinal colonisation is believed 
to be the major K. pneumoniae reservoir and is associated with increased risk for subsequent 
infections in hospitalised patients, including UTIs (Podschun & Ullmann, 1998; Martin et al., 
2016; Gorrie et al., 2017). Notably, there is high concordance between the colonising and 
subsequent infection strains (Martin et al., 2016; Gorrie et al., 2017). This is particularly 
relevant regarding ESBL/carbapenemase-producing K. pneumoniae and regarding 
hypervirulent strains due to limited therapeutic options and/or high morbidity (Gorrie et al., 
2017; Martin & Bachman, 2018). Colonisation rates vary according to the study and studied 
population (Podschun & Ullmann, 1998; Martin & Bachman, 2018). Nasopharingeal 
colonisation by K. pneumoniae in humans varies from 3 to 15% in community settings and 
19% in hospitals (Podschun & Ullmann, 1998; Martin & Bachman, 2018). Reported 
gastrointestinal colonisation in humans can reach 35% in the community and 20-77% in 
hospitalised patients (Podschun & Ullmann, 1998; Martin & Bachman, 2018). The higher 
colonisation rates in hospital settings are associated with higher lengths of stay, working 
hospital personal and antimicrobial use, among others (Podschun & Ullmann, 1998; Martin & 
Bachman, 2018). Most K. pneumoniae colonisation studies are focussed on hospital settings; 
however, few reports have also suggested the possible transmission of K. pneumoniae 
between humans within the same household (Gottesman, Agmon, Shwartz & Dan, 2008; Löhr 
et al., 2013). Little is known about the colonisation rates in dogs and cats and studies regarding 
animal-human transmission are lacking. Although most studies were focussed on 
ESBL/carbapenemase-producing bacteria, K. pneumoniae has been detected in faecal 
samples from healthy and diseased dogs (Olson, Hedhammar, Faris, Krovacek & Wadström, 
1985; Balish, Cleven, Brown & Yale, 1977; Ewers et al., 2014b; González-Torralba et al., 2016; 
Sabbioni et al., 2016; Sharif, Sreedevi, Chaitanya & Sreenivasulu, 2017; Silva et al., 2018). 
Balish et al. (1977) detected a 57% K. pneumoniae gut colonisation in enclosed healthy 
beagles while Shariff et al. (2017) reported 26% of colonised healthy dogs in India. The 
persistent colonisation of a dog by a CTX-M-15-producing K. pneumoniae ST231 after 
recovery of a respiratory infection and pyometra was recently described by Silva et al. (2018). 
                                               
12 Available as a preprint at bioRxiv at https://www.biorxiv.org/content/early/2018/04/17/302885. 
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1.6.2 P. mirabilis gut colonisation 
The gut is also suggested as a reservoir of Proteus spp. bacteria (Drzewiecka, 2016). 
Interestingly, Peerbooms et al. (1986), showed that faecal P. mirabilis have similar virulence 
traits as strains causing UTI in humans. Faecal colonisation frequencies of bacteria in humans 
vary according to the intestinal section considered and Proteus spp. ranges from 12% to 45% 
(Zilberstein et al., 2007). Lower frequencies of P. mirabilis colonisation (~2%) have been 
reported (Müller, 1986; Porres-Osante, Sáenz, Somalo & Torres, 2015). Several studies have 
pointed to the gut colonisation as a source of uropathogenic P. mirabilis strains in human 
patients with UTI (Drzewiecka, 2016). In fact, catheterised human patients are usually 
colonised in the gut by the same uropathogenic P. mirabilis stain causing UTI (Mathur, 
Sabbuba, Suller, Stickler & Feneley, 2005). Gaastra et al. (1996) did not detect P. mirabilis in 
the faeces of healthy dogs, however, dogs with UTI were shown to have a high burden of the 
uropathogenic P. mirabilis in urine and faeces. Hariharan et al. (2010) found 6% P. mirabilis 
positive faecal samples in feral cat from Grenada and Balish et al. (1977) detected a 43%  
P. mirabilis gut colonisation in enclosed healthy beagles. Studies addressing the sharing and 






 Study goals 
Chapter 2 – Study goals 
The major goal of this thesis was to contribute to the understanding of the antimicrobial 
resistance epidemiology of UTI pathogens in companion animals and its public health 
relevance, with a special focus to K. pneumoniae and P. mirabilis species. The experimental 
work was divided in three main parts: 
 
 
In the first part, the aim of the work was to obtain up-to-date epidemiological 
information on antimicrobial resistance of bacteria isolated from companion animals 
with UTI. This goal was pursued by determining the prevalence of uropathogens and 
antimicrobial resistance across several European countries. Furthermore, the 
secular temporal trends of antimicrobial resistance and the public health relevance 
of bacteria harbouring critical antimicrobial resistance genes causing UTI in 
companion animals from Portugal (Lisbon) was studied. 
 
 
The second part of this work aimed to characterise the molecular epidemiology of 
clinical K. pneumoniae and P. mirabilis strains from companion animals and humans 
with UTI. By studying the population structure, antimicrobial resistance and virulence 
genotype of strains of both origins, this part of the study aimed to get insights on the 
role of infected companion animals as reservoirs and in the dissemination of clinical 
K. pneumoniae and P. mirabilis. 
 
 
The third part of this thesis aimed to characterise the gut colonisation by  
K. pneumoniae and P. mirabilis in healthy companion animals and humans.  
Through the study of households composed of companion animals and humans 
living in close contact, this part of the study aimed at providing new data about  
K. pneumoniae and P. mirabilis animal-human sharing and assess the role of 











  Epidemiology of uropathogenic bacteria 
in companion animals 
 
Chapter 3 Epidemiology of uropathogenic bacteria in companion animals 
3.1 European multicenter study on antimicrobial resistance in bacteria isolated 
from companion animal urinary tract infections. 
 
Full paper published at the BMC Veterinary Research 
 
Marques, C.*, Gama, L.T., Belas, A., Bergström, K., Beurlet, S., Briend-Marchal, A., Broens. 
E.M., Costa, M., Criel, D., Damborg, P., van Dijk, M.A., van Dongen, A.M., Dorsch, R., Espada, 
C.M., Gerber, B., Kritsepi-Konstantinou, M., Loncaric, I., Mion, D., Misic, D., Movilla, R., 
Overesch, G., Perreten, V., Roura, X., Steenbergen, J., Timofte, D., Wolf, G., Zanoni, R.G., 
Schmitt, S., Guardabassi, L., Pomba, C. (2016). European multicenter study on antimicrobial 
resistance in bacteria isolated from companion animal urinary tract infections. BMC Veterinary 
Research, 12, 213. 
 
*The author jointly conceived the design of the study and contacted the collaborating laboratories. The 
author managed all datasets and jointly conducted statistical analysis. The author wrote the initial draft 




Partial results were presented as, 





European multicenter study on antimicrobial resistance in 
bacteria isolated from companion animal urinary tract 
infections. 
 
Cátia Marques1, Luís Telo Gama1, Adriana Belas1, Karin Bergström2, Stéphanie Beurlet3, 
Alexandra Briend-Marchal3, Els M. Broens4, Marta Costa5, Delphine Criel6, Peter 
Damborg7, Marloes A. M. van Dijk4, Astrid M. van Dongen8, Roswitha Dorsch9, Carmen 
Martin Espada10, Bernhard Gerber11, Maria Kritsepi-Konstantinou12, Igor Loncaric13, 
Domenico Mion14, Dusan Misic15, Rebeca Movilla16, Gudrun Overesch17, Vincent 
Perreten17, Xavier Roura16, Joachim Steenbergen6, Dorina Timofte18,19,20, Georg Wolf21, 
Renato Giulio Zanoni14, Sarah Schmitt22, Luca Guardabassi7,23, Constança Pomba1 
 
1Faculdade de Medicina Veterinária, Centro de Investigação Interdisciplinar em Sanidade Animal 
(CIISA), Lisboa, Portugal. 
2The National Veterinary Institute (SVA), Uppsala, Sweden. 
3Laboratoire Vebiotel, Arcueil, France. 
4Department of Infectious Diseases and Immunology, Utrecht University, Utrecht, The Netherlands. 
5Department of Clinical Veterinary Sciences, Faculty of Medical and Veterinary Sciences, University of 
Bristol, Langford, UK. 
6AML-Medvet laboratory, Antwerp, Belgium. 
7Department of Veterinary Disease Biology, Faculty of Health and Medical Sciences, University of 
Copenhagen, Frederiksberg, Denmark. 
8Department of Clinical Sciences of Companion Animals, University of Utrecht, Utrecht, The 
Netherlands. 
9Clinic of Small Animal Medicine, LMU Munich, Munich, Germany. 
10Hospital Clínico Veterinario Complutense, Universidad Complutense, Servicio de Microbiologia y 
Parasitologia, Madrid, Spain. 
11Vetsuisse Faculty, University of Zurich, Clinic for Small Animal Internal Medicine, Zurich, Switzerland. 
12Department of Clinical Studies, Companion Animal Clinic, Faculty of Health Sciences, School of 
Veterinary Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece. 
13Institute of Microbiology, University of Veterinary Medicine, Vienna, Austria. 
14Department of Veterinary Medical Science, University of Bologna, Bologna, Italy. 
15Department of microbiology, Faculty of Veterinary Medicine, University of Belgrade, Belgrade, Serbia. 
16Hospital Clínic Veterinari, Universitat Autònoma de Barcelona, Bellaterra, Spain. 
17Institute of Veterinary Bacteriology, Vetsuisse Faculty, University of Bern, Bern, Switzerland. 
18School of Veterinary Science, University of Liverpool, Cheshire, UK. 
19Faculty of Veterinary Medicine, University of Agronomical Sciences Veterinary Medicine, Lasi, 
Romania. 
20Institute of Infection and Global Health, University of Liverpool, Liverpool, UK. 
21Institute for Infectious Diseases and Zoonoses, LMU Munich, Munich, Germany. 
22Institute of Veterinary Bacteriology, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland. 
23Department of Biomedical Sciences, Ross University School of Veterinary Medicine, Basseterre, St 





Background: There is a growing concern regarding the increase of antimicrobial resistant 
bacteria in companion animals. Yet, there are no studies comparing the resistance levels of 
these organisms in European countries. The aim of this study was to investigate geographical 
and temporal trends of antimicrobial resistant bacteria causing urinary tract infection (UTI) in 
companion animals in Europe. The antimicrobial susceptibility of 22 256 bacteria isolated from 
dogs and cats with UTI was determined. Samples were collected between 2008 and 2013 from 
16 laboratories of 14 European countries. The prevalence of antimicrobial resistance of the 
most common bacteria was determined for each country individually in the years 2012–2013 
and temporal trends of bacteria resistance were established by logistic regression.  
Results: The aetiology of uropathogenic bacteria differed between dogs and cats. For all 
bacterial species, Southern countries generally presented higher levels of antimicrobial 
resistance compared to Northern countries. Multidrug-resistant Escherichia coli were found to 
be more prevalent in Southern countries. During the study period, the level of fluoroquinolone-
resistant E. coli isolated in Belgium, Denmark, France and the Netherlands decreased 
significantly. A temporal increase in resistance to amoxicillin/clavulanate and gentamicin was 
observed among E. coli isolates from the Netherlands and Switzerland, respectively. Other 
country-specific temporal increases were observed for fluoroquinolone-resistant Proteus spp. 
isolated from companion animals from Belgium. 
Conclusions: This work brings new insights into the current status of antimicrobial resistance 
in bacteria isolated from companion animals with UTI in Europe and reinforces the need for 
strategies aiming to reduce resistance. 
 
Keywords: Antimicrobial resistance, Temporal trends, MRSA, MRSP, Dog, Cat 
 
Introduction 
Bacterial urinary tract infections (UTI) are frequently diagnosed in dogs and are considered 
rare in cats (Dowling, 1996; Thompson et al., 2011). Lately, increased frequencies of UTI in 
cats have been reported in some European countries (Gerber et al., 2005; Eggertsdóttir et al., 
2007; Sævik et al., 2011) in particularly when concurrent diseases are present (Mayer-Roenne 
et al., 2007). 
Escherichia coli is the most frequent isolated bacteria causing UTI in dogs and cats. Several 
studies show frequencies greater than 30% (Litster et al., 2007b; Hall et al., 2013; Dorsch et 
al., 2015). Other commonly isolated bacteria genera include Staphylococcus spp., 
Enterococcus spp., Proteus spp. and Klebsiella spp. (Féria et al., 2000; Litster et al., 2007b; 
Hall et al., 2013; Dorsch et al., 2015). 
Previous studies in the United Kingdom and in Missouri-Columbia (USA) analysing the 
temporal trends of antimicrobial resistance in small collections of bacterial isolates from 
companion animal infections point to a significant increase in antimicrobial resistance 
(Normand et al., 2000a; Cohn et al., 2013). Furthermore, the emergence of multidrug-resistant 
bacteria (isolates resistant to three or more antimicrobial categories) in companion animals is 
an increasing concern (Pellerin et al., 1998; Normand et al., 2000a; Pomba et al., 2014a; 
Pomba et al., 2017). This creates new therapeutic challenges in veterinary medicine and is 
also a public health issue, since these pathogens may be zoonotic (Johnson & Clabots, 2006) 
and companion animals may play a role in the spread of resistant bacteria due to their close 
contact to humans (Guardabassi et al., 2004; Pomba et al., 2017). 
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Antimicrobial resistance may vary according to the geographic location (European Centre for 
Disease Prevention and Control [ECDC], 2014; Dorsch et al., 2015). Data on antimicrobial 
resistance in bacteria isolated from companion animals with UTI in Europe are not easily 
comparable due to differences in study design, such as variations in host species, inclusion 
criteria and/or time period. Thus, it is difficult to get a European overview of antimicrobial 
resistance as seen in human medicine surveillance programmes such as the European 
Antimicrobial Resistance Surveillance Network (ECDC, 2014). 
Antimicrobial therapy in UTI should ideally rely on susceptibility testing of the isolated bacteria 
(Weese et al., 2011). Yet, antimicrobials are frequently administered empirically based on the 
presence of compatible clinical signs, urine cytological findings and in the absence of urine 
culture and are required to alleviate UTI symptoms while waiting for antimicrobial susceptibility 
testing results (Weese et al., 2011). Besides the pharmacokinetic-pharmacodynamic 
properties, the empiric antimicrobial selection should consider the most likely causative agent 
as well as its regional susceptibility patterns (Hall et al., 2013). Moreover, according to the 
World Organization for Animal Health (World Organization for Animal Health [OIE], 2018), 
veterinarians should adopt strategies aimed at the reduction of antimicrobial resistance. 
Therefore, current information on the aetiology and antimicrobial resistance focussed on UTI 
is of crucial importance. 
Under the umbrella of the European Society of Veterinary Nephrology and Urology, a 
multicenter retrospective study was launched in November 2013 with the goal of getting 
antimicrobial resistance data on bacteria isolated from companion animal with UTI across 
Europe. A Urinary Tract Infection Resistance – Veterinary Network (UTIR-VNet) was 
constituted with this purpose in mind. Partial results were presented at the annual Society 
meeting included in the 25th congress of the European College of Veterinary Internal Medicine, 
4–6 September 2014, Mainz, Germany. The aim of this study was to determine the frequency 
of uropathogens in dogs and cats with urinary tract infection in Europe and to characterise the 
frequency and temporal trends of antimicrobial resistance over a period of six years. We 




Between January and September 2014, 16 veterinary microbiology laboratories from  
14 European countries (Austria, Belgium, Denmark, France, Germany, Greece, Italy, the 
Netherlands, Portugal, Serbia, Spain, Sweden, Switzerland, United Kingdom), were invited to 
participate in this study (Figure 1). Laboratories were requested to send available retrospective 
data on animal species, age and gender, bacterial identification and antimicrobial susceptibility 
testing conducted in bacteria obtained from dogs and cats with UTI between 2008 and 2013. 
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The bacteria identification varied between laboratories. Most laboratories used standard 
phenotypic tests, including API, while others used techniques such as PCR and MALDI-TOF. 
This discrepancy was particularly evident for staphylococci, which were classified to either the 
species or genus level depending on the laboratory. 
 
Figure 1 - Participating countries in the urinary tract infection antimicrobial resistance 
veterinary network – UTIR-VNet 
 
Legend: Countries: AT- Austria; BE- Belgium; DK- Denmark; FR- France; DE- Germany; EL- Greece; 
IT- Italy; NL- the Netherlands; PT- Portugal; RS- Serbia; ES- Spain; SE- Sweden; CH- Switzerland;  
UK- United Kingdom 
 
Susceptibility testing 
The following antimicrobials were included: amoxicillin/clavulanate (AMC), ampicillin (AMP), 
cefotaxime (CTX), cefovecin (CVN), cefoxitin (FOX), ceftazidime (CAZ), cefpodoxime (CPD), 
ceftiofur (EFT), ciprofloxacin (CIP), enrofloxacin (ENR), gentamicin (CN), marbofloxacin 
(MAR), oxacillin (OX), penicillin (P) and trimethoprim/sulfamethoxazole (SXT). 
The retrospective nature of the study forced us to include two in vitro antimicrobial susceptibility 
testing methods. Laboratories from Austria, France, Germany, Greece, Italy, the Netherlands, 
Belgium (VITEK 2, BioMérieux) used broth microdilu-
tion method.
Human CLSI breakpoints [22] were used for interpret-
ation of minimal inhibitory concentration and disk diffu-
sion results for CAZ (30 μg), CTX (30 μg), and CIP (5 μg),
whereas veterinary CLSI breakpoints [23] were used for
AMC (30 μg), AMP (30 μg), CN (10 μg), CPD (10 μg),
ENR (5 μg), FOX (30 μg), MAR (5 μg), OX (1 μg), P
(10U), and SXT (25 μg). Clinical breakpoints from the
Societé Française de Microbiology [24] were used for EFT
(30 μg). Results for CVN (30 μg) were interpreted accord-
ing to the manufacturer guidelines. As seen in the human
European Antimicrobi l Resistance Surveillance Network
(EARS-Net) report [18], when data on minimal inhibitory
concentrations or inhibition zone diameter were not avail-
able, the laboratories’ own interpretations (susceptible,
intermediate and resistant) were accepted. This was the
case for Spain, Serbia, and Germany that used contempor-
ary CLSI guidelines, for the United Kingdom that used the
breakpoints from the British Society of Antimicrobial
Chemotherapy [25] and for the Netherlands and
Switzerland (2008–2010) that used breakpoints recom-
mended by the Dutch Committee on Guidelines for Sus-
ceptibility testing [26].
Fig. 1 Participating countries in the Urinary tract infection antimicrobial resistance veterinary network – UTIR-VNet. Countries: AT- Austria; BE- Belgium;
DK- Denmark; FR- France; DE- Germany; EL- Greece; IT- Italy; NL- the Netherlands; PT- Portugal; RS- Serbia; ES- Spain; SE- Sweden; CH- Switzerland;
UK- United Kingdom
Marques et al. BMC Veterinary Research  (2016) 12:213 Page 3 of 17
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Portugal, Serbia, Spain, United Kingdom, used standard disc diffusion method according to 
Clinical Laboratory Standards Institute (CLSI) guidelines (Clinical and Laboratory Standards 
Institute [CLSI], 2013b), whereas Sweden (VetMIC, SVA, Uppsala, Sweeden), Denmark and 
United Kingdom (COMPAN1F Sensititre panels, Thermo Fisher), Switzerland and Belgium 
(VITEK 2, BioMérieux) used broth microdilution method. 
Human CLSI breakpoints (Clinical and Laboratory Standards Institute [CLSI], 2015) were used 
for interpretation of minimal inhibitory concentration and disk diffusion results for CAZ (30 μg), 
CTX (30 μg), and CIP (5 μg), whereas veterinary CLSI breakpoints (Clinical and Laboratory 
Standards Institute [CLSI], 2013b) were used for AMC (30 μg), AMP (30 μg), CN (10 μg),  
CPD (10 μg), ENR (5 μg), FOX (30 μg), MAR (5 μg), OX (1 μg), P (10U), and SXT (25 μg). 
Clinical breakpoints from the Societé Française de Microbiology (Societe Française de 
Microbiology [SFM], 2012) were used for EFT (30 μg). Results for CVN (30 μg) were 
interpreted according to the manufacturer guidelines. As seen in the human European 
Antimicrobial Resistance Surveillance Network (EARS-Net) report (ECDC, 2014), when data 
on minimal inhibitory concentrations or inhibition zone diameter were not available, the 
laboratories’ own interpretations (susceptible, intermediate and resistant) were accepted. This 
was the case for Spain, Serbia, and Germany that used contemporary CLSI guidelines, for the 
United Kingdom that used the breakpoints from the British Society of Antimicrobial 
Chemotherapy (Howe, Andrews & BSAC Working Party on Susceptibility Testing, 2012) and 
for the Netherlands and Switzerland (2008–2010) that used breakpoints recommended by the 
Dutch Committee on Guidelines for Susceptibility testing (Commissie Richtlijnen 
Gevoeligheidsbepalingen, 2000). 
 
Data analysis and statistical methods 
Statistical analysis was performed using the SAS statistical software package for Windows, 
version 9.3, (SAS Institute Inc, Cary, North Carolina, USA). 
The Fisher exact test was used to compare pathogen frequencies by species or gender of the 
host, by simple/multiple infection and by country. An alpha value of 0.05 was used. 
Isolates were considered fully-resistant when found to be resistant according to the clinical 
breakpoint applied. An isolate was considered susceptible when found to be susceptible or 
intermediate according to the clinical breakpoint applied. The antimicrobials included in this 
study are known to be highly concentrated in the urine so their report as susceptible may be 
appropriated for isolates categorised as intermediate (Weese et al., 2011). 
Regarding third-generation cephalosporins (3GC), laboratories tested different 3GC-
resistance surrogates. Therefore, to evaluate the antimicrobial resistance to 3GC, an isolate 
was considered as 3GC-resistant when it was resistant to at least one of the five 3GC tested 
(CTX, CAZ, CVN, EFT or CPD). The same rational was applied to evaluate resistance to 
fluoroquinolones (FLU), namely using ENR, CIP or MAR as a marker of resistance. Methicillin-
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resistance in staphylococci was determined according to CLSI guidelines (CLSI, 2013a) using 
cefoxitin or oxacillin to evaluate resistance depending on the bacterial species considered. Yet, 
Germany and Spain did not send data on methicillin-resistance. France did not test 
staphylococci against oxacillin and thus did not report methicillin-resistance regarding 
Staphylococcus pseudintermedius (MRSP). The Netherlands did not have data on 
staphylococci susceptibility to OX or FOX but instead reported data on the detection of the 
mecA gene by PCR. The frequency of methicillin-resistance did not include staphylococci only 
identified to the genus level. 
Enterobacteriaceae were considered multidrug-resistant (MDR) when fully-resistant to three 
or more categories of antimicrobials, namely AMC, 3GC, SXT, CN and/or FLU. Unlike the MDR 
definition proposed by other authors (Magiorakos et al., 2012), intermediate isolates from this 
study were considered as susceptible. This difference was applied because we are considering 
drugs that can be highly concentrated in urine. Furthermore, this approach will reduce any 
overestimation of MDR frequency due to the use of different breakpoint guidelines. Full-
susceptibility (FullS) was defined as an isolate being susceptible for all the above-mentioned 
categories of antimicrobials. Since Belgium had no data available on 3GC and the Netherlands 
had little data on CN, MDR and FullS percentages do not include resistance to 3GC for Belgium 
and resistance to CN for the Netherlands. 
As a rule, statistical analysis was only done when at least ten isolates for a specific  
organism-antimicrobial agent combination were reported for a given country. All frequencies 
are presented with a confidence interval of 95% (95% CI). 
Maps of European resistance distribution were drawn considering the percentage of fully-
resistant isolates to the considered antimicrobial agent, over the years 2012–2013. A scale of 
colours was applied composed of six resistance intervals after the example of EARS-Net 
surveillance programme reports (ECDC, 2014). 
Statistical analysis of temporal trends of antimicrobial resistance for a specific  
organism-antimicrobial agent combination were determined within each country. Temporal 
trends were only determined for countries reporting data on at least three consecutive years 
and ten isolates per year. A SAS LOGISTIC regression, with the year as a continuous variable 
and an alpha value of 0.05 was conducted. Temporal trends of resistance were mainly 
determined for E. coli since this was the most represented bacterial species. Yet, temporal 
trends of AMC, FLU and SXT in Proteus spp. were also determined for Belgium, France, the 
Netherlands and Sweden. 
 
Results 
Overall, data on 22256 uropathogenic bacteria were obtained from 15097 dog and 5963 cat 




Considering the records containing information about the age, dogs (n =  4425) and cats  
(n =  1514) had similar mean ages, namely 8.77 years (SD ± 4.04, 9.00 median, 6.00 IQR, 
range 0.1–20) and 8.82 years (SD ± 5.03, 8.50 median, 8.1 IQR, range 0.2–22) respectively. 
Gender was only specified in 3885 records where 61.41% (95%CI 59.69–63.12%,  
n =  1900/3094) of dogs and 48.29% (95% CI 44.81–51.78%, n =  382/791) of cats were 
females. 
Among all urine cultures, 94.64% (95% CI 94.33–94.94%, n =  19932/21060) resulted in the 
growth of bacterial pure cultures, with no significant difference between cats and dogs  
(p =  0.1856). Both in dogs and cats, E. coli was the most frequently identified bacteria and 
accounted for 59.45% (95% CI 58.80–60.09%, n =  13231/22256) of all isolates. The frequency 
of the remaining bacterial species differed significantly between dogs and cats (Table 2). 
Enterococcus spp. and Staphylococcus spp. frequencies were higher in cats, whereas  
Proteus spp. and Klebsiella spp. were more prevalent in dogs. 
 
Table 1 - Total number of isolated bacteria by year and country 
Countrya Year 
 
2008 2009 2010 2011 2012 2013 Total 
AT - - - - 144 185 329 
BE - - 547 578 623 739 2487 
DK 29 30 53 116 153 205 587 
FR - - 620 733 780 995 3128 
DE - 64 93 140 161 146 604 
EL 24 29 13 11 32 43 152 
IT - 36 29 36 77 65 243 
NL 480 867 958 1132 1195 1307 5939 
PT 77 54 57 34 32 45 299 
RS 17 19 10 2 3 3 54 
ES 14 23 27 40 47 79 230 
SE 730 924 1071 1202 1355 1647 6929 
CH 109 120 112 125 114 174 754 
UK 31 44 81 117 126 122 521 
Total 1511 2210 3671 4267 4842 5755 22256 
 
Legend: aAT, Austria; BE, Belgium; DK, Denmark; FR, France; DE, Germany; EL, Greece; IT, Italy;  
NL, the Netherlands; PT, Portugal; RS, Serbia; ES, Spain; SE, Sweden; CH, Switzerland; UK, United 
Kingdom. 
 
Considering the years 2012–2013, the major differences in E. coli (Table 3, Figure 2) and 
Proteus spp. (Table 4, Figure 3) antimicrobial resistance frequencies were seen between 
Northern (Denmark and Sweden) and Southern (Italy, Greece, Portugal and Spain) countries. 
The lowest frequencies of AMC resistance in E. coli were detected in isolates from Denmark 
(2.88%) and Belgium (4.29%). E. coli from Portugal (48.15%) had a significantly higher AMC 
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Table 2 - Uropathogenic bacteria aetiology, single versus mixed infections and cat versus dog as host species 
















































































































Legend: a95 % CI, 95 % Confidence interval; 
n – Total number of isolates; 





Table 3 - Percentage of resistance in E. coli by antimicrobial and country in 2012–2013 
Countrya AMC 3GC FLU CN SXT Combined resistance 
n % R  
(95% CI)b 
[Stat. Dif.]c 
n % R  
(95% CI)b 
[Stat. Dif.]c 
n % R  
(95% CI)b 
[Stat. Dif.]c 
n % R  
(95% CI)b 
[Stat. Dif.]c 
n % R  
(95% CI)b 
[Stat. Dif.]c 
n % MDR  
(95% CI)b 
[Stat. Dif.]c 
% FullS  
(95% CI)b 
[Stat. Dif.]c 
AT 142 14.08  
(8.36–19.81) 
[a,b] 
142 5.63  
(1.84–9.43) 
[a, b] 
142 11.97  
(6.63–17.31) 
[a] 
142 5.63  
(1.84–9.43) 
[a, b] 
142 14.08  
(8.36–19.81) 
[a, b] 











769 6.63  
(4.87–8.39) 
[b] 
840 1.67  
(0.80–2.53) 
[c] 









DK 206 2.88  
(0.61–5.16) 
[c] 
208 4.33  
(1.41–7.09) 
[a, c] 
208 2.88  
(0.61–5.16) 
[c] 
208 1.92  
(0.06–3.79) 
[a, c] 
208 8.17  
(4.45–11.90) 
[a, c] 






FR 954 12.79  
(10.67–15.91) 
[a, d] 
933 10.83  
(8.83–12.82) 
[b] 
948 12.76  
(10.64–14.89) 
[a] 
951 3.36  
(2.22–4.51) 
[a, d] 
959 16.27  
(13.93–18.60) 
[b, d] 






DE 153 11.76  
(6.66–16.87) 
[a, d] 
152 11.84  
(6.71–16.98) 
[b, d] 
153 16.34  
(10.48–22.20) 
[a, d] 
153 1.96  
(0.00–4.16) 
[a, c, d] 
153 17.65  
(11.61–23.69) 
[b, d, e] 






EL 31 25.81  
(10.40–41.21) 
[b, d, e, f] 
9 7R/2S 
- 












IT 69 26.09  
(15.73–36.45) 
[e, f] 
69 24.64  
(14.47–34.80) 
[e] 
69 31.88  
(20.89–42.88) 
[e] 
69 14.49  
(6.19–22.80) 
[e] 
69 28.99  
(18.28–39.69) 
[e, f] 





[d, e, f] 
NL 1461 10.81  
(9.22–12.41) 
[a] 
1380 3.77  
(2.76–4.77) 
[a, c] 
1457 4.94  
(3.83–6.05) 
[b, c] 
81 3.70  
(0.00–7.82) 
[a, c, f] 









PT 27 48.15  
(29.30-66.99) 
[e] 
32 31.25  
(15.19-47.31) 
[e] 
31 29.03  
(13.05-45.01) 
[d, e] 
30 10.00  
(0.00-20.74) 
[b, d, e, f] 
31 32.26  
(15.80-48.71) 
[e, f] 
25 24.00  
(7.26-40.74) 







Table 3 (continuation) - Percentage of resistance in E. coli by antimicrobial and country in 2012–2013 
Countrya AMC 3GC FLU CN SXT Combined resistance 
n % R  
(95% CI)b 
[Stat. Dif.]c 
n % R  
(95% CI)b 
[Stat. Dif.]c 
n % R  
(95% CI)b 
[Stat. Dif.]c 
n % R  
(95% CI)b 
[Stat. Dif.]c 
n % R  
(95% CI)b 
[Stat. Dif.]c 
n % MDR  
(95% CI)b 
[Stat. Dif.]c 
% FullS  
(95% CI)b 
[Stat. Dif.]c 














ES 60 31.67  
(19.90–43.44) 
[e, f] 
52 21.15  
(10.05–32.25) 
[d, e] 
61 29.51  
(18.06–40.95) 
[e] 
46 15.22  
(4.84–25.60) 
[b, e] 
60 26.67  
(15.48–37.86) 
[e, f] 












2091 1.05  
(0.61–1.49) 
[f] 
2091 0.19  
(0.00–0.38) 
[g] 
2091 4.97  
(4.04–5.91) 
[c] 






CH 133 10.53  
(5.31–15.74) 
[a, g] 
133 8.27  
(3.59–12.95) 
[b, c] 
132 13.64  
(7.78–19.49) 
[a, d] 
132 6.82  
(2.52–11.12) 
[b, d, e, f] 
131 13.74  
(7.85–19.64) 
[a, d, g] 






UK 143 21.68  
(14.92–28.43) 
[b, f] 
143 20.98  
(14.31–27.65) 
[d, e] 
143 11.89  
(6.58–17.19) 
[a] 
92 6.52  
(1.48–11.57) 
[a, e, f] 
142 21.13  
(14.41–27.84) 
[b, f, g] 





[a, d, f] 
 
Legend: AMC, amoxicillin/clavulanate; 3GC, third-generation cephalosporins; FLU, fluoroquinolones; CN, gentamicin; SXT, trimethoprim/sulfamethoxazole;  
MDR, multidrug-resistant; FullS, fully-susceptible; 
aCountries: AT, Austria; BE, Belgium; DK, Denmark; FR, France; DE, Germany; EL, Greece; IT, Italy; NL, the Netherlands; PT, Portugal; RS, Serbia; ES, Spain;  
SE, Sweden; CH, Switzerland; UK, United Kingdom; 
b95% CI, 95% Confidence interval; 
cStat. Dif., Statistical significant differences. Countries with no statistical difference are marked with the same letter. Countries were compared by Fisher exact test with 
an alpha value of 0.05. Countries with less than ten tested isolates were not compared. Regarding MDR and FullS, only countries tested for all the considered 
antimicrobials were compared; 
dMDR and FullS percentages do not include resistance to 3GC for Belgium and resistance to CN for the Netherlands; 




Figure 2 - Percentage (%) of E. coli antimicrobial resistance by antimicrobial and 
country in the years 2012–2013 
 
 
Legend: Countries: AT, Austria; BE, Belgium; DK, Denmark; FR, France; DE, Germany; EL, Greece; 
IT, Italy; NL, the Netherlands; PT, Portugal; RS, Serbia; ES, Spain; SE, Sweden; CH, Switzerland;  
UK, United Kingdom. 
Multidrug resistance considering combined resistance to three or more of the following antimicrobial 
categories: AMC, 3GC, FLU, CN and SXT. Full-susceptibility (FullS) was defined as an isolate being 
susceptible for all the above-mentioned categories of antimicrobials. 
Regarding multidrug resistance and full-susceptibility frequencies, countries marked by asterisk: 3GC 
was not included for Belgium and CN for the Netherlands. Thus, these frequencies may be 
underestimated when compared with the remaining countries. 
Fig. 2 Percentage (%) of Escherichia coli antimicrobial resistance by antimicrobial and country in the years 2012–2013. Countries: AT- Austria;
BE- Belgium; DK- Denmark; FR- France; DE- Germany; EL- Greece; IT- Italy; NL- the Netherlands; PT- Portugal; RS- Serbia; ES- Spain; SE- Sweden;
CH- Switzerland; UK- United Kingdom. Multidrug-resistance considering combined resistance to three or more of the following antimicrobial
categories: AMC, 3GC, FLU, CN and SXT. Full-susceptibility (FullS) was defined as a isolate being susceptible for all the abov -mentioned categories of
antimicrobials. Regarding multidrug-resistance and full-susceptibility frequencies, countries marked by asterisk: 3GC was not included for Belgium and
CN for the Netherlands. Thus, these frequencies may be underestimated when compared with the remaining countries
Marques et al. BMC Veterinary Research  (2016) 12:213 Page 7 of 17
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Table 4 - Percentage of resistance in Proteus spp. by antimicrobial and country in 2012-2013 
Countrya AMC 3GC FLU CN SXT Combined resistance 
n % R  
(95% CI)b 
[Stat. Dif.]c 
n % R  
(95% CI)b 
[Stat. Dif.]c 
n % R  
(95% CI)b 
[Stat. Dif.]c 
n % R  
(95% CI)b 
[Stat. Dif.]c 
n % R  
(95% CI)b 
[Stat. Dif.]c 






AT 29 10.34  
(0.00–21.43) 






[a, b, c] 
29 6.90  
(0.00–16.12) 
[a, b] 
29 37.93  
(20.27–55.59) 
[a, b] 












135 28.15  
(20.56–35.73) 
[a, d] 
155 9.68  
(5.02–14.33) 
[a] 






























FR 215 7.44  
(3.93–10.95) 
[b, d] 
211 6.64  
(3.28-9.99) 
[a] 
212 17,92  
(12.76-23.09) 
[b, g] 
214 9.81  
(5.83-13.80) 
[a] 
216 27.78  
(21.80-33.75) 
[a] 






DE 10 0 
- 
[a, b, f] 
10 10.00  
(0.00–28.59) 
[a, b, c] 





[a, b, c] 
10 20.00  
(0.00–44.79) 





















IT 12 0 
- 
[a, b, c] 
12 8.33  
(0.00–23.97) 
[a, b, c] 
12 41.67  
(13.77–69.56) 
[a, d, g] 
12 8.33  
(0.00–23.97) 
[a, b, c] 
12 66.67  
(39.99–93.34) 
[b, e] 
12 8.33  
(0.00–23.97) 




NL 261 6.13  
(3.22–9.04) 
[a, b, e] 
244 2.87  
(0.77–4.96) 
[a] 
260 8.85  
(5.39–12.30) 
[c, e, h] 
17 11.76  
(0.00–27.08) 
[a, c] 









PT 14 50.00  
(23.81–76.19) 
[e] 
15 33.33  
(9.48–57.19) 
[c, d] 
15 40.00  
(15.21–64.79) 
[a, g, i] 
15 33.33  
(9.48–57.19) 
[c] 
15 46.67  
(21.42–71.91) 
[a, e] 





[b, d, e] 














ES 15 26.67  
(4.29–49.05) 
[c, e, f] 
13 15.38  
(0.00–35.00) 
[a, d] 






15 53.33  
(28.09–78.58) 









Table 4 (continuation)- Percentage of resistance in Proteus spp. by antimicrobial and country in 2012-2013 
Countrya AMC 3GC FLU CN SXT Combined resistance 
n % R  
(95% CI)b 
[Stat. Dif.]c 
n % R  
(95% CI)b 
[Stat. Dif.]c 
n % R  
(95% CI)b 
[Stat. Dif.]c 
n % R  
(95% CI)b 
[Stat. Dif.]c 
n % R  
(95% CI)b 
[Stat. Dif.]c 






SE 170 2.35  
(0.07–4.63) 




170 0.59  
(0.00–1.74) 
[f] 
170 0.59  
(0.00–1.74) 
[b] 









CH 17 0 
- 




17 23.53  
(3.37–43.69) 
[a, g, h, I, j] 
17 5.88  
(0.00–17.07) 
[a, b, c] 









UK 16 12.50  
(0.00–28.70) 






[b, e, f, j] 
11 0 
- 
[a, b, c] 








[a, c, e] 
 
Legend: AMC, amoxicillin/clavulanate; 3GC, third-generation cephalosporins; FLU, fluoroquinolones; CN, gentamicin; SXT, trimethoprim/sulfamethoxazole;  
MDR, multidrug-resistant; FullS, fully-susceptible; 
aCountries: AT, Austria; BE, Belgium; DK, Denmark; FR, France; DE, Germany; EL, Greece; IT, Italy; NL, the Netherlands; PT, Portugal; RS, Serbia; ES, Spain;  
SE, Sweden; CH, Switzerland; UK, United Kingdom; 
b95% CI,95 % Confidence interval; 
cStat. Dif., Statistical significant differences. Countries with no statistical difference are marked with the same letter. Countries were compared by Fisher exact test with 
an alpha value of 0.05. Countries with less than ten tested isolates were not compared. Regarding MDR and FullS, only countries tested for all the considered 
antimicrobials were compared;  
dMDR and FullS percentages do not include resistance to 3GC for Belgium and resistance to CN for the Netherlands; 





Figure 3 - Percentage (%) of Proteus spp. antimicrobial resistance by antimicrobial 





Legend: Countries: AT, Austria; BE, Belgium; DK, Denmark; FR, France; DE, Germany; EL, Greece; 
IT, Italy; NL, the Netherlands; PT, Portugal; RS, Serbia; ES, Spain; SE, Sweden; CH, Switzerland;  
UK, United Kingdom. 
Multidrug resistance considering combined resistance to three or more of the following antimicrobial 
categories: AMC, 3GC, FLU, CN and SXT. Full-susceptibility was defined as an isolate being susceptible 
for all the above-mentioned categories of antimicrobials. 
Regarding multidrug resistance and full-susceptibility frequencies, countries marked by asterisk: 3GC 
was not included for Belgium and CN for the Netherlands. Thus, these frequencies may be 
underestimated when compared with the remaining countries. 
  
Fig. 3 Percentage (%) of Proteus spp. antimicrobial resistance by antimicrobial and country in the years 2012–2013. Countries: AT- Austria; BE- Belgium; DK-
Denmark; FR- France; DE- Germany; EL- Greece; IT- Italy; NL- the Netherlands; PT- Portugal; RS- Serbia; ES- Spain; SE- Sweden; CH- Switzerland; UK- United
Kingdom. Multidrug resistance considering combined resistance to three or more of the following antimicrobial categories: AMC, 3GC, FLU, CN and SXT.
Full-susceptibility was defined as an isolate being susceptible for all the above-mentioned categories of antimicrobials. Regarding multidrug-resistance and
full-susceptibility frequencies, countries marked by asterisk: 3GC w s not included for Belgium and CN for the Netherlands. Thus, these frequencies may be
underestimated when compared with the remaining countries




resistance frequency (P  <  0.05) when compared with all countries except for Spain, Italy and 
Greece (Table 3). Less than 15% of Proteus spp. were resistant to AMC in all countries with 
exception of Portugal (50%) and Spain (26.67%) (Table 4). 
E. coli resistance to 3GC had a similar distribution to what was seen for AMC (Figure 2). The 
highest 3GC-resistance frequencies were found in Southern countries, namely Portugal  
(31.25%), Italy (24.64%) and Spain (21.15%) (Table 3). Proteus spp. 3GC-resistance was 
lower than 5% in Austria, Denmark, Sweden, Switzerland, United Kingdom and the 
Netherlands, whereas Portugal (33.33%) and Spain (15.38%) were the countries with the 
highest resistance levels (Table 4). 
SXT-resistance in Southern countries was higher than 25 and 45% for E. coli and Proteus spp., 
respectively (Tables 3 and 4; Figures 2 and 3). Sweden and Denmark had the lowest SXT-
resistance values (lower than 9%). The remaining included countries had frequencies ranging 
between 10.21-21.13% and 20–37.93% in E. coli and Proteus spp., respectively (Tables 3  
and 4). 
E. coli FLU-resistance was higher in the Southern countries and ranged from 29.03% in 
Portugal to 31.88% in Italy (Table 3). Concerning Proteus spp., Spain and Germany had 
around 50% FLU-resistance, followed by Italy and Portugal with around 40% (Table 4). 
Sweden, Denmark, Belgium and the Netherlands had less than 10% FLU-resistant E. coli. 
Denmark, Sweden, United Kingdom and the Netherlands had less than 10% FLU-resistant 
Proteus spp. (Figures 2 and 3). 
Overall, E. coli CN-resistance was lower than 16% (Table 3). Regarding resistance to CN in 
Proteus spp. the same resistance frequency occurred with the exception of Portugal where a 
higher resistance frequency was recorded (33.33%) (Table 4). 
E. coli from Portugal, Spain and Italy, and Proteus spp. from Portugal showed the highest 
frequencies of MDR (Tables 3 and 4). As expected, Portugal was one of the countries with 
lowest FullS, both in E. coli (32.00%) and Proteus spp. (35.71%). Italy had even lower FullS in 
Proteus spp. (16.67%). Most of the remaining countries had MDR levels lower than 10%, with 
the exception of MDR E. coli from United Kingdom (15.56%) and France (11%). The highest 
E. coli and Proteus spp. FullS frequencies were found in Denmark and Sweden (Tables 3  
and 4). 
Due to the limited number of Staphylococcus spp. isolates available, the percentage of 
resistance to antimicrobials was determined on fewer countries for this group of bacteria 
(Tables 5 and 6). In most countries, Staphylococcus pseudintermedius was the most frequently 
isolated followed by coagulase negative staphylococci (CoNS) (Table 5). In general, the overall 
antimicrobial resistance levels in Southern countries were higher than in Northern countries 




Table 5 - Staphylococcus spp. and methicillin-resistance by country in 2012–2013 
 
Staphylococci species by country Methicillin-resistance within each group 
Countrya N SA SP CoPS CoNS SPP MRSA MRSP MRCoNS 
























































































































































































































Table 5 (continuation)- Staphylococcus spp. and methicillin-resistance by country in 2012–2013 
 
Staphylococci species by country Methicillin-resistance within each group 
Countrya N SA SP CoPS CoNS SPP MRSA MRSP MRCoNS 























































Legend: Staphylococci identification varied according to the country. Some countries identified staphylococci to species level, others to genus level and others included 
data on the coagulase test. Thus, the staphylococci results were grouped as follows: 1. Staphylococcus aureus (SA); 2. Staphylococcus pseudintermedius (SP);  
3. coagulase positive staphylococci (CoPS), 4. coagulase negative staphylococci (CoNS) and 5. other staphylococci (SPP). Group 3 includes staphylococci identified 
only as CoPS or staphylococci species known to be coagulase positive other than SA and SP. Group 4 includes staphylococci identified only as CoNS or staphylococci 
species known to be coagulase negative. Group 5 includes staphylococci identified as Staphylococcus spp.; 
MRSA methicillin-resistant Staphylococcus aureus, MRSP methicillin-resistant Staphylococcus pseudintermedius, MRCoNS methicillin-resistant coagulase negative 
staphylococci; 
aCountries: AT, Austria; BE, Belgium; DK, Denmark; FR, France; DE, Germany; EL, Greece; IT, Italy; NL, the Netherlands; PT, Portugal; RS, Serbia; ES, Spain;  
SE, Sweden; CH, Switzerland; UK, United Kingdom; 
b95 % CI, 95 % Confidence interval; 
N, Total number of staphylococci; 




Table 6 - Percentage of resistance in Staphylococcus spp. by antimicrobial and 
country in 2012–2013 
Countrya FLU CN SXT 
n % R (95% CI)b 
[Stat. Dif.]c 
n % R (95% CI)b 
[Stat. Dif.]c 
n % R (95% CI)b 
[Stat. Dif.]c 

















[a, b, c] 
DK 51 1.96 
(0.00–5.77) 
















DE 55 18.18 
(7.99–28.38) 







EL 10 20.00 
(0.00–44.79) 











































ES 13 15.38 
(0.00-35.00) 






[a, b, c] 

















[a, b, c] 
UK 31 12.90 
(1.10–24.70) 
[b, c, e, g] 
22 4.55 
(0.00–13.25) 
[a, b, c] 
30 16.67 
(3.33–30.00) 
[a, b, c] 
 
Legend: FLU, fluoroquinolones; CN, gentamicin; SXT, trimethoprim/sulfamethoxazole;  
aCountries: AT, Austria; BE, Belgium; DK, Denmark; FR, France; DE, Germany; EL, Greece; IT, Italy; 
NL, the Netherlands; PT, Portugal; RS, Serbia; ES, Spain; SE, Sweden; CH, Switzerland; UK, United 
Kingdom;  
b95% CI,95 % Confidence interval;  
cStat. Dif., Statistical significant differences. Countries with no statistical difference are marked with the 
same letter. Countries were compared by Fisher exact test with an alpha value of 0.05. Countries with 
less than ten tested isolates were not compared;  




Figure 4 - Percentage (%) of Staphylococcus spp. antimicrobial resistance by 
antimicrobial and country in the years 2012–2013 
 
 
Legend: Countries: AT, Austria; BE, Belgium; DK, Denmark; FR, France; DE, Germany; EL, Greece; 
IT, Italy; NL, the Netherlands; PT, Portugal; RS, Serbia; ES, Spain; SE, Sweden; CH, Switzerland;  
UK, United Kingdom 
 
Besides the limited number of staphylococci, methicillin-resistance results were also limited 
due to the identification only to genus level or lack of testing the appropriate antimicrobial 
surrogate. Denmark and Sweden showed the lowest S. pseudintermedius methicillin-
resistance (MRSP) (0 and 1.15%, respectively). The remaining countries had MRSP 
frequencies higher than 8%, attaining 50% in Italy. Methicillin-resistance was also high in CoNS 
(Table 5). 
Staphylococci SXT-resistance ranged from 2.77 to 63.16% and showed similar geographical 
distribution to Gram-negative bacteria (Figure 4). Among the participating countries, 
Staphylococci FLU-resistance frequencies were higher in Italy (42.11%) and again lower in 
Sweden (1.54%) and Denmark (1.96%), with the remaining countries varying between  
6.59 and 26.92% (Table 6). Italy, Austria, Germany and Switzerland CN-resistant 
staphylococci frequencies ranged between 26.32 and 9.76% while the remaining countries had 
less than 6% (Table 6). 
Regarding resistance temporal trends, most countries had no significant changes in E. coli 
resistance over the time periods considered (Table 7). Belgium showed a significant decrease 
in E. coli resistance to all antimicrobials and an increase in fully-susceptible isolates. Denmark 
(AMC, FLU, SXT), France (3GC, FLU), the Netherlands (3GC, FLU, SXT, MDR) and Sweden 
(CN, MDR) had also significant decreases in E. coli resistance over time (Table 7). However, 
the Netherlands (AMC) and Switzerland (CN) had a significant increase in E. coli resistance 






Published data on antimicrobial resistance in bacteria
isolated from companion animal UTIs over Europe is
scarce [19] and the comparison between studies is
impaired by the use of different inclusion criteria and
differ nt time periods. Moreover, UTI resi tance fre-
quencies are usually reported together with susceptibility
d ta from other sites of infection [1 , 28], combining
different bacteria genera [8, 9] and several countries
[29, 30]. These facts impair the establishment of a global
epidemiological overview of UTI bacteria resistance in
Europe. This is the first large study to analyse antimicro-
bial susceptibility data of canine and feline isolates from
several European countries allowing an epidemiological
overview of UTI resistance trends in Europe.
In accordance to previous studies [7–9, 31, 32], E.
coli was the most frequently isolated bacteria in dogs
and cats. Enterococcus presented a significantly higher
fr quency in cats and Proteus spp. in dogs. While not
compared in previous studies, this difference could be
expected based on some published data focused on
cats [7, 9] and dogs [32] separately.
One of the most important findings from this study
was the overall higher resistance frequencies found in
the Southern countries (Italy, Greece, Portugal and
Spain) when compared with the Northern countries
(Denmark and Sweden). The lower frequency of anti-
microbial resistance in Northern countries, such as
Sweden, is likely a consequence of the tight regulations
and su veillance on antimicrobial prescri ing and resist-
ance in companion animals. In light of the present
results, such strategies could be useful in aiming the




Considering that AMC is one of the most used antimicro-
bials in animals, the levels of resistance detected in this
study are worrisome, especially in the Southern countries.
Previous published reports showed different frequenc es
of AMC resistance in E. coli and in Proteus spp. that are
likely due to the fact they report to different time frames
and inclusion criteria [10, 32–37]. In the absence of clin-
ical data it is not possible to know if this resistance relates
to uncomplicated or complicated UTI [19]. Thus, these
results need to be further investigated in order to establish
whether AMC is a suitable empiric therapeutic choice for
companion animals UTI in Southern Europe.
Third generation cephalosporins
Southern countries had also higher levels of resistance to
3GCs. Although Greece was not included due to limited
da a, considering that seven ou of the nine tested isolates
were resistant to 3GCs, one can expect the prevalence of
3GC resistance to be high. Previous studies in Portugal
found a considerable lower 3GC resistance value (1.4 %)
in E. coli from dogs in earlier years [10]. In the present
work, the lower Swedish results for 3GC resistance in E.
coli and Proteus spp. are in agreement with early studies
[38]. Being of critical importance to humans [39], prudent
use of 3GC is of upmost importance.
Methicillin-resistance
The freque cy of methicillin-resistant staphylococci,
especially S. pseudintermedius and CoNS, varied consid-
erably between countries and confirmed previous reports
on a low MRSP prevalence in Scandinavia compared to
elsewhere in Europe [40]. Resistance to methicillin in
Fig. 4 Percentage (%) of Staphylococcus spp. antimicrobial resistance by antimicrobial and country in the years 2012–2013. Countries: AT- Austria;
BE- Belgium; DK- Denmark; FR- France; DE- Germany; EL- Greece; IT- Italy; NL- the Netherlands; PT- Portugal; RS- Serbia; ES- Spain; SE- Sweden;
CH- Switzerland; UK- United Kingdom




Table 7 - Temporal trends of antimicrobial resistance in E. coli by country 
Countrya 
(Years) 








































































































































































































































Table 7 (continuation)- Temporal trends of antimicrobial resistance in E. coli by country 
Countrya 
(Years) 



























































































Legend: AMC, amoxicillin/clavulanate; 3GC, third-generation cephalosporins; FLU, fluoroquinolones; CN, gentamicin; SXT, trimethoprim/sulfamethoxazole;  
MDR, multidrug-resistant; FullS, fully-susceptible; 
aBE, Belgium; DK, Denmark; FR, France; DE, Germany; EL, Greece; IT, Italy; NL, the Netherlands; PT, Portugal; ES, Spain; SE, Sweden; CH, Switzerland; UK, United 
Kingdom; 
bOR, Odds ratio; 
c95% CI, 95% Confidence interval; 
dMDR and FullS temporal trends do not include resistance to 3GC for Belgium and CN for the Netherlands; 
eData regarding the years 2010 and 2012 were excluded from Greece resistance trends analysis since less than ten isolates were tested in those years; 




Table 8 - Temporal trends of antimicrobial resistance in Proteus spp. by country 
Countrya 
(Years) 
AMC FLU SXT 
ORb (95% CI)c 
P value 
ORb (95% CI)c 
P value 
ORb (95% CI)c 
P value 
























Legend: AMC, amoxicillin/clavulanate; FLU, fluoroquinolones; SXT, trimethoprim/sulfamethoxazole; 
aBE, Belgium; DK, Denmark; FR, France; NL, the Netherlands; SE, Sweden; CH, Switzerland; 
bOR, Odds ratio; 
c95% CI, 95% Confidence interval; 
Statistically significant trends are highlighted in bold. 
 
Discussion 
Published data on antimicrobial resistance in bacteria isolated from companion animal UTIs 
over Europe is scarce (Weese et al., 2011) and the comparison between studies is impaired 
by the use of different inclusion criteria and different time periods. Moreover, UTI resistance 
frequencies are usually reported together with susceptibility data from other sites of infection 
(Normand et al., 2000a; Ruscher et al., 2009), combining different bacteria genera (Hall et al., 
2013; Dorsch et al., 2015) and several countries (Meunier et al., 2004; Kroemer et al., 2014). 
These facts impair the establishment of a global epidemiological overview of UTI bacteria 
resistance in Europe. This is the first large study to analyse antimicrobial susceptibility data of 
canine and feline isolates from several European countries allowing an epidemiological 
overview of UTI resistance trends in Europe. 
In accordance to previous studies (Litster et al., 2007b; Ball et al., 2008; Hall et al., 2013; 
Windahl et al., 2014; Dorsch et al., 2015), E. coli was the most frequently isolated bacteria in 
dogs and cats. Enterococcus spp. presented a significantly higher frequency in cats and  
Proteus spp. in dogs. While not compared in previous studies, this difference could be 
expected based on some published data focussed on cats (Litster et al., 2007b; Dorsch et al., 
2015) and dogs (Féria et al., 2002) separately. 
One of the most important findings from this study was the overall higher resistance 
frequencies found in the Southern countries (Italy, Greece, Portugal and Spain) when 
compared with the Northern countries (Denmark and Sweden). The lower frequency of 
antimicrobial resistance in Northern countries, such as Sweden, is likely a consequence of the 
tight regulations and surveillance on antimicrobial prescribing and resistance in companion 
animals. In light of the present results, such strategies could be useful in aiming the reduction 




Resistance to b-lactams 
Amoxicillin/clavulanate 
Considering that AMC is one of the most used antimicrobials in animals, the levels of 
resistance detected in this study are worrisome, especially in the Southern countries. Previous 
published reports showed different frequencies of AMC-resistance in E. coli and in  
Proteus spp. that are likely due to the fact they report to different time frames and inclusion 
criteria (Féria et al., 2000; Féria et al., 2002; Lanz et al., 2003; Grobbel et al., 2007a; Pedersen 
et al., 2007; Windahl et al., 2014; Criel et al., 2015). In the absence of clinical data it is not 
possible to know if this resistance relates to uncomplicated or complicated UTI (Weese et al., 
2011). Thus, these results need to be further investigated in order to establish whether AMC 
is a suitable empiric therapeutic choice for companion animals UTI in Southern Europe. 
 
Third-generation cephalosporins 
Southern countries had also higher levels of resistance to 3GCs. Although Greece was not 
included due to limited data, considering that seven out of the nine tested isolates were 
resistant to 3GCs, one can expect the prevalence of 3GC-resistance to be high. Previous 
studies in Portugal found a considerable lower 3GC-resistance value (1.4%) in E. coli from 
dogs in earlier years (Féria et al., 2000). In the present work, the lower Swedish results for 
3GC-resistance in E. coli and Proteus spp. are in agreement with early studies (Hagman & 




The frequency of methicillin-resistant staphylococci, especially S. pseudintermedius and 
CoNS, varied considerably between countries and confirmed previous reports on a low MRSP 
prevalence in Scandinavia compared to elsewhere in Europe (Swedres-Svarm, 2016). 
Resistance to methicillin in coagulase-positive Staphylococcus (S. aureus and  
S. pseudintermedius) was detected in this study and is a great animal and public health 
concern (Guardabassi & Prescott, 2015). Currently, the recommended methods for the 
detection of methicillin-resistance in staphylococci are mainly phenotypic but in some 
circumstances the molecular detection of the mecA gene is clinically and epidemiologically 
necessary (CLSI, 2013a; CLSI, 2015; European Committee on Antimicrobial Susceptibility 
Testing [EUCAST], 2013). This should be taken in consideration for the harmonisation of 
veterinary susceptibility testing in Europe. 
 
Resistance to fluoroquinolones 
In this study, high resistance frequencies towards the fluoroquinolones were found in E. coli, 
Proteus spp. and Staphylococcus spp. isolates in the southern European countries but also in 
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Proteus spp. from Germany, Belgium and Switzerland and Staphylococcus spp. from Austria, 
Switzerland and France. Several authors (Grobbel et al., 2007a; Oliveira, Dias & Pomba, 2014; 
Tramuta et al., 2014; Windahl et al., 2014) have reported lower FLU-resistance frequencies 
than the ones found in this study, especially regarding the Southern countries (Oliveira et al., 
2014; Tramuta et al., 2014). The results of high resistance frequencies towards the 
fluoroquinolones found in this study are concerning because fluoroquinolones are considered 
a good first choice for pyelonephritis treatment and should otherwise be used as a second line 
antimicrobial (Weese et al., 2011). 
 
Resistance to folate inhibitors and to aminoglycosides 
In this study, resistance to SXT in Europe was high, especially in E. coli and Proteus spp.. The 
higher SXT-resistance found in Proteus spp., than in E. coli from several European countries, 
is consistent with other reports (Grobbel et al., 2007a; Criel et al., 2015; Grobbel et al., 2007b). 
Compared with previous studies, these results show a superior SXT-resistance in E. coli and 
Proteus spp. from Italy and Portugal (Féria et al., 2000; Tramuta et al., 2014) and 
Staphylococcus spp. from Belgium (Criel et al., 2015). 
Also in agreement to previous studies, gentamicin was the antimicrobial with lower resistance 
in E. coli, Proteus spp. and Staphylococcus spp. all-over Europe (Lanz et al., 2003; Hagman 
et al., 2005; Grobbel et al., 2007a; Grobbel et al., 2007b; Pedersen et al., 2007; Tramuta et 
al., 2014; Windahl et al., 2014). Nevertheless, the distribution seemed to follow the same 
pattern, with increased resistance in Southern over Northern countries. 
 
Multidrug resistance 
Finally, MDR bacteria presented the worst scenario once again in E. coli from Southern 
countries and in Proteus spp. from Portugal. The emergence of MDR bacteria in companion 
animals has been previously described (Pomba et al., 2010; Wagner et al., 2014) and 
represents a great therapeutic challenge and public health concern. However, MDR/FullS 
frequencies are seldom reported and published data account for different antimicrobials, thus 
impairing any comparisons with the present results (Féria et al., 2000; Lanz et al., 2003; 
Hagman et al., 2005; Grobbel et al., 2007b; Windahl et al., 2014). 
 
Trends in antimicrobial resistance 
The surveillance of antimicrobial resistance is an important tool to guide the implementation of 
antimicrobial stewardship strategies. In this study, most countries had no significant changes 
in antimicrobial resistance over the time frame considered. Nevertheless, decreasing trends in 
antimicrobial resistance were found in E. coli. These encouraging trends were not detected in 
AMC and CN-resistance in E. coli from the Netherlands and Switzerland, respectively, where 
an increasing trend was observed. Although no changes over time were detected in E. coli 
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resistance against AMC and 3CGs in Portugal, the considerably lower resistance frequencies 
previously reported in earlier years (Féria et al., 2000), point to a possible increasing trend 
(Féria et al., 2002). The same may be the case for E. coli AMC-resistance in Germany and 
Switzerland (Lanz et al., 2003; Grobbel et al., 2007a). 
Despite reporting clear trends such as the difference in resistance between Northern and 
Southern countries, data from this study should be interpreted with caution. Due to the 
retrospective nature of this study, data on clinical history such as the type of UTI and previous 
antimicrobial treatment were unavailable. Furthermore, the use of laboratory data may 
represent a bias towards resistance, since urine cultures from complicated cases tend to be 
requested more often than simple uncomplicated UTI (Ball et al., 2008; Hall et al., 2013). These 
limitations are not restricted to certain countries, and are therefore not likely to hamper 
comparison of data across borders. Given the limitations of retrospective studies, a veterinary 
European surveillance network gathering data prospectively on antimicrobial resistance, as 
well as, on clinical data is of the upmost importance to facilitate development of national 
evidence-based guidelines that take into consideration type of UTI, local regulations and 
patterns of antimicrobial resistance. 
The use of different susceptibility testing methods and different clinical breakpoints is 
considered a major limitation. The lack of harmonisation became evident in this study when 
trying to compare 3GC and methicillin-resistance. Although it also happens in the well-
established EARS network reports of resistance on bacteria from human invasive infections 
(ECDC, 2014), this limitation weakens the comparison of resistance between countries in the 
present and future surveillance studies. This harmonisation would allow future within and 
between countries resistance frequencies comparisons over time and would also provide 
relevant information on the impact of different antimicrobial usage policies. Thus, the authors 
agree that the harmonisation of methods and interpretative criteria in veterinary medicine 
should be a priority. The role of the new veterinary committee on antimicrobial susceptibility 
testing VetCAST (Veterinary Committee on Antimicrobial Susceptibility Testing [VetCAST], 
(2015) may be crucial in this harmonisation process. Despite these limitations, the results from 
this study provide relevant and updated information on the current antimicrobial resistance in 
UTI bacteria from companion animals in Europe. Similar studies should also be conducted 
regarding other types of infection to improve the awareness on the European distribution of 
antimicrobial resistance in companion animals. Ideally, monitoring of companion animal 
antimicrobial resistance should be implemented in Europe, as it is the case for food producing 
animals. Such surveillance would provide crucial information to promote the appropriate use 







This work brings new insights into the current scenario of the European antimicrobial 
resistance bacteria isolated from companion animals with UTI. An important finding from this 
study was the higher frequency of resistance in Southern European countries (Italy, Greece, 
Spain, Portugal) when compared to Northern European countries (Denmark, Sweden). 
Furthermore, there is an evident need to harmonise methods and interpretative criteria in 
veterinary medicine. Given the limitations of retrospective studies, an European surveillance 
network gathering data on antimicrobial resistance is of the upmost importance to facilitate the 
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Objectives: To evaluate temporal trends in antimicrobial resistance, over 16 years, in bacteria 
isolated from dogs and cats with urinary tract infection (UTI) and the clonal lineages of bacteria 
harbouring critical antimicrobial resistance mechanisms. 
Methods: Antimicrobial susceptibility testing was conducted for 948 bacteria isolated from 
dogs and cats with UTI (1999–2014). Resistance mechanisms were detected by PCR, namely 
ESBL/AmpC in third-generation cephalosporin (3GC)-resistant Escherichia coli and Proteus 
mirabilis, mecA in methicillin-resistant staphylococci, and aac(6′)-Ieaph(2″)-Ia and aph(2″)-1d 
in high-level gentamicin-resistant (HLGR) enterococci. Resistant bacteria were typed by 
MLST, and temporal trends in E. coli and Enterobacteriaceae antimicrobial resistance were 
determined by logistic regression. 
Results: Enterobacteriaceae had a significant temporal increase in resistance to 
amoxicillin/clavulanate, 3GCs, trimethoprim/sulfamethoxazole, fluoroquinolones, gentamicin 
and tetracycline (P  <  0.001). An increase in MDR was also detected (P  <  0.0001). 3GC-
resistance was mainly caused by the presence of blaCTX-M-15 and blaCMY-2 in E. coli and the 
presence of blaCMY-2 in P. mirabilis. Two major 3GC-resistant E. coli clonal lineages were 
detected: O25b:H4-B2-ST131 and ST648. The mecA gene was detected in 9.2% (n =  11/119) 
of Staphylococcus spp., including MRSA clonal complex (CC) 5 (n =  2) and methicillin-
resistant Staphylococcus epidermidis CC5 (n =  4). A temporal increase in MDR methicillin-
resistant Staphylococcus pseudintermedius was detected (P  =  0.0069). Some ampicillin-
resistant and/or HLGR Enterococcus spp. were found to belong to hospital-adapted CCs, 
namely Enterococcus faecalis ST6-CC6 (n =  1) and Enterococcus faecium CC17 (n =  8). 
Conclusions: The temporal increase in antimicrobial resistance and in MDR bacteria causing 
UTI in dogs and cats creates important therapeutic limitations in veterinary medicine. 
Furthermore, the detection of MDR high-risk clonal lineages raises public health concerns 
since companion animals with UTI may contribute to the spread of such bacteria. 
 
Introduction 
Urinary tract infections (UTIs) are frequently diagnosed in veterinary medicine (Hall et al., 
2013) and may require antimicrobial treatment (Weese et al., 2011). Since antimicrobial 
resistance is known to change geographically and over time (European Centre for Disease 
Prevention and Control [ECDC], 2015), updated and long-term studies are critical to 
investigate the spread of antimicrobial resistance. Escherichia coli and Proteus mirabilis are 
the most frequently isolated Gram-negative bacteria from dogs and cats with UTI, while 
Staphylococcus spp. and Enterococcus spp. are the most common Gram-positive bacteria 
(Litster et al., 2007b; Hall et al., 2013). These bacteria, isolated from dogs and cats, may 
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harbour clinically and epidemiologically important resistance mechanisms of human and 
veterinary relevance such as ESBL (Féria et al., 2002; Ewers et al., 2010), cephalosporinases 
(AmpC) (Wagner et al., 2014), PBP2a (Couto et al., 2016) and high-level gentamicin-
resistance (HLGR) bifunctional enzyme (Jackson et al., 2010). Moreover, the detection of MDR 
bacteria in dogs and cats is being increasingly reported (Wagner et al., 2014; Couto et al., 
2016), posing a difficult veterinary therapeutic challenge and often requiring the use of 
antimicrobials critically important to humans (WHO, 2017a). With the growing contact between 
companion animals and humans, the risk of animal-to-human transfer of such bacteria is of 
concern (Pomba et al., 2017). Additionally, several studies have shown that dogs and cats may 
share uropathogenic bacteria with the remaining household members (Johnson et al., 2009). 
Therefore, the identification of the clonal lineages of bacteria isolated from dogs and cats with 
UTI, especially those harbouring important resistance mechanisms, is crucial to evaluate the 
extent to which dogs and cats with UTI may act as reservoirs for resistant bacteria. 
The goal of this study was to determine the temporal trends of antimicrobial resistance of 
bacteria isolated from dogs and cats with UTI over 16 years and to characterise their major 
antimicrobial resistance mechanisms, namely ESBL and AmpC in E. coli and P. mirabilis, 
methicillin-resistance in Staphylococcus spp., and ampicillin and HLGR in Enterococcus spp. 
Furthermore, this study aimed to determine the clonal lineages of E. coli, Staphylococcus spp. 
and Enterococcus spp. harbouring such resistance genes and hence evaluate their potential 
public health relevance. 
 
Materials and methods 
Bacterial isolates 
A total of 948 consecutive positive bacterial isolates from dogs and cats with UTI (n =  869), 
collected from 1999 to 2014 at the Laboratory of Antimicrobial Resistance from the Veterinary 
Teaching Hospital of the Faculty of Veterinary Medicine/University of Lisbon and from several 
private practices in the Lisbon region were included in this study. Samples were collected by 
cystocentesis, catheterisation or free catch as part of the routine care of dogs and cats with 
UTI. UTI was diagnosed based on clinical and urine cytological findings together with the 
detection of significant bacteriuria by quantitative urine culture. 
 
Bacteriological methods 
Quantitative urine culture was performed. Briefly, 10 μL of urine was inoculated onto 5% sheep 
blood (bioMérieux, Marcy-l’Étoile, France) and MacConkey (Biokar Diagnostics, Allonne, 
France) agar plates. After incubation at 37 °C for 24–48 h under atmospheric conditions, 
colonies were quantified and scored as having significant bacteriuria according to the urine 
sample collection method as defined elsewhere (Bartges et al., 2004). Samples were included 
in the study regardless of the type of UTI. 
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Species identification was conducted by phenotypic tests (API, bioMérieux and BD™ BBL™ 
Crystal Gram Positive ID Kit, Becton Dickinson, MD, USA). At the time of collection, isolated 
bacteria were stored in 20% glycerol (Sigma–Aldrich, St Louis, MO, USA) brain heart infusion 
broth (Biokar Diagnostics) at −80 °C for future studies. 
For the present study, stored isolates were recovered by streaking them onto 5% sheep blood 
agar. Whenever recovery was not possible, existing antimicrobial susceptibility results were 
used. E. coli (Doumith, Day, Hope, Wain & Woodford, 2012), Klebsiella spp. (Kovtunovych et 
al., 2003; Padmavathy et al., 2012), Proteus spp. (Stankowska, Kwinkowski & Kaca, 2008), 
Enterococcus spp. (Woodford, Egelton & Morrison, 1997) and Staphylococcus spp. (Couto et 
al., 2016) were confirmed by PCR and/or sequencing of 16S rRNA. 
 
Susceptibility testing 
Susceptibility testing was performed by the disc diffusion method according to CLSI guidelines, 
and E. coli ATCC 25922 and Staphylococcus aureus ATCC 25923 were used for quality control 
(CLSI, 2013b). The following antimicrobials were tested (Oxoid, Hampshire, UK): 
amoxicillin/clavulanate 30 μg, cefotaxime 30 μg, cefovecin 30 μg, cefoxitin 30 μg, ceftazidime 
30 μg, ciprofloxacin 5 μg, enrofloxacin 5 μg, gentamicin 10 μg, high-level gentamicin 120 μg, 
oxacillin 1 μg, penicillin 10 U, tetracycline 30 μg and trimethoprim/sulfamethoxazole 25 μg. 
Veterinary CLSI breakpoints (CLSI, 2013a) were used for amoxicillin/clavulanate, cefoxitin, 
enrofloxacin, gentamicin, high-level gentamicin, oxacillin, penicillin, tetracycline and 
trimethoprim/sulfamethoxazole; human CLSI breakpoints (Clinical and Laboratory Standards 
Institute [CLSI], 2016) were used for cefotaxime, ceftazidime and ciprofloxacin. Finally, 
cefovecin results were interpreted according to the manufacturer’s breakpoints. Initial ESBL 
screening was conducted by a double-disc synergy test (CLSI, 2013b). Cefoxitin or oxacillin 
were used to predict methicillin-resistance in Staphylococcus spp. according to CLSI 
guidelines (CLSI, 2013a; CLSI, 2016). 
 
DNA extraction, sample purification and sequencing 
DNA extraction was conducted using a boiling method (Féria et al., 2002). For PCR amplicon 
sequencing, DNA purification was conducted using a NZYTech Gel Pure Kit (NZYTech—
Genes and Enzymes, Lisbon, Portugal) and sequencing was performed by Stabvida 
(Caparica, Portugal). Sequences were analysed using Ugene Unipro software (Unipro, 
Novosibirsk, Russia) and the nucleotide basic local alignment search tool 
(http://blast.ncbi.nlm.nih.gov/). 
 
Antimicrobial resistance genes 
Third-generation cephalosporin (3GC)-resistant E. coli and P. mirabilis were screened for the 
presence of ESBL blaCTX-M-type and AmpC blaCIT-type, blaDHA-type, blaMOX-type, blaACT-type, blaFOX-type 
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and blaMIR-type by PCR and sequencing (Pérez-Pérez & Hanson, 2002; Guessennd et al., 2008; 
Belas et al., 2014). 3GC-resistant Enterobacteriaceae without blaCTX-M-type or AmpC genes were 
further tested for the presence of blaTEM-type and blaSHV-type ESBL genes (Féria et al., 2002). 
Staphylococcus spp. were screened for the presence of the mecA gene (Couto et al., 2016) 
and HLGR Enterococcus spp. for the presence of aac(6′)-Ieaph(2″)-Ia and aph(2″)-1d (Kao et 
al., 2000) genes by PCR. Negative and previously sequenced positive controls were included 
in all PCR reactions. 
 
Clonal lineages of resistant isolates 
ESBL- or AmpC-producing E. coli were tested for the clonal lineage O25b:H4-B2-ST131 by 
PCR (Doumith et al., 2012; Johnson et al., 2014). 3GC-resistant E. coli isolates not belonging 
to the O25b:H4-B2-ST131 clonal lineage were typed by MLST (Wirth et al., 2006). Methicillin-
resistant Staphylococcus spp. were previously characterised by MLST, SCCmec and spa 
typing elsewhere (Couto et al., 2016). Ampicillin-resistant and/or HLGR Enterococcus faecium 
and Enterococcus faecalis were also typed by MLST (Homan et al., 2002; Ruiz-Garbajosa et 
al., 2006). eBURSTv.3 software (http://eburst.mlst.net/) was used to estimate the relationships 
between the isolate STs from this study and all MLST profiles known to date. 
 
Statistical analysis 
The SAS statistical software package for Windows v. 9.3 (SAS Institute Inc., Cary, NC, USA) 
was used for statistical analysis. Antimicrobial resistance frequencies were only calculated if 
at least 10 isolates were tested for a specific organism/antimicrobial combination and results 
were presented with the 95% CI. For statistical purposes, intermediate isolates were 
considered susceptible. An isolate was considered resistant to 3GCs when it was found to be 
resistant to at least one of the three 3GCs tested (cefotaxime, ceftazidime and cefovecin). 
Ciprofloxacin and enrofloxacin were used as markers of fluoroquinolone-resistance. An isolate 
was considered MDR when it was found to be fully-resistant to three or more antimicrobial 
categories. The antimicrobial categories were adapted from those proposed by other authors 
(Magiorakos et al., 2012) and varied according to the bacterial species considered (Table S1). 
When at least 10 isolates were tested per year, temporal trends of antimicrobial resistance 
were determined using an SAS LOGISTIC regression model with the year as a continuous 
variable and an α value of 0.05. Thus, temporal trends in antimicrobial resistance were 
determined for E. coli and for Enterobacteriaceae (including E. coli, Proteus spp.,  
Klebsiella spp. and Enterobacter spp. as a group). When determining Enterobacteriaceae 
temporal trends, intrinsic resistance data was excluded from analysis. Furthermore, P. mirabilis 
and Staphylococcus spp. antimicrobial resistance were compared between two time periods: 
1999–2006 and 2007–14. The Fisher’s exact test was used for comparisons between groups 




From 1999 to 2014, 948 bacteria were isolated from 649 dogs and 220 cats with UTI. The 
majority of UTIs (91.1%, CI 89.2%–93.0%, n =  792/869) were caused by single organisms. 
Coinfections were most commonly caused by the combinations of E. coli/Enterococcus spp. 
(14.3%, CI 6.5%–22.1%, n =  11/77), E. coli/P. mirabilis (11.7%, CI 4.5%–18.9%, n =  9/77) and 
E. coli/Streptococcus spp. (10.4%, CI 3.6%–17.2%, n =  8/77). 
Although E. coli (43.5%) was the most frequently isolated bacterium, Proteus spp. (16.4%), 
Staphylococcus spp. (13.2%) and Enterococcus spp. (7.0%) were also common (Table S2). 
The frequency of infection by Proteus spp. was significantly higher (P  <  0.0001) in dogs and 
Enterococcus spp. in cats, respectively (Table S2). Overall, Staphylococcus spp. had similar 
frequencies in cats and dogs. However, Staphylococcus pseudintermedius was significantly 
more common in dogs (P  <  0.0001), while cats were infected by a higher diversity of 
staphylococcal species, with S. pseudintermedius, Staphylococcus felis and Staphylococcus 
epidermidis being the most frequent (Table S2). 
Enterobacteriaceae accounted for 66.1% (CI 63.1%–69.2%) of all isolated bacteria and 
showed a significant temporal increase in resistance to all tested antimicrobials (Table S3 and 
Figure 1). In 2012–14, resistance of Enterobacteriaceae to all the antimicrobials tested, except 
gentamicin, was >30% (Figure 1). 
Considering E. coli and Proteus spp. alone, no significant change over time was detected in 
trimethoprim/sulfamethoxazole-resistance (Tables S3 and S4). Nevertheless, from 1999/2006 
to 2007/2014, E. coli showed a 3-fold increase in amoxicillin/clavulanate-resistance and a  
4-fold increase in 3GC-resistance. Proteus spp. had an even higher increase in resistance, 
showing a 5- and 9-fold increase in amoxicillin/clavulanate and 3GC-resistance, respectively 
(Table S4). Proteus spp. and E. coli also had a significant increase in gentamicin-resistance 
(Tables S3 and S4). Detection of MDR Enterobacteriaceae, E. coli and Proteus spp. increased 
significantly over time (Tables S3 and S4 and Figure 1). Most MDR Enterobacteriaceae 
(excluding Enterobacter spp.) were susceptible to at least one antimicrobial (Table S5). 
Gentamicin was the antimicrobial to which most MDR Enterobacteriaceae (excluding 
Enterobacter spp.) were susceptible (46.2%, CI 36.1%–56.4%). On the contrary, MDR 
Enterobacteriaceae were seldom susceptible to fluoroquinolones (9.7%, CI 3.7%–15.7%) 
(Table S5). Furthermore, among MDR E. coli, only 19.35% (CI 9.5%–29.2%) were susceptible 
to tetracycline. 
A total of 33 E. coli and 9 P. mirabilis that were 3GC-resistant were recovered and screened 
for the presence of ESBL and AmpC genes. The first 3GC-resistant E. coli isolate was detected 
in 1999, yet none of the tested genes were detected. Another resistance mechanism may be 
involved. In total, only seven 3GC-resistant E. coli were negative for all tested genes, including 
blaTEM-type and blaSHV-type ESBLs. E. coli 3GC-resistance was mainly related to the presence of 
blaCTX-M-15 and blaCMY-2 (Tables 1 and 2). The first CTX-M-producing E. coli was detected in 
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2004 and belonged to the O25b:H4-B2-ST131 clonal lineage (Table 1). Besides O25b:H4-B2-
ST131, CTX-M-producing E. coli were frequently found to belong to clonal complex (CC) 23, 
including a novel ST described here (Table 1 and Figure S1). From 2010 onwards, an increase 
in 3GC-resistant E. coli ST648 harbouring blaCMY-2 was observed (Table 2). 3GC-resistant  
P. mirabilis was first detected in 2004. All isolates with this phenotype were blaCMY-2 positive, 
except one P. mirabilis from 2007 possessing blaDHA-1 (Table S6). 
 
Figure 1 - Enterobacteriaceae and E. coli resistance trends over the 16 years of the 
study 
 
Legend: Depiction of the temporal trends in resistance obtained by logistic regression over 16 years. 
(a) Enterobacteriaceae. There was a significant increase (P  <  0.05) in antimicrobial resistance to all 
antimicrobials. (b) E. coli. There was a significant increase (P  <  0.05) in antimicrobial resistance to all 
antimicrobials, except trimethoprim/sulfamethoxazole. AMC, amoxicillin/clavulanate;  
3GCs, third-generation cephalosporins; SXT, trimethoprim/sulfamethoxazole; FQs, fluoroquinolones; 
GEN, gentamicin; TET, tetracycline. 
 
Regarding Staphylococcus spp., 9.2% (CI 4.0%–14.4%, n =  11/119) of Staphylococcus spp. 
were methicillin-resistant and were found to harbour the mecA gene. Overall only resistance 
to fluoroquinolones was significantly higher in the second time period (2007–14; P  =  0.0189) 
(Table S4). However, if S. pseudintermedius are analysed alone, a significant increase in  
 
Results
From 1999 to 2014, 948 bacteria were isolated from 649
dogs and 220 cats with UTI. The majority of UTIs (91.1%,
CI 89.2%–93.0%, n"792/869) were caused by single organisms.
Coinfections were most commonly caused by the combinations
of E. coli/Enterococcus spp. (14.3%, CI 6.5%–22.1%, n"11/77),
E. coli/P. mirabilis (11.7%, CI 4.5%–18.9%, n"9/77) and E. coli/
Streptococcus spp. (10.4%, CI 3.6%–17.2%, n"8/77).
Although E. coli (43.5%) was the most frequently isolated bac-
terium, Proteus spp. (16.4%), Staphylococcus spp. (13.2%) and
Enterococcus spp. (7.0%) were also common (Table S2). The fre-
quency of infection by Proteus spp. was significantly higher
(P , 0.0001) in dogs and Enterococcus spp. in cats, respectively
(Table S2). Overall, Staphylococcus spp. had similar frequencies in
cats and dogs. However, Staphylococcus pseudintermedius was
significantly more common in dogs (P , 0.0001), while cats were
infected by a higher diversity of staphylococcal species, with
S. pseudintermedius, Staphylococcus felis and Staphylococcus epi-
dermidis being the most frequent (Table S2).
Enterobacteriaceae accounted for 66.1% (CI 63.1%–69.2%) of all
isolated bacteria and showed a significant temporal increase in re-
sistance to all tested antimicrobials (Table S3 and Figure 1). In 2012–
14, resistance of Enterobacteriaceae to all the antimicrobials tested,
except gentamicin, was .30% (Figure 1). Considering E. coli and
Proteus spp. alone, no significant change over time was detected in

























































































































Figure 1. Enterobacteriaceae and E. coli resistance trends over the 16 years of the study. Depiction of the temporal trends in resistance obtained by
logistic regression over 16 years. (a) Enterobacteriaceae. There was a significant increase (P , 0.05) in antimicrobial resistance to all antimicrobials.
b) E. coli. There was a significant increase (P , 0.05) in antimicrobial resistance to all antimicrobials, except trimeth pr m/sulfame hoxazole. AMC,
amoxicillin/clavulanate; SXT, trimethoprim/sulfamethoxazole; FQs, fluoroquinolones; GEN, gentamicin; TET, tetracycline.




Table 1 - CTX-M-producing E. coli clonal lineages 
Isolate Year β-Lactamase Clonal lineage CC Animal MDR AMC 3GCs SXT FQs GEN TET 
FMV5825/04 2004 CTX-M-15 O25b:H4-B2-ST131 CC131 Dog Yes R R R R R R 
FMV521/07 2007 CTX-M-32 ST224 — Cat Likely I R S R S R 
FMV1630/07 2007 CTX-M-15 unassigned STb CC23 Dog Yes I R R R S R 
FMV7261/07 2007 CTX-M-32 ST609 CC46 Dog Yes I R R R S R 
FMV635/08 2008 CTX-M-32 ST23 CC23 Cat Yes R R R R S S 
FMV2777/08 2008 CTX-M-15 O25b:H4-B2-ST131 CC131 Cat Yes R R S R R R 
FMV5827/08 2008 CTX-M-15 ST23 CC23 Dog Yes R R R R S S 
FMV1952/10a 2010 CTX-M-9 ST648 CC648 Cat Yes R R R R R R 
FMV4479/13a 2013 CTX-M-15 ST533 — Dog Yes R R R R S S 
FMV5338/13 2013 CTX-M-15 O25b:H4-B2-ST131 CC131 Dog Yes I R S R R R 
FMV58/2013 2013 CTX-M-1-type O25b:H4-B2-ST131 CC131 Cat Yes S R R R S R 
FMV121/2014RE 2014 CTX-M-1-type ST539 — Dog Yes S R R R S R 
 
Legend: AMC, amoxicillin/clavulanate; 3GCs, third-generation cephalosporins; SXT, trimethoprim/sulfamethoxazole; FQs, fluoroquinolones; GEN, gentamicin;  
TET, tetracycline; R, resistant; I, intermediate; S, susceptible; 
aAlso harbours blaCMY-2; 





Table 2 - AmpC-producing E. coli clonal lineages 
Isolate Year β-Lactamase Clonal lineage CC Animal MDR AMC 3GCs SXT FQs GEN TET 
FMV434/00 2000 CMY-2 ST1775 — Dog Yes R R R S S R 
FMV1953/01 2001 CMY-2 ST57 CC350 Dog Yes R R R I I R 
FMV203/03 2003 CMY-2 ST405 CC405 Dog Yes R R S R S R 
FMV6346/05 2005 CMY-2 ST539 — Cat Yes R R S R R R 
FMV3389/06 2006 CMY-2 ST354 CC354 Dog Yes R R R R R R 
FMV1952/10a 2010 CMY-2 ST648 CC648 Cat Yes R R R R R R 
FMV25/2011 2011 CMY-2 ST648 CC648 Cat Yes R R R R R R 
FMV29/2011 2011 CMY-2 ST648 CC648 Dog Yes R R S R R R 
FMV469/13 2013 CMY-2 ST648 CC648 Dog Yes R R R R R R 
FMV1389/13 2013 CMY-2 ST648 CC648 Cat Yes R R R R R R 
FMV4479/13a 2013 CMY-2 ST533 — Dog Yes R R R R S S 
FMV55/2013 2013 CMY-2 ST648 CC648 Cat Yes R R R R R R 
FMV546/14 2014 CMY-2 ST648 CC648 Cat Yes R R R R R R 
FMV966/14 2014 CMY-2 ST648 CC648 Dog Yes R R R R S R 
FMV1549/14 2014 CMY-2 ST648 CC648 Cat Yes R R S R S R 
FMV43/2014 2014 CMY-2 ST648 CC648 Cat Yes R R S R S  R 
 
Legend: AMC, amoxicillin/clavulanate; 3GCs, third-generation cephalosporins; SXT, trimethoprim/sulfamethoxazole; FQs, fluoroquinolones; GEN, gentamicin;  
TET, tetracycline; R, resistant; I, intermediate; S, susceptible; 
aAlso harbours blaCTX-M. 
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methicillin (14.8%, CI 1.4%–28.2%, in 2007–14; P  =  0.0069) and gentamicin (17.9%,  
CI 3.7%–32.0%, in 2007–14; P  =  0.0099) resistance was also detected. All MDR 
Staphylococcus spp. were associated with the presence of the mecA gene. Methicillin-resistant 
Staphylococcus pseudintermedius (MRSP; n =  4) and methicillin-resistant S. epidermidis 
(MRSE; n =  4) were the most common methicillin-resistant Staphylococcus species, followed 
by MRSA (n =  2) and methicillin-resistant Staphylococcus lentus (n =  1). Although uncommon, 
S. epidermidis showed a high frequency of methicillin-resistance (n =  4/6). MRSP showed 
resistance to all the tested antimicrobials, except two that were susceptible to tetracycline. 
Thus all MRSP were considered MDR. All methicillin-resistant Staphylococcus spp. but one 
were isolated from cats. The 11 methicillin-resistant Staphylococcus spp. found in this study 
were fully characterised elsewhere (Couto et al., 2016). Briefly, MRSP belonged to ST71-II-III 
(n =  3) and ST196-V (n =  1); MRSE belonged to CC5 (ST2-nt, ST20-nt, ST23-IV, ST35-nt) 
and MRSA to CC5 (ST5-t311-VI, ST105-t002-II). 
Enterococcus spp. showed very high tetracycline (75.8%, CI 65.2%–86.5%, n =  47/62) and 
fluoroquinolone (56.4%, CI 44.1%–68.8%, n =  35/62) resistance. Ampicillin-resistance in 
Enterococcus spp. (12.1%, CI 4.2%–20.0%, n =  8/66) was lower, though if only E. faecium 
were considered, almost all were ampicillin-resistant (n =  8/9). HLGR was detected in 15.2% 
(CI 6.1%–24.4%, n =  9/59) of the tested Enterococcus spp. and was mostly found in E. faecalis 
harbouring aac(6′)-Ieaph(2″)-Ia (Table S7). HLGR E. faecalis belonged to known sequence 
types, including one isolate from ST6-CC6 (former CC2) (Table S7). All ampicillin-resistant 
and/or HLGR E. faecium belonged to CC17 (Table S7), including two novel STs (ST1282 and 
ST1283) identified in this study (Figure S2). 
 
Discussion 
As seen in other studies, E. coli was the most frequently isolated bacterium in dogs and cats 
with UTI (Litster et al., 2007b; Hall et al., 2013). Overall, Enterobacteriaceae caused more than 
half of the UTIs in dogs and cats; therefore, given that β-lactams are among the most important 
antimicrobials nowadays (WHO, 2017a), the great increase detected in this study in 
Enterobacteriaceae resistance to amoxicillin/clavulanate and 3GCs is worrisome (Figure 1 and 
Table S4). 
3GCs are considered highest priority critically important antimicrobials for humans (WHO, 
2017a), and resistance is frequently associated with the production of β-lactamases (ECDC, 
2015). The increase in 3GC-resistance observed in this study was frequently associated with 
the presence of blaCTX-M-15 and blaCMY-2 in E. coli and blaCMY-2 in P. mirabilis (Tables 1 and 2 and 
Table S6). 
ESBL CTX-M-15 is distributed worldwide in E. coli (Ewers et al., 2012). Moreover, E. coli 
O25b:H4-B2-ST131 is a widespread human uropathogenic clonal lineage that frequently 
harbours blaCTX-M-15 (Nicolas-Chanoine et al., 2008) and has been previously described in dog 
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and cat faecal samples (as a commensal), (Johnson et al., 2009) and also causes UTI (Ewers 
et al., 2010). Therefore, the detection of E. coli O25b:H4-B2-ST131 in this study came as no 
surprise. Furthermore, E. coli CC23 has been described in humans with UTI in the community 
(Lau et al., 2008) and has also been shown to be a common CC among CTX-M-producing  
E. coli (Brisse et al., 2012). 
This study shows an increase in the detection of CMY-2-producing E. coli and Proteus spp. 
over time. Although less frequently reported than blaCTX-M in previously published data (Aragón 
et al., 2008; Ewers et al., 2010), this increase in blaCMY-2 should not be neglected since this 
enzyme shows stronger β-lactamase activity (Jacoby, 2009) and may in the future become 
more prevalent. Furthermore, blaCMY-2-carrying Enterobacteriaceae may exhibit resistance to 
carbapenems in the absence of carbapenemases, owing to the presence of other resistance 
mechanisms such as porin deficiency (Chia et al., 2009), which further highlights their clinical 
relevance. 
In the present study, the first CMY-2-producing E. coli was detected in 2000, yet it was from 
2010 onwards that the E. coli CMY-2-producing ST648 clonal lineage was increasingly 
detected (Table 2). E. coli ST648 has been described in human infections harbouring several 
β-lactamases, such as ESBL and carbapenemases (Ewers et al., 2012; Pitout, 2012). 
Nevertheless, both in humans and companion animals, the ST648 E. coli clonal lineage has 
mostly been described harbouring blaCTX-M genes (Pitout, 2012; Ewers et al., 2014a). The 
significant increase in ST648 CMY-2-producing E. coli observed in this study in companion 
animals with UTI may point to the possible expansion of a blaCMY-2-producing MDR ST648 
clonal lineage, though more studies are needed to clarify the clonal relatedness between these 
isolates. However, a few studies have also found a high frequency of ST648 CMY-2-producing 
E. coli in faecal samples and specimens from infections of companion animals (Tamang et al., 
2012; Liu et al., 2016). Although only detected once in this study, E. coli ST405 also belongs 
to a highly successful clonal lineage that causes human infection (Pitout, 2012). Dogs and cats 
with UTI are, therefore, shown in this study to be infected with 3GC-resistant E. coli belonging 
to clonal lineages of great importance to humans. Furthermore, CTX-M- and CMY-producing 
E. coli and P. mirabilis were also found to be MDR, thus increasing the relevance of these 
findings. 
Additionally, Enterobacteriaceae from this study showed a significant increase in resistance to 
all the antimicrobials commonly used in the treatment of dogs and cats with UTI (Figure 1). 
Together with the significant increase in detection of MDR Enterobacteriaceae over time, these 
results point to growing therapeutic limitations in veterinary medicine that in the future may 
lead to an increasing need to prescribe antimicrobials originally intended for human use. 
ESBL- and AmpC-producing E. coli presented MDR susceptibility phenotypes with limited 
therapeutic options (Tables 1 and 2). A study in humans showed that the use of 
amoxicillin/clavulanate for the treatment of UTIs caused by ESBL-producing E. coli may be 
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suitable if the isolate is fully-susceptible to this antimicrobial (Beytur et al., 2015). Although 
most ESBL-producing E. coli from this study displayed intermediate resistance to 
amoxicillin/clavulanate, similar studies should be conducted in veterinary medicine to evaluate 
its effectiveness in the treatment of MDR ESBL-producing Enterobacteriaceae. 
MDR Enterobacteriaceae were more often susceptible to gentamicin; hence, although 
sometimes impractical, the use of this antimicrobial should be considered for the treatment of 
UTIs caused by MDR Enterobacteriaceae in dogs and cats (Table S5). 
Staphylococcus spp. were the second most frequently isolated bacteria; however, the 
identified Staphylococcus species varied significantly between dogs and cats (Table S2). The 
high frequency of S. felis in cats with UTI is in agreement with a previous study conducted in 
Australia, in which the authors associated the presence of S. felis with clinical signs of lower 
urinary tract disease in cats (Litster et al., 2007b). 
The significant increase in the detection of MDR MRSP over time is a concerning finding since 
it creates major therapeutic limitations. The MRSP detected in this study belonged mainly to 
ST71-II-III, which is known to be one of the most disseminated clonal lineages in dogs and 
cats in Europe (Kadlec et al., 2010; Perreten et al., 2010). Although rarely, human infection by 
MRSP ST71-II-III has already been described, thus highlighting its zoonotic potential 
(Stegmann, Burnens, Maranta & Perreten, 2010). 
As seen in reports on humans, S. epidermidis showed a high frequency of methicillin-
resistance (Becker, Heilmann & Peters, 2014) and all belonged to STs also found in humans 
(Rolo, de Lencastre & Miragaia, 2012). The two MRSA isolated in this study belonged to  
S. aureus CC5, which is frequently associated with human hospital-acquired MRSA (Aires-de-
Sousa, 2017). Furthermore, both MRSA STs have been reported in humans from Portugal 
(Conceição et al., 2010; Espadinha et al., 2013). Interestingly, in this study, the mecA gene 
was mainly detected in Staphylococcus spp. isolated from cats. As this was a retrospective 
study, it was not possible to obtain information on the possible source of these infections. 
Nevertheless, the detection of MRSA and MRSE in dogs and cats with UTI is a public health 
issue since companion animals will have a role in dissemination of these bacteria to the 
household and public environment. 
Ampicillin-resistance and HLGR in Enterococcus spp. strongly limit the therapeutic options 
against enterococcal infections (Chow, 2000). Although in this study ampicillin-resistant and/or 
HLGR Enterococcus spp. were uncommon, some belonged to high-risk CCs associated with 
hospital-acquired infections in humans, such as E. faecalis CC6 (formerly CC2) and E. faecium 
CC17 (Table S7) (Leavis, Bonten & Willems, 2006; Kuch et al., 2012). HLGR was mostly 
detected in E. faecalis and was caused by the presence of a bifunctional enzyme that is known 
to also confer resistance to a wide range of aminoglycosides (Chow, 2000). E. faecalis ST6 
(CC6) has been previously described in hospitalised patients from Portugal but also in samples 
from pigs and from hospital waste waters (Freitas, Novais, Ruiz-Garbajosa, Coque & Peixe, 
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2009). As in this study, the E. faecalis ST16 is a clonal lineage that has been found to frequently 
harbour the bifunctional enzyme (Ruiz-Garbajosa et al., 2006; Larsen et al., 2010). Also,  
E. faecalis ST16 has been previously detected in healthy and hospitalised humans as well as 
in animals (Ruiz-Garbajosa et al., 2006; Freitas et al., 2009; Larsen et al., 2010). 
E. faecium isolates were less frequent than those of E. faecalis, but were more commonly 
ampicillin-resistant (Table S7). A previous study has pointed to healthy dogs as reservoirs of 
ampicillin-resistant E. faecium CC17 including ST19 (Damborg et al., 2009). Besides belonging 
to CC17, the E. faecium ST19 and ST440 strains isolated in this study are also noteworthy for 
being simultaneously ampicillin-resistant and HLGR. 
Enterobacteriaceae and Staphylococcus spp. together caused around 79% of the UTIs in dogs 
and cats. Thus, the increase in fluoroquinolone-resistance in both groups of bacteria is of great 
relevance. Furthermore, Enterococcus spp. also showed high levels of resistance to this 
antimicrobial class. Bearing in mind fluoroquinolones are considered highest priority critically 
important antimicrobials for humans (WHO, 2017a), and of great importance in the treatment 
of pyelonephritis in companion animals (Weese et al., 2011), judicious use of these 
antimicrobials should be pursued. 
The fact that this study relied on samples submitted to the laboratory based on clinical 
judgement could be considered a bias towards resistance because urine cultures from 
complicated UTIs may be requested more frequently than from simple uncomplicated UTIs 
(Hall et al., 2013). However, if present, this bias was constant throughout the study time frame 
and therefore the increase in antimicrobial resistance is unequivocal. 
Only in recent years has the EMA started to publish data about antimicrobial sales for 
companion animals. Nevertheless, the high β-lactam and fluoroquinolone-resistance 
frequencies detected in this study could be expected since these are the first and second most 
sold antimicrobials for companion animals in Portugal (EMA, 2017b). The high frequency of 
tick-borne diseases in Portugal that require the use of doxycycline in companion animals could 
have contributed to the high tetracycline-resistance seen in this study. Also, the increase in 
MDR Enterobacteriaceae may, to some extent, explain the increasing resistance trends 
observed for all the tested antimicrobials. 
The limited access to complete data about the epidemiological and clinical history of the dogs 
and cats infected with high-risk clonal lineages was also a limitation of this study. Nevertheless, 
since most of these animals were treated at home by their owners, the role of dogs and cats 
with UTI in the spread of resistant bacteria into the environment should be considered. 
Furthermore, it has been shown that companion animals may share uropathogenic bacteria 
with their household members (Johnson et al., 2009), and therefore the role of dogs and cats 
as reservoirs of high-risk clonal lineages is a concern to veterinary professionals and owners. 
This study showed that bacteria causing UTI in dogs and cats, especially Enterobacteriaceae, 
are increasingly resistant to the antimicrobials most widely used in UTI treatment. These 
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bacteria were found to harbour clinically relevant antimicrobial resistance mechanisms and 
simultaneously belong to high-risk clonal lineages, namely 3GC-resistant E. coli O25b:H4-B2-
ST131, CC23 and ST648, MRSA CC5, MRSE CC5, HLGR E. faecalis CC6, and 
ampicillin/HLGR E. faecium CC17. Therefore, when such resistance mechanisms are 
suspected based on susceptibility testing, veterinary professionals and owners should be 
advised to take measures in order to reduce the spread of these bacteria, such as strict hand 
washing, cleaning of the animals’ living environment as well as adequate faecal disposal. Also, 
longitudinal studies on the faecal carriage of these resistant high-risk clonal lineages during 
and after UTI should be conducted to assess the time of carriage and evaluate the extent and 




Supplementary Table 1 – Antimicrobial agents and antimicrobial categories 
considered for MDR isolates classification 
Antimicrobial categories Enterobacteriaceaea Staphylococcus spp. 
Penicillins + b-lactamase inhibitors AMC - 
Anti-staphylococcal b-lactams (or cephamycis) - OXA or FOXb 
Third-generation cephalosporins CTX, CAZ and/or CVN - 
Folate pathway inhibitors SXT SXT 
Fluoroquinolones CIP and/or ENR CIP and/or ENR 
Aminoglycosides GEN GEN 
Legend: AMC, amoxicillin/clavulanate; OXA, Oxacillin; FOX, cefoxitin; CTX, cefotaxime; CAZ, 
ceftazidime; CVN, cefovecin; SXT, trimethoprim/sulfamethoxazole; CIP, ciprofloxacin; ENR, 
enrofloxacin; GEN, gentamicin. 
aData on intrinsic resistance was not considered for analysis (e.g. amoxicillin/clavulanate in Enterobacter 
spp.). 
bOxacillin or cefoxitin were used according to the Staphylococcus species following CLSI (2013a) 
guidelines. Tetracycline-resistance was not included in MDR analysis because it is not routinely used 
for UTI treatment and tetracycline-resistance may not indicate resistance to doxycycline (more used in 




Supplementary Table 2 - Frequency of bacterial species in dogs and cats 
Organism  Overall  Cat  Dog P n % (CI) n % (CI) n % (CI) 
Escherichia coli 412 43.5 (40.3-46.6) 96 38.9 (32.8-45.0) 316 45.1 (41.4-48.8) 0.1006 
Proteus spp. 155 16.4 (14.0-18.7) 18 7.3 (4.0-10.5) 137 19.5 (16.6-22.5) <0.0001 
P. mirabilis 153 16.1 (13.8-18.5) 17 6.9 (3.7-10.0) 136 19.4 (16.5-22.3) <0.0001 
P. vulgaris 2 0.2 (0-0.5) 1 0.4 (0-1.2) 1 0.1 (0-0.4) 0.4534 
Staphylococcus spp. 125 13.2 (11.0-15.3) 34 13.8 (9.5-18.1) 91 13.0 (10.5-15.5) 0.7438 
S. pseudintermedius 91 9.6 (7.7-11.5) 9 3.6 (1.3-6.0) 82 11.7 (9.3-14.1) <0.0001 
S. felis 5 0.5 (0.1-1.0) 5 2.0 (0.3-3.8) 0 0 0.0012 
S. aureus 5 0.5 (0.1-1.0) 3 1.2 (0-2.6) 2 0.3 (0-0.7) 0.1144 
S. epidermidis 6 0.6 (0.1-1.1) 5 2.0 (0.3-3.8) 1 0.1 (0-0.4) 0.0055 
Other 18 1.9 (1.0-2.8) 12 4.9 (2.2-7.5) 6 0.9 (0.2-1.5) - 
Enterococcus spp. 66 7.0 (5.3-8.6) 34 13.8 (9.5-18.1) 32 4.6 (3.0-6.1) <0.0001 
E. faecalis 53 5.6 (4.1-7.0) 30 12.2 (8.1-16.2) 23 3.3 (2.0-4.6) <0.0001 
E. faecium 9 1.0 (0.3-1.6) 3 1.2 (0-2.6) 6 0.9 (0.2-1.5) 0.7034 
Other 4 0.4 (0-0.8) 1 0.4 (0-1.2) 3 0.4 (0-0.9) - 
Pseudomonas spp. 48 5.1 (3.7-6.5) 15 6.1 (3.1-9.0) 33 4.7 (3.1-6.3) 0.4012 
Klebsiella spp. 33 3.5 (2.3-4.6) 13 5.3 (2.5-8.0) 20 2.8 (1.6-4.1) 0.1037 
Streptococcus spp. 34 3.6 (2.4-4.8) 6 2.4 (0.5-4.4) 28 4.0 (2.5-5.4) 0.3218 
Corynebacterium spp. 21 2.2 (1.3-3.2) 13 5.3 (2.5-8.1) 8 1.1 (0.4-1.9) 0.0004 
Enterobacter spp. 27 2.8 (1.8-3.9) 9 3.6 (1.3-6.0) 18 2.6 (1.4-3.7) 0.3784 
Other 27 2.8 (1.8-3.9) 9 3.6 (1.3-6.0) 18 2.6 (1.4-3.7) - 
Legend: n, number of isolates; %, frequency of isolates; CI, 95% confidence interval; P, probability: 
bold highlights statistically significant differences as determined by Fisher’s exact test. 
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Supplementary Table 3 – E. coli and Enterobacteriaceae resistance temporal trends. 
Antimicrobial Escherichia coli Enterobacteriaceae OR (CI) P OR (CI) P 
Amoxicillin/clavulanate 1.155 (1.090-1.225) <0.0001 1.187 (1.129-1.248) <0.0001 
Trimethoprim/sulfamethoxazole 1.037 (0.990-1.086) 0.1267 1.052 (1.015- 1.090) 0.0052 
Third-generation cephalosporins 1.188 (1.107-1.274) <0.0001 1.202 (1.140-1.268) <0.0001 
Fluoroquinolones 1.053 (1.005-1.104) 0.0301 1.080 (1.041- 1.121) <0.0001 
Gentamicin 1.087 (1.015-1.165) 0.0177 1.120 (1.062- 1.182) <0.0001 
Tetracycline 1.075 (1.029-1.123) 0.0011 1.092 (1.049- 1.138) <0.0001 
Multidrug resistance 1.120 (1.056-1.188) 0.0002 1.162 (1.106- 1.221) <0.0001 
Legend: OR, Odds ratio; CI, 95% Confidence interval; P, probability: bold highlights statistically 
significant differences as determined by logistic regression.
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Supplementary Table 4 – Proteus spp. and Staphylococcus spp. antimicrobial resistance 
 AMC SXT 3GC FQ GEN TET MET MDR 
 % (CI) % (CI) % (CI) % (CI) % (CI) % (CI) % (CI) % (CI) 

























- - 21.2 (10.0-32.2) 
n=52 
P 0.0029 0.0748 0.0006 0.0673 0.0045 - - 0.0006 
Staphylococcus spp.         
1999-2006 
- 8.9 (2.6-15.1) 
n=79 











- 13.0 (3.3-22.8) 
n=46 










P - 0.5471 - 0.0189 0.1427 0.2306 0.1847 0.1780 
Legend: AMC, amoxicillin/clavulanate; 3GC, third-generation cephalosporins; SXT, trimethoprim/sulfamethoxazole; FQ, fluoroquinolones; GEN, gentamicin; 
TET, tetracycline; MET, Methicillin; n, number of tested isolates; %, frequency of fully-resistant isolates; CI, 95% Confidence interval; P, probability, bold 
highlights statistically significant differences as determined by Fisher’s exact test. 
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n % (CI) 
3 
AMC, 3GC, SXT FQ, GEN 7 7.5 (2.2-12.9) 
AMC, 3GC, FQ SXT, GEN 7 7.5 (2.2-12.9) 
AMC, 3GC, GEN FQ, SXT 1 1.1 (0-3.2) 
AMC, SXT, FQ 3GC, GEN 5 5.4 (0.8-10.0) 
3GC, SXT, FQ AMC, GENa 7 7.5 (2.2-12.9) 
3GC, FQ, GEN AMC, SXTa 2 2.2 (0-5.1) 
SXT, FQ, GEN AMC, 3GC 18 19.4 (11.3-27.4) 
  Total 47 50.5 (40.4-60.7) 
4 
AMC, 3GC, SXT, GEN FQ 1 1.1 (0-3.2) 
AMC, 3GC, SXT, FQ GEN 17 18.3 (10.4-26.1) 
AMC, 3GC, FQ, GEN SXT 3 3.2 (0-6.8) 
AMC, SXT, FQ, GEN 3GC 6 6.4 (1.5-11.4) 
3GC, SXT, FQ, GEN AMCa 2 2.2 (0-5.1) 
  Total 29 31.2 (21.8-40.6) 
5 AMC, 3GC, SXT, FQ, GEN - 17 18.3 (10.4-26.1) 
  Total 17 18.3 (10.4-26.1) 
Legend: Enterobacter spp. antimicrobial resistance data was not included in this analysis due to its 
intrinsic resistance against amoxicillin/clavulanate. Intermediate susceptible isolates were considered 
as susceptible. AMC, amoxicillin/clavulanate; 3GC, third-generation cephalosporins;  
SXT, trimethoprim/sulfamethoxazole; FQ, fluoroquinolones; GEN, gentamicin;  




Supplementary Table 6 – AmpC-producer P. mirabilis 
Isolate Year b-Lactamase Animal MDR AMC 3GC SXT FQ GEN 
FMV6933/04 2004 CMY-2 Cat Yes R R R R S 
FMVBeiças/07 2007 CMY-2 Dog Yes R R R R S 
FMVLord/07 2007 CMY-2 Dog Yes R R R R S 
FMV1089/07 2007 CMY-2 Dog Yes R R R R R 
FMV4138/10 2010 CMY-2 Dog Yes R R R R S 
FMV74/2012 2012 CMY-2 Dog Yes R R R R R 
FMV5017/13 2013 DHA-1 Dog Yes R R R S S 
FMV62/2013 2013 CMY-2 Dog Yes R R R R R 
FMV3252/14 2014 CMY-2 Dog Yes R R R S I 
Legend: AMC, amoxicillin/clavulanate; 3GC, third-generation cephalosporins;  
SXT, trimethoprim/sulfamethoxazole; FQ, fluoroquinolones; GEN, gentamicin; R, resistant; I, 




Supplementary Table 7 – Ampicillin and/or HLGR Enterococcus spp. clonal lineages 
Isolate Year Species Clonal lineage Clonal complex (CC)a HLGR enzyme Animal AMP HLGEN CIP TET 
FMV95/99 1999 E. faecium ST18 CC17 - Dog R S R S 
FMV1678/01 2001 E. faecium ST132 CC17 - Cat R S R S 
FMV337/03 2003 E. faecium ST440 CC17 aac(6’)-Ieaph(2’’)-Ia Dog R R R R 
FMV3626/03 2003 E. faecalis ST59 CC59 aac(6’)-Ieaph(2’’)-Ia Cat S R R S 
FMV6735/06 2006 E. faecalis ST35 none aac(6’)-Ieaph(2’’)-Ia Cat S R R R 
FMV6736B/06 2006 E. faecalis ST36 CC355 aac(6’)-Ieaph(2’’)-Ia Dog S R I R 
FMV6210/08 2008 E. faecium ST1282 CC17 - Cat R S R S 
FMV1899/09 2009 E. faecium ST19 CC17 aph(2’’)-1d Dog R R I R 
FMV2859/09 2009 E. faecium ST1282 CC17 - Dog R S R S 
FMV4233/09 2009 E. faecalis ST86 none aac(6’)-Ieaph(2’’)-Ia Cat S R R R 
FMV5944/10 2010 E. faecalis ST6 CC6 aac(6’)-Ieaph(2’’)-Ia Dog S R R R 
FMV40/2014 2014 E. faecalis ST16 CC16 aac(6’)-Ieaph(2’’)-Ia Cat S R R R 
FMV43/2014 2014 E. faecalis ST16 CC16 aac(6’)-Ieaph(2’’)-Ia Cat S R R R 
FMV81/2014 2014 E. faecium ST1283 CC17 - Dog R S R R 
Legend: AMP, ampicillin; HLGR, high-level gentamicin-resistance; HLGEN, high-level gentamicin; CIP, ciprofloxacin; TET, tetracycline; R, resistant;  
I, intermediate; S, susceptible; 
aclonal complexes based on eBUSRT analysis of entire E. faecium or E. faecalis MLST database.
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Supplementary Figure 1 – New ST of E. coli belonging to CC23 
a) 
 adk fumC gyrB icd mdh purA recA CC 
ST23 6 4 12 1 20 13 7 23 
New ST (FMV1630/07) 6 4 12 1 20 13 New 23 
 
b) 
Allele recA 7   CGCACGTAAACTGGGCGTCGATATCGATAACCTGCTGTGCTCCCAGCCGGACACCGGCGA 
New recA allele CGCACGTAAACTGGGCGTCGATATCGATAACCTGCTGTGCTCCCAGCCGGACACCGGCGA 
                ************************************************************ 
Allele recA 7   GCAGGCACTGGAAATCTGTGACGCCCTGGCGCGTTCTGGCGCAGTAGACGTTATCGTCGT 
New recA allele GCAGGCACTGGAAATCTGTGACGCCCTGGCGCGTTCTGGCGCAGTAGACGTTATCGTCGT 
                ************************************************************ 
Allele recA 7   TGACTCCGTGGCGGCACTGACGCCGAAAGCGGAAATCGAAGGCGAAATCGGCGACTCTCA 
New recA allele TGACTCCGTGGCGGCACTGACGCCGAAAGCGGAAATCGAAGGCGAAATCGGCGACTCTCA 
                ************************************************************ 
Allele recA 7   CATGGGCCTTGCGGCACGTATGATGAGCCAGGCGATGCGTAAGCTGGCGGGTAACCTGAA 
New recA allele CATGGGCCTTGCGGCACGTATGATGAGCCAGGCGATGCGTAAGCTGGCGGGTAACCTGAA 
                ************************************************************ 
Allele recA 7   GCAGTCCAACACGCTGCTGATCTTCATCAACCAGATCCGTATGAAAATTGGTGTGATGTT 
New recA allele GCAGTCCAACACGCTGCTGATCTTCATCAACCAGATCCGTATGAAAATTGGTGTGATGTT 
                ************************************************************ 
Allele recA 7   CGGTAACCCGGAAACCACTACCGGTGGTAACGCGCTGAAATTCTACGCCTCTGTTCGTCT 
New recA allele CGGTAACCCGGAAACCACTACCGGTGGTAACGCGCTGAAATTCTACGCCTCTGTTCGTCT 
                ************************************************************ 
Allele recA 7   CGACATCCGTCGTATCGGCGCGGTGAAAGAGGGCGAAAACGTGGTGGGTAGCGAAACCCG 
New recA allele CGACATCCGTCGTATCGGCGCGGTGAAAGAGGGCGAAAACGTGGTGGGTAGCGAAACCCG 
                ************************************************************ 
Allele recA 7   CGTGAAAGTGGTGAAGAACAAAATCGCTGCACCGTTTAAACAGGCTGAATTTCAGATCCT 
New recA allele CGTGAAAGTGGTGAAGAACAAAATCGCTGCACCGTTTAAACAGGCTGAATTTCAGATCCT 
                ************************************************************ 
Allele recA 7   CTACGGCGAAGGTATCAACTTCTACGGCGA 
New recA allele CTACGGCGAAGGTATCAATTTCTACGGCGA 
                ****************** *********** 
Legend: a) Comparison of allelic MLST profile of new E. coli ST with E. coli ST23 (CC23). The new ST 
varies from ST23, the predicted founder of CC23, in a single locus variation (SLV) namely recA. MLST 
genes: adk, adenylate kinase; fumC, fumarate hydratase; gyrB, DNA gyrase; icd, 
isocitrate/isopropylmalate dehydrogenase; mdh, malate dehydrogenase; purA, adenylosuccinate 
dehydrogenase; recA, ATP/GTP binding motif. 
b) Sequence alignment of new recA allele with its closest match, namely allele 7. The new allele differs 





Supplementary Figure 2 – eBURST analysis of E. faecium strains 
 
Legend: eBURST clustering analysis of all known ST allelic profiles of E. faecium (n= 1284) from the  
E. faecium central MLST database (https://pubmlst.org/efaecium/) at 19th February 2017. Each ST is 
represented as a dot and each line indicates a single-locus difference between STs. The clonal complex 
(CC) assignment was based on the ST assigned as the founder genotype by eBURST analysis. Black 
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Abstract 
Objectives: To characterise the population structure, antimicrobial resistance and virulence 
genes of Klebsiella spp. isolated from dogs, cats and humans with urinary tract infections 
(UTIs). 
Methods: Klebsiella spp. from companion animals (n =  27) and humans (n =  77) with UTI 
were tested by the disc diffusion method against 29 antimicrobials. Resistant/intermediate 
isolates were tested by PCR for 16 resistance genes. Seven virulence genes were screened 
for by PCR. All Klebsiella pneumoniae from companion animals and third-generation 
cephalosporin (3GC)-resistant isolates from humans were typed by MLST. All Klebsiella spp. 
were compared after PFGE XbaI macro-restriction using Dice/UPGMA with 1.5% tolerance. 
Results: blaCTX-M-15 was detected in >80% of 3GC-resistant strains. K. pneumoniae high-risk 
clonal lineage ST15 predominated in companion animal isolates (60%, n =  15/25). Most 
companion animal ST15 K. pneumoniae belonged to two PFGE clusters (C4, C5) that also 
included human strains. Companion animal and human ST15-CTX-M-15 K. pneumoniae 
shared a fimH-1/mrkD/entB/ycfM/kfu virulence profile, with a few (n =  4) also harbouring the 
yersiniabactin siderophore-encoding genes. The hospital-adapted ST11 K. pneumoniae clonal 
lineage was detected in a cat (n =  1) and a human (n =  1); both were MDR, had 81.1% 
Dice/UPGMA similarity and shared several virulence and resistance genes. Two 3GC-resistant 
ST348 strains with 86.7% Dice/UPGMA similarity were isolated from a cat and a human. 
Conclusions: Companion animals with UTI become infected with high-risk K. pneumoniae 
clonal lineages harbouring resistance and virulence genes similar to those detected in strains 
from humans. The ST15-CTX-M-15 K. pneumoniae clonal lineage was disseminated in 
companion animals with UTI. Caution must be applied by companion animal caretakers to 
avoid the spread of K. pneumoniae high-risk clonal lineages. 
 
Introduction 
Urinary tract infections (UTIs) are commonly diagnosed in companion animals and humans 
and frequently require antimicrobial treatment (Weese et al., 2011; Flores-Mireles et al., 2015). 
Although less frequently than Escherichia coli, UTIs in humans and companion animals can 
be caused by Klebsiella pneumoniae (Flores-Mireles et al., 2015; Marques et al., 2018b). 
Furthermore, K. pneumoniae is a major pathogen of nosocomial infections, including UTIs, 
that is frequently associated with resistance to the highest priority critically important 
antimicrobials (European Centre for Disease Prevention and Control [ECDC], 2016b). 
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Recently, the WHO published a global priority list of antimicrobial resistant bacteria, where 
third-generation cephalosporin (3GC)- and/or carbapenem-resistant Enterobacteriaceae, 
including K. pneumoniae, were included in the Priority 1 group (WHO, 2017b). Therefore, the 
detection of ESBL/AmpC-producing K. pneumoniae in veterinary medicine is an important 
issue since animals may contribute to its spread (Pomba et al., 2017). Moreover, ESBL-
producing Enterobacteriaceae are frequently MDR, posing great therapeutic challenges 
(ECDC, 2017). 
Some studies regarding ESBL-producing K. pneumoniae infections in companion animals 
have reported that these bacteria may belong to high-risk clonal lineages found in humans 
(Hidalgo et al., 2013; Donati et al., 2014; Ewers et al., 2014b; Wohlwend et al., 2015; Harada 
et al., 2016; Kuan et al., 2016; Maeyama et al., 2018; Zogg et al., 2018a). However, current 
knowledge of K. pneumoniae epidemiology in veterinary medicine is still limited when 
compared with human medicine. 
K. pneumoniae may harbour several virulence genes that contribute to its pathogenicity. A 
recent study, using WGS, detected several virulence factors that were significantly more 
frequent among invasive K. pneumoniae, such as yersiniabactin, aerobactin and the regulators 
of mucoid phenotype (Holt et al., 2015). Additionally, some virulence factors are known to play 
an important role in UTI infection, such as type-1 fimbriae and aerobactin (Stahlhut et al., 2009; 
Flores-Mireles et al., 2015). However, studies reporting the frequency of such K. pneumoniae 
virulence genes are limited in isolates from companion animals and humans with UTI 
(Podschun et al., 1993; El Fertas-Aissani et al., 2013; Ranjbar et al., 2016; Wasfi, Elkhatib & 
Ashour, 2016). 
This study aimed to characterise the antimicrobial resistance and virulence genes of  
K. pneumoniae strains causing UTI in companion animals (dogs and cats) and humans. It also 
aimed to characterise the population structure of Klebsiella spp. isolated from companion 
animals and humans with UTI. 
 
Materials and methods 
Bacteria isolates 
Twenty-five K. pneumoniae and two Klebsiella oxytoca were isolated at the Laboratory of 
Antimicrobial Resistance in the Faculty of Veterinary Medicine, University of Lisbon, from 24 
dogs and cats with UTI living in the Lisbon area. Seventy-six K. pneumoniae and one  
K. oxytoca were collected from human patients with UTI at a private clinical analysis laboratory 
and from hospital microbiology laboratories in the Lisbon area. Epidemiological data regarding 
the type of UTI were not available. The clinical Klebsiella spp. from companion animals and 
from the human private analysis laboratory were isolated sequentially during 2002–15 and 
2014, respectively. Isolates from the hospital microbiology laboratories were part of a randomly 
non-sequential bacterial collection stored from 2006 to 2015. Samples from the human private 
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laboratory (n =  58) were obtained from humans with community-acquired UTI. The hospital 
laboratory samples (n =  19) were obtained from hospitalised patients with UTI; however, the 
nosocomial origin of infection was uncertain due to insufficient patient data. 
 
Bacteriological methods 
Standard quantitative urine culture was performed, and initial species identification was 
conducted by phenotypical tests (API20E or VITEK II, BioMérieux, Marcy-l’Étoile, France). 
Bacterial identification was confirmed by species-specific PCR (Kovtunovych et al., 2003; 
Padmavathy et al., 2012). 
 
Susceptibility testing 
Susceptibility testing was performed by the disc diffusion method according to CLSI guidelines 
with the following antimicrobials: (Oxoid, Hampshire, UK) ampicillin 10 μg, 
amoxicillin/clavulanate 30 μg, cephalothin 30 μg, cefoxitin 30 μg, cefotaxime 30 μg, ceftazidime 
30 μg, cefovecin 30 μg, piperacillin/tazobactam 110 μg, cefepime 30 μg, imipenem 10 μg, 
meropenem 10 μg, aztreonam 30 μg, ertapenem 10 μg, nalidixic acid 30 μg, ciprofloxacin 5 μg, 
enrofloxacin 5 μg, norfloxacin 10 μg, levofloxacin 5 μg, gentamicin 10 μg, kanamycin 30 μg, 
netilmicin 30 μg, tobramycin 10 μg, amikacin 30 μg, chloramphenicol 30 μg, florfenicol 30 μg, 
tetracycline 30 μg, fosfomycin 50 μg, nitrofurantoin 300 μg and trimethoprim/sulfamethoxazole 
25 μg (CLSI, 2013b). 
Veterinary CLSI breakpoints (CLSI, 2013a; Clinical and Laboratory Standards Institute [CLSI], 
2018) were used for cephalothin, cefovecin and enrofloxacin. Florfenicol (a fluorinated 
compound in use for bovine respiratory infections) breakpoints were derived from the 
veterinary CLSI breakpoints for swine infections (CLSI, 2013a). Fosfomycin results were 
interpreted according to the Societé Française de Microbiology (SFM, 2010). Human CLSI 
breakpoints (Clinical and Laboratory Standards Institute [CLSI], 2017) were used for the 
remaining antimicrobials. 
Antimicrobial categories were used to characterise multidrug resistance as previously 
proposed (Magiorakos et al., 2012). Klebsiella spp. were considered as MDR when fully-
resistant to three or more antimicrobial categories. 
 
Antimicrobial resistance determinants 
β-Lactam-resistant/intermediate Klebsiella spp. (excluding only ampicillin-resistant isolates) 
were tested for the presence of blaTEM and blaOXA genes (Pomba et al., 2006). 3GC-
resistant/intermediate Klebsiella spp. were further screened for ESBL (blaCTX-M-type) and AmpC 
(blaCIT-type, blaDHA-type, blaMOX-type, blaACT-type, blaFOX-type and blaMIR-type) β-lactamase genes by PCR 
and sequencing (Pérez-Pérez & Hanson, 2002; Guessennd et al., 2008). 3GC-
resistant/intermediate isolates lacking blaCTX-M-type or AmpC genes were characterised by 
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nucleotide sequencing for detection of the blaTEM and blaSHV ESBL genes. The presence of 
ISEcp1 upstream of the blaCTX-M-type gene was investigated by PCR and sequencing (Edelstein, 
Pimkin, Palagin, Edelstein & Stratchounski, 2003; Gonullu et al., 2008). 
The presence of genes conferring resistance to aminoglycosides [aphAI-IAB, aac(6′)-Ib, 
aac(3′)-IV] (Frana, Carlson & Griffith, 2001; Sáenz et al., 2004; Robicsek et al., 2006a), 
tetracyclines [tet(A), tet(B)] (Guardabassi, Dijkshoorn, Collard, Olsen & Dalsgaard, 2000), 
phenicols (floR) (Sáenz et al., 2004), fluoroquinolones (qnrA, qnrB, qnrC, qnrD, qnrS) 
(Robicsek et al., 2006b; Cavaco, Hasman, Xia & Aarestrup, 2009; Wang et al., 2009) and 
trimethoprim/sulfamethoxazole [sul1, sul2, sul3, dfrA12, dfrIa (targeting dfrA1, dfrA5, dfrA15, 
dfrA15b, dfrA16, dfrA16b)] (Guerra, Soto, Argüelles & Mendoza, 2001; Maynard et al., 2003; 
Navia, Ruiz, Sanchez-Cespedes & Vila, 2003; Perreten & Boerlin, 2003; Sáenz et al., 2004) 
was evaluated in all resistant/intermediate isolates. 
Furthermore, all Klebsiella spp. were tested for the presence of oqxAB (Kim et al., 2009c) efflux 
pump genes and ompK35 and ompK36 outer membrane protein genes (Lee et al., 2007). 
 
Virulence genes 
Klebsiella spp. were screened by PCR for the following virulence genes: type-1 (fimH-1) 
adhesin; type-3 (mrkD) adhesin and FimH-like (kpn) adhesin (El Fertas-Aissani et al., 2013; 
Compain et al., 2014); outer membrane lipoprotein (ycfM) (El Fertas-Aissani et al., 2013); 
catecholate siderophore receptor (iroN) (Johnson et al., 2000); enterobactin (entB) (Compain 
et al., 2014); aerobactin (iutA) (Compain et al., 2014); iron transporter with phosphotransferase 
function (kfu) (Compain et al., 2014); yersiniabactin high-pathogenicity island (YHPI) (fyuA,  
irp-1, irp-2, ybtS) (Johnson & Stell, 2000; Schubert, Cuenca, Fischer & Heesemann, 2000; 
Compain et al., 2014) serum resistance-associated outer membrane lipoprotein (traT) 
(Johnson & Stell, 2000); regulator of mucoid phenotype A (rmpA) (Compain et al., 2014); 
cytotoxic necrotizing factor-1 (cnf-1) (Yamamoto et al., 1995); and allantoin metabolism 
associated gene (allS) (Compain et al., 2014). 
 
Population structure analysis 
Klebsiella spp. were characterised by PFGE after XbaI (New England Biolabs, Beverly, MA, 
USA) restriction on a CHEF DR II apparatus (Biorad, Hercules, CA, USA) as previously 
described (Rodrigues et al., 2016). 
All K. pneumoniae from companion animals and 3GC-resistant K. pneumoniae from humans 








Statistical analysis was conducted with the SAS statistical software package for Windows, 
version 9.3 (SAS Institute, Cary, NC, USA). Fisher’s exact test was used with an α value of 
0.05. 
eBURSTv3 software was used to analyse the K. pneumoniae STs found in this study. 
Interpretation of Klebsiella spp. PFGE patterns was conducted with Bionumerics software, 
version 6.6 (BioMérieux, Marcy-l’Étoile, France) using the Dice/UPGMA clustering method with 
a tolerance of 1.5% and a clustering cut-off of 80%. 
 
Results 
Klebsiella spp. antimicrobial resistance 
K. pneumoniae from companion animals presented high antimicrobial resistance, especially 
against cephalothin, 3GC, fluoroquinolones, kanamycin, tetracycline and 
trimethoprim/sulfamethoxazole (>60%). K. pneumoniae from humans showed higher 
resistance frequencies against nitrofurantoin and trimethoprim/sulfamethoxazole. Fosfomycin, 
amikacin and carbapenems were the antimicrobials with the lowest resistance frequencies in 
all K. pneumoniae (Table 1). 
The blaTEM and blaOXA-1 β-lactamase genes were frequent among β-lactam-non-susceptible  
K. pneumoniae (strains categorised as antimicrobial resistant or intermediate) (Table 2) and 
41.3% (n =  19/46) harboured both. The ESBL blaCTX-M-15 gene was detected in >80% of 3GC-
resistant strains (Table 2). Two K. pneumoniae from companion animals harboured blaCTX-M-15 
and an AmpC gene simultaneously (blaCTX-M-15/blaDHA-1, blaCTX-M-15/blaCMY-2). The genotype 
blaTEM/blaOXA-1/blaCTX-M-15 was the most common (56.2%, n =  18/32) among all 3GC-resistant 
strains. ISEcp1 was located upstream of all blaCTX-M-15 genes except in two strains. 
Among the tested qnr genes, qnrB was the most common and was significantly more frequent 
among fluoroquinolone-non-susceptible K. pneumoniae from humans (P  =  0.0284) (Table 2). 
Most qnrB-positive K. pneumoniae (86.7%, n =  13/15) also harboured blaCTX-M-15. 
Kanamycin was the aminoglycoside with the highest resistance frequency, followed by 
tobramycin and gentamicin (Table 1). Aminoglycoside-non-susceptible K. pneumoniae from 
companion animals and humans frequently harboured aac(6′)-Ib (80.0%) and fewer were 
positive for aphAi-iAB (25.7%) (Table 2). All strains were negative for aac(3′)-IV. 
Trimethoprim/sulfamethoxazole-non-susceptible K. pneumoniae frequently harboured sul1, 
sul2 and/or dfrIa (Table 2). The genotype sul1/sul2/dfrIa was the most common in companion 
animals (37.5%, n =  6/16) followed by sul1/sul2/dfrA12 (18.8%, n =  3/16) and sul2 alone 
(18.8%, n =  3/16). In K. pneumoniae from humans, sul2 was frequently detected alone (40.9%, 




Table 1 - Antimicrobial resistance of K. pneumoniae strains 
Antimicrobials 






%R (n) %I (n) %R (n) %I (n) %R (n) %I (n) 
Ampicillin 100 (25) 0 (0) 100 (19) 0 (0) 96.5 (55) 0 (0) 
Amoxicillin/clavulanate 32.0 (8) 32.0 (8) 15.8 (3) 21.0 (4) 15.8 (9) 14.0 (8) 
Cephalothin 64.0 (16) 4.0 (1) 36.8 (7) 0 (0) 22.8 (13) 5.3 (3) 
Cefoxitin 20.0 (5) 0 (0) 5.3 (1) 0 (0) 1.8 (1) 1.8 (1) 
Cefotaxime 60.0 (15) 0 (0) 21.0 (4) 0 (0) 22.8 (13) 0 (0) 
Ceftazidime 44.0 (11) 12.0 (3) 21.0 (4) 0 (0) 8.8 (5) 8.8 (5) 
Cefovecin 60.0 (15) 0 (0) 21.0 (4) 0 (0) 22.8 (13) 0 (0) 
Piperacillin/tazobactam 12.0 (3) 16.0 (4) 21.0 (4) 15.8 (3) 1.8 (1) 10.5 (6) 
Cefepime 32.0 (8) 16.0 (4) 15.8 (3) 0 (0) 14.0 (8) 5.3 (3) 
Imipenem 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
Meropenem 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
Aztreonam 52.0 (13) 4.0 (1) 15.8 (3) 0 (0) 15.8 (9) 5.3 (3) 
Ertapenem 0 (0) 4.0 (1) 0 (0) 0 (0) 0 (0) 0 (0) 
Nalidixic acid 80.0 (20) 4.0 (1) 21.0 (4) 10.5 (2) 21.0 (12) 12.3 (7) 
Ciprofloxacin 72.0 (18) 8.0 (2) 21.0 (4) 15.8 (3) 14.0 (8) 14.0 (8) 
Enrofloxacin 72.0 (18) 12.0 (3) 21.0 (4) 15.8 (3) 15.8 (9) 12.3 (7) 
Norfloxacin 72.0 (18) 0 (0) 21.0 (4) 0 (0) 12.3 (7) 10.5 (6) 
Levofloxacin 72.0 (18) 0 (0) 21.0 (4) 0 (0) 7.0 (4) 5.3 (3) 
Gentamicin 32.0 (8) 0 (0) 21.0 (4) 5.3 (1) 14.0 (8) 0 (0) 
Kanamycin 60.0 (15) 4.0 (1) 21.0 (4) 10.5 (2) 17.5 (10) 0 (0) 
Netilmicin 24.0 (6) 0 (0) 5.3 (1) 0 (0) 1.8 (1) 0 (0) 
Tobramycin 48.0 (12) 4.0 (1) 26.3 (5) 5.3 (1) 19.3 (11) 0 (0) 
Amikacin 4.0 (1) 4.0 (1) 0 (0) 0 (0) 0 (0) 0 (0) 
Chloramphenicol 44.0 (11) 0 (0) 31.6 (6) 0 (0) 15.8 (9) 5.3 (3) 
Florfenicol 24.0 (6) 44.0 (11) 5.3 (1) 10.5 (2) 10.5 (6) 22.8 (13) 
Tetracycline 64.0 (16) 4.0 (1) 31.6 (6) 0 (0) 19.3 (11) 0 (0) 
Fosfomycinb 0 (0) 0 (0) 0 (0) 0 (0) 8.8 (5) 0 (0) 
Nitrofurantoin 44.0 (11) 24.0 (6) 57.9 (11) 21.0 (4) 31.6 (18) 15.8 (9) 
Trimethoprim/sulfamethoxazole 64.0 (16) 0 (0) 47.4 (9) 0 (0) 22.8 (13) 0 (0) 
Legend: %R, percentage of resistant isolates; %I, percentage of intermediate isolates; Human-HA, 
human hospital patients with UTI; Human-CA, human community-acquired UTI. 
aThe number shown is the total number of isolates tested. 
bThe use of the disc diffusion method for fosfomycin antimicrobial susceptibility testing is debatable 
(Kaase, Szabados, Anders & Gatermann, 2014); nevertheless, all fosfomycin-resistant isolates had 




Most tetracycline-non-susceptible K. pneumoniae from companion animals harboured tet(A) 
or tet(B) alone (88.2%, n =  15/17). Only tet(A) was detected in tetracycline-non-susceptible  
K. pneumoniae from humans; nevertheless, the majority were negative for both genes (50.0%, 
n =  9/18) (Table 2). 
 
Table 2- Antimicrobial resistance genes among antimicrobial non-susceptible  
K. pneumoniae strains 






β-Lactams blaTEM 56.5% (26/46) 66.7% (12/18) 5/8 45.0% (9/20) 0.3640 
 
blaOXA-1 63.0% (29/46) 66.7% (12/18) 4/8 65.0% (13/20) 0.7613 
Third-generation 
cephalosporins 
blaCTX-M-15 81.2% (26/32) 80.0% (12/15) 3/4 84.6% (11/13) 1 
 
blaCMY-2 15.6% (5/32) 26.7% (4/15) 0/4 7.69% (1/13) 0.1609 
 
blaDHA-1 6.2% (2/32) 6.7% (1/15) 1/4 0% (0/13) 1 
Fluoroquinolones qnrB 31.9% (15/47) 14.3% (3/21) 3/7 47.4% (9/19) 0.0284 
 
qnrS 2.1% (1/47) 0% (0/21) 1/7 0% (0/19) 1 
Aminoglycosides aac(6')-Ib 80.0% (28/35) 76.5% (13/17) 4/7 100% (11/11) 0.6906 
 
aphAi-iAB 25.7% (9/35) 29.4% (5/17) 4/7 0% (0/11) 0.7112 
Folate pathway 
inhibitors 
sul1 65.8% (25/38) 75.0% (12/16) 6/9 53.9% (7/13) 0.4898 
 
sul2 76.3% (29/38) 81.2% (13/16) 6/9 76.9% (10/13) 0.7060 
 
sul3 2.6% (1/38) 6.2% (1/16) 0/9 0% (0/13) 0.4211 
 
dfrA12 15.8% (6/38) 25.0% (4/16) 2/9 0% (0/13) 0.2170 
 
dfrIa 38.8% (14/38) 37.5% (6/16) 3/9 38.5% (5/13) 1 
Tetracycline tet(A) 50.0% (17/34) 52.9% (9/17) 5/6 27.3% (3/11) 1 
 
tet(B) 17.6% (6/34) 35.3% (6/17) 0/6 0% (0/11) 0.0184 
Phenicols floR 2.1% (1/47) 5.6% (1/18) 0/7 0% (0/22) 0.4500 
Legend: Human-HA, human hospital patients with UTI; Human-CA, human community-acquired UTI. 
aK. pneumoniae from companion animals were compared with K. pneumoniae from humans (Human-
CA + Human-HA) by Fisher’s exact test. 
 
K. pneumoniae chloramphenicol-resistance was high (Table 1); however, only one  
K. pneumoniae of companion animal origin harboured the floR gene (Table 2 and Table S1). 
All K. pneumoniae were positive for ompK35 and ompK36 genes, except one that was negative 
for ompK35 (FMV4919/09). The oqxAB efflux pump was also common (95.0%, n =  96/101) 
and likely chromosome encoded (Holt et al., 2015). 
Eighty percent of K. pneumoniae from companion animals were MDR and most strains were 
resistant to more than five antimicrobial categories (Table S2). The frequency of MDR  
K. pneumoniae from humans was also high (30%, n =  23/76) (Table S2). Notably, all 
ESBL/AmpC-producers were MDR, except for one strain from human infection (Table S1). 
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K. oxytoca from companion animals were both MDR (resistant to 9 out of 12 tested 
antimicrobial categories) and harboured several resistance genes, including blaDHA-1 (Table 
S3). 
 
K. pneumoniae virulence 
All K. pneumoniae were positive for fimH-1, mrkD and entB. Furthermore, ycfM, kpn and kfu 
were also frequent (Table S4). Two main virulence genotypes (VGs) were detected, namely 
VG1 [fimH-1/mrkD/ent(B)/ycfM/kfu; 52.5%, n =  53/101] and VG2 [fimH-1/ 
mrkD/ent(B)/ycfM/kpn; 40.6%, n =  41/101] (Table 3). K. pneumoniae from companion animals 
had a significantly higher frequency of VG1 (P  =  0.0023) and a lower frequency of VG2  
(P  =  0.0045) than isolates from humans. In K. pneumoniae from humans, the frequencies of 
VG1 (43.4%, n =  33/76) and VG2 (48.7%, n =  37/76) were similar (Table 3). Although YHPI 
gene frequency was higher in K. pneumoniae from humans (P  =  0.0165), it was also detected 
in strains from companion animals (16%) (Table 3 and Table S4). The remaining virulence 
genes were absent or seldom detected (Table S4). 
 










fimH-1, entB, mrkD, ycfM, kfu 28.7% (n = 29) 60.0% (n = 15) 21.0% (n = 4) 17.5% (n = 10) 
fimH-1, entB, mrkD, ycfM, kpn 24.8% (n = 25) 12.0% (n = 3) 31.6% (n = 6) 28.1% (n = 16) 
fimH-1, entB, mrkD, ycfM, kfu, YHPI 21.8% (n = 22) 12.0% (n = 3) 31.6% (n = 6) 22.8% (n = 13) 
fimH-1, entB, mrkD, ycfM, kpn, YHPI 12.9% (n = 13) 0% (n = 0) 10.5% (n = 2) 19.3% (n = 11) 
fimH-1, entB, mrkD, ycfM, kpn, iutA, 
traT, YHPI 
1.0% (n = 1) 4.0% (n = 1) 0% (n = 0) 0% (n = 0) 
fimH-1, entB, mrkD, ycfM, kpn, traT 1.0% (n = 1) 0% (n = 0) 0% (n = 0) 1.8% (n = 1) 
fimH-1, entB, mrkD, ycfM, kpn, allS 1.0% (n = 1) 0% (n = 0) 0% (n = 0) 1.8% (n = 1) 
fimH-1, entB, mrkD, ycfM, kpn, kfu 1.0% (n = 1) 0% (n = 0) 0% (n = 0) 1.8% (n = 1) 
fimH-1, entB, mrkD, ycfM, kfu, iutA 1.0% (n = 1) 4.0% (n = 1) 0% (n = 0) 0% (n = 0) 
fimH-1, entB, mrkD, ycfM, kfu, traT 1.0% (n = 1) 4.0% (n = 1) 0% (n = 0) 0% (n = 0) 
fimH-1, entB, mrkD, ycfM, YHPI  1.0% (n = 1) 0% (n = 0) 0% (n = 0) 1.8% (n = 1) 
fimH-1, entB, mrkD, ycfM, allS 1.0% (n = 1) 0% (n = 0) 0% (n = 0) 1.8% (n = 1) 
fimH-1, entB, mrkD, ycfM 3.0% (n = 3) 0% (n = 0) 5.3% (n = 1) 3.5% (n = 2) 
fimH-1, entB, mrkD, allS 1.0% (n = 1) 4.0% (n = 1) 0% (n = 0) 0% (n = 0) 
Legend: Human-HA, human hospital patients with UTI; Human-CA, human community-acquired UTI; 
fimH-1, type-1 adhesin; mrkD, type-3 adhesin; kpn, FimH-like adhesin; ycfM, outer membrane 
lipoprotein; entB, enterobactin; iutA, aerobactin; kfu, iron transporter with phosphotransferase function; 
YHPI, yersiniabactin high-pathogenicity island; traT, serum resistance-associated outer membrane 
lipoprotein; allS, allantoin metabolism-associated gene. 







Companion animal MDR 3GC-resistant K. pneumoniae belonged mainly to ST15 (73.3%,  
n =  11/15), but ST37, ST11, ST147 and ST348 were also detected (Figure 1 and Table S1). 
The 3GC-resistant K. pneumoniae from humans belonged to a large number of clonal lineages 
(n =  14), but also included MDR ST15 (n =  2), ST348 (n =  1) and ST11 (n =  1) (Figure 1 and 
Table S1). The 3GC-susceptible K. pneumoniae from companion animals showed additional 
lineage diversity; however, two ST15 were also found (Figure 1 and Table S1). All ST15  
K. pneumoniae from animal or human origin were fluoroquinolone-resistant regardless of  
3GC-susceptibility (Table S1 and Figure S1). 
Seven new STs were described (ST3027–ST3033) (Figure 1 and Table S1). In eBURST 
analysis two of the new STs from companion animals (ST3027 and ST3030) were single- or 
double-locus variants of ST35, which was detected in three human UTI strains (Figure 1). 
The PFGE analysis resulted in 19 clusters (C1–C19) and 43 single pulse-types (S1–S43) 
(Figure S1). Four clusters included K. pneumoniae strains from community and hospital 
patients with UTI. Moreover, six clusters included strains from companion animals and humans 
(C1, C2, C4, C5, C16, C18) that contained at least one human and companion animal strain 
sharing 80%–86.7% similarity (Figure S1). 
 
Figure 1 - Population snapshot by eBURST analysis of all K. pneumoniae strains typed 
in this study against all K. pneumoniae STs known as of 24 November 2017 
 
Legend: Detected clonal complexes (CCs) were assigned based on the predicted founder ST and are 
grouped with a dashed line. Each ST is represented by a circle and lines connect single-locus variants. 
The relative size of the circles indicates the prevalence of each ST. The black boxes indicate the  
K. pneumoniae STs found in this study. CAS, 3GC-susceptible K. pneumoniae from companion animals 
with UTI; CAR, 3GC-resistant K. pneumoniae from companion animals with UTI; HCA, 3GC-resistant  
K. pneumoniae from human community-acquired UTI; HHA, 3GC-resistant K. pneumoniae from human 


















































The K. pneumoniae ST15 strains from companion animals belonged mainly to two clusters 
(C4 and C5) that also included strains from humans (Figure S1). All C4 and C5 strains shared 
VG1 (Figure S1). Four ST15 K. pneumoniae were obtained from three urine samples collected 
from the same animal at 2 month intervals (FMV3133/08, FMV4290/08, FMV5704/08A and 
FMV5704/08B). Although with some genetic variability, all strains clustered together with >85% 
similarity (Figure S1). In one human urine sample, two 100% similar strains with distinct 
antimicrobial resistance to 3GC were isolated (GTAFD58A, GTAFD58B) (Figure S1). Strains 
FMV3133/08 and FMV4290/08 were 100% similar to other strains (FMV338/08 and 
FMV4300/08, respectively) that were collected from unrelated companion animals in the same 
year. 
The 3GC-resistant ST11 strains from one cat and one unrelated human shared 81.1% 
similarity, had similar MDR resistance and virulence profiles and were both isolated in 2007 
(Table S1 and Figure S1). 
The ST348 strains from a human and a cat were 86.7% similar and shared several virulence 
genes; however, the antimicrobial resistance profile differed extensively (Table S1 and Figure 
S1). 
PFGE analysis of K. oxytoca revealed that both companion animal MDR strains clustered 
together but were unrelated to the human strain (Figure S2). 
 
Discussion 
The number of MDR 3GC-resistant K. pneumoniae was high among companion animal strains, 
hence creating great therapeutic limitations. The frequent detection of blaCTX-M-15 among  
3GC-resistant strains of animal and human origin is in agreement with previous published data 
(Ewers et al., 2014b; Rodrigues et al., 2014a). Interestingly, the blaCTX-M-15/blaOXA-1/blaTEM 
genotype has been reported in K. pneumoniae strains from humans in Portugal (Machado et 
al., 2006). 
The 3GC-resistant and -susceptible K. pneumoniae isolated from companion animals in this 
study belonged mainly to ST15. This result agrees with previous studies showing that  
K. pneumoniae ST15-CTX-M-15-producers are widely disseminated among companion 
animals with several infections (Ewers et al., 2014b; Harada et al., 2016). K. pneumoniae ST15 
has also been described in community- and hospital-onset infections in humans from Portugal, 
including UTIs (Rodrigues et al., 2014a; Vubil et al., 2017). 
K. pneumoniae ST11 is a worldwide-disseminated high-risk clonal lineage that is associated 
with human hospital-acquired infections and with the dissemination of carbapenemases 
(Rodrigues et al., 2016). ST11 has been previously detected in hospital patients in Portugal 
(Managueiro et al., 2015), as in this study. The detection of ST11 in companion animals is 
therefore worrisome and has also been reported in Germany, Spain, Italy, Switzerland, Taiwan 
and Japan (Hidalgo et al., 2013; Donati et al., 2014; Wohlwend et al., 2015; Kuan et al., 2016; 
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Ovejero et al., 2017; Maeyama et al., 2018; Pulss et al., 2018; Zogg et al., 2018a). 
Unfortunately, it was not possible to investigate possible epidemiological links between the 
infected cat and human hospital settings. Remarkably, carbapenemase-producing  
K. pneumoniae ST11 and ST15 have been previously reported in companion animals (Pulss 
et al., 2018; Stolle et al., 2013). 
The K. pneumoniae ST147 high-risk clonal lineage also seems to be disseminated worldwide 
in companion animals since it has been reported in China, Spain, Switzerland, Japan and now 
in Portugal (Harada et al., 2016; Ovejero et al., 2017; Xia et al., 2017; Maeyama et al., 2018; 
Zogg et al., 2018a). It should be noted that ST147 is one of the predominant KPC-3-producing 
K. pneumoniae clonal lineages in hospital-acquired infections in human patients in Portugal 
(Rodrigues et al., 2016). 
K. pneumoniae ST348 is starting to be reported among ESBL- and carbapenemase-producing 
K. pneumoniae (Baraniak et al., 2013; Mshana et al., 2013; Rodrigues et al., 2016; Vubil et al., 
2017), including in hospital-acquired infections in Portugal (Rodrigues et al., 2016; Vubil et al., 
2017). To our knowledge, this is the first report of K. pneumoniae ST348 in companion animals 
and of MDR CMY-2-producing K. pneumoniae ST37 in Portugal. Interestingly, tigecycline-
resistant K. pneumoniae ST37 has been detected in companion animals from Asia (Xia et al., 
2017). 
While 3GC-resistant K. pneumoniae from companion animals showed a main clonal lineage 
(ST15), human isolates were more diversified. The same was true in the overall PFGE 
analysis, pointing to different clonal epidemiology. The fact that the K. pneumoniae strains 
from humans and animals relate to different time periods is a limitation of the present study 
that could have hampered the detection of additional similarities. Nonetheless, the detection 
of K. pneumoniae ST15 in samples from unrelated companion animals over such a wide time-
span suggests its dissemination. 
Although PFGE is a more discriminatory typing method than MLST, it still lacks enough 
resolution to establish a definite link between strains of human and animal origin. Nevertheless, 
the detection of some PFGE clusters composed of K. pneumoniae strains from companion 
animals and humans belonging to high-risk clonal lineages is a concerning finding. WGS 
studies are warranted in the future to clarify the true role of companion animals as reservoirs 
of K. pneumoniae to humans in direct contact and vice versa. 
The analysis of several strains from the same animal (three urine collections over a 4 month 
period), revealed the persistence of MDR K. pneumoniae ST15 strains. These results highlight 
the importance of conducting antimicrobial susceptibility testing and treating all  
UTI-predisposing co-morbidities to promote a definite cure and thus reduce the spread of such 
high-risk clonal lineages. 
An association between ST15 K. pneumoniae and resistance to all fluoroquinolones was 
observed in this study, including resistance to levofloxacin, which is a third-generation 
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fluoroquinolone. The fluoroquinolone-resistance in K. pneumoniae was likely due to 
chromosomal mutations; nevertheless, qnrB was detected in human and companion animal  
K. pneumoniae. The link between blaCTX-M-15 ESBL and qnrB genes observed in this study has 
been reported previously (Garcia-Fulgueiras et al., 2017). Several fluoroquinolone-resistant 
ST15 K. pneumoniae were also positive for aac(6′)-Ib. Although this gene was not sequenced 
in this study, K. pneumoniae has been shown to frequently harbour the  
aac(6′)-Ib-cr variant (Ewers et al., 2014b) and thus this resistance mechanism could also be 
involved. 
Trimethoprim/sulfamethoxazole-resistant K. pneumoniae frequently harboured sul1 and/or 
sul2. The same has been reported regarding K. pneumoniae from humans and companion 
animals (Ewers et al., 2014b; Holt et al., 2015). 
The overall high frequency of tet(A) in K. pneumoniae is in line with previous findings showing 
that tet(A) is the most disseminated tet gene, followed by tet(D) (Holt et al., 2015). 
Fosfomycin and amikacin are antimicrobials for human use that are suitable for UTI treatment 
(Gupta et al., 2010). The low amikacin-resistance frequency in this study is in agreement with 
previous reports of humans with K. pneumoniae UTI from Aveiro, Portugal (Linhares, Raposo, 
Rodrigues & Almeida, 2013). The low K. pneumoniae resistance to amikacin and fosfomycin 
makes its rational use critical, since these antimicrobials may gain importance in the future to 
avoid the use of carbapenems in the treatment of emerging MDR K. pneumoniae UTIs in 
humans. 
Two main virulence genotypes were detected (VG1, VG2) that varied in the composition of 
less common virulence genes. Although VG1 and VG2 frequencies varied significantly 
between K. pneumoniae from companion animals and humans, VG1 and VG2 were detected 
in both. fimH-1 and mrkD are thought to be ubiquitous among K. pneumoniae (El Fertas-
Aissani et al., 2013; Holt et al., 2015) and in fact were detected in all K. pneumoniae in this 
study. Moreover, the type-1 adhesin is an important virulence factor for UTI and the type-3 
adhesin strongly promotes biofilm formation (Stahlhut et al., 2009; Schroll et al., 2010). 
Although to a lesser extent than in E. coli, K. pneumoniae fimH-1 seems to undergo 
pathoadaptive mutations (Stahlhut et al., 2009). Hence, in the future, fimH-1 sequencing of 
isolates from companion animals and humans could help further understanding of the potential 
zoonotic nature of K. pneumoniae in UTI. 
Frequencies of genes encoding yersiniabactin siderophore have been shown to be higher 
among invasive K. pneumoniae and a strong predictor of human infection (Holt et al., 2015). 
Additionally, yersiniabactin has been considered an important virulence factor in cystitis 
caused by E. coli (Brumbaugh et al., 2015). In this study, despite being more frequent among 
strains isolated from humans, the yersiniabactin-encoding genes were also detected in  




In agreement with previous studies, the virulence genes not belonging to VG1/VG2 were less 
common (Podschun et al., 1993; Schubert et al., 2000; El Fertas-Aissani et al., 2013). 
Nevertheless, some important virulence genes (Compain et al., 2014; Holt et al., 2015), such 
as allS and iutA, were detected in K. pneumoniae isolated from companion animals from this 
study. 
The two K. oxytoca isolated from companion animals showed a significant MDR phenotype 
and harboured several major antimicrobial resistance genes. Therefore, despite being 
considered as an opportunistic bacterium, K. oxytoca may create significant therapeutic 
challenges and act as reservoirs of major antimicrobial resistance genes. 
To the best of our knowledge, this is the first report of the K. pneumoniae clonal lineages 
affecting companion animals from Portugal. Notably, most of the 3GC-resistant K. pneumoniae 
clonal lineages isolated from companion animals with UTI overlapped the most frequent  
high-risk clonal lineages previously detected from human infection in Portugal and worldwide 
(Rodrigues et al., 2014a; Rodrigues et al., 2016; Vubil et al., 2016; Navon-Venezia et al., 
2017). Although further studies are needed to explore the true zoonotic potential of  
K. pneumoniae isolated from companion animals, these results point to the need for a One 
Health approach to control the dissemination of important MDR K. pneumoniae high-risk clonal 
lineages. 
K. pneumoniae from companion animals were frequently MDR and harboured clinically 
relevant antimicrobial resistance genes, thus highlighting the role of companion animals as 
reservoirs of major resistance determinants. This raises great concern in veterinary medicine 
since previous studies have shown that K. pneumoniae is prone to nosocomial dissemination 
(Ewers et al., 2014b). Precaution is advised when dealing with companion animals with UTI 






Supplementary Table 1 - Characterisation of K. pneumoniae strains typed by MLST 
Strain Year Species Resistance phenotypea Resistance genotype Virulence genotype ST PFGE Cluster 
3598/07 2007 Cat 
AMC, tzp, CEF, FOX, CTX, CAZ, CVN, 
atm, etp, NAL, ENR, CIP, LVX, NOR, 
KAN, tob, CHL, FFC, NIT, TET, SXT 
blaOXA-1, blaCTX-M-15, blaDHA-1, qnrB, 
aphAI-IAB, aac(6')-Ib, tet(A), sul1 
fimH-1, entB, mrkD, ycfM, kpn, iutA, 
traT, YHPI ST11 C1 
PC263/07B 2007 Human-HA 
AMC, tzp, CEF, FOX, CTX, CAZ, CVN, 
NAL, ENR, CIP, LVX, NOR, KAN, TOB, 
CHL, FFC, NIT, TET, SXT 
blaTEM, blaDHA-1, aphAI-IAB, aac(6')-
Ib, tet(A), sul1, dfrA12 fimH-1, entB, mrkD, ycfM, kpn, YHPI ST11 C1 
3760/02 2002 Cat 
NAL, ENR, CIP, LVX, NOR, KAN, CHL, 
ffc, NIT, SXT  aphAI-IAB, sul1, sul2, dfrA12 fimH-1, entB, mrkD, ycfM, kfu ST15 C4 
5107/06 2006 Dog 
NAL, ENR, CIP, LVX, NOR, KAN, GEN, 
NIT, TET, SXT 
aphAI-IAB, tet(A), tet(B), sul1, sul2, 
dfrA12 fimH-1, entB, mrkD, ycfM, kfu, traT ST15 C4 
6045/08 2008 Dog 
CEF, CTX, CVN, FEP, ATM, NAL, ENR, 
CIP, LVX, NOR, CHL, FFC, nit, TET, 
SXT 
blaCTX-M-15, tet(A), sul1, sul 2, dfrA12 fimH-1, entB, mrkD, ycfM, kfu ST15 C4 
460/14 2014 Cat 
amc, CEF, CTX, caz, CVN, FEP, ATM, 
NAL, ENR, CIP, LVX, NOR, KAN, TOB, 
ffc, NIT, TET 
blaOXA-1, blaCTX-M-15, aac(6')-Ib, tet(A) fimH-1, entB, mrkD, ycfM, kfu ST15 C4 
53/2014 2014 Dog 
amc, CEF, CTX, caz, CVN, FEP, ATM, 
NAL, ENR, CIP, LVX, NOR, KAN, TOB, 
ffc, TET, SXT 
blaTEM, blaOXA-1, blaCTX-M-15, aac(6')-Ib, 
tet(A), sul1, dfrA12 fimH-1, entB, mrkD, ycfM, kfu ST15 C4 
338/08 2008 Cat 
amc, tzp, CEF, CTX, CAZ, CVN, FEP, 
ATM, NAL, ENR, CIP, LVX, NOR, AMK, 
GEN, KAN, NET, TOB, CHL, ffc, nit, 
TET, SXT 
blaTEM, blaOXA-1, blaCTX-M-15, aac(6')-Ib, 
tet(B), sul1, sul2, dfrIa fimH-1, entB, mrkD, ycfM, kfu ST15 C5 
3133/08 2008 Cat 
amc, cef, NAL, ENR, CIP, LVX, NOR, 
kan, TOB, FFC, TET, SXT 
blaTEM, blaOXA-1, aac(6')-Ib, tet(B), 




Supplementary Table 1 (continuation)- Characterisation of K. pneumoniae strains typed by MLST 
Strain Year Species Resistance phenotypea Resistance genotype Virulence genotype ST PFGE Cluster 
4290/08 2008 Cat 
amc, CEF, CTX, caz, CVN, fep, ATM, 
NAL, ENR, CIP, LVX, NOR, KAN, TOB, 
ffc, TET, SXT 
blaTEM, blaOXA-1, blaCTX-M-15, aac(6')-Ib, 
tet(B), sul1, sul2, dfrIa fimH-1, entB, mrkD, ycfM, kfu ST15 C5 
4300/08 2008 Dog 
amc, CEF, CTX, CAZ, CVN, fep, ATM, 
NAL, ENR, CIP, LVX, NOR, KAN, TOB, 
FFC, TET, SXT 
blaTEM, blaOXA-1, blaCTX-M-15, aac(6')-Ib, 
tet(B), sul1, sul2, dfrIa fimH-1, entB, mrkD, ycfM, kfu ST15 C5 
5704A/08 2008 Cat 
AMC, CEF, CTX, CAZ, CVN, FEP, ATM, 
NAL, ENR, CIP, LVX, NOR, amk, GEN, 
KAN, NET, TOB, CHL, ffc, TET, SXT 
blaTEM, blaOXA-1, blaCTX-M-15, aac(6')-Ib, 
tet(B), sul1, sul2, dfrIa fimH-1, entB, mrkD, ycfM, kfu ST15 C5 
5704B/08 2008 Cat 
CEF, CTX, CAZ, CVN, fep, ATM, NAL, 
ENR, CIP, LVX, NOR, GEN, CHL, FFC 
blaCTX-M-15 fimH-1, entB, mrkD, ycfM, kfu ST15 C5 
21/2011 2011 Dog 
AMC, tzp, NAL, ENR, CIP, LVX, NOR, 
GEN, KAN, NET, TOB, CHL, ffc, tet, 
SXT 
blaOXA-1, aac(6')-Ib fimH-1, entB, mrkD, ycfM, kfu ST15 C5 
86/2015 2015 Cat 
AMC, tzp, CEF, FOX, CTX, CAZ, CVN, 
fep, ATM, NAL, ENR, CIP, LVX, NOR, 
GEN, KAN, NET, TOB, CHL, ffc, NIT, 
TET, SXT 
blaCMY-2, qnrB, aac(6')-Ib, sul1, sul2, 
dfrIa fimH-1, entB, mrkD, ycfM, kfu ST15 C5 
GTAFD58A 2014 Human-CA 
AMC, CEF, CTX, CVN, fep, atm, NAL, 
ENR, CIP, LVX, NOR 
blaTEM, blaCTX-M-15 fimH-1, entB, mrkD, ycfM, kfu, YHPI ST15 C5 
GTAN4020 2014 Human-CA 
CEF, CTX, CAZ, CVN, ATM, NAL, ENR, 
CIP, LVX, NOR, GEN, KAN, TOB, CHL, 
FOF, TET, SXT 
blaTEM-1, blaSHV-28, qnrB, aac(6')-Ib, 
sul1, sul2, dfrIa fimH-1, entB, mrkD, ycfM, kfu, YHPI ST15 S7 
38/2015 2015 Cat 
amc, CEF, CTX, CAZ, CVN, FEP, ATM, 
NAL, ENR, CIP, LVX, NOR, GEN, KAN, 
NET, TOB, ffc, NIT, SXT 
blaTEM, blaOXA-1, blaCTX-M-15, aac(6')-Ib, 
sul2 fimH-1, entB, mrkD, ycfM, kfu, YHPI ST15 S8 
72/2012KP 2012 Dog 
AMC, TZP, CEF, FOX, CTX, CAZ, CVN, 
FEP, ATM, NAL, ENR, CIP, LVX, NOR, 
KAN, TOB, NIT, TET 
blaTEM, blaOXA-1, blaCTX-M-15, blaCMY-2, 




Supplementary Table 1 (continuation)- Characterisation of K. pneumoniae strains typed by MLST 
Strain Year Species Resistance phenotypea Resistance genotype Virulence genotype ST PFGE Cluster 
GTBJ307 
Rosa 
2014 Human-CA CEF, CTX, CAZ, CVN, FEP, ATM, NIT blaCTX-M-15 fimH-1, entB, mrkD, ycfM, kpn, YHPI ST29 C8 
GTCJ3923 2014 Human-CA 
amc, tzp, CEF, CTX, caz, CVN, FEP, 
ATM, nal, enr, cip, nor, GEN, KAN, TOB, 
CHL, ffc, SXT 
blaTEM, blaOXA-1, blaCTX-M-15, qnrB, 
aac(6')-Ib, sul1, dfrIa fimH-1, entB, mrkD, ycfM, kfu, YHPI ST35 C8 
PC28/15B 2015 Human-HA 
AMC, TZP, CEF, CTX, CAZ, CVN, FEP, 
ATM, nal, enr, cip, GEN, kan, TOB, 
CHL, NIT, SXT 
blaTEM, blaOXA-1, blaCTX-M-15, qnrB, 
aac(6')-Ib, sul1, sul2, dfrA12 fimH-1, entB, mrkD, ycfM, kfu, YHPI ST35 C8 
GTML38039 2014 Human-CA 
AMC, TZP, CEF, FOX, CTX, CAZ, CVN, 
atm, FOF, NIT 
blaCMY-2 fimH-1, entB, mrkD, ycfM, kfu, YHPI ST35 C3 
4919/09 2009 Cat 
AMC, TZP, CEF, FOX, CTX, CAZ, CVN, 
ATM, NAL, ENR, CIP, LVX, NOR, CHL, 
FFC, NIT, TET, SXT 
blaTEM, blaCMY-2, floR, tet(A), sul2 fimH-1, entB, mrkD, ycfM, kpn ST37 S33 
GTPD2025 2014 Human-CA 
amc, CEF, CTX, CVN, fep, ATM, nal, 
enr, cip, nor, GEN, KAN, TOB, nit, TET, 
SXT 
blaOXA-1, blaCTX-M-15, qnrB, aac(6')-Ib, 
tet(A), sul2 fimH-1, entB, mrkD, ycfM, kfu ST42 S35 
GTMR923 2014 Human-CA 
AMC, tzp, CEF, CTX, CAZ, CVN, FEP, 
ATM, nal, ENR, CIP, lvx, NOR, GEN, 
KAN, NET, TOB, NIT, SXT 
blaTEM, blaOXA-1, blaCTX-M-15, qnrB, 
aac(6')-Ib, sul2 fimH-1, entB, mrkD, ycfM, kpn, YHPI ST45 C15 
GTLS335 2014 Human-CA 
amc, CEF, CTX, caz, CVN, FEP, ATM, 
nal, enr, cip, GEN, KAN, TOB, SXT 
blaTEM, blaOXA-1, blaCTX-M-15, qnrB, 
aac(6')-Ib, sul2 fimH-1, entB, mrkD, ycfM, kpn ST3031
b C15 
5659/13 2013 Cat 
amc, CEF, CTX, CAZ, CVN, FEP, ATM, 
NAL, ENR, CIP, LVX, NOR, GEN, KAN, 
NET, TOB, NIT, TET, SXT 
blaTEM, blaOXA-1, blaCTX-M-15, aac(6')-Ib, 
tet(A), sul2 fimH-1, entB, mrkD, ycfM, kpn ST147 S24 




Supplementary Table 1 (continuation)- Characterisation of K. pneumoniae strains typed by MLST 
Strain Year Species Resistance phenotypea Resistance genotype Virulence genotype ST PFGE Cluster 
26/2015 2015 Dog nit - fimH-1, entB, mrkD, ycfM, kfu ST294 C34 
Sisi/vet 2014 Cat 
AMC, CEF, FOX, CTX, CAZ, CVN, nal, 
enr 
blaTEM, blaCMY-2, qnrB fimH-1, entB, mrkD, ycfM, kpn ST348 C18 
GTDN614 2014 Human-CA 
amc, CEF, CTX, CAZ, CVN, FEP, ATM, 
nal, enr, cip, nor, GEN, KAN, TOB, nit, 
TET, SXT 
blaOXA-1, blaCTX-M-15, aac(6')-Ib, tet(A), 
sul2 fimH-1, entB, mrkD, ycfM, kpn, YHPI ST348 C18 
PC25/15B 2015 Human-HA 
amc, tzp, CEF, CTX, CAZ, CVN, FEP, 
ATM, GEN, kan, TOB, NIT, SXT 
blaTEM, blaOXA-1, blaCTX-M-15, aac(6')-Ib, 
sul2 fimH-1, entB, mrkD, ycfM ST423 C17 
GTET170 2014 Human-CA 
amc, CEF, CTX, caz, CVN, FEP, ATM, 
nal, enr, cip, nor, KAN, TOB, ffc, TET, 
SXT 
blaTEM, blaOXA-1, blaCTX-M-15, qnrB, 
aac(6')-Ib, tet(A), sul2 fimH-1, entB, mrkD, ycfM, kpn ST648 C6 
GTMR2019 2014 Human-CA 
AMC, tzp, CEF, CTX, caz, CVN, fep, 
ATM, NAL, ENR, CIP, lvx, NOR, GEN, 
KAN, TOB, chl, FFC, FOF, NIT, SXT 
blaTEM, blaOXA-1, blaCTX-M-15, qnrB, 
aac(6')-Ib, sul1, sul2 fimH-1, entB, mrkD, ycfM, kpn, YHPI ST1674 C13 
GTML31905 2014 Human-CA 
AMC, CEF, CTX, CVN, FEP, nal, ENR, 
CIP, nor, KAN, TOB, ffc, NIT, SXT 
blaTEM, blaOXA-1, blaCTX-M-15, qnrB, 
aac(6')-Ib, sul2 fimH-1, entB, mrkD, ycfM, kfu, YHPI ST 2620 S17 
4898/03 2003 Dog TET, nit tet(A) fimH-1, entB, mrkD, ycfM, kfu, iutA ST3027b C2 
5942/07 2007 Dog nit - fimH-1, entB, mrkD, allS ST3028b S36 




Supplementary Table 1 (continuation)- Characterisation of K. pneumoniae strains typed by MLST 
Strain Year Species Resistance phenotypea Resistance genotype Virulence genotype ST PFGE Cluster 
3919/11 2011 Dog AMC, TZP, CEF, NIT blaTEM, fimH-1, entB, mrkD, ycfM, kfu ST3030b C16 
PC67/15B 2015 Human-HA 
amc, tzp, CEF, CTX, CAZ, CVN, FEP, 
ATM, NAL, ENR, CIP, LVX, NOR, TOB, 
NIT, TET, SXT 
blaTEM, blaOXA-1, blaCTX-M-15, qnrB, 
aac(6')-Ib, tet(A), sul2 fimH-1, entB, mrkD, ycfM, kpn ST3033
b C16 
GTMR2457 2014 Human-CA 
AMC, CEF, CTX, caz, CVN, fep, atm, 
GEN, KAN, TOB, ffc, nit, SXT 
blaTEM, blaOXA-1, blaCTX-M-15, aac(6')-Ib, 
sul1, sul2, dfrIa fimH-1, entB, mrkD, ycfM, kfu, YHPI ST3032
b C8 
Legend: aFully-resistance is presented in caps lock and the intermediate resistance is presented in small caps. 
bSTs first described in this study. 
fimH-1, type-1 adhesin; mrkD, type-3 adhesin; kpn, FimH-like adhesin; ycfM, outer membrane lipoprotein; entB, enterobactin; iutA, aerobactin; kfu, iron transporter 
with phosphotransferase function; YHPI, yersiniabactin high-pathogenicity island; traT, serum resistance-associated outer membrane lipoprotein; allS, allantoin 
metabolism associated gene; AMC, amoxicillin/clavulanate; CEF, cephalothin, FOX, cefoxitin; CTX, cefotaxime; CAZ, ceftazidime; CVN, cefovecin;  
TZP, piperacillin/tazobactam; FEP, cefepime; ATM, aztreonam; ETP, ertapenem; NAL, nalidixic acid; CIP, ciprofloxacin; ENR, enrofloxacin; NOR, norfloxacin;  
LVX, levofloxacin; GEN, gentamicin; KAN, kanamycin; NET, netilmicin; TOB, tobramycin; AMK, amikacin; CHL, chloramphenicol; FFC, florfenicol; TET, tetracycline; 




Supplementary Table 2 - Frequency of MDR K. pneumoniae strains 





(Total N =19) 
Human-CA 
(Total N =57) 
3 12.0% (n=3) 15.8% (n=3) 3.5% (n=2) 
4 8.0% (n=2) 5.3% (n=1) 5.3% (n=3) 
5 16.0% (n=4) 5.3% (n=1) 10.5% (n=6) 
6 16.0% (n=4) 10.5% (n=2) 1.75% (n=1) 
7 12.0% (n=3) 5.3% (n=1) 1.75% (n=1) 
8 8.0% (n=2) 5.3% (n=1) 1.75% (n=1) 
9 8.0% (n=2) 0% (n=0) 0% (n=0) 
Total 80.0% (n=20) 47.4% (n=9) 24.6% (n=14) 
Legend: aAntimicrobial categories were defined according to Magiorakos et al. (2012). Total N, total number of tested isolates; n, number of positive isolates;  
Human-HA, human hospital-patients with UTI; Human-CA, human community-acquired UTI. 
 
Supplementary Table 3 - Characteristics of K. oxytoca strains 
Strain Year Species Resistance profilea Resistance genes Virulence profile PFGE Cluster 
FMV1489/04 2004 Cat 
AMC, CEF, FOX, CTX, CAZ, CVN, ATM, 
NAL, ENR, CIP, LVX, NOR, GEN, KAN, 
NET, TOB, CHL, ffc, TET 
blaTEM, blaDHA-1, aphAI-IAB, aac(6')-
Ib, tet(B), sul1 entB C1 
FMV72/2012KO 2012 Dog 
AMC, CEF, FOX, CTX, CAZ, CVN, ATM, 
NAL, ENR, CIP, LVX, NOR, GEN, KAN, 
TOB, CHL, ffc, TET 
blaTEM, blaDHA-1, aphAI-IAB, aac(6')-
Ib, sul1 entB C1 
GTLI2612 2014 Human-CA - - entB S1 
Legend: aFully-resistance is presented in caps lock and the intermediate resistance is presented in small caps. entB, enterobactin; AMC, amoxicillin/clavulanate;  
CEF, cephalothin, FOX, cefoxitin; CTX, cefotaxime; CAZ, ceftazidime; CVN, cefovecin; TZP, piperacillin/tazobactam; FEP, cefepime; ATM, aztreonam;  
ETP, ertapenem; NAL, nalidixic acid; CIP, ciprofloxacin; ENR, enrofloxacin; NOR, norfloxacin; LVX, levofloxacin; GEN, gentamicin; KAN, kanamycin; NET, netilmicin; 




Supplementary Table 4 - Frequency of virulence genes in K. pneumoniae strains 





(Total N =19) 
Human-CA 
(Total N =57) P value 
Type-1 adhesin fimH-1 100% (n=25) 100% (n=19) 100% (n=57) 1 
Type-3 adhesin mrkD 100% (n=25) 100% (n=19) 100% (n=57) 1 
Outer membrane lipoprotein ycfM 96.0% (n=24) 100% (n=19) 100% (n=57) 0.2475 
FimH-like adhesin kpn 16.0% (n=4) 42.1% (n=8) 52.6% (n=30) 0.0044 
Catecholate-siderophore receptor iroN 0% (n=0) 0% (n=0) 0% (n=0) 1 
Enterobactin entB 100% (n=25) 100% (n=19) 100% (n=57) 1 
Aerobactin iutA 8.0% (n=2) 0% (n=0) 0% (n=0) 0.0594 
Iron transporter with 
phosphotransferase function 
kfu 80.0% (n=20) 52.6% (n=10) 42.1% (n=24) 0.0025 
Yersiniabactin high-pathogenicity 
island 
fyuA, irp-1,  
irp-2, ybtS 
16.0% (n=4) 42.1% (n=8) 43.9% (n=25) 0.0165 
Serum resistance-associated outer 
membrane lipoprotein 
traT 8.0% (n=2) 0% (n=0) 1.8% (n=1) 0.1506 
Regulator of mucoid phenotype A rmpA 0% (n=0) 0% (n=0) 0% (n=0) 1 
Cytotoxic necrotizing factor-1 cnf-1 0% (n=0) 0% (n=0) 0% (n=0) 1 
Allantoin metabolism associated gene allS 4.0% (n=1) 0% (n=0) 3.5% (n=2) 1 
Legend: Total N, total sample number; n, number of isolates; Human-HA, human hospital-patients with 




Supplementary Figure 1 - PFGE patterns of chromosomal DNA restriction fragments from K. pneumoniae strains from companion animals 

























Supplementary Figure 1 (continuation)- PFGE patterns of chromosomal DNA restriction fragments from K. pneumoniae strains from 













Legend: Dashed line, cluster cut-off of 80%; Regarding PFGE: Grey circle, indicates urine samples collected from the same animal with two month intervals (total of 
three sample collections). The number inside the circle indicates the urine collection order; Grey square, indicates urine samples collected from the same human 
patient from the same urine sample; S, single pulse-type; C, pulse-type cluster; Regarding porins and efflux pumps: Black square, positive; Light grey square, negative; 
Regarding antimicrobials: Black square, resistant; Grey square, intermediate resistant; Light grey square, susceptible; AMP, ampicillin; AMC, amoxicillin/clavulanate; 
CEF, cephalothin; CTX, cefotaxime; CAZ, ceftazidime; CVN, cefovecin; FEP, cefepime; FOX, cefoxitin; IMP, imipenem; ETP, ertapenem; MEM, meropenem;  
TZP, piperacillin/tazobactam; ATM, aztreonam; NAL, nalidixic acid; ENR, enrofloxacin; CIP, ciprofloxacin; NOR, norfloxacin; LVX, levofloxacin; KAN, kanamycin;  
GEN, gentamicin; TOB, tobramycin; NET, netilmicin; AMK, amikacin; SXT, trimethoprim/sulfamethoxazole; TET, tetracycline; CHL, chloramphenicol; FFC, florfenicol; 
NIT, nitrofurantoin; FOF, fosfomycin; CA, community-acquired UTI; HA, hospital-patients with UTI; fimH-1, type-1 adhesin; mrkD, type-3 adhesin; kpn, FimH-like 
adhesin; ycfM, outer membrane lipoprotein; entB, enterobactin; iutA, aerobactin; kfu, iron transporter with phosphotransferase function; YHPI, yersiniabactin high-
pathogenicity island; traT, serum resistance-associated outer membrane lipoprotein; allS, allantoin metabolism associated gene.
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Supplementary Figure 2 - PFGE patterns of chromosomal DNA restriction fragments 
from K. oxytoca strains from companion animals (n= 2) and humans (n= 1) with UTI 
 


















4.2 Clonal relatedness of Proteus mirabilis strains causing urinary tract 
infections in companion animals and humans 
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Abstract 
Proteus mirabilis is a major cause of urinary tract infection (UTI) in humans and companion 
animals. This study aimed to evaluate the antimicrobial resistance, virulence and clonal 
relatedness of P. mirabilis isolated from dogs, cats and humans with UTI. 
P. mirabilis isolated from companion animals (n = 107) and humans (n = 76) with UTI were 
compared by PFGE analysis after overnight NotI macro-restriction using Dice/UPGMA with a 
1.5% tolerance. Strains were characterised for antimicrobial resistance by disk diffusion. 
Twenty-four resistance genes and four virulence genes were screened by PCR. 
Thirty-nine clusters (similarity >80%) and 73 single pulse-types were detected. Nine clusters 
included P. mirabilis isolated from community and hospital patients, including strains with 
100% similarity. A high number of clusters (43.6%, n =  17/39) included strains from companion 
animals and humans. Similarity between some companion animal and human strains varied 
between 80–100%. One strain from a dog was 100% similar to one human community-
acquired P. mirabilis. One P. mirabilis from a cat was found to be 94.7% and 92.4% similar to 
community and hospital patient strains, respectively. P. mirabilis CMY-2-producers did not 
cluster all together. Nevertheless, cluster C36 included five P. mirabilis from companion 
animals (similarity 85.8%–95.7%), of which, four (80%) were multidrug-resistant  
CMY-2-producers. 
This study shows that companion animals and humans become infected with closely related 
P. mirabilis strains. The high number of clusters containing companion animals and human 
strains points to the zoonotic nature of P. mirabilis. These results underline the potential role 
of companion animals as reservoirs and in the dissemination of uropathogenic P. mirabilis to 
humans and vice versa. 
 




Proteus mirabilis are known to cause community-acquired urinary tract infections (UTI) in 
humans and are important agents of nosocomial UTIs (Armbruster & Mobley, 2012; Costa, 
Linhares, Ferreira, Neves & Almeida, 2018). After E. coli, which is the main cause of UTI,  
P. mirabilis is the second most common Enterobacteriaceae isolated in companion animals 
with UTI (Moyaert et al., 2017). The increasing antimicrobial resistance trends in bacteria 
isolated from companion animals creates concerns regarding the role of companion animals 
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as reservoirs of resistant bacteria to humans (Marques et al., 2018b; Pomba et al., 2017). 
CMY-2-producing P. mirabilis, which are resistant to third-generation cephalosporins and 
frequently multidrug-resistant (MDR), are increasingly being reported in companion animals in 
Portugal (Marques et al., 2018b). Since companion animals with UTI caused by P. mirabilis 
have high loads of bacteria in urine and faeces (Gaastra et al., 1996), the risk of dissemination 
of uropathogenic P. mirabilis, including potential resistant strains, into the owners living 
environment may be an important hazard. 
Little is known about the clonal relatedness between human and companion animal 
uropathogenic P. mirabilis. Yet, this information is relevant to understand the role of companion 
animals and human as reservoirs of P. mirabilis. Only a limited number of European studies 
on resistance monitoring of UTI in companion animals are available (Marques et al., 2018b; 
Moyaert et al., 2017). Furthermore, only early studies report the frequency of virulence factors 
among P. mirabilis from companion animals (Bijlsma et al., 1995; Gaastra et al., 1996). 
The main goal of this study was to determine the clonal relatedness of P. mirabilis isolated 
from companion animals (dogs and cats) and humans with UTI. Additionally, these 
uropathogenic P. mirabilis were characterised for the presence of antimicrobial resistance and 
virulence genes. 
 
Material and methods 
Bacteria isolates 
This study included P. mirabilis isolated from humans with UTI (n =  76) at a private clinical 
analysis laboratory (n =  50) in 2014 and between 2006–2015 from hospital microbiology 
laboratories (n =  26) collecting samples from patients in the Lisbon area. The P. mirabilis 
isolated at the human private laboratory were obtained from humans with community-acquired 
UTI (CA-human). Samples from the hospital laboratories were obtained from hospital patients 
with UTI (HA-human) and were likely hospital-acquired. However, it was not possible to ensure 
that these infections were nosocomial due to insufficient patient data. Non-duplicate  
P. mirabilis strains from companion animals with UTI (dogs n= 94, cats n = 13) were obtained 
from 1999 to early 2015 at the Laboratory of Antimicrobial Resistance from the Veterinary 
Teaching Hospital of the Faculty of Veterinary Medicine/University of Lisbon and therefore all 
companion animals were also from the Lisbon area. 
Besides being collected from the same geographical region, there were no direct 
epidemiological relations between the sampled humans and companion animals. It was also 
not possible to obtain information regarding the overall daily contact of the sampled humans 







P. mirabilis strains were isolated by standard quantitative urine cultures and species 
identification was conducted by phenotypical tests (API20E and VITEKII, BioMérieux, Marcy-
l'Étoile, France) and confirmed by P. mirabilis species-specific PCR (Marques et al., 2018b). 
 
Susceptibility testing 
Antimicrobial susceptibility testing was performed by disk diffusion method according to CLSI 
guidelines (CLSI, 2017; CLSI, 2018). Isolates were tested for susceptibility against a total of 
twenty-six antimicrobials (Oxoid, Hampshire, UK): ampicillin 10μg, amoxicillin/clavulanate 
30μg, cefoxitin 30μg, cefotaxime 30μg, ceftazidime 30μg, cefovecin 30μg, 
piperacillin/tazobactam 110μg, cefepime 30μg, imipenem 10μg, meropenem 10μg, aztreonam 
30μg, ertapenem 10μg, nalidixic acid 30μg, ciprofloxacin 5μg, enrofloxacin 5μg, norfloxacin 
10μg, levofloxacin 5μg, gentamicin 10μg, kanamycin 30μg, netilmicin 30μg, tobramycin 10μg, 
amikacin 30μg, chloramphenicol 30μg, florfenicol 30μg, fosfomycin 50μg and 
trimethoprim/sulfamethoxazole 25μg. 
For cefovecin and enrofloxacin results interpretation, the veterinary CLSI breakpoints were 
applied (CLSI, 2018). Florfenicol (a fluorinated compound in use for bovine respiratory 
infections) was tested for epidemiological purposes only. Since there are no defined florfenicol 
breakpoints for companion animals nor humans, interpretation diameter limits were derived 
from the veterinary CLSI breakpoints for swine infections (CLSI, 2018). The Societé Française 
de Microbiology breakpoints were used for fosfomycin (SFM, 2010). Since gentamicin 
breakpoints only vary between veterinary and human CLSI guidelines by 1 mm in the 
susceptible/intermediate categorisation (CLSI, 2017; CLSI, 2018), human CLSI was used. The 
remaining antimicrobials were interpreted according to human CLSI breakpoints (CLSI, 2017), 
since breakpoints either are equal or are not determined in veterinary CLSI standards. 
Antimicrobial categories were used to characterise MDR Enterobacteriaceae (Magiorakos et 
al., 2012). P. mirabilis were considered as MDR when resistant to three or more antimicrobial 
categories. 
 
Antimicrobial resistance determinants 
Ampicillin-resistant/intermediate isolates were tested for the presence of blaTEM, blaSHV and 
blaOXA-1 b-lactamase genes by PCR (Pomba et al., 2006). The presence of ESBL (blaCTX-M-type) 
and AmpC (blaCMY-type, blaLAT-type, blaBIT-1, blaDHA-type, blaMOX-type, blaACT-type, blaFOX-type and blaMIR-
type) b-lactamase genes among third-generation cephalosporin-resistant strains has been 
characterised elsewhere (Marques et al., 2018b). 
Antimicrobial-resistant/intermediate isolates were further screened by PCR for the presence 
of antimicrobial resistance genes against aminoglycosides [aphAI-IAB, aac(6′)-Ib and aac(3′)-
IV] (Frana et al., 2001; Sáenz et al., 2004; Robicsek et al., 2006a), phenicols (floR) (Sáenz et 
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al., 2004), fluoroquinolones (qnrA, qnrB, qnrC, qnrD and qnrS) (Robicsek et al., 2006b; Cavaco 
et al., 2009; Wang et al., 2009) and trimethoprim/sulfamethoxazole (sul1, sul2, sul3, dfrA12 
and dfrIa [targeting dfrA1, dfrA5, dfrA15, dfrA15b, dfrA16, dfrA16b]) (Sáenz et al., 2004; Guerra 
et al., 2001; Maynard et al., 2003; Perreten & Boerlin, 2003). 
 
Virulence genes 
All P. mirabilis were screened by PCR for the presence of ucaA (urothelial cell adhesion 
fimbriae [UCA/NAF]), mrpA (mannose-resistant Proteus-like fimbriae [MR/P]) and pmfA 
(Proteus mirabilis fimbriae [PMF]) fimbriae genes and for the presence of haemolysin 
hpmA/hpmB codifying genes (Sosa et al., 2006; Cestari et al., 2013). 
 
Population structure and data analysis 
P. mirabilis were characterised by overnight restriction with NotI (Thermo Scientific™, Lisbon, 
Portugal) and subsequent PFGE on a CHEF DR II-apparatus (Biorad, Hercules, CA, USA). 
The restriction fragments were resolved in a 1% agarose gel (agarose pulse-field grade, 
Nzytech - Genes and Enzymes, Lisbon, Portugal) using the following previously described 
block conditions: 1–30 s for 8 h followed by 30–70 s for 16 h at 14 °C, 6 V/cm2 (Sabbuba et al., 
2003). 
P. mirabilis NotI restriction PFGE-pattern analysis was conducted with the Bionumerics 
software, version 6.6, (Applied Maths from BioMérieux, Marcy-l'Étoile, France) using 
Dice/UPGMA clustering method with a tolerance of 1.5% and a clustering cut-off of 80%. 
The SAS statistical software package for Windows, version 9.3, (SAS Institute Inc, Cary, North 
Carolina, USA) was used to perform statistical analysis. Comparisons between groups were 
conducted by Fisher’s exact test, with an alpha value of 0.05. 
 
Results 
Antimicrobial resistance and antimicrobial resistance determinants 
Considering b-lactam non-susceptible strains (categorised as antimicrobial resistant or  
-intermediate isolates), P. mirabilis from companion animals and CA-humans were frequently 
resistant only to ampicillin (46.9%, n= 15/32 and 86.7%, n = 13/15, respectively) while  
HA-human P. mirabilis were frequently resistant to ampicillin and intermediate or resistant to 
amoxicillin/clavulanate (61.5%, n= 8/13) (Table 1). 
b-lactam non-susceptible P. mirabilis strains frequently harboured blaTEM (88.3%) while  
blaOXA-1 and blaSHV were not detected (Table 2). Third-generation cephalosporin-resistance was 
only present in P. mirabilis from companion animals and was mostly linked to the presence of 




Table 1 - Antimicrobial resistance frequencies of companion animal and human  








%R %I %R %I %R %I 
Ampicillin 28.0% (n = 30) 1.9% (n = 2) 30.0% (n = 15) 0% (n = 0) 50.0% (n = 13) 0% (n = 0) 
Amoxicillin/clavulanate 9.4% (n = 10) 5.6% (n = 6) 2.0% (n = 1) 2.0% (n = 1) 3.8% (n = 1) 26.9% (n = 7) 
Cefoxitin 9.4% (n = 10) 0% (n = 0) 0% (n = 0) 0% (n = 0) 0% (n = 0) 0% (n = 0) 
Cefotaxime 9.4% (n = 10) 0% (n = 0) 0% (n = 0) 0% (n = 0) 0% (n = 0) 0% (n = 0) 
Ceftazidime 5.6% (n = 6) 3.7% (n = 4) 0% (n = 0) 0% (n = 0) 0% (n = 0) 0% (n = 0) 
Cefovecin 9.4% (n = 10) 0% (n = 0) 0% (n = 0) 0% (n = 0) 0% (n = 0) 0% (n = 0) 
Piperacillin/tazobactam 1.9% (n = 2) 0% (n = 0) 0% (n = 0) 0% (n = 0) 0% (n = 0) 0% (n = 0) 
Cefepime 0% (n = 0) 5.6% (n = 6) 0% (n = 0) 0% (n = 0) 0% (n = 0) 0% (n = 0) 
Imipenem 0% (n = 0) 7.5% (n = 8) 0% (n = 0) 2% (n = 1) 0% (n = 0) 0% (n = 0) 
Meropenem 0% (n = 0) 0% (n = 0) 0% (n = 0) 0% (n = 0) 0% (n = 0) 0% (n = 0) 
Aztreonam 1.9% (n = 2) 0% (n = 0) 0% (n = 0) 0% (n = 0) 0% (n = 0) 0% (n = 0) 
Ertapenem 0% (n = 0) 0% (n = 0) 0% (n = 0) 0% (n = 0) 0% (n = 0) 0% (n = 0) 
Nalidixic acid 26.2% (n = 28) 4.7% (n = 5) 16.0% (n = 8) 4.0% (n = 2) 42.3% (n = 11) 0% (n = 0) 
Ciprofloxacin 8.4% (n = 9) 5.6% (n = 6) 8.0% (n = 4) 2.0% (n = 1) 26.9% (n = 7) 3.8% (n = 1) 
Enrofloxacin 26.2% (n = 28) 1.9% (n = 2) 16.0% (n = 8) 0% (n = 0) 42.3% (n = 11) 0% (n = 0) 
Norfloxacin 5.6% (n = 6) 1.9% (n = 2) 6.0% (n = 3) 0% (n = 0) 19.2% (n = 5) 3.8% (n = 1) 
Levofloxacin 7.5% (n = 8) 0% (n = 0) 8.0% (n = 4) 0% (n = 0) 23.1% (n = 6) 0% (n = 0) 
Gentamicin 6.5% (n = 7) 2.8% (n = 3) 10.0% (n = 5) 0% (n = 0) 30.8% (n = 8) 0% (n = 0) 
Kanamycin 20.6% (n = 22) 5.6% (n = 6) 12.0% (n = 6) 2.0% (n = 1) 11.5% (n = 3) 0% (n = 0) 
Netilmicin 3.7% (n = 4) 2.8% (n = 3) 2.0% (n = 1) 0% (n = 0) 7.7% (n = 2) 0% (n = 0) 
Tobramycin 5.6% (n = 6) 1.9% (n = 2) 4.0% (n = 2) 0% (n = 0) 0% (n = 0) 0% (n = 0) 
Amikacin 2.8% (n = 3) 0.9% (n = 1) 0% (n = 0) 0% (n = 0) 0% (n = 0) 0% (n = 0) 
Trimethoprim/sulfa. 35.5% (n = 38) 1.9% (n = 2) 26.0% (n = 13) 0% (n = 0) 38.5% (n = 10) 3.8% (n = 1) 
Chloramphenicol 28.0% (n = 30) 18.7% (n = 20) 20.0% (n = 10) 8.0% (n = 4) 11.5% (n = 3) 11.5% (n = 3) 
Florfenicol 5.6% (n = 6) 10.3% (n = 11) 4.0% (n = 2) 2.0% (n = 1) 0% (n = 0) 15.4% (n = 4) 
Fosfomycin 5.6% (n = 6) 0% (n = 0) 2.0% (n = 1) 0% (n = 0) 0% (n = 0) 0% (n = 0) 
Legend: N, total sample number; %R, percentage of resistant isolates; %I percentage of intermediate 
isolates; n, number of isolates; HA-human, human hospital-patient UTI; CA-human, human community-
acquired UTI. 
 
Resistance to fluoroquinolones was higher in isolates from HA-human UTIs, followed by 
companion animal and CA-Human UTIs (Table 1). Three main fluoroquinolone-non-
susceptible phenotypes were detected, namely non-susceptibility to nalidixic acid and 
enrofloxacin with or without ciprofloxacin-non-susceptibility and non-susceptibility to all tested 
fluoroquinolones including norfloxacin and levofloxacin. Interestingly, the non-susceptibility to 
nalidixic acid and enrofloxacin phenotype was significantly more common in companion animal 
P. mirabilis strains isolated prior to 2006 (75%, n = 12/16, P  = 0.0003) while non-susceptibility 
to all fluoroquinolones became significantly more frequent thereafter (44.4%, n = 8/18,  
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P  =  0.0031) (data not shown). Only qnrD was detected in P. mirabilis from companion animals 
and humans (Table 2). 
 
Table 2- Antimicrobial resistance genes detected in antimicrobial non-susceptible  
P. mirabilis strains 
Antimicrobial Gene Overall Companion animal CA-human HA-human P value
a 







Third-generation cephalosporins blaCMY-2 90.0% (n = 9/10) 
90.0% 
(n = 9/10) – – – 
 blaDHA-1 10.0% (n = 1/10) 
10.0% 
(n = 1/10) – – – 
























































Legend: n, number of positive among tested isolates; HA-human, human hospital-patient UTI;  
CA-human, human community-acquired UTI; -, no strains were tested since all strains were susceptible; 
aP. mirabilis from companion animals were compared with P. mirabilis from humans (CA-human+HA-
human) by Fisher’s exact test. 
 
Among aminoglycosides, kanamycin and gentamicin showed the highest non-susceptibility 
frequencies (Table 1) and the aphAI-IAB was the most common resistance gene detected 
(Table 2). 
Both in companion animal and human P. mirabilis, resistance against 
trimethoprim/sulfamethoxazole was high (26.0%–38.5%) (Table 1). The frequency of sul1 was 
significantly lower in P. mirabilis from companion animals when compared to strains from 
humans overall (Table 2). However, when compared to strains from CA-human only, a 
statistical significant difference was not detected (P  =  0.1403). The frequency of sul2 in  
P. mirabilis from CA-human was significantly higher than in strains from HA-human  
(P  =  0.0470). Nonetheless, sul1 and sul2 were detected in P. mirabilis from all patients while 
sul3 was only detected in P. mirabilis from companion animals (Table 2). All 
trimethoprim/sulfamethoxazole non-susceptible P. mirabilis lacked dfrA12 and several strains 
were negative for sul1, sul2 and sul3 (companion animal 37.5%, n = 15/40; CA-human 15.4%, 
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n = 2/13; HA-human 18.2%, n = 2/11). Overall, dfrIa was common in P. mirabilis from all 
patients (Table 2). 
Chloramphenicol-resistance was high, especially in companion animal and CA-human  
P. mirabilis (Table 1). The floR gene was only detected in P. mirabilis from companion animals 
(Table 2) and all were co-resistant to chloramphenicol and florfenicol. 
MDR P. mirabilis were more frequent among HA-human (42.3%, n = 11/26) strains, followed 
by companion animal (21.5%, n = 23/107) and CA-human (18%, n = 9/50). However, most 
MDR P. mirabilis were only resistant to three antimicrobial categories (HA-human, 30.8%, 
n = 8/26; CA-human, 10%, n = 5\50 and companion animals, 10.3%, n = 11/107). P. mirabilis 
from human patients were resistant to up to 5 antimicrobial categories while third-generation 




All fimbriae genes (ucaA, pmfA and mrpA) were highly frequent among P. mirabilis isolated 
from companion animals and humans (Table 3), nevertheless, ucaA gene was less frequent 
(Table 3). The haemolysin HmpA/HmpB genes were present in all tested P. mirabilis  
(Table 3). 
 
Table 3- Companion animal and human P. mirabilis strains virulence genes 









Fimbriae      
mrpA 
98.9% (n=181) 99.1% (n=106) 98% (n=49) 100% (n=26) 1 
pmfA 
98.9% (n=181) 100% (n=107) 96% (n=48) 100% (n=26) 0.1711 
ucaA 
85.2% (n=156) 86.9% (n=93) 80% (n=40) 88.5% (n=23) 0.5272 
Haemolysin      
HmpA/HmpB 
100% (n=183) 100% (n=107) 100% (n=50) 100% (n=26) 1 
Legend: n, number of isolates; HA-human, human hospital-patient UTI; CA-human, human community-
acquired UTI; 
aP. mirabilis from companion animals were compared with P. mirabilis from humans (CA-human+HA-
human) by Fisher’s exact test. 
 
Population structure 
Thirty-nine clusters and 73 unique pulse-types were detected (Figure S1). Nine clusters 
included P. mirabilis from both CA-human and HA-human UTIs (C2, C3, C8, C10, C13, C24, 
C26, C28 and C29) with some including highly related (Dice index 90%–100%) CA-human and 
HA-human P. mirabilis strains (C2, C10, C13, C24, C26 and C28). It should be noted that 




A high number of clusters (43.6% n = 17/39) included P. mirabilis from companion animals and 
humans (C2, C3, C6, C13, C14, C15, C16, C17, C22, C25, C26, C27, C28, C31, C37, C38 
and C39). The clonal relatedness between companion animal and human P. mirabilis varied 
between 80–100%. Several companion animal strains included in these clusters were isolated 
from different time periods. Cluster C28 is noteworthy since it includes one strain, from a dog, 
100% similar to one CA-human P. mirabilis. Furthermore, one P. mirabilis from a cat (C2) was 
also found to be 94.7% and 92.4% similar to one CA-human and HA-human strain, 
respectively. Some P. mirabilis strains isolated from dogs and cats (C21 and C34) also showed 
high similarity (90%–100%). Based on veterinary records, only strains FMV5954B/03 and 
FMV5955/03 were found to be epidemiologically related, since they were isolated in the same 
week from two cats admitted at the same veterinary practice. 
P. mirabilis CMY-2-producer strains from companion animals did not cluster all together. 
However, C36 included five P. mirabilis from companion animals (85.8%–95.7% similarity), of 
which, four (80%) were multidrug-resistant CMY-2-producers. 
 
Discussion 
Currently there are few studies characterising the clonal population structure epidemiology of 
human or companion animal uropathogenic P. mirabilis strains (Gaastra et al., 1996; Sabbuba 
et al., 2003; Mathur et al., 2008). A high number of single pulse-types were detected both in 
human and in companion animal P. mirabilis strains in this study. Nevertheless, several PFGE 
clusters composed of P. mirabilis isolated in different years were detected, pointing to a higher 
dissemination of some clusters. 
P. mirabilis is known to cause nosocomial infections (Armbruster & Mobley, 2012). The 
detection of several closely related HA-human strains likely resulted from nosocomial 
dissemination. The two identical P. mirabilis from two cats admitted at the same clinic, may 
also point to nosocomial events. Notably, the nine clusters that included P. mirabilis from  
CA-human and HA-human UTIs highlight the possible circulation of some strains between the 
hospital and community environment. 
One previous study conducted on a limited number of P. mirabilis of several sources, detected 
one P. mirabilis strain from a dog that was closely related to one strain from a human (Schultz 
et al., 2015). In the present study, a high number of PFGE clusters (43.6%) contained strains 
from companion animal and human origin, including some with significant similarity (90%–
100%). Thus, these results point to the zoonotic potential of uropathogenic P. mirabilis. The 
close similarity of some strains from cats and dogs also highlights the possibility of P. mirabilis 
transfer between pets. 
Overall, HA-human P. mirabilis seemed to have higher antimicrobial resistance frequencies. 
However, the fact that this study relied on convenience samples collected in different time-
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spans is a study limitation that restricts more extensive comparisons. Another limitation from 
this study was the lack of data regarding any prior antimicrobial treatment to the sampling.  
Nonetheless, some of the higher resistance frequencies in this study were detected against 
important antimicrobials for UTI treatment, such as trimethoprim/sulfamethoxazole, 
fluoroquinolones and b-lactams. A previous study from Portugal reported higher antimicrobial 
resistance frequencies among P. mirabilis from humans with community-acquired UTI (Costa 
et al., 2018). Part of the companion animal P. mirabilis strains here characterised have been 
included in a previous study analysing the temporal trends of antimicrobial resistance in UTI 
(Marques et al., 2018b). It is noteworthy that in this previous study, a significant increase in 
MDR P. mirabilis third-generation cephalosporin-resistance was detected due to the presence 
of CMY-2 b-lactamase (Marques et al., 2018b). 
The P. mirabilis isolated from humans in this study were all third-generation cephalosporin-
susceptible. However, the detection of AmpC-producing P. mirabilis from human infection is 
being increasingly reported in Europe (D’Andrea et al., 2011; Aogáin et al., 2016). Interestingly, 
in our study, several MDR CMY-2-producing P. mirabilis strains from companion animals, 
including unrelated strains from a wide time frame, clustered together. This may point to the 
expansion of MDR CMY-2-producing PFGE C36 among companion animals. A previous study 
conducted in the UK, using whole genome sequencing (WGS), has reported the expansion of 
two clones of CMY-2-producing P. mirabilis in human infection (Aogáin et al., 2016). Since all 
CMY-2-producing P. mirabilis from companion animals from the present study were MDR and 
resistant to 5–9 antimicrobial categories, their possible expansion is worrisome. 
Companion animal and human P. mirabilis strains harboured similar antimicrobial resistance 
genes except blaCMY-2, sul3, floR and aac(3)-IV, only detected in companion animals. 
Therefore, P. mirabilis from companion animals were reservoirs of important resistance genes. 
The high dissemination of sul1 and sul2 in P. mirabilis is in line with the high frequency of these 
resistance genes in other Enterobacteriaceae from Portugal (Antunes, Machado, Sousa & 
Peixe, 2005). The trimethoprim/sulfamethoxazole non-susceptible strains lacking sul1, sul2 
and sul3 may harbour untested resistance mechanism such as the recently described sul4 
(Razavi et al., 2017). The presence of qnrD among fluoroquinolone-non-susceptible  
P. mirabilis agrees with previous published data (Harada et al., 2014; Jacoby et al., 2014; 
Schultz et al., 2017a; de Jong et al., 2018). Nevertheless, the frequency of qnrD detected in 
P. mirabilis from companion animals in the present study was higher than in previous studies 
(Harada et al., 2014; Schultz et al., 2017a). The main acquired fluoroquinolone-resistance 
mechanism in Enterobacteriaceae is the acquisition of mutations on the quinolone resistance-
determining regions (QRDR) (Weigel et al., 2002; Harada et al., 2014). Furthermore, generally 
resistance to a given fluoroquinolone is accompanied by elevated non-wild type MIC values of 
other fluoroquinolones (Hernández, Martínez-Martínez, Pascual, Suárez & Perea, 2000). It 
was interesting to notice that several P. mirabilis strains from the present study did not have 
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clinical cross-resistance to all tested fluoroquinolones. The higher clinical resistance of  
P. mirabilis towards enrofloxacin than to ciprofloxacin was also noted in a previous study 
conducted in P. mirabilis of dog origin and several QRDR mutations were reported (Harada et 
al., 2014). QRDR mutations of ciprofloxacin-resistant and levofloxacin-susceptible P. mirabilis 
strains from humans have also been reported (Weigel et al., 2002). The temporal change in 
fluoroquinolone-resistance phenotype in P. mirabilis from companion animals could be a 
consequence of antimicrobial use over time. The characterisation of QRDR and determination 
of fluoroquinolone minimal inhibitory concentrations should be pursued in the future. 
The aphAI-IAB aminoglycoside phosphotransferase has been previously detected in  
P. mirabilis through WGS (Di Pilato et al., 2016). To our knowledge, this is the first detection 
of aphAI-IAB in P. mirabilis from companion animals and the first report of its frequency among 
clinical relevant P. mirabilis. The detection of floR only in companion animal strains arguments 
to different chloramphenicol/florfenicol-resistance epidemiology between companion animals 
and humans. In Salmonella, the floR is sometimes present in the Salmonella genomic island 
1 (SGI1) (Hall, 2010). Interestingly, some SGI1 variants have already been described in MDR 
P. mirabilis from companion animals and humans (Schultz et al., 2015). 
The high frequency of ucaA, mrpA and pmfA fimbriae genes detected in this study could be 
expected based on previous phenotypical and genotypic studies conducted in P. mirabilis from 
companion animals and humans, respectively (Bijlsma et al., 1995; Gaastra et al., 1996; Sosa 
et al., 2006). The comparison of UCA/NAF, MR/P and PMF fimbrial adhesins among strains 
from companion animals and humans in the future may help to better understand P. mirabilis 
zoonotic potential. Although, early phenotypical studies have shown that most P. mirabilis from 
dogs with UTI were haemolytic (Gaastra et al., 1996), to our knowledge, this is the first report 
of the haemolysin HmpA/HmpB coding genes presence and frequency among companion 
animal strains. The high frequency of HmpA/HmpB in P. mirabilis from humans agrees with 
previous results (Cestari et al., 2013). 
There is a lack of studies comparing the clonal relatedness between P. mirabilis from 
companion animals and humans. Furthermore, the few existing studies are focussed in 
selected resistant population from several infection sources (Schultz et al., 2015; Schultz et 
al., 2017b). To our best knowledge, this is the first study comparing the clonal relatedness of 
a large number of P. mirabilis obtained exclusively from humans and companion animals with 
UTIs. 
In this study, the P. mirabilis clonal relatedness was accessed only by PFGE analysis and not 
also by MLST because the latter isn’t available for this bacterial specie. Future studies using 
whole genome sequencing could help to overcome this limitation and further contribute to 
understand the risk of uropathogenic P. mirabilis animal-human transfer. 
Studies conducted on E. coli, have found that companion animals and humans may share 
uropathogenic strains within the same household (Johnson & Clabots, 2006). Similar studies 
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should be conducted regarding P. mirabilis to fully evaluate the risk of animal-human transfer 
during UTI. Nevertheless, considering the clonal relatedness between P. mirabilis from 
companion animals and humans in this study, the role of companion animals in the 
dissemination of uropathogenic resistant P. mirabilis should not be neglected. The route of 
transfer (human to animal and vice versa) is also unknown and warrants attention in future 
studies. The lack of hygiene practices has been pointed as a factor for dissemination of  




This study shows that UTI in companion animals and humans may be caused by closely 
related P. mirabilis strains and that P. mirabilis from both origins have common antimicrobial 
resistant and virulence genes. Taken together, these results underline the possible zoonotic 
nature of P. mirabilis causing UTIs in companion animals, which has important public-health 
implications. 
Pending additional research, companion animals might be regarded as possible sources of 




Supplementary Figure 1 - PFGE patterns of chromosomal DNA restriction fragments from P. mirabilis strains from companion animals and 

























Supplementary Figure 1 (continuation)- PFGE patterns of chromosomal DNA restriction fragments from P. mirabilis strains from 

























Supplementary Figure 1 (continuation)- PFGE patterns of chromosomal DNA restriction fragments from P. mirabilis strains from 



















Legend: Dashed line, cluster cut-off of 80%; Regarding virulence genes: Black square, positive; Light grey square, negative; Regarding antimicrobials: Black square, 
resistant; Grey square, intermediate resistant; Light grey square, susceptible; S, Single pulse-type; C, pulse-type cluster; AMP, ampicillin; AMC, amoxicillin/clavulanate; 
CTX, cefotaxime; CAZ, ceftazidime; CVN, cefovecin; FEP, cefepime; FOX, cefoxitin; IMP, imipenem; ETP, ertapenem; MEM, meropenem;  
TZP, piperacillin/tazobactam; ATM, aztreonam; NAL, nalidixic acid; ENR, enrofloxacin; CIP, ciprofloxacin; NOR, norfloxacin; LVX, levofloxacin; KAN, kanamycin;  
GEN, gentamicin; TOB, tobramycin; NET, netilmicin; AMK, amikacin; SXT, trimethoprim/sulfamethoxazole; CHL, chloramphenicol; FFC, florfenicol; FOF, fosfomycin; 







 Sharing of K. pneumoniae and P. mirabilis 
between companion animals and humans 
Chapter 5 Sharing of K. pneumoniae and P. mirabilis between companion animals and humans. 
 
5.1 Evidence of sharing of Klebsiella pneumoniae strains between healthy 
companion animals and co-habiting humans. 
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Abstract 
This study aimed to characterise the faecal colonisation and sharing of Klebsiella pneumoniae 
strains between companion animals and humans living in close contact. 
Faecal samples were collected from 50 healthy participants (24 humans, 18 dogs and 8 cats) 
belonging to 18 households. Samples were plated onto MacConkey agar plates (MCK) with 
and without cefotaxime or meropenem supplementation. Up to five K. pneumoniae colonies 
per participant were compared by pulsed-field gel electrophoresis (PFGE) after XbaI 
restriction. K. pneumoniae strains with unique pulse-types from each participant were 
characterised for antimicrobial susceptibility, virulence genes and multilocus sequence type 
(MLST). Faecal K. pneumoniae pulse-types were compared to those of clinical K. pneumoniae 
strains from animal and human patients with urinary tract infections (n= 104). 
K. pneumoniae colonisation was detected in non-supplemented MCK in around 38% of dogs 
(n= 7) and humans (n= 9). K. pneumoniae isolated from dogs belonged to sequence type 17 
(ST17), ST188, ST252, ST281, ST423, ST1093, ST1241, ST3398 and ST3399. None of the 
K. pneumoniae strains were multidrug-resistant or hypervirulent. Two households included 
multiple colonised participants. Notably, two colonised dogs within-household 15 (H15) shared 
a strain each (ST252 and ST1241) with one co-living human. One dog from H16 shared one 
PFGE undistinguishable K. pneumoniae ST17 strain with two humans from different 
households; however, the antimicrobial susceptibility phenotypes of these three strains 
differed. Two main virulence genotypes were detected, namely fimH-1/mrkD/ycfM/entB/kfu 
and fimH-1/mrkD/ycfM/entB/kpn. 
These results highlight the potential role of dogs as reservoir of K. pneumoniae to humans and 
vice versa. Furthermore, to our best knowledge, this is the first report of healthy humans and 
dogs sharing K. pneumoniae strains that were undistinguishable by PFGE/MLST. 
 
Keywords: Klebsiella pneumoniae, clonal relatedness, animal-human sharing, companion 
animals, dog, humans 
 
Introduction 
Klebsiella pneumoniae is an important nosocomial agent that is known to spread easily (Martim 
et al., 2016; Martin & Bachman, 2018). K. pneumoniae can also cause community onset 
infections in companion animals and humans and is the second most common 
Enterobacteriaceae species causing urinary tract infections (UTI) in humans (Gupta et al., 
1999; Ewers et al., 2014b; Marques et al., 2018b). 
 
 155 
Extended spectrum beta-lactamase (ESBL) and carbapenemase-producing 
Enterobacteriaceae are frequently multidrug-resistant, which leads to important therapeutic 
limitations (Marques et al., 2018b; ECDC, 2017). ESBL/Carbapenemase-producing  
K. pneumoniae strains are frequently reported worldwide and their dissemination is of great 
importance (Ewers et al., 2014b; ECDC, 2017). 
Companion animals may become infected with K. pneumoniae high-risk clonal lineages, such 
as ST15, which is frequently a CTX-M-15-producer (Ewers et al., 2014b; Harada et al., 2016; 
Maeyama et al., 2018; Marques et al., 2018c). However, little is known about the role of healthy 
dogs and cats as reservoirs of such clonal lineages. 
Gut colonisation by K. pneumoniae is strongly linked to subsequent extraintestinal infections 
in hospitalised human patients (Martin et al., 2016). Moreover, Enterobacteriaceae species 
that cause UTI, such as K. pneumoniae, are frequently part of the host gut microbiota (Martin 
et al., 2016). The gut of companion animals may be colonised by high-risk clonal lineages of 
Escherichia coli (Johnson et al., 2016) and Enterococcus faecium (Damborg et al., 2009), thus 
potentially acting as reservoirs to humans. In humans, most studies on K. pneumoniae faecal 
colonisation are focussed on hospitalised and/or infected patients and therefore less 
information is available regarding healthy humans (Martin et al., 2016; Martin et al., 2018). 
Studies on the population structure of K. pneumoniae strains colonising healthy dogs and cats 
are also lacking. 
The transmission of pathogenic bacteria from companion animals to humans has been a 
growing matter of concern (Pomba et al., 2017). The close contact between companion 
animals and humans in modern society leads to greater chances of interspecies transmission 
of bacteria (Pomba et al., 2017), including through faecal contamination. Previous studies 
focussed on E. coli transmission dynamics have reported that the index strains from humans 
or dogs with UTI are extensively shared with other human and dog household members 
(Johnson & Clabots, 2006; Johnson, Clabots & Kuskowski, 2008a). Sharing of E. coli between 
healthy humans and dogs living in close contact has also been described (Johnson, Owens, 
Gajewski & Clabots, 2008b; Stenske et al., 2009; Harada et al., 2012b; Naziri, Derakhshandeh, 
Firouzi, Motamedifar & Shojaee Tabrizi, 2016). To our knowledge, studies on animal-human 
sharing have not been conducted regarding K. pneumoniae. However, this information is 
crucial to a better understanding of the epidemiology of this important pathogen. 
In the current study, several households composed of healthy companion animals (dogs and 
cats) and humans living in close contact were enrolled to evaluate the frequency of  
K. pneumoniae colonisation and animal-human sharing. Additionally, this study aimed to 
characterise the population structure, antimicrobial resistance and virulence of faecal  
K. pneumoniae to aid the understanding of the role of healthy companion animals as reservoirs 
to humans and vice versa. A special focus regarding UTI was given by comparing the faecal 
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K. pneumoniae strains with a previously characterised collection of clinical K. pneumoniae 
isolates from humans, dogs and cats with UTI (Marques et al., 2018c). 
 
Materials and methods 
Study population 
The study population included households with at least one human and one companion animal 
(dog or cat) living in close contact. Prior to inclusion, all human participants were informed of 
the main goals of the study and were asked to sign a consent form. Participants were 
considered “healthy” and were included in the study if no bacterial infection nor antimicrobial 
use was reported in the previous month. To ensure that inclusion was anonymous, 
households, humans and animals were coded with numbered letters H, Hu and A, respectively. 
A total of 50 participants (24 humans, 18 dogs and 8 cats) living in 18 households were enrolled 
in 2016. Therefore, the household composition varied in the number of humans and companion 
animals (Figure 1). Human participants had lived in the same household as the included 
companion animals for at least 6 months, except one cat that had been recently adopted to 
H16 (Figure 1). 
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All human participants were more than 18 years of age and 70.8% (n= 17/24) were women. 
Companion animal ages ranged from 2 months to 17 years, and 57.7% (n= 15/26) were 
females. Thirty-three percent (n= 8/24) of humans and 19.2% (n= 5/26) of companion animals 
had undergone antimicrobial treatment within the previous year. All cats lived exclusively 
indoors except one. All dogs had access to the outdoors, 83.3% (n= 15/18) lived indoors with 
the owners while, 16.7% (n= 3/18) stayed at private yards. 
 
Sample collection and bacteriological methods 
Ethical approval for this study was obtained from the Comissão de Ética e Bem-Estar Animal 
(CEBEA) from the Faculty of Veterinary Medicine of the University of Lisbon. All faecal samples 
were collected using non-invasive methods after informed, written consent was obtained. 
Enrolled humans collected their own faecal samples and the faecal samples from the co-living 
companion animals into sterile containers. Immediately after collection, faecal samples were 
stored at 4ºC until processing. 
One gramme of homogenised faecal sample was added to 10 mL of sterile 0.85% NaCl (Merk, 
Germany) solution and mixed thoroughly. Ten microlitres of faecal suspension were plated 
onto MacConkey agar plates (Scharlau, Spain) with or without 1.5 µg/mL of cefotaxime 
(Sigma-Aldrich, USA) or meropenem (Sigma-Aldrich, USA) supplementation. To improve 
detection of low number K. pneumoniae, one gramme of feces was added to 5 mL of sterile 
buffered peptone water (Biokar diagnostics, France), vortexed and incubated at 36±1ºC during 
18h. A negative quality control consisting of buffered peptone water alone was also incubated. 
Following incubation, 1 µL of buffered peptone water faecal suspension was plated onto the 
MacConkey agar plates described above. MacConkey agar plates were incubated at 36±1ºC 
for 18h, followed by inspection for K. pneumoniae suspected colonies. 
To guide presumptive K. pneumoniae identification, suspected colonies obtained from 
MacConkey agar plates were streaked onto UriSelect™ agar plates (Biorad, USA). Up to five 
K. pneumoniae suspected colonies per participant were isolated and stored in 20% glycerol 
(Sigma-Aldrich, USA) brain heart infusion broth (Biokar diagnostics, France) at -20 ºC until 
processing. Total DNA was extracted by boiling method and K. pneumoniae species confirmed 
by PCR as previously described (Féria et al., 2002; Padmavathy et al., 2012). 
All faecal samples had a high number of colony forming units of Enterobacteriaceae after direct 
plating onto MacConkey agar plates, thus confirming sample viability. 
 
K. pneumoniae population structure analysis 
All K. pneumoniae isolates were compared by pulse field gel electrophoresis (PFGE) after 3h 
XbaI (New England Biolabs, USA) restriction. Restriction fragments were separated on a 
CHEF DR II-apparatus (Biorad, USA) using a 1% agarose gel (agarose pulse-field grade, 
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Nzytech - Genes and Enzymes, Portugal) and previously described electrophoresis conditions 
(5 to 20 s for 4 h followed by 25 to 50 s for 18 h at 14ºC, 6 V/cm2) (Rodrigues et al., 2016). 
K. pneumoniae strains with unique pulse-types from each animal or human were further typed 
by MLST according to the published consensus MLST scheme 
(http://bigsdb.pasteur.fr/klebsiella/klebsiella.html). 
 
Collection of clinical UTI K. pneumoniae 
The faecal K. pneumoniae PFGE restriction patterns from this study were compared with a 
previously typed collection of clinical K. pneumoniae strains isolated from dogs, cats (n= 27) 
and humans (n= 77 [n= 19 hospital patients and n= 58 community patients]) with UTI (Marques 
et al., 2018c). 
 
Susceptibility testing 
K. pneumoniae strains with unique pulse-types from each animal and human were tested for 
antimicrobial resistance to amoxicillin/clavulanate 30 µg, cefoxitin 30 µg, cefotaxime 30 µg, 
meropenem 10 µg, ciprofloxacin 5 µg, gentamicin 10 µg, amikacin 30 µg, nitrofurantoin  
300 µg, chloramphenicol 30 µg, tetracycline 30 µg and trimethoprim/sulfamethoxazole 25 µg 
(Oxoid, Hampshire, UK). Antimicrobial susceptibility was conducted by disk diffusion according 
to CLSI guidelines (CLSI, 2017). 
 
Antimicrobial resistance determinants 
K. pneumoniae isolates that were not susceptible to at least one of the tested b-lactams, except 
ampicillin, were tested by PCR for the presence of blaTEM, blaSHV, blaOXA, blaCTX-M-type, blaCIT-type, 
blaDHA-type, blaMOX-type, blaACT-type, blaFOX-type and blaMIR-type b-lactamase genes using previously 
described primers (Pérez-Pérez & Hanson, 2002; Pomba et al., 2006; Guessennd et al., 2008). 
K. pneumoniae strains with unique pulse-types were tested for the presence of efflux pump 
(oqxAB) (Kim et al., 2009c) and outer membrane proteins (ompK35 and ompK36) (Lee et al., 
2007) coding genes. 
 
Virulence genes 
The K. pneumoniae strains that were tested for antimicrobial susceptibility were also screened 
by PCR for the presence of the following virulence genes: type-1 (fimH-1), type-3 (mrkD) and 
FimH-like (kpn) fimbriae adhesins (El Fertas-Aissani et al., 2013; Compain et al., 2014), outer 
membrane lipoprotein (ycfM) (El Fertas-Aissani et al., 2013), catecholate siderophore receptor 
(iroN) (Johnson et al., 2000), enterobactin (entB) (Compain et al., 2014), aerobactin (iutA) 
(Compain et al., 2014), iron transporter with phosphotransferase function (kfu) (Compain et 
al., 2014), yersiniabactin high-pathogenicity island ([YHPI], irp-1, irp-2, fyuA, ybtS) (Johnson & 
Stell, 2000; Schubert et al., 2000; Compain et al., 2014), serum resistance-associated outer 
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membrane lipoprotein (traT) (Johnson & Stell, 2000), regulator of mucoid phenotype A (rmpA) 
(Compain et al., 2014) and allantoin metabolism associated gene (allS) (Compain et al., 2014). 
 
Data analysis 
K. pneumoniae PFGE-patterns were compared using the Bionumerics software version 6.6, 
(BioMérieux, France) and Dice/unweighted pair group method with arithmetic mean (UMPGA) 
clustering method with a tolerance of 1.5% and a clustering cut-off of 80%. Previously 
proposed criteria for bacterial strain typing were used (Tenover et al., 1995). 
The Fisher’s exact test was used for comparisons between groups, with an alpha value of 
0.05, using SAS statistical software package for Windows version 9.3 (SAS Institute Inc, Cary, 
USA). 
K. pneumoniae STs from this study were compared with all known STs from the Institut Pasteur 
K. pneumoniae database (http://bigsdb.pasteur.fr/klebsiella/klebsiella.html) through 
eBURSTV3 analysis (http://eburst.mlst.net/). K. pneumoniae STs were assigned to the same 
group if they shared identical alleles at 6 out of 7 loci with at least one other ST. 
 
Results 
K. pneumoniae colonisation was detected in 16 participants (7 dogs and 9 humans) from 12 
households (Figure 1). All samples were negative for K. pneumoniae growth in MacConkey 
agar plates with cefotaxime or meropenem supplementation. 
The faecal colonisation by K. pneumoniae was equally high in dogs (38.9%, n= 7/18) and in 
humans (37.5%, n= 9/24). However, K. pneumoniae colonisation was not detected in cats 
despite the use of pre-enrichment prior to plating. 
The majority of positive households (83.3%, n= 10/12) had a single colonised participant and 
therefore within-household sharing of K. pneumoniae was absent in these cases (Figure 1). 
The two households with multiple colonised participants included colonised humans and dogs 
(Figure 1). 
A total of 59 K. pneumoniae isolates were obtained from the 16 positive participants and the 
number of isolates per participant ranged from one to five. The PFGE analysis revealed a total 
of 22 different restriction patterns (A to U) (Figure 2). 
In samples from which two to five K. pneumoniae colonies were isolated, 61.5% (n= 8/13) of 
the participants were colonised by two or more different K. pneumoniae strains according to 
the PFGE results (Figure 2, Table 1). The PFGE analysis of the K. pneumoniae isolates from 
the participants living in household H21 showed that the human and dog were colonised by 
unrelated K. pneumoniae strains (pulse-type R and H, respectively) (Figure 2). In household 
H15, which was composed by two colonised humans and two colonised dogs, it is interesting 
to notice that while both humans were colonised by unrelated K. pneumoniae strains, the 
human H15Hu2 shared one K. pneumoniae strain undistinguishable by PFGE with dog-H15A1 
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(pulse-type C.1) and another with dog-H15A2 (pulse-type O) (Figure 2). In both dogs from 
household H15, the colonising K. pneumoniae strain was detected without pre-enrichment, 
while in the human H15Hu2 pre-enrichment was needed. 
 
Figure 2- PFGE analysis of commensal K. pneumoniae from humans and animals 
living in close contact 
 



































































































































































































































































Table 1 - Characterisation of faecal K. pneumoniae strains 






H3 Human Hu1 H3Hu1PWK1 E ST626 - None fimH-1, mrkD, ycfM, entB, kfu, allS 
H3 Human Hu1 H3Hu1PWK2 B ST17 CC11 None fimH-1, mrkD, ycfM, entB, kpn 
H4 Dog A1 H4A1TBK1 T ST1093 CC11 (AK), NIT fimH-1, mrkD, ycfM, entB, kfu 
H5 Human Hu1 H5Hu1MCKK1 E ST626 - (NIT) fimH-1, mrkD, ycfM, entB, kfu, allS 
H5 Human Hu1 H5Hu1MCKK4 B ST17 CC11 (CTX), (CN), (AK) fimH-1, mrkD, ycfM, entB, kpn 
H7 Human Hu1 H7Hu1TBK1 I ST3397a CC11 None fimH-1, mrkD, ycfM, entB, kfu, allS 
H7 Human Hu1 H7Hu1TBK3 Q ST3345 CC11 NIT fimH-1, mrkD, ycfM, entB, kpn 
H10 Dog A1 H10A1PWK1 N ST423 CC11 NIT fimH-1, mrkD, ycfM, entB, kpn 
H15 Dog A1 H15A1MCKK1 C.1 ST252 CC11 NIT fimH-1, mrkD, ycfM, entB, kpn 
H15 Dog A1 H15A1MCKK3 K ST281 CC505 NIT fimH-1, mrkD, ycfM, entB, kpn, YHPI 
H15 Dog A1 H15A1MCKK5 C.2 ST252 CC11 (CN), (AK), NIT fimH-1, mrkD, ycfM, entB, kpn 
H15 Dog A2 H15A2MCKK1 O ST1241 - NIT fimH-1, mrkD, ycfM, entB, kfu 
H15 Human Hu1 H15Hu1MCKK4 D ST1748 Singleton NIT fimH-1, mrkD, ycfM, entB, kpn 
H15 Human Hu2 H15Hu2TBK1 O ST1241 - NIT fimH-1, mrkD, ycfM, entB, kfu 
H15 Human Hu2 H15Hu2TBK2 C.1 ST252 CC11 NIT fimH-1, mrkD, ycfM, entB, kpn 
H15 Human Hu2 H15Hu2TBK3 F ST20 CC11 CN, (AK), NIT fimH-1, mrkD, ycfM, entB, kpn 
H16 Dog A1 H16A1MCKK1 B ST17 CC11 (CN), (AK) fimH-1, mrkD, ycfM, entB, kpn 
H17 Human Hu1 H17Hu1TBK3 A ST1500 CC11 NIT fimH-1, mrkD, ycfM, entB, kpn 
H19 Dog A1 H19A1K1 U ST3398a Singleton (CN), NIT fimH-1, mrkD, ycfM, entB, kfu 
H19 Dog A1 H19A1K4 S ST3399a Singleton (CN), NIT fimH-1, mrkD, ycfM, entB, kfu 
H20 Human Hu2 H20Hu2TBK2 M ST1198 CC11 C, NIT fimH-1, mrkD, ycfM, entB, kpn 
H20 Human Hu2 H20Hu2TBK5 L ST187 CC187 (CTX), NIT fimH-1, mrkD, ycfM, entB, kpn 
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Table 1 (continuation)- Characterisation of faecal K. pneumoniae strains 






H21 Dog A2 H21A2TBK3 H ST188 Singleton (CN) fimH-1, mrkD, ycfM, entB, kfu 
H21 Human Hu1 H21Hu1TBK1 R ST2217 Singleton (CN), NIT fimH-1, mrkD, ycfM, entB, kfu 
H22 Human Hu2 H22Hu2MCKK1 P ST277 CC11 (CN), NIT fimH-1, mrkD, ycfM, entB, kpn 
H22 Human Hu2 H22Hu2MCKK2 J ST465 CC11 TE fimH-1, mrkD, ycfM, entB, kpn 
H22 Human Hu2 H22Hu2MCKK4 G ST502 CC502 None fimH-1, mrkD, ycfM, entB, kpn 
Legend: fimH-1, type-1 adhesin; mrkD, type-3 adhesin; kpn, FimH-like adhesin; ycfM, outer membrane lipoprotein; entB, enterobactin; kfu, iron transporter with 
phosphotransferase function; YHPI, yersiniabactin high-pathogenicity island; allS, allantoin metabolism associated gene; AK, amikacin; C, chloramphenicol;  
CN, gentamicin; CTX, cefotaxime; NIT, nitrofurantoin; TE, tetracycline;  
aST3397, ST3398 and ST3399 new STs described in this study; 
bClonal complex (CC) were assigned based on the predicted founder ST based on a population snapshot by eBURSTV3 analysis of all K. pneumoniae Sequence types 
known until 31th of August 2018; 





Two K. pneumoniae pulse-types, namely E and B, were shared between humans living in 
distinct households (Figure 1, 2). K. pneumoniae pulse-types E and B were shared by one 
human from household H3 and another from household H5. Furthermore, K. pneumoniae 
pulse-type B was also shared by the dog-H16A1 from household H16 (Figure 1, 2). The 
colonised human participants from household H3 and H5 and the human living in close contact 
(H16Hu1) with the colonised dog-H16A1 share the same workplace and thus are 
epidemiologically related. Notably, the colonised dog-H16A1 does not visit the workplace of 
human H16Hu1. 
Overall, within-household human-animal sharing of K. pneumoniae strains occurred in 5.5% 
(n= 1/18) of all included households and in 8.3% (n= 1/12) of positive households. Considering 
the positive participants, there were a total of 20 human-animal pairs where potential within-
household sharing was possible. Based on PFGE results, 10% (n= 2/20) of these human-
animal potential pairs shared undistinguishable K. pneumoniae strains. Although several 
households included multiple human participants, none of the colonised humans shared  
K. pneumoniae strains with the co-living humans (n= 5 households) (Figure 1). The same was 
true for animals living with colonised dogs (n= 3 households) (Figure 1). 
Overall, 27 K. pneumoniae strains were typed by MLST and characterised for antimicrobial 
resistance and for the presence of virulence genes. 
A total of 21 STs, corresponding to the different PFGE pulse-types, were detected, thus 
revealing high K. pneumoniae population diversity in colonised dogs and humans (Table 1). 
Three novel K. pneumoniae STs were described, namely ST3397 to ST3399. In eBURSTv3 
analysis, the novel ST3398 and ST3399 isolated from a dog were found to be singletons. The 
K. pneumoniae ST3397 isolated from a human was a double locus variant from ST65. 
Most K. pneumoniae strains were susceptible to the tested antimicrobials. The only exception 
was the antimicrobial nitrofurantoin against which 70.4% (n= 19/27) of strains were not 
susceptible. Furthermore, several strains were intermediately resistant against gentamicin 
and/or amikacin (Table 1). The two K. pneumoniae strains with intermediate resistance to 
cefotaxime were negative for all the b-lactamase genes tested except for blaSHV. 
Two main virulence genotypes were detected, namely fimH-1/mrkD/ycfM/entB/kfu and  
fimH-1/mrkD/ycfM/entB/kpn (Table 1). The allS gene was only detected in K. pneumoniae 
strains from humans belonging to ST626 and to the novel ST3397. The yersiniabactin high-
pathogenicity island was present in one strain from a dog belonging to ST281 (Table 1). All  
K. pneumoniae isolates were negative for rpmA, iutA, iroN and traT genes and positive for 
ompK35 and ompK36. Moreover, only one strain lacked oqxAB genes by PCR. 
The K. pneumoniae strains from the participants sharing identical pulse-type/STs also shared 
the same virulence genotype. However, the antimicrobial resistance phenotype was not always 
similar (pulse-type E and B) (Table 1). 
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The K. pneumoniae strains shared between the H15 human/dog pairs belonged to ST252 
(pulse-type C.1) and ST1241 (pulse-type O) and also had identical antimicrobial resistance 
phenotype and an identical virulence genotype (Table 1). Both household H15 human 
participants reported that they allowed all the household dogs (n= 3) to lick their faces and 
sleep in their beds. No difference in dog-dog or dog-human behavior was noted regarding the 
three dogs living together. Interestingly, the dog-H15A1 was colonised by two variants (pulse-
type C.1 and C.2) of the same K. pneumoniae pulse-type (Figure 1, Table 1). The  
K. pneumoniae strains (pulse-type B) shared between the two humans and one dog from 
different households all belonged to ST17, however, these strains presented different 
antimicrobial resistant phenotypes (Table 1). 
Some of the faecal K. pneumoniae strains, mostly from humans, showed a ≥80% similarity to 
strains from humans with UTI (Figure 3). Of note, dog H10A1 was colonised with a  
K. pneumoniae strain that was closely related (92.3% similarity) to a clinical ST423  
CTX-M-15-producing K. pneumoniae strain (PC25/15B) from a human (Figure 3). The dog and 
human from household H10 did not have prior clinical history of UTI, were not under 
antimicrobial treatment in the last year, and had no contact with the hospital environment. 
 
Discussion 
To our best knowledge, this is the first report of the faecal colonisation and sharing of  
K. pneumoniae clonal lineages between healthy humans and dogs living in close contact. 
The high K. pneumoniae population diversity detected in this study is in line with that in 
previous reports (Harada et al., 2016; Maeyama et al., 2018; Holt et al., 2015). There are 
several K. pneumoniae STs disseminated worldwide, including in Portugal, that are considered 
to be high-risk clonal lineages or are recognised as important international outbreaks clones 
(Manageiro et al., 2015; Navon-Venezia et al., 2017). Considering that the gut is a reservoir of 
pathogenic Enterobacteriaceae (Martin et al., 2016), it is interesting to notice that only the high-
risk ST17 and the international outbreak ST20 K. pneumoniae clonal lineages were detected 
in this study. The K. pneumoniae high-risk clonal lineages are frequently ESBL and 
carbapenemase-producers (Navon-Venezia et al., 2017). The fact that most of the faecal  
K. pneumoniae strains from this study were susceptible to b-lactams may explain the low 
frequency of high-risk clonal lineages detected. 
K. pneumoniae ST15, which is a high-risk clonal lineage, seems to predominate among clinical 
CTX-M-15-producing strains from companion animals from several countries (Ewers et al., 
2014b; Harada et al., 2016; Maeyama et al., 2018; Marques et al., 2018c). In a previous study 
conducted in dogs and cats with UTI from Portugal, most uropathogenic K. pneumoniae 
isolates also belonged to ST15 (Marques et al., 2018c). The absence of colonised dogs with 
K. pneumoniae ST15 was therefore a surprise. 
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Figure 3 - Clusters of K. pneumoniae isolated from clinical UTIs and from faecal 
samples of human and companion animal origin 
 
Legend: UTI-C, community patient with UTI; UTI-H, hospitalised patient with UTI. 
 
Several studies have reported the colonisation and sharing of E. coli strains between 
companion animals and humans (Johnson & Clabots, 2006; Johnson et al., 2008a; Johnson 
et al., 2008b; Stenskeet al., 2009; Harada et al., 2012b; Naziri et al., 2016). To our best 
knowledge, data on K. pneumoniae is still lacking. The use of PFGE over whole genome 
sequencing (WGS) could be considered a limitation of the current study since the latter is more 
discriminatory and necessary to definitely ascertain the similarity of bacterial strains. However, 
previous studies on K. pneumoniae outbreaks have found that WGS based phylogeny is 
consistent with the PFGE and MLST data combined, especially in strains differing in less than 
3 bands (Marsh et al., 2015; Sabirova et al., 2016). Therefore, the detection of dogs and a 
human living in the same household (H15) colonised by K. pneumoniae strains belonging to 
the same ST, with undistinguishable PFGE restriction patterns, with an identical antimicrobial 
resistance phenotype and an identical virulence genotype is strongly suggestive of human-dog 
K. pneumoniae sharing. 
Household H15 is also remarkable because although 2 humans and 2 dogs were colonised by 
K. pneumoniae, within-household sharing was only detected between human-dog pairs. The 












































































































































































































































































Strain code Participant Species Source UTI vs Helthy Year ST
 
 166 
of households with multiple colonised humans or dogs. The K. pneumoniae ST252 clonal 
lineage shared between the human H15Hu2 and dog H15A1 has been previously detected in 
faecal samples from hospitalised patients and long-term care facility residents from Portugal 
(Papagiannitsis et al., 2015; Rodrigues et al., 2017). This could suggest that colonisation had 
human origin. However, the higher K. pneumoniae ST252 and ST1241 faecal burden detected 
in these dogs could point to dog-to-human transmission. Allowing the dog to lick the face has 
been suggested as a risk factor for dog-human E. coli sharing (Naziri et al., 2016). However, 
in household H15 this was not a determining factor. A common source of K. pneumoniae 
acquisition should also be hypothesised, but since the three dogs had a common living 
environment and behaviors, it would be likely that the three dogs would be colonised by the 
same strains. K. pneumoniae is known to spread easily (Martin et al., 2016), therefore, 
additional studies are necessary to clarify its routes of human-dog dissemination. 
The two humans and one dog living in different households that were colonised by PFGE 
undistinguishable K. pneumoniae ST17 strains were epidemiologically related and therefore 
the K. pneumoniae transmission could have occurred through direct (human-human) or 
indirect (human-dog) contact. However, it should be noted that the antimicrobial resistance 
phenotypes of these K. pneumoniae ST17 strains differed. Thus, since the K. pneumoniae 
ST17 clonal lineage is disseminated worldwide (Navon-Venezia et al., 2017), the circulation of 
this strain in the community and the colonisation of these participants through unrelated 
sources is the likely explanation. For instance, retail meat has been pointed to as a potential 
source of uropathogenic K. pneumoniae to humans (Davis et al., 2015). The detection of a 
high-risk K. pneumoniae clonal lineage colonising a healthy dog highlights its possible role as 
a reservoir. Furthermore, other K. pneumoniae clonal lineages that were detected in dogs, 
namely ST188, ST252, ST281, ST423 and ST1093, have also been previously implicated in 
human infections (Davis et al., 2015; Ito et al., 2015; Papagiannitsis et al., 2015; da Silva et 
al., 2018; Garza-Ramos et al., 2018). 
The colonisation of humans and dogs by K. pneumoniae was equally high (~38%) and 10% of 
the potential within-household human-animal pairs shared K. pneumoniae strains 
undistinguishable by PFGE. Since this study relied on standard culture procedures,  
K. pneumoniae colonisation and sharing could be underestimated due to the overgrowth of 
other Enterobacteriaceae species. Nevertheless, a previous study from India has reported that 
only 26% of the healthy dogs were colonised by K. pneumoniae (Sharif et al., 2017). 
Considering that 61.5% of participants were colonised by multiple strains, it can be speculated 
that the PFGE typing of a higher number of colonies per sample could be advantageous in 
future studies to detect additional sharing pairs. The nasopharynx is also a K. pneumoniae 
colonisation site (Martin et al., 2018). In retrospect, we find that the study of nasopharyngeal 
colonisation could have undisclosed further epidemiological links between colonised dogs and 
humans. The absence of colonised cats in this study may be related to the number of cats 
 
 167 
tested, since infections caused by K. pneumoniae have been previously reported in cats 
(Marques et al., 2018c). 
The frequency of K. pneumoniae virulence genes agrees with previously published data (El 
Fertas-Aissani et al., 2013; Compain et al., 2014; Holt et al., 2015). The absence or low 
frequency of virulence genes associated with higher K. pneumoniae invasiveness (Holt et al., 
2015) is a positive outcome from this study. The first hypervirulent K. pneumoniae ST23 
detected in Portugal was only recently described in a human patient (Pereira et al., 2017). 
Therefore, the absence of hypervirulent K. pneumoniae clonal lineages in this study was 
expected. 
According to the annual report of the European Antimicrobial Resistance Surveillance Network, 
Portugal is among the countries with a higher frequency of resistance to third-generation 
cephalosporins, carbapenems and fluoroquinolones in invasive K. pneumoniae strains (ECDC, 
2017). Additionally, a high frequency of faecal colonisation by ESBL/AmpC-producing  
K. pneumoniae has been reported in long-term care facility residents from Portugal (Rodrigues 
et al., 2017). The high susceptibility and lack of multidrug-resistant K. pneumoniae isolates in 
the present study is, therefore, considered a positive finding. Nevertheless, these results may 
be a consequence of the study design due to the limited sample size and because it relied on 
healthy humans and animals without reported infections or antimicrobial use in the prior month. 
Another interesting finding from this study was the detection of one healthy dog (H10A1) 
colonised by a K. pneumoniae ST423 strain that was 92.3% similar by PFGE to one strain 
isolated from an unrelated hospitalised patient with UTI. The use of WGS is warranted to fully 
disclose the relatedness of these strains; nevertheless, this finding should not be neglected. 
K. pneumoniae can cause other important infections, such as pneumonia (Martin et al., 2016; 
Holt et al., 2015). For this reason, future comparative studies should include K. pneumoniae 
strains from other clinical origins to further understand the role of dogs as reservoirs of 
pathogenic K. pneumoniae. In fact, the K. pneumoniae clonal lineages detected in dogs from 
this study have been previously isolated from several types of human infections besides UTI 
(Papagiannitsis et al., 2015; Ito et al., 2015; da Silva et al., 2018; Garza-Ramos et al., 2018). 
To conclude, this study presents novel epidemiological data regarding K. pneumoniae 
colonisation and suggests that healthy humans and dogs may share similar K. pneumoniae 
clonal lineages. The role of dogs as reservoirs of K. pneumoniae clonal lineages previously 
described in human infections is noteworthy, even though those strains were neither multidrug 
resistant nor hypervirulent. Some questions remain to be answered regarding the routes of 
transmission and persistence of K. pneumoniae colonisation over time in co-living humans and 
dogs. Future studies using longitudinal designs should be conducted to clarify these issues 
regarding infected and healthy companion animals. Meanwhile, good hygiene practices and 
proper faecal disposal should be advised to dog caretakers to minimise the chances of direct 
or indirect K. pneumoniae interspecies transmission.   
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5.2 Human and companion animal interspecies sharing of faecal Proteus 
mirabilis. 
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Abstract 
This study aimed to determine the colonisation and sharing of P. mirabilis strains between 
healthy companion animals and humans living in close contact. It also aimed to compare the 
population structure of faecal and uropathogenic P. mirabilis strains from human and 
companion animal origin. 
Eighteen households (24 humans, 18 dogs, 8 cats) with at least one human and one animal 
were studied. Faecal samples were plated onto MacConkey and Hektoen agar plates with and 
without pre-enrichment. P. mirabilis PFGE analysis (NotI; Dice/UPGMA; 1.5% tolerance) was 
conducted in households with multiple positive participants (up to 5 strains/participant) and in 
70% of the remaining households. Antimicrobial susceptibility testing and screening of 
virulence genes was performed. Faecal P. mirabilis pulse-types were compared with 
uropathogenic clinical strains from human and companion animal origin (n= 183). 
Forty-Nine P. mirabilis strains belonging to three humans (12.5%, n= 3/24) and eight dogs 
(44.4%, n= 8/18) were isolated from eight households (44.4%, n= 8/18). Dog colonisation was 
significantly higher (P = 0.0329). Three households had multiple colonised participants 
(dog/dog, n= 1; human/dog, n= 2). One human/dog and the dog/dog pairs shared closely 
related P. mirabilis strains. Some human and dog P. mirabilis faecal strains clustered with 
clinical P. mirabilis strains (>80% Dice/UPGMA index). Strains were susceptible to most 
antimicrobials and frequently encoded HmpA/HmpB, mrpA, pmpA and ucaA. 
To our knowledge, this is the first report of dogs and humans living in close contact sharing 
closely related P. mirabilis strains. The high frequency of colonisation in dogs and inter/intra-
species sharing suggests the role of dogs as reservoirs of P. mirabilis to humans and dogs. 
 
Keywords: Proteus mirabilis, Dogs, Humans, Faeces, Sharing 
 
Introduction 
Proteus mirabilis is a common cause of urinary tract infections (UTI) (Drzewiecka, 2016). In 
humans, P. mirabilis is frequently associated with complicated, recurrent and/or catheter 
associated UTIs (CAUTI) (Drzewiecka, 2016; Armbruster et al., 2018). UTIs caused by  
P. mirabilis are medically demanding because they are prone to persistence and to secondary 
complications such as urolithiasis, obstruction and pyelonephritis (Armbruster et al., 2018).  
P. mirabilis is also relevant in companion animals with UTI since it is the second most common 
Gram-negative bacteria isolated from dogs and cats (Marques et al., 2018b). 
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The increasing number of companion animals in modern society has raised concerns 
regarding the role of dogs and cats as reservoirs of pathogenic and/or antimicrobial resistant 
bacteria (Damborg et al., 2016; Pomba et al., 2017). In a recent study using PFGE, a high 
number of clusters (cluster >80% Dice/UPGMA index) were shown to contain clinical  
P. mirabilis strains isolated from humans and companion animals (dogs and cats) with UTI 
(Marques et al., 2018a). 
The closer contact between owners and their pets increases the opportunities for pathogen 
interchange through direct and indirect contact (Damborg et al., 2016; Pomba et al., 2017). In 
fact, healthy dogs may share colonising E. coli strains with humans living in the same 
household (Johnson et al., 2008b; Stenske et al., 2009; Harada et al., 2012b; Naziri et al., 
2016). The gut is pointed as the major reservoir of uropathogenic bacteria, including  
P. mirabilis (Drzewiecka, 2016). Notably, healthy dogs have been found to become colonised 
by E. coli clonal lineages known to cause UTI in humans, namely ST131 (Johnson et al., 2016). 
The worldwide P. mirabilis clonal epidemiology is still poorly understood due, to some extent, 
to the lack of portable P. mirabilis molecular typing methods such as MLST. Few studies have 
addressed the gut P. mirabilis colonisation of healthy dogs and cats (Balish et al., 1977; 
Gaastra et al., 1996). Furthermore, to our best knowledge, there is a lack of studies 
characterising the P. mirabilis sharing between companion animals and humans living in close 
contact. 
This study aimed to evaluate the P. mirabilis faecal colonisation and sharing between 
companion animals and humans living in the same household. Furthermore, the faecal  
P. mirabilis strains where compared by PFGE with clinical strains from companion animals and 
humans with UTI. 
 
Materials and methods 
Study population 
Households composed of healthy humans and companion animals (dogs and/or cats) were 
enrolled in 2016. The health status of participants was accessed through a questionnaire and 
“healthy” was defined as the absence of known bacterial infections and/or antimicrobial use in 
the prior month. Human participants were informed of the main goals of the study and were 
required to sign a consent form. The studied population, included a total of 50 individuals  
(24 humans, 18 dogs and 8 cats) comprising 18 households. All human participants had lived 
together with the corresponding companion animals for at least 6 months prior to the study, 
except one cat that had been recently adopted to H16. Each family was composed of at least 
one human and one companion animal (dog or cat), yet the number of humans and companion 
animals varied among households (Figure 1). Enrolment was anonymous, therefore 




Figure 1 - Faecal colonisation and within-household sharing of P. mirabilis 
 
 
Sample collection and bacteriological methods 
Ethical approval was obtained from the Comissão de Ética e Bem-Estar Animal (CEBEA) from 
the Faculty of Veterinary Medicine of the University of Lisbon. Human participants were asked 
to collect their own faecal samples, as well as the faecal samples from their pets, into sterile 
containers using non-invasive methods. Faecal samples were immediately stored at 4ºC until 
processing. 
After sample homogenisation, one gramme of faeces was added to 10 mL of sterile 0.85% 
NaCl (Merk, Germany) solution and vortexed. Following thorough mixing, 10 µL of faecal 
suspension were plated onto MacConkey agar plates (Scharlau, Spain) and Hektoen Enteric 
agar plates (Biokar diagnostics, France). Ten microlitres of faecal suspension were also plated 
onto MacConkey agar plates supplemented with 1.5 µg/mL of cefotaxime (Sigma-Aldrich, 
USA) or meropenem (Sigma-Aldrich, USA). 
One gramme of faeces was added to 5 mL of tetrathionate broth (tetrathionate broth base 
[Oxoid, UK] supplemented with iodine [AlliedSignal, Germany] and potassium iodide 
[Scharlau, Spain] according to the manufacturer instructions) to improve detection of  
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36±1ºC during 18h prior to plating in the agar plates described above. One tube of tetrathionate 
broth without faecal sample and one tube of tetrathionate broth inoculated with known  
P. mirabilis strains were included as negative and positive quality controls, respectively. 
After incubation at 36±1ºC during 18h, all agar plates were inspected for the presence of 
Proteus spp. suspected colonies. When present, up to five colonies of each participant were 
isolated and stored in 20% glycerol (Sigma-Aldrich, USA) brain heart infusion broth (Biokar 
diagnostics, France) at -20 ºC until further analysis. Growth of a high number of colony forming 
units of Enterobacteriaceae after direct plating in MacConkey agar plates were deemed 
warrant as a quality control of sample viability. 
 
Bacteria identification 
Total DNA extraction of each suspected isolate of Proteus spp. was processed by boiling 
method (Féria et al., 2002) and species identification was conducted by PCR using previously 
described species-specific primers (Stankowska et al., 2008). 
 
Population structure analysis 
The clonal relatedness of all P. mirabilis isolates obtained from households with multiple 
colonised members was determined by pulse field gel electrophoresis (PFGE) after overnight 
NotI (New England Biolabs, USA) restriction. P. mirabilis from 70% of households with a single 
colonised member were also characterised. Restriction fragments were resolved in a 1% 
agarose gel (Agarose pulse-field grade, Nzytech - Genes and Enzymes, Portugal) using 
previously described electrophoresis conditions (1-30 s for 8 h followed by 30-70 s for 16 h at 
14ºC, 6 V/cm2) on a CHEF DR II-apparatus (Biorad, USA) (Sabbuba et al., 2003). 
 
Clinical UTI P. mirabilis collection 
The PFGE restriction patterns of faecal P. mirabilis strains from healthy companion animals 
and humans were compared to a previously characterised collection of clinical P. mirabilis 
isolated from companion animals (n= 107) and humans (n= 76 [n= 26 hospital patients and  
n= 50 community patients]) with UTI (Marques et al., 2018a). 
 
Susceptibility testing 
All unique P. mirabilis pulse-type/participant strains and one isolate per participant from 
untyped households were tested for antimicrobial resistance by disk diffusion. Susceptibility 
testing was conducted according to CLSI guidelines (CLSI, 2017; CLSI, 2018) for the following 
antimicrobials: ampicillin 10 µg, amoxicillin/clavulanate 30 µg, cefoxitin 30 µg, cefotaxime  
30 µg, meropenem 10 µg, ciprofloxacin 5 µg, gentamicin 10 µg, amikacin 30 µg, fosfomycin 
50 µg, tetracycline 30 µg, choramphenicol 30 µg and trimethoprim/sulfamethoxazole 25 µg 
(Oxoid, Hampshire, UK). 
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Human CLSI breakpoints (CLSI, 2017) were used since Veterinary CLSI breakpoints (CLSI, 
2018) are either not determined for the tested antimicrobials or are the same as recommended 
in the Human CLSI guidelines. The only exception is the gentamicin breakpoint that varies by 
1mm in the intermedium/susceptible categorisation (CLSI, 2018; CLSI, 2017). 
 
Virulence genes 
All P. mirabilis tested for antimicrobial resistance were also screened for the presence of the 
urothelial cell adhesion fimbriae (UCA/NAF [ucaA]), the mannose-resistant Proteus-like 
fimbriae (MR/P [mrpA]), the Proteus mirabilis fimbriae (PMF [pmfA]) and HpmA/HpmB 
haemolysin (HpmA and HpmB) codifying genes by PCR using previously described primers 
(Sosa et al., 2006; Cestari et al., 2013). 
 
Data analysis 
The Fisher exact test was used to compare groups using the SAS statistical software package 
for Windows, version 9.3 (SAS Institute Inc, Cary, North Carolina, USA). 
The Bionumerics software version 6.6 (BioMérieux, Marcy-l'Étoile, France) was used to 
compare the P. mirabilis restriction PFGE-patterns using Dice/UPGMA clustering method with 
a tolerance of 1.5% and a clustering cut-off of 80%. 
 
Results 
All human participants had more than 18 years of age. Women were over represented (70.8%, 
n= 17/24) and 33.3% (n= 8/24) of human participants underwent antimicrobial treatment in the 
prior year. Companion animals had ages ranging from 2 months to 17 years old, 19.2%  
(n= 5/26) underwent antimicrobial treatment in the prior year and 57.7% (n= 15/26) were 
females. Only one cat had access to the outdoors, 83.3% (n= 15/18) of dogs lived indoors 
while the remaining dogs lived in private yards. 
A total of 11 participants from 8 households had faecal colonisation by P. mirabilis (Figure 1). 
The use of tetrathionate broth was necessary for the detection of P. mirabilis in 36% (n= 4/11) 
of faecal samples of human and animal origin. Nevertheless, all the faecal samples (n= 50) 
were negative for P. mirabilis growth in cefotaxime and meropenem supplemented agar plates. 
When considering each participant species by itself, the P. mirabilis faecal colonisation was 
significantly higher (P = 0.0329) in dogs (44.4%, n= 8/18) than in humans (12.5%, n= 3/24). 
None of the cats had detectable P. mirabilis in faecal samples despite the use of tetrathionate 
broth prior to plating. 
Most positive households included at least one colonised dog (87.5%, n= 7/8) (Figure 1). 
Interestingly, the only household containing solely a colonised human (H2), was composed of 
a non-colonised cat. Five out of the 8 positive households had a single participant colonised 
and therefore within-household sharing of P. mirabilis between these human/animal pairs was 
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absent (Figure 1). Two of the three households with multiple colonised participants included 
colonised human/dog pairs (H17, H18), while the third household (H14) had two positive dogs 
(Figure 1). 
PFGE analysis was conducted in 39 P. mirabilis isolated from 3 households with multiple 
colonised participants (n= 28) and from 3 households with single colonised participants  
(n= 11). A total of 8 P. mirabilis PFGE clusters (from A to H) were identified. None of the  
P. mirabilis from different households clustered together, therefore P. mirabilis was not shared 
across-households (Figure 2). 
 
Figure 2- PFGE analysis of P. mirabilis colonising the gut of humans and dogs 
 
 
The PFGE analysis of the multiple P. mirabilis isolates obtained from each participant revealed 
that two dogs (H14A2 and H17A1) and one human (H18Hu1) had several variants of the same 
colonising strain (Figure 2, Table 1). Following Tenover et al. (1995) criteria these variants are 























































































































































Table 1- Characterisation of faecal P. mirabilis strains 
Household Household member Strain ID Pulse-type Antimicrobial resistance Virulence 
H2 Human Hu1 H2Hu1MCKPM1 Not determined TE mrpA, pmfA, ucaA, hmpA/hmpB 
H4 Dog A1 H4A1HECPM1 Not determined TE mrpA, pmfA, ucaA, hmpA/hmpB 
H10 Dog A1 H10A1HECPM3 H C, TE, SXT mrpA, pmfA, ucaA, hmpA/hmpB 
H11 Dog A1 H11A1PWPM1 D TE mrpA, pmfA, ucaA, hmpA/hmpB 
H13 Dog A1 H13A1TBPM1 B TE mrpA, pmfA, hmpA/hmpB 
H14 Dog A1 H14A1MCKPM1 F.2 TE mrpA, pmfA, ucaA, hmpA/hmpB 
H14 Dog A2 H14A2MCKPM1 F.1 TE mrpA, pmfA, ucaA, hmpA/hmpB 
H14 Dog A2 H14A2MCKPM2 F.3 TE mrpA, pmfA, ucaA, hmpA/hmpB 
H14 Dog A2 H14A2MCKPM5 F.2 TE mrpA, pmfA, ucaA, hmpA/hmpB 
H17 Human Hu1 H17Hu1TBPM1 G TE mrpA, pmfA, ucaA, hmpA/hmpB 
H17 Dog A1 H17A1HECTPM4 A.1 AMP, CN, C, TE, SXT mrpA, pmfA, ucaA, hmpA/hmpB 
H17 Dog A1 H17A1HECTPM5 A.2 AMP, CN, C, TE, SXT mrpA, pmfA, ucaA, hmpA/hmpB 
H17 Dog A1 H17A1TBPM1 C TE mrpA, pmfA, ucaA, hmpA/hmpB 
H18 Human Hu1 H18Hu1TBPM1 E.1 TE mrpA, pmfA, ucaA, hmpA/hmpB 
H18 Human Hu1 H18Hu1TBPM2 E.2 TE mrpA, pmfA, ucaA, hmpA/hmpB 
H18 Human Hu1 H18Hu1TBPM3 E.3 TE mrpA, pmfA, ucaA, hmpA/hmpB 
H18 Human Hu1 H18Hu1TBPM4 E.4 CN, TE mrpA, pmfA, ucaA, hmpA/hmpB 
H18 Dog A1 H18A1TBPM1 E.4 TE mrpA, pmfA, ucaA, hmpA/hmpB 
Legend: hpmA/hpmB, haemolysin HpmA/HpmB; mrpA, mannose-resistant Proteus-like fimbriae (MR/P); pmfA, Proteus mirabilis fimbriae (PMF); ucaA, urothelial cell 
adhesion fimbriae (UCA/NAF); AMP, ampicillin; C, chloramphenicol; CN, gentamycin; SXT, trimethoprim/sulfamethoxazole; TE, tetracycline. 
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Another interesting finding was that only one dog (H17A1) was colonised by several unrelated 
P. mirabilis strains (Figure 2, Table 1). 
The H17 household human/dog pair (H17Hu1 and H17A1) were colonised by unrelated  
P. mirabilis stains (Figure 2, Table 1). On the other hand, the H18 household human/dog pair 
(H18Hu1 and H18A1) were colonised by indistinguishable and closely related P. mirabilis 
strains (89-100% Dice/UPGMA index), thus showing that P. mirabilis are likely shared between 
humans and animals living in close contact (Figure 2, Table 1). It should be noted that although 
the P. mirabilis strains from the dog H18A1 (H18A1TBPM1) and the human H18Hu1 
(H18Hu1TBPM4) were considered indistinguishable by DICE/UPGMA, the resistance 
phenotype varied in the gentamicin-susceptibility (Figure 2, Table 1). Furthermore, at visual 
inspection, the second and third restriction band from the top seem to vary slightly. The 
detection of P. mirabilis colonisation in dog H18A1 required the use of tetrathionate broth while 
in the human H18Hu1 faecal sample this was not necessary. Both colonised humans from 
household H17 and H18 reported to frequently allow the colonised dogs to lick their faces. 
Indistinguishable and closely related P. mirabilis strains (91.7-100% Dice/UPGMA index) were 
also shared by the two dogs living in household H14 (Figure 2, Table 1). Here, the dog H14A2 
presented a higher faecal burden than the dog H14A1. 
Overall, P. mirabilis human-dog sharing occurred in 5.5% (n= 1/18) of all included households 
and in 12.8% (n= 1/8) of positive households. If only the households that included dogs were 
to be considered, these percentages go up to 7.7% (n= 1/13) and 14.3% (n= 1/7), respectively 
(Figure 1). Furthermore, if the potential within-household human-dog sharing-pairs are 
considered, 11.1% (n= 1/9) or 4.2% (n= 1/24) of these shared P. mirabilis strains, depending 
on whether households without colonised participants are included. 
A total of 18 P. mirabilis strains were screened for antimicrobial resistance and for the presence 
of virulence genes (Table 1). 
Most P. mirabilis (77.7%, n= 14/18) were fully-susceptible to all tested antimicrobials except 
tetracycline, for which P. mirabilis is intrinsically resistant. Only the dog H17A1 was colonised 
by a P. mirabilis strain with acquired resistant to three or more antimicrobial categories  
(Table 1). 
The HmpA/HmpB hemolysin and the MR/P and PMF fimbriae codifying genes were present in 
all strains. Furthermore, only one strain lacked ucaA (Table 1). All the PFGE indistinguishable 
and closely related P. mirabilis strains also presented identical antimicrobial resistance 
phenotype and virulence genotype, with the exception of the H18Hu E.4 (H18Hu1TBPM4)  
P. mirabilis variant. 
When comparing the faecal P. mirabilis isolated in this study with the previously characterised 
collection of clinical P. mirabilis from companion animals and humans with UTI (Marques et 
al., 2018a), faecal strains from the H11 (pulse-type D), H14 (pulse-type F) and H18 (pulse-
type E) clustered with at least one uropathogenic clinical strain (Figure 3). 
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Figure 3 - Clusters containing faecal P. mirabilis strains and clinical P. mirabilis 
strains from UTI 
 
Legend: UTI-C, community patient with UTI; UTI-H, hospitalised patient with UTI. 
 
P. mirabilis colonising the dog H11A1 clustered with two clinical strains causing UTI in human 
community patients in 2014 (GTBA591 and GTNAL94) and with one clinical strain isolated 
from a cat with UTI in 2004 (FMV5298/04). Data concerning prior history of UTI in the dog 
H11A1 or in his household members was not disclosed. 
P. mirabilis strains from the human (H18Hu1) and the dog (H18A1) living in household H18 
were 82.5% similar (Dice/UPGMA) with the P. mirabilis clinical strain FMV4938/07 isolated 
from a dog with UTI in 2007. Neither human H18Hu1 nor dog H18A1 had previous history of 
UTI. 
Finally, the P. mirabilis strain shared by both dogs of the household H14 showed 83.7% 
similarity with a clinical strain isolated from a dog with UTI in 2008 (FMV566/08). Both dogs 
from H14 household were never diagnosed with UTI. 
 
Discussion 
To date only few studies have reported data on the P. mirabilis faecal colonisation of healthy 
humans and companion animals (Balish et al., 1977; Gaastra et al., 1996; Drzewiecka, 2016). 
Moreover, to our best knowledge this is the first study that focuses on humans and companion 
animals living in close contact. 
P. mirabilis is an important cause of UTI and the gut is pointed as its major reservoir 
(Drzewiecka, 2016; Armbruster et al., 2018). In fact, several studies associate the faecal 
colonisation by P. mirabilis with cross and auto-infections (Drzewiecka, 2016). 
Little is known regarding the role of healthy dogs and cats as reservoirs of P. mirabilis. Only 
















































































































































































the rectum (Hariharan et al., 2010). The absence of colonised healthy domestic cats in the 
present study may, therefore, be explained by the small sample size. The high P. mirabilis 
colonisation of healthy dogs agrees with one early study conducted in enclosed beagles 
(42.8%) (Balish et al., 1977). However, another early study focussed on dogs with UTI failed 
to detect P. mirabilis in faecal samples of the control group composed by healthy dogs (Gaastra 
et al., 1996). The P. mirabilis colonisation in healthy humans ranges from 4% to 45% according 
to the study and to the gastro-intestinal section considered (Drzewiecka, 2016; Zilberstein et 
al., 2007). It is important to notice that P. mirabilis colonisation frequencies may vary between 
studies due to methodological differences. Furthermore, the normal E. coli faecal burden may 
disguise and limit the detection of less frequent bacteria. Hence, it is possible that P. mirabilis 
colonisation frequencies are being underestimated. 
The growing concerns regarding the transmission of pathogenic bacteria between companion 
animals and humans (Damborg et al., 2016; Pomba et al., 2017) are validated by studies 
reporting that E. coli strains may be shared between companion animals and humans from the 
same household (Stenske et al., 2009; Naziri et al., 2016). P. mirabilis is a common 
uropathogen among cats, dogs and humans (Drzewiecka, 2016; Armbruster et al., 2018; 
Marques et al., 2018b); however, there is a lack of studies evaluating the colonisation of 
epidemiologically related companion animals and humans. One important finding from this 
study was the detection of within-household P. mirabilis sharing between human/dog and 
dog/dog pairs. These results suggest that dogs may be reservoirs of P. mirabilis to humans 
and vice versa but also that dogs are likely reservoirs to other dogs. These outcomes are also 
relevant in infection settings since dogs with UTI caused by P. mirabilis are known to have a 
significantly higher P. mirabilis faecal burden (Gaastra et al., 1996) which hypothetically may 
increase the transmission risk through direct or indirect contact. Care must be taken when 
interpreting these results since the faecal P. mirabilis strains from humans and dogs isolated 
in this study where not compared using the state of the art methods used nowadays, namely 
whole genome sequencing. Nevertheless, following the Tenover et al. (1995) criteria and 
considering that these strains were epidemiologically related, these findings support that 
humans and dogs may share P. mirabilis strains. 
The indistinguishable P. mirabilis strains from the dog H18A1 and human H18Hu1 showed 
distinct gentamicin-susceptibility which may be related with acquisition or loss of the 
gentamicin-resistance mechanisms after gut colonisation. The study design used in this work 
does not allow to determine the transmission dynamics of P. mirabilis; however, since  
P. mirabilis was only detected without the use of tetrathionate broth in the colonised human 
(H18Hu1), it could be speculated that he had a higher P. mirabilis faecal burden and was more 
likely to transmit it. The same rational applies to the household H14 dog/dog sharing. A 
common source of acquisition, such as a fomite, could also have been involved in the co-
colonisation of both household members. Future studies using whole genome sequencing and 
 
 179 
preferably a longitudinal design are warranted to clarify the P. mirabilis transmission dynamics 
and colonisation persistence in humans and dogs. 
E. coli within-household sharing has been found to be significantly more common among 
dog/human pairs that report to allow the dog to lick the human’s face (Naziri et al., 2016). It 
was not possible to establish such association in the current study due to sample size. 
The presence of several variants of the same pulse-type colonising a single host suggests that 
within-host P. mirabilis evolution may be occurring, which is a known phenomenon already 
reported in other bacteria (Didelot, Walker, Peto, Crook & Wilson, 2016). 
Previous studies on E. coli found that 17%, 9.8%, 8.8% or 3.5% of households had human/dog 
pairs sharing indistinguishable or closely related E. coli clones by PFGE (94-100% PFGE 
profile similarity) (Johnson et al., 2008b; Stenske et al., 2009; Harada et al., 2012b; Naziri et 
al., 2016). The different sharing frequencies reported in these studies may be explained by the 
different number of participants per household included and by the different number of E. coli 
isolates typed per participant. Overall, a higher number of participant per household and a 
higher number of isolates per participant usually lead to the detection of a higher percentage 
of sharing (Johnson et al., 2008b; Stenske et al., 2009; Harada et al., 2012b; Naziri et al., 
2016). It was interesting to notice that the human/dog P. mirabilis sharing frequency detected 
in this study is within a similar range as previously published for E. coli. On the other hand, 
unlike in E. coli studies (Stenske et al., 2009; Naziri et al., 2016), P. mirabilis strains were not 
shared across-households. Likelly, this was related to the small sample size. 
Johnson et al. (2008b) reported that adult humans shared E. coli strains more frequently with 
cats than with dogs. Regarding P. mirabilis the opposite was noted. 
The detection of multidrug-resistant CMY-2-producing P. mirabilis is increasing in companion 
animals with UTI living in the same geographic region where the present study was conducted 
(Marques et al., 2018b). CMY-2-like b-lactamases are also important in human infection in 
Europe (D'Andrea et al., 2011). Furthermore, antimicrobial use in the prior year is a known risk 
factor for the gut colonisation by third-generation cephalosporin-resistant bacteria (Belas et al., 
2014; Karanika, Karantanos, Arvanitis, Grigoras & Mylonakis, 2016). Despite the inclusion of 
participants that underwent antimicrobial use in the prior year, third-generation cephalosporin 
and/or meropenem-resistant P. mirabilis were not detected. Although the sample size from the 
current study is a limitation that could explain this result, this is considered a positive finding. 
The gut of catheterised humans with UTI is usually colonised by the index uropathogenic  
P. mirabilis strain (Mathur et al., 2005; Drzewiecka, 2016). The clonal relatedness between  
P. mirabilis clinical strains from individuals with UTI and P. mirabilis strains colonising healthy 
individuals is poorly studied. In the present study, some P. mirabilis strains from faecal samples 
(from household H11, H14 and H18 colonised participants) clustered with UTI clinical strains 
from unrelated patients with UTI. Regarding the household H14 and H18, none of the colonised 
participants have had prior UTI in their life. These findings suggest the role of the gut as 
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reservoir of uropathogenic P. mirabilis in healthy individuals. The detection of P. mirabilis 
colonising a dog that clustered with clinical P. mirabilis isolated from human community-
associated UTI also points to the possible role of dogs as reservoirs to humans. Regretfully, it 
was not possible to obtain epidemiological data on this dog concerning prior UTI or contact 
with infected individuals. Furthemore, future studies using whole genome sequencing are 
warrented to confirm the clonal reladness between these strains. 
Notably almost all P. mirabilis colonising healthy companion animals and humans codified for 
HmpA/HmpB hemolysin and UCA/NAF, PMP and MR/P fimbriae, which are important 
virulence factors for UTI (Armbruster et al., 2018). 
In conclusion, to our knowledge, this study showed for the first time that co-living dogs and 
humans may share closely related P. mirabilis strains in the gut that may also be closely related 
with clinical strains from UTI. Taken together with the high frequency of  
P. mirabilis faecal colonisation in dogs, these findings underline the likely role of dogs in the 
transmission cycle of uropathogenic P. mirabilis. Although this study has a limited sample size 
and used PFGE instead of whole genome sequencing, it provides new epidemiological data 
that has important implications in P. mirabilis dissemination control. Until further studies are 
conducted, risk factors that have been associated with higher E. coli human/dog sharing (e.g. 
dog liking and kissing the face) (Naziri et al., 2016) should be assumed to also contribute for 





Discussion, conclusions and  
future perspectives 
Chapter 6 Discussion, conclusions and future perspectives 
6.1 General discussion 
The discovery of antimicrobials revolutionised the treatment of infections in human and 
veterinary medicine (Prescott, 2017). However, the use of antimicrobials led to the acquisition 
of antimicrobial resistance by bacteria with consequent treatment failure (Prescott, 2017). Due 
to the limited number of antimicrobials available nowadays and the lack of new antimicrobial 
class development, the rising of antimicrobial resistance is a major concern in veterinary and 
human medicine (Prescott, 2017). Research on antimicrobial resistance epidemiology is 
essential to support antimicrobial stewardship programmes and to limit further antimicrobial 
resistance dissemination. 
 
Antimicrobial resistance of uropathogenic bacteria in companion animals 
UTIs are among the most common infections diagnosed in dogs and humans and therefore 
are a frequent reason for antimicrobial prescription (Harding & Ronald, 1994; Schappert & 
Rechtsteiner, 2011; Weese et al., 2011; ECDC, 2013). This infection is also an important cause 
of antimicrobial use in groups of cats with higher frequency of UTI, such as elderly cats 
(Lekcharoensuk et al., 2001). Bacterial antimicrobial resistance frequencies may vary over 
time and the with geographical location (Dorsch et al., 2015; ECDC, 2017). Therefore, global 
surveillance of the antimicrobial resistance trends in small animal veterinary medicine is 
essential to guide the rational use of antimicrobials. 
The study included in the Chapter 3.1 from this thesis aimed at obtaining an overview of the 
European geographic distribution of antimicrobial resistance in bacteria causing UTI in 
companion animals following the example of the EARS-Net on reporting antimicrobial 
resistance of invasive bacteria from humans over Europe (ECDC, 2017). Although there are 
several published studies reporting data on antimicrobial resistance in bacteria causing UTIs 
in companion animals, results are not easily comparable due to the use of different inclusion 
criteria (e.g. studied population, time frame, type of UTI) (Normand, et al., 2000a; Normand et 
al., 2000b; Meunie et al., 2004; Authier et al., 2006; Bailiff et al., 2006; Pedersen et al., 2007; 
Ball et al., 2008; Harada et al., 2012a; Hall et al., 2013; Kroemer et al., 2014; Beever et al., 
2015; Dorsch et al., 2015; Wong et al., 2015; Moyaert et al., 2017; Rampacci et al., 2018; 
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Teichmann-Knorrn et al., 2018). Furthermore, the few studies that included samples from 
different countries usually present data as total antimicrobial resistance frequencies (Meunier 
et al., 2004; Kroemer et al., 2014; Moyaert et al., 2017). 
Reporting the geographic distribution of antimicrobial resistance is useful to identify the 
locations where efforts should be made to improve awareness and implement new strategies 
aiming to decrease antimicrobial resistance. The multicentric study here presented, included 
samples from 16 veterinary microbiology laboratories from 14 European countries and showed 
striking geographical differences on E. coli and P. mirabilis antimicrobial resistance between 
Northern (Denmark and Sweden) and Southern (Italy, Greece, Portugal and Spain) European 
countries. It is interesting to notice that the European geographic distribution of antimicrobial 
resistance in uropathogenic E. coli from companion animals closely resembles that from 
EARS-Net reports (Chapter 1-Figure 5 and Chapter 6-Figure 1). 
 
Figure 1 – E. coli resistance to third-generation cephalosporins and fluoroquinolones 
in companion animals with UTI by country 
 
Legend: Results from the study presented at Chapter 3.1; Left image, third-generation cephalosporins; 
Right image, fluoroquinolones. 
 
The use of different antimicrobial testing methods and interpretation criteria in some countries 
is a study limitation that could have biased these findings. However, the wide differences 
detected between some countries (e.g. 2.88% and 48.15% amoxicillin/clavulanate-resistance 
in Denmark and Portugal, respectively) are likely a result from true geographic differences. 
This limitation is also faced by the EARS-Net reports (ECDC, 2017) and should not, in our 
view, restrain researchers to gather such important epidemiological data. 
The lack of harmonisation regarding the testing and reporting of antimicrobial susceptibility of 
Staphylococcus spp. was profound and strongly limited the analysis of methicillin-resistance. 
Identification of staphylococci to species and testing of the adequate methicillin surrogate is 
essential; however, data was not always provided. Efforts should be made in the future to 
harmonise veterinary microbiology methods across Europe to ensure proper testing and 
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reporting. Hopefully, the VetCAST (Toutain et al., 2017) will play a pivotal role in this issue by 
being a opensource resource to veterinary microbiologists. 
The selection of antimicrobial resistance is a complex and multifactorial process (Prescott, 
2017). Different antimicrobial use policies in each European country may contribute to the 
lower E. coli and P. mirabilis antimicrobial resistance in the Northern (Denmark and Sweden) 
countries when compared to Southern countries (Italy, Greece, Portugal and Spain). 
Nevertheless, antimicrobial use data about companion animals in different European countries 
is still scarce (Pomba et al., 2017) which limits further conclusions. The use of culture and 
antimicrobial susceptibility testing prior to prescribing avoids the misuse of antimicrobials and 
therefore may also lead to a decrease in local antimicrobial selective pressure. A study 
conducted in Europe found, for instance, that veterinarians in Sweden were 15.64 times more 
likely to conduct antimicrobial susceptibility testing to guide antimicrobial choice than in Spain 
(de Briyne, Atkinson, Pokludová, Borriello & Price, 2013). 
Since for most countries from this study samples were obtained from a single veterinary 
microbiology laboratory, these findings may not be representative of the entire country. Despite 
this limitation, these results should prompt the Southern countries to evaluate the geographic 
distribution and temporal trends in antimicrobial resistance within each country. 
The little updated information available regarding antimicrobial resistance in companion 
animals with UTI from Portugal (Féria et al., 2000; Féria et al., 2002), led to the second study 
here presented in Chapter 3.2. The first aim of this study was to determine the antimicrobial 
resistance temporal trends in uropathogenic bacteria over 16 years. Notably, a significant 
increase in Enterobacteriaceae antimicrobial resistance to the main antimicrobials used for 
UTI treatment in veterinary medicine was observed in Portugal (Lisbon). The high frequency 
of antimicrobial resistance detected in Enterobacteriaceae in recent years was worrisome. 
Since the antimicrobial classes used in veterinary medicine are common to those used in 
human medicine (Chapter 1-Table 3), these results are also important for human health. 
The fact that the two studies presented in Chapter 3 relied on samples sent to the laboratory 
based on the clinician judgment could be considered a bias towards resistance (de Briyne et 
al., 2013). Another European study (Portugal not included) showed extremely high 
antimicrobial susceptibility frequencies among bacteria from companion animals with UTI 
obtained between 2008 and 2010 (Moyaert et al., 2017). Although apparently contradicting our 
results, the fact that Moyaert et al. (2017) study excluded samples from companion animals 
with chronic diseases or with previous history of antimicrobial use in the past 4 weeks may 
have biased these results towards susceptibility. Nevertheless, both studies have important 
epidemiological value. The Moyaert et al. (2017) study is more useful to guide empirical 
antimicrobial treatment since it likely included a higher number of simple uncomplicated UTIs. 
On the other hand, the Chapter 3.1 study shows the real therapeutic limitations that 
veterinarians face nowadays in overall UTIs according to each country. Furthermore, the fact 
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that Moyaert et al. (2017) study reports to earlier years may also have contributed to this 
difference. 
In the study presented in the Chapter 3.2, the clonal lineages of methicillin-resistant 
staphylococci, ampicillin-resistant and HLGR enterococci and third-generation cephalosporin-
resistant E. coli were determined by MLST. The significant increase in the detection of MDR 
Enterobacteriaceae, including E. coli, noted in Portugal (Lisbon) creates important therapeutic 
limitations. The two main MDR E. coli clonal lineages detected in this study (ST648 and 
O25b:H4-B2-ST131) are worldwide disseminated in human infection and mostly associated 
with CTX-M-producing strains (Coque et al., 2008; Doi et al., 2017; Poirel et al., 2018). 
Interestingly, previous studies about the population structure of E. coli have shown that some 
ST131 and ST648 E. coli strains isolated from companion animals cluster with E. coli strains 
from humans (Pomba et al., 2014b; Fernandes et al., 2018b). Therefore, the significant 
increase in MDR CMY-2-producing E. coli ST648 detected in Portugal (Lisbon) is worrisome. 
Furthermore, although ampicillin-resistant and/or HLGR Enterococci, MRSA and MRSE were 
not as frequent, they also belonged to important clonal lineages previously associated to 
human infection (Leavis et al., 2006; Kuch et al., 2012; Rolo et al., 2012; Aires-de-Sousa, 
2017; Lee, Pang, Abraham & Coombs, 2018; Torres et al., 2018). Overall, this study showed 
that bacterial species causing UTI in companion animals are becoming more resistant and 
some MDR strains belong to clonal lineages associated to human infection. Studies using 
WGS are needed to clarify the true zoonotic nature of these strains; nevertheless, the role of 
companion animals as reservoirs should not be neglected and is considered a public health 
concern. 
 
Molecular epidemiology of K. pneumoniae and P. mirabilis causing UTI 
The results from the two studies presented in Chapter 3 were in line with previous reports 
showing that E. coli predominates among dogs and cats with UTI (Bush, 1976; Wooley & Blue, 
1976; Forrester et al., 1999; Gupta et al., 1999; Hess et al., 2000; Ling et al., 2001; Cohn et 
al., 2003; Kahlmeter & ECO.SENS, 2003; Pressler et al., 2003; Torres et al., 2005; Bailiff et 
al., 2006; Litster et al., 2007b; Mayer-Roenne et al., 2007; Passmore et al., 2008; Martinez-
Ruzafa et al., 2012; Dorsch et al., 2015; Flores-Mireles et al., 2015; Moyaert et al., 2017). 
Although less frequent, P. mirabilis is the second most common Enterobacteriaceae isolated 
in companion animals with UTI, particularly in dogs (Wooley & Blue, 1976; Lekcharoensuk et 
al., 2001; Ling et al., 2001; Cohn et al., 2003; Bailiff et al., 2006; Bailiff et al., 2008; Litster et 
al., 2007b; Moyaert et al., 2017). In humans, P. mirabilis is an important nosocomial pathogen 
causing CAUTI (Szabo & Paterson, 2002; Manos & Belas, 2006; Drzewiecka, 2016); 
nevertheless, it has deserved little attention in companion animals. In Portugal (Lisbon), the 
study from Chapter 3.2 showed a significant increase in P. mirabilis resistance to several CIAs 
over time that was associated with an increase in the detection of MDR CMY-2-producing  
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P. mirabilis. The frequent detection of CMY-2 among third-generation cephalosporin-resistant 
P. mirabilis is in line with previous reports about companion animals (Dierikx et al., 2012; 
Hordijk et al., 2013; Harada et al., 2014; Schultz et al., 2017b). The population structure of 
these strains was analysed by PFGE in the study from Chapter 4.2 and showed that several 
MDR CMY-2-producing P. mirabilis from companion animals clustered together. These MDR 
CMY-2-producing strains were resistant to 5-9 antimicrobial categories. Therefore, their 
possible dissemination is worrisome and should be monitored in the future. Interestingly, the 
detection of CMY-2-producing P. mirabilis is also being increasingly reported among human 
infections (Aragón et al., 2008; D’Andrea et al., 2011; Song et al., 2011; Miró et al., 2013a; 
Aogáin et al., 2016). 
K. pneumoniae is currently in the spot light due to their role in the dissemination of ESBLs and 
carbapenemases (Brisse et al., 2006; ECDC, 2017; Navon-Venezia et al., 2017; Martin & 
Bachman, 2018). In women, K. pneumoniae is the second most frequent Enterobacteriaceae 
causing UTI (Gupta et al., 1999) while in dogs and cats it seems less frequent. Due to the 
limited number of K. pneumoniae from companion animals with UTI included in the study from 
Chapter 3.2 and Chapter 4.1, it was not possible to evaluate its antimicrobial resistance trends 
over time. Nevertheless, it was surprising that more than 50% of isolates were MDR 
ESBL/AmpC-producers. The main ESBL gene detected in K. pneumoniae strains from 
companion animals with UTI was the blaCTX-M-15, which is in line with previous reports in humans 
and animals (Ewers et al., 2014b; Calbo & Garau, 2015; Harada et al., 2016; Navon-Venezia 
et al., 2017). 
The high detection of MDR Enterobacteriaceae, including K. pneumoniae and P. mirabilis, 
causing UTIs in companion animals is worrisome because it frequently leads to the need to 
prescribe off-label antimicrobials under the cascade principals (EMA, 2018). Besides important 
ethical issues, this use creates additional resistance selective pressure to an already limited 
number of antimicrobials available nowadays (EMA, 2018). The urgent implementation of 
antimicrobial stewardship programmes in veterinary medicine is essential to improve the 
judicious use of antimicrobials (Lloyd & Page, 2018). Following the 5 Rs (responsibility, 
reduction, replacement, refinement and review) of the antimicrobial stewardship framework 
(Lloyd & Page, 2018), there is a need to test new therapeutic approaches to address UTIs 
caused by MDR bacteria in companion animals. Recently, following the example of studies 
from humans (Lagacé-Wiens et al., 2006; Beytur et al., 2015), a pilot study was conducted to 
evaluate the use of amoxicillin/clavulanate for the treatment of a cat with UTI by a MDR  
CTX-M-15-producing K. pneumoniae (Marques, Belas, Vetpoint Team, Salas & Pomba, 2017). 
Although clinical cure was not achieved and further studies are needed, a decrease in 
bacteriuria during treatment was observed. 
The close contact between companion animals and humans in modern society is viewed as 
an important route for the dissemination of antimicrobial resistant bacteria (Guardabassi et al., 
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2004; Damborg et al., 2016; Pomba et al., 2017). Furthermore, companion animals with UTI 
have high bacterial loads in urine and frequently present polyakuria (Gaastra et al., 1996; 
Bartges et al., 2004; Weese et al., 2011), which likely enhances the risk of dissemination. 
There is very little information regarding the molecular epidemiology of P. mirabilis from 
companion animals with UTI (Schultz et al., 2015; Schultz et al., 2017b) and only recently 
studies started to focus on K. pneumoniae (Chapter 1-Table 6). In the studies presented in the 
Chapter 4, K. pneumoniae and P. mirabilis from companion animals and humans with UTI 
were characterised for their population structure, antimicrobial resistance and virulence 
genotype. Previous studies about K. pneumoniae and P. mirabilis strains of companion animal 
origin only rarely included isolates from humans (Stolle et al., 2013; Ewers et al., 2014b; 
Schultz et al., 2015; Wohlwend et al., 2015; Schultz et al., 2017b). 
Interestingly, the main antimicrobial resistant genes detected in K. pneumoniae and P. mirabilis 
from companion animals and humans with UTI were similar. Regarding E. coli, some studies 
suggest that different CTX-M ESBLs predominate in strains from animals or humans (Coque, 
Baquero & Canton, 2008; Ewers et al., 2012). In the third-generation cephalosporin-resistant 
K. pneumoniae studied in Chapter 4.1, CTX-M-15 predominated regardless of its origin. 
Furthermore, other antimicrobial resistant genes, such as blaTEM, blaOXA-1, blaCMY-2, blaDHA-1, 
qnrB, aac(6’)-Ib, sul1, sul2 and tet(A), were also detected in K. pneumoniae strains of both 
origins. A similar overlap was observed in P. mirabilis from humans and companion animals 
regarding blaTEM, qnrD, aphAI-IAB, sul1, sul2 and dfrIa. 
A positive finding from Chapter 4 studies was the lack of carbapenem-resistance due to the 
production of carbapenemases in K. pneumoniae and P. mirabilis from humans and 
companion animals. So far the isolation of carbapenemase-producing K. pneumoniae in 
companion animals still remains a sporadic finding (Stolle et al., 2013; Schmiedel et al., 2014; 
González-Torralba set al., 2016; Pulss et al., 2018). On the other hand, carbapenemase-
producing K. pneumoniae have been extensively detected in human patients from Portugal 
(ECDC, 2017) (Chapter 1-Table 7). 
In the study presented in Chapter 4.1, the population structure of the clinical K. pneumoniae 
strains from companion animals and humans with UTI was characterised by PFGE and MLST. 
PFGE has the advantage of being a more discriminatory typing method while MLST allows the 
comparison of results with published data worldwide (Hansen et al., 2002; Vimont et al., 2008). 
Since 2012, the number of studies typing K. pneumoniae from companion animals by MLST 
has increased; however, data is mainly focussed on ESBL/carbapenamase-producers  
(Chapter 1-Table 6). In this study, K. pneumoniae from companion animals with UTI belonged 
predominantly to ST15 regardless of being or not an ESBL or AmpC-producer. The 
predominance of ST15 among CTX-M-15-producing K. pneumoniae is in line with reports from 
other countries (Chapter 1-Table 6) and our results agree with the hypothesis that companion 
animals may be reservoirs of this high-risk clonal lineage (Ewers et al., 2014b). Other high-risk 
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clonal lineages previously associated with the dissemination of ESBLs and carbapenemases 
in humans (Navon-Venezia et al., 2017) were also detected in companion animals with UTI in 
Portugal (Lisbon), namely ST11, ST37 and ST147. In fact, it should be noted that the third-
generation cephalosporin-resistant K. pneumoniae from companion animals in this study 
belonged mainly to high-risk clonal lineages to humans. These K. pneumoniae high-risk clonal 
lineages have also been found in companion animals from other European and Asian 
countries, with ST147 being the second most disseminated after ST15 (Chapter 1-Table 6). 
Notably, most of the MDR K. pneumoniae clonal lineages here detected in companion animals 
with UTI (ST15, ST11, ST147 and ST348) are also among the most reported in humans from 
Portugal, including carbapenemase-producers (Chapter 1-Table 7). 
The K. pneumoniae strains from humans with UTI included in Chapter 4.1 showed higher 
diversity by PFGE and MLST, which may point to different clonal epidemiology between 
humans and companion animals. Similar findings were also reported by Poirel et al. (2013) 
and Wohlwend et al. (2015). Since UTIs caused by K. pneumoniae are more common in 
humans than in companion animals (Gupta et al., 1999; Moyaert et al., 2017) this higher 
diversity may suggest that K. pneumoniae are less adapted to the urinary tract of dogs and 
cats. In fact, as pointed by Ewers et al. (2014b), it is still unclear whether K. pneumoniae ST15 
clonal lineage is truly zoonotic or if a separate host microevolution is in place. 
The PFGE analysis of P. mirabilis from UTIs conducted in Chapter 4.2 showed a high clonal 
diversity and that a big number of PFGE clusters included strains (43.6%) isolated from 
companion animals and humans. Furthermore, some P. mirabilis strains from cats had  
92%-100% similarity to strains isolated from humans, thus suggesting that some P. mirabilis 
strains may be able to cause UTI in both hosts. 
The use of WGS offers maximum discrimination between bacterial strains by comparing almost 
the entire bacterial genome (Struelens & Brisse, 2013; Quainno et al., 2017). The fact that the 
phylogenetic relatedness of K. pneumoniae and P. mirabilis strains was only characterised by 
PFGE is considered a study limitation because it restricted the recognition of a definite link 
between companion animals and humans. Nevertheless, the detection of K. pneumoniae and 
P. mirabilis PFGE clusters containing strains of both origins is noteworthy and should 
encourage further investigations. The lack of an available P. mirabilis MLST typing scheme 
also strongly limits the comparison of results regarding clonality worldwide and is likely one of 
the reasons why the global P. mirabilis clonal epidemiology is fairly unknown. 
Several K. pneumoniae and P. mirabilis virulence genes were very abundant regardless of the 
strain origin. The high virulence gene frequencies detected in P. mirabilis could be expected 
based on several reports from humans and early studies from companion animals (Old & 
Adegbola, 1982; Mobley & Chippendale, 1990; Swihart & Welch, 1990b; Bijlsma et al., 1995; 
Gaastra et al., 1996; Sosa et al., 2006; Cestari et al., 2013; Kuan et al., 2014). Some of the 
virulence genes tested in K. pneumoniae, namely fimH-1, mrkD and entB, are thought to be 
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ubiquitous and therefore the results obtain in Chapter 4.1 were not a surprise (Podschun & 
Ullmann, 1998; Paczosa & Mecsas, 2016; Martin & Bachman, 2018). All K. pneumoniae 
included in this study had virulence genotypes characteristic of “classic” K. pneumoniae (Shon 
et al., 2013; Paczosa & Mecsas, 2016). Nevertheless, some virulence genes associated with 
invasive K. pneumoniae (Shon et al., 2013; Holt et al., 2015; Paczosa & Mecsas, 2016), such 
as the yersiniabactin, were also detected in strains from companion animals belonging to high-
risk clonal lineages. The absence of hypervirulent K. pneumoniae was expected since only 
recently it was reported in a human infection from Portugal (Pereira et al., 2017). 
The similarities noted between the K. pneumoniae or P. mirabilis strains isolated from 
companion animals and humans with UTI raise concerns regarding its possible animal-to-
human transmission or vice versa. Nonetheless, it should be noted that a significant number 
of K. pneumoniae and P. mirabilis strains from companion animals with UTI were unrelated 
with strains isolated from humans. Additionally, differences were also noted in some 
antimicrobial resistance gene and virulence gene frequencies. One possible explanation is the 
fact that although companion animals and humans live in close contact, they are also exposed 
to different bacterial sources (e.g. food, living environment and lifestyle, etc). Furthermore, the 
inclusion of K. pneumoniae and P. mirabilis strains from companion animals and humans 
collected in different time frames may have limited the detection of additional epidemiological 
links. It could also be speculated that some K. pneumoniae and P. mirabilis strains may be 
more adapted to one of the host species through separate evolution. Future studies using 
WGS are warranted to clarify these questions. Since the adhesion to the urinary tract is an 
essential step for UTI (Flores-Mireles et al., 2015), the comparison of adhesin sequences that 
are known to contribute for UTI could disclose the existence of host-specific adaptations or, on 
the contrary, show similar and zoonotic features. 
 
Sharing of K. pneumoniae and P. mirabilis between humans and companion animals 
Most studies characterising the population structure of K. pneumoniae and P. mirabilis isolated 
from companion animals are focussed on clinical strains from a wide range of infections 
(Schultz et al., 2015; Schultz et al., 2017b) (Chapter 1-Table 6). The role of healthy companion 
animals as reservoirs of K. pneumoniae and P. mirabilis has seldom been addressed (Balish 
et al.,1977; Gaastra et al., 1996; Hariharan et al., 2010; Shariff et al., 2017) and there is a lack 
of information regarding the population structure of colonising strains. However, the number of 
healthy companion animals surely surpasses those with infections and therefore their role as 
reservoirs of K. pneumoniae and P. mirabilis should be investigated. In Chapter 5, the  
K. pneumoniae and P. mirabilis gut colonisation of healthy humans and companion animals 
living together was evaluated regarding sharing and population structure. 
Only dogs and humans were found to be colonised by both bacteria. The K. pneumoniae and 
P. mirabilis gut colonisation frequencies detected in dogs were in line with the Balish et al. 
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(1977) study. The gut is thought to be the reservoir of uropathogenic bacteria (Podschun & 
Ullmann, 1998; Drzewiecka, 2016; Johnson et al., 2016; Martin et al., 2016) and therefore the 
lower frequency of K. pneumoniae and P. mirabilis in the gut when compared to E. coli may 
explain the predominance of this latter as a cause of UTI. 
Considering the high frequency of CMY-2-producing P. mirabilis and ESBL-producing  
K. pneumoniae detected in recent years in companion animals with UTI from Portugal (Lisbon), 
it was surprising not to detect gut colonisation by third-generation cephalosporin-resistant  
P. mirabilis or K. pneumoniae in dogs and cats. Likewise for humans, considering the EARS-
Net reports about human infection by third-generation cephalosporin and carbapenem-
resistant K. pneumoniae (ECDC, 2017). The fact that these studies relied on samples from 
healthy dogs and humans without antimicrobial treatment in the prior month may have biased 
the results towards the detection of susceptible strains. 
The K. pneumoniae strains detected in the gut of companion animals and humans belonged 
to a diverse number of clonal lineages. This finding is consistent with the high K. pneumoniae 
diversity detected in the study presented in Chapter 4.1 and was also initially noted by Doumith 
et al. (2005). 
Considering the frequency and dissemination of the K. pneumoniae high-risk clonal lineage 
ST15 in companion animal and human infections (Chapter 1-Table 6 and Chapter 1-Table 7) 
(Navon-Venezia et al., 2017), it was surprising not to detected this clonal lineage colonising 
healthy individuals. The same could be said about other frequently detected K. pneumoniae 
high-risk clonal lineages detected in humans from Portugal (Chapter 1-Table 7) and worldwide 
(Navon-Venezia et al., 2017) such as ST11 and ST147. Studies on K. pneumoniae are usually 
focussed on resistant strains, such as ESBL or carbapenemase-producers, and therefore data 
on susceptible strains is scarce (Martin et al., 2016; Martin & Bachman, 2018). The fact that 
only susceptible K. pneumoniae strains to third-generation cephalosporins were typed in 
Chapter 5.1 may explain these unexpected results. Importantly, the high-risk clonal lineage 
ST17 (Navon-Venezia et al., 2017), which is frequently associated with the production of 
ESBLs, was detected in the gut of dogs and humans. When searching the Institut Pasteur 
Bigsdb (2018) for the K. pneumoniae clonal lineages detected in the gut of dogs, it becomes 
clear that these clonal lineages have been mainly associated with human infection (Chapter 
6-Table 1). This is an important finding from the Chapter 5.1 study because it suggests that 
healthy dogs may be reservoirs of K. pneumoniae to humans. 
Due to the lack of an MLST scheme, such epidemiological conclusions could not be drawn 
regarding P. mirabilis clonal lineages. P. mirabilis colonising the gut of dogs and humans also 
showed high diversity by PFGE as seen in Chapter 4.2 regarding uropathogenic strains. 
Previous studies on the gut colonisation and sharing of Enterobacteriaceae between humans 
and companion animals have been mainly focussed on E. coli. These studies have found that 
dogs may share identical E. coli strains with humans living within the same household and 
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across non-related households (Johnson & Clabots, 2006; Johnson et al., 2008a; Johnson et 
al., 2008b; Stenske et al., 2009; Harada et al., 2012b; Naziri et al., 2016; Damborg et al., 
unpublished data13). To our best knowledge, the studies presented in Chapter 5 are the first 
reports regarding the faecal sharing of K. pneumoniae and P. mirabilis between healthy 
humans and companion animals living in close contact. These two studies seem to support 
the hypothesis that K. pneumoniae and P. mirabilis strains may be shared between healthy 
humans and dogs living in close contact as previously reported for E. coli. 
 
Table 1 – K. pneumoniae clonal lineages detected in the gut of dogs in Chapter 5.1 
Sequence type Host (Source or Infection) 
ST17 
Human (bacteraemia /blood, sputum, sepsis, urine and UTI, pneumonia, diarrhoea 
and faecal carriage, nose and throat swabs); 
Pig (pneumoniaa); 
Raw cow milka. 
ST188 
Human (bacteraemia, UTIa); 
Dog (swab teacheaa); 
Rat (lung tissue); 
Retail meata. 
ST281 Human (urine, antral biopsya). 
ST252 Human (blood, urine and UTIa, carriagea). 
ST423 Human (trachea aspirate, UTI
a,b, skina, cerebrospinal fluida). 
ST1093 Human (pneumonia/blooda). 
ST1241 Human (blood). 
ST3398 Newly described in this study. 
ST3399 Newly described in this study. 
Legend: Information from: Institut Pasteur Bigsdb (2018) and aBowring, Fahy, Morris and Collins (2017); 
Davis et al. (2015); Diab et al. (2017); Ewers et al. (2014b); Gomez-Simmonds et al. (2015); Ito et al. 
(2015); Papagiannitsis et al. (2015); Rodrigues et al. (2017); da Silva et al. (2018); Garza-Ramos et al. 
(2018). b Also detected at the study presented in Chapter 4.1. 
 
Interestingly, within and across-household K. pneumoniae sharing was noted between 
humans and dogs. The K. pneumoniae strains shared by the three participants from different 
households belonged to the high-risk clonal lineage ST17. These ST17 K. pneumoniae strains 
shared indistinguishable PFGE pulse-types but had slightly different antimicrobial resistance 
phenotypes. Since the three households were epidemiologically related it could be 
hypothesised that the acquisition of different antimicrobial resistance genes occurred after the 
direct or indirect dissemination of this strain to all hosts. However, it is also plausible that this 
high-risk ST17 strain is more disseminated and was independently acquired by each 
participant. It is intriguing that, to our knowledge, the K. pneumoniae ST17 has only been 
recently reported once in humans from Portugal (Chapter 1-Table 7). One possible explanation 
                                               
13 Available as a preprint at bioRxiv at https://www.biorxiv.org/content/early/2018/04/17/302885. 
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is that this clonal lineage is more disseminated in community than in hospital and health-care 
settings. 
The household H15 is an interesting case of within-household K. pneumoniae sharing that 
highlights the need of future studies to clarify the 1) K. pneumoniae colonisation dynamics 
between household members; 2) the risk factors associated with sharing; and 3) the potential 
sources/routes of K. pneumoniae transfer. Interestingly, E. coli colonisation shows a complex 
transmission dynamics where certain strains circulate and are intermittently detected among 
humans and companion animals from the same household (Johnson & Clabots, 2006). 
The household H18 included one human and one dog that shared the same P. mirabilis strain, 
according to PFGE, but with distinct susceptibility to gentamicin. Although the Bionumeric 
software rendered these strain as undistinguishable, at visual examination a slight difference 
between the second and third upper restriction band seems to exist. These small size 
differences may be related with acquisition or loss of gentamicin-resistance mechanisms or 
other mobile genetic elements during colonisation. Ideally, WGS should be conducted in the 
future to compare the entire P. mirabilis genome of these strains and clarify their clonal 
relatedness. 
Companion animals and humans make part of the dissemination cycle of pathogenic and 
antimicrobial resistant bacteria through direct and indirect contact (Prescott, 2017). If a higher 
gut colonisation would lead to higher chances of transmission, it could be speculated that dog-
to-human and human-to-dog transmission likely occurred regarding in the K. pneumoniae and  
P. mirabilis studies, respectively. However, since the K. pneumoniae detected in the gut of 
dogs have been mainly previously associated with human infection (Chapter 6-Table 1), the 
acquisition of K. pneumoniae from human sources could be suggested. It should also be noted 
that, the clonal epidemiology of K. pneumoniae from healthy dogs is so far understudied, and 
therefore the most frequent strains colonising companion animals still need to be determined 
worldwide. Finally, a common source of K. pneumoniae and P. mirabilis dissemination could 
also have occurred. 
When comparing the colonising K. pneumoniae and P. mirabilis strains, by PFGE, with the 
clinical strains from patients with UTI studied in Chapter 4, some strains clustered together 
using a clustering cut-off of 80%. Regarding P. mirabilis, the strain colonising dog H11A1 is 
noteworthy because it shows only a two band difference and 88.9% similarity from a strain 
isolated from a human patient with UTI (GTBA591). The same is true for the K. pneumoniae 
strain isolated from the dog H10A1 which was 92.3% similar with a strain isolated from a 
hospital patient with UTI (PC25/15B) belonging to ST423. Although WGS is needed to evaluate 
the relatedness between these strains, these findings seem to suggest that healthy dogs may 






The studies conducted under this thesis contributed with important epidemiological findings to 
small animal veterinary medicine and public health, namely: 
 
Antimicrobial resistance of uropathogenic bacteria in companion animals 
There are significant differences in the antimicrobial resistance frequencies, including against 
CIAs, of uropathogenic bacteria from companion animals across Europe. The major 
differences, were detected between Northern (Denmark and Sweden) and Southern (Italy, 
Greece, Portugal and Spain) European countries. In Portugal (Lisbon), there was an increasing 
trend in uropathogenic Enterobacteriaceae resistance to the main antimicrobials used for UTI 
treatment in small animal veterinary medicine. The significant increase in detection of MDR 
bacteria is worrisome since it leads to bigger therapeutic limitations. The detection of high-risk 
clonal lineages harbouring clinically relevant antimicrobial resistant mechanisms, such as 
third-generation cephalosporin-resistant E. coli O25b:H4-B2-ST131, CC23 and ST648, MRSA 
CC5, MRSE CC5, HLGR E. faecalis CC6, and ampicillin/HLGR E. faecium CC17, highlights 
the role of dogs and cats with UTI in its dissemination. 
 
Molecular epidemiology of K. pneumoniae and P. mirabilis causing UTI 
The ST15 is the most common K. pneumoniae clonal lineage causing UTI in companion 
animals from Portugal (Lisbon) and is frequently MDR and CTX-M-15-producer. Furthermore, 
third-generation cephalosporin-resistant K. pneumoniae from companion animals with UTI 
mainly belong to high-risk clonal lineages to humans. Regarding P. mirabilis, a high number of 
P. mirabilis from companion animals with UTI cluster in PFGE analysis with strains isolated 
from human patients, some with >90% similarity. K. pneumoniae and P. mirabilis from 
companion animals and humans harboured similar antimicrobial resistance determinants and 
virulence genes. Such similarities highlight the possible role of companion animals in the 
dissemination and as reservoirs of uropathogenic K. pneumoniae and P. mirabilis. 
 
Sharing of K. pneumoniae and P. mirabilis between humans and dogs 
To our best knowledge, the possibility for K. pneumoniae and P. mirabilis sharing between 
healthy humans and dogs living in close contact was here demonstrated for the first time. Dogs 
also seem to be reservoirs of K. pneumoniae clonal lineages associated with human infection 
which supports their role as reservoirs. The detection of some faecal K. pneumoniae and  
P. mirabilis strains that were closely related to uropathogenic clinical strains is also an 
important finding from these studies. 
 
Taken together, the results from this thesis are in line with the need of a One Health approach.  
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6.3 Future perspectives 
 
The works here presented point to some research fields that need be further explored in the 
in the future. 
 
Multicentric surveillance studies and antimicrobial stewardship. 
Considering the wide geographical differences detected in antimicrobial resistance in Europe, 
studies on other types of infection in companion animals are needed. Ideally, future studies 
should pursue the characterisation of the bacterial clonal lineages affecting companion 
animals and their antimicrobial resistance mechanisms in order to also evaluate the 
dissemination of pathogenic bacterial clonal lineages and antimicrobial resistance genes. 
Furthermore, the development of antimicrobial stewardship programmes suitable to small 
animals veterinary medicine are urgent, especially in the Southern European countries. 
 
K. pneumoniae and P. mirabilis population structure. 
The similarities detected between K. pneumoniae and P. mirabilis from companion animals 
and humans points to its possible zoonotic nature. Futures studies using WGS are needed to 
ultimately link the population structure and molecular antimicrobial resistance epidemiology of 
K. pneumoniae and P. mirabilis of both origins. Furthermore, K. pneumoniae and  
P. mirabilis from other types of infection, besides UTI, need to also be compared in the future 
to investigate additional similarities and risk factors. 
The development of a MLST scheme for P. mirabilis typing would improve the comparability 
of results worldwide while WGS techniques becomes more affordable and user-friendly. 
 
Transmission dynamics of K. pneumoniae and P. mirabilis between companion animals 
and humans. 
After demonstrating that healthy dogs and humans may share K. pneumoniae and P. mirabilis 
strains, new studies using a longitudinal design are needed to clarify the colonisation length 
and transmission dynamics over time. The use of a larger sample size would also allow to 
identify possible risk factors and transmission routes leading to the detection of potential 
control measures that would limit the dissemination of resistant and/or virulent K. pneumoniae 
and P. mirabilis. Studies on a higher number of cats should also be conducted. 
Future colonisation studies should also be conducted in households with infected companion 
animals and/or humans to evaluate if infection (UTI or other) increases the chances of  
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Annex 1 - WHO list of critically important antimicrobials for human medicine 
(WHO CIA list) 
 
WHO list of Critically Important Antimicrobials
for  Human Medicine (WHO CIA list ) 
WHO supports optimization of the use of antimicrobial medicines in human and 
animal to preserve their effectiveness by taking a One Health approach 
*The scope of this  list is limited to the antibacterial drugs (antibiotics).





Drug resistant bacteria can 
spread to the environment …and to food
…and can be 
transferred to 
people by eating 
food
Infections from drug resistant 
bacteria can be more severe and 
difficult to treat than those from 
drug susceptible bacteriaAn
timicrobials*
Since 2005, WHO has produced a regularly updated list 
of all antimicrobials currently used for human medicine 
(mostly also used in veterinary medicine), grouped 
into 3 categories based on their importance to human 
medicine. The list is intended to assist in managing 
antimicrobial resistance, ensuring that all antimicrobials, 
especially critically important antimicrobials, are used 
prudently both in human and veterinary medicine.
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Penicillins (natural, aminopenicillins, and antipseudomonal)
Phosphonic acid derivatives
Drugs used solely to treat tuberculosis or other mycobacterial 
diseases
CRITICALLY IMPORTANT ANTIMICROBIALS P3P2P1C2C1
Antimicrobial class Criterion ( Yes=● )
Amidinopenicillins
Amphenicols







Sulfonamides, dihydrofolate reductase inhibitors and combinations
Sulfones
Tetracyclines
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The antimicrobial class is the 
sole, or one of limited available 
therapies, to treat serious 
bacterial infections in people.
C1 Criterion 1 
The antimicrobial class is used 
to treat infections in people 
caused by either: (1) bacteria 
that may be transmitted to 
humans from nonhuman 
sources, or (2) bacteria that 
may acquire resistance genes 
from nonhuman sources.
C2 Criterion 2
High absolute number of people, 
or high proportion of use in 
patients with serious infections 
in health care settings affected 
by bacterial diseases for which 
the antimicrobial class is the 
sole or one of few alternatives 
to treat serious infections in 
humans.  
P1 Prioritization criterion 1
High frequency of use of the 
antimicrobial class for any 
indication in human medicine, 
or else high proportion of use in 
patients with serious infections 
in health care settings, since 
use may favour selection of 
resistance in both settings. 
P2 Prioritization criterion 2
The antimicrobial class is used 
to treat infections in people 
for which there is evidence 
of transmission of resistant 
bacteria or resistance genes 
from non-human sources. 
P3 Prioritization criterion 3 
H
ig
he
st
 P
rio
rit
y
M
ed
ic
al
ly
 I
m
p
o
rt
an
t 
A
n
ti
m
ic
ro
b
ia
ls
